

ECMCC Board of Director's Meeting

March 26, 2024

Zizzi Conference Center

Erie County Medical Center

462 Grider Street

Buffalo, NY 14215

AGENDA

REGULAR MEETING OF THE BOARD OF DIRECTORS OF ERIE COUNTY MEDICAL CENTER CORPORATION MARCH 26, 2024

- I. CALL TO ORDER: JENNIFER PERSICO, CHAIR
- II. APPROVAL OF MINUTES:
- III. RESOLUTIONS MAY BE DISTRIBUTED TO THE BOARD OF DIRECTORS DURING THE MEETING ON MARCH 26, 2024
- IV. REPORTS FROM THE CORPORATION'S LEADERSHIP TEAM
 - A) Chief Executive Officer & President
 - **B)** Chief Financial Officer
 - C) All other reports from leadership are received and filed
- V. REPORTS FROM STANDING COMMITTEE CHAIRS
 - A) **Executive Committee** (by Eugenio Russi)
 - B) Finance Committee (by Michael Seaman)
 - C) **Audit Committee** (Darby Fishkin)
 - D) **Human Resources Committee** (by Michael Seaman)
 - E) Quality Improvement and Patient Safety Committee (by Michael Hoffert)
- VI. EXECUTIVE SESSION
- VII. ADJOURN

ERIE COUNTY MEDICAL CENTER CORPORATION FEBRUARY 27, 2024 MINUTES OF THE BOARD OF DIRECTORS MEETING HYBRID MEETING HELD

Present: Ronald Bennett (virtual), Reverend Mark Blue, Ronald A Chapin (virtual),

Jonathan Dandes, Darby Fishkin, Sharon Hanson, Michael Hoffert (virtual), James Lawicki (virtual), Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman (virtual), Philip Stegeman, Benjamin

Swanekamp

Excused: Christian Johnson, Christopher O'Brien, Hon. John O'Donnell, Jennifer

Persico

Also

Present: Donna Brown, Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra

Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene

Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski

I. <u>Call to Order</u>

The meeting was called to order at 4:30 pm by Vice Chair, Eugenio Russi.

II. Minutes

Upon a motion made by Jonathan Dandes and seconded by Reverend Kinzer Pointer, the minutes of the January 23, 2024 regular meeting of the Board of Directors were unanimously approved.

III. Action Items

Resolution Appointing Officers of the Corporation

Moved by Sharon Hanson and seconded by Darby Fishkin that the following members of the Board of Directors be appointed until their successors are appointed by subsequent resolution of the Board of Directors:

Officer PositionAppointmentChair, Board of DirectorsEugenio RussiImmediate Past ChairJonathan DandesSecretarySharon HansonTreasurerDarby Fishkin

Motion approved unanimously.

Resolution Receiving and Filing Medical-Dental Staff Meeting Minutes for February

Moved by Reverend Kinzer Pointer and seconded by Reverend Mark Blue **Motion approved unanimously.**

VI. Reports from the Corporation's Leadership Team

Chief Executive Officer and President

Dr. Thomas Quatroche reported that the Patient Safety Indicators continue to reflect positive work by the employees. January Human Experience Scores reflect higher than benchmark and New York State totals. Dr. Quatroche reviewed February's hospital events and celebrations. Also, awards received by individuals and the hospital were announced. A summary of ECMC Foundation events since the beginning of the year was presented. One hundred and twenty (120) new employees have begun working at ECMC since the beginning of the year. In February, Terrace View LTC experienced its highest census (379) since September of 2019.

Chief Financial Officer

Jonathan Swiatkowski reviewed the January 2024 Key Statistics. Discharges, ER visits and inpatient surgeries were higher than last year. However, ER visits and Outpatient visits and surgeries were lower than budget. This was attributed to the inclement weather in January. Length-of-stay (both Acute Average and Total Average) was in line with budget. A summary of the preliminary financial results through January 31, 2024 was reviewed and the full set of these materials are received and filed. Mr. Swiatkowski reported that days operating cash on hand is currently 48 days. Additionally, Mr. Swiatkowski gave an update on payers and presented a look at future financial events.

V. Standing Committees

- a. **Executive Committee:** Mr. Russi had nothing to report from the Executive Committee.
- b. **Buildings and Grounds Committee**: Ronald Bennett gave an update on all ongoing projects and reported on the completion of surgical lighting in the operating rooms and the update of exam rooms.
- c. **MWBE** Committee: Reverend Mark Blue reported on the MWBE meeting that was held on February 20th, 2024. ECMC is ranked as one of the top hospitals in the area for MWBE vendors and continues to excel at finding and using minority and women's business groups. ECMC also strives to use local groups for business.
- d. **Quality Improvement and Patient Safety Committee:** Michael Hoffert updated the group on the February meeting. Presentations were given on the Commission on Cancer, Trauma and Transplants.

All reports except that of the Performance Improvement Committee are received and filed.

VI.

Adjournment
Moved by Reverend Kinzer Pointer to adjourn the Board of Directors meeting at 5:12

Corporation Secretary

Resolution Appointing Officers of the Corporation

Approved February 27, 2024

WHEREAS, the Board of Directors of the Corporation is designated by law as the governing body of the Corporation and has the authority to appoint officers of the Corporation as it deems necessary in order to fulfill its purposes; and

WHEREAS, the Corporation annually appoints or re-appoints certain officers of the Corporation's governing body in accordance with its by-laws and practices;

Now, THEREFORE, the Corporation resolves as follows:

1. The Corporation's officers shall be:

| Officer Position | <u>Appointment</u> |
|---------------------------|--------------------|
| Chair, Board of Directors | Eugenio Russi |
| Immediate Past Chair | Jonathan Dandes |
| Secretary | Sharon Hanson |
| Treasurer | Darby Fishkin |

2. This resolution shall take effect immediately.

Sharon L. Hanson Corporation Secretary

MINUTES

Credentials Committee Meeting February 1, 2024

Executive Conference Room/Teams Meeting

Present: Dr. Yogesh Bakhai, Dr. Victor Vacanti, Dr. Mandip Panesar, and Dr. Richard Hall, Dr. Samuel Cloud, Dr. Thamer Qaqish and

Christopher Resetartis, CRNA

Excused: Dr. Ashvin Tadakamalla

| Agenda Item | Discussion/Recommendation | Action | Follow-up |
|--|---|---|---|
| I. CALL TO ORDER | Dr. Bakhai called the meeting to order at 3:02pm | | |
| II. ADMINISTRATIVE | | | |
| A. Minutes | Minutes from the January 4 th meeting were reviewed and approved | Motion made, all in favor, to approve as written. | Via these minutes, the actions of the Credentials Committee are submitted to the Medical Executive Committee for review and action. |
| B. Deceased | None | None | None |
| C. Applications Withdrawn/Processing Cessation | None | None | None |
| D. Automatic Conclusion (Initial Appointment) | None | None | None |
| E. Name Changes (1) | Neurosurgery ■ Marisa Phillips, PA-C changed name to Marisa Lisinski, PA-C | None | Informational purposes only |
| F. Leave of Absence (6) | Anesthesiology Nicole Bonito, CRNA- maternity; RTW 06/29/24 Emergency Medicine Jennifer McCaul, PA-C- maternity; RTW 05/01/24 Family Medicine Jamie Interlichia, PA-C- maternity; RTW 05/03/24 Robert Reed, MD- military; RTW 07/12/24 Neurology | None | Informational purposes only |

| G. Resignations (2 | 2) | Pooja Sofat, MD- maternity; RTW 05/01/24 Psychiatry Abigail Green, MD- maternity; RTW 02/16/24 Files are updated and resignation protocol followed. The Committee discussed retention rates and Wellness Committee initiatives to investigate and manage. | | | Directors, Ro Managemer Support | MEC, Board of evenue ot, Decision |
|--|--------------|---|--|--|---------------------------------------|---|
| NAME | DEPART | MFNT | PRACTICE PLAN/REASON | COVERING/COLLABORATING/ SUPERVISING | RESIGN DATE | INITIAL DATE |
| Darren Alicandri, MD | Family Medic | | UBMD Leaving practice plan and ECMC Confirmed in email | N/A | 02/06/24 | 06/27/17 |
| Richard Cheney, MD | Pathology | | UBMDRetiredConfirmed in email | N/A | 01/03/24 | 09/26/17 |
| III. CHANGE IN ST. CATEGORY | AFF | | | | | |
| | | None | | | | |
| IV. CHANGE/ADD DEPA | RTMENT | | | | | |
| | | None | | | | |
| V. CHANGE/ADDITION Collaborating/Supervising | | | | | | |
| | | None | | | | |
| VI. PRIVILEGE ADDITION (2) | N/ REVISION | | | | | |
| A. Meghan Rochester | , MD | Internal Medicine Adding Joint Injections Case logs were submitted and reviewed | | The Committee voted, all in favor, to approve the privilege addition as requested. | Medical Exe | for approval. via these Revenue nt and |

| VII. | PRIVILEGE WITHDRAWAL | Adding TORS- Robotic All criteria has been submitted and reviewed | The Committee voted, all in favor, to approve the privilege addition as requested. | Recommendation to the Medical Executive Committee for approval. Notification via these minutes to Revenue Management and Decision Support. |
|--------------|-------------------------------|---|---|--|
| | | None | | |
| VIII. (1) | UNACCREDITED FELLOWSHIPS | | | |
| | | Surgery-Bariatric ■ Dr. Schiavone's start date has changed to 02/05/2024 | None | Informational purposes only |
| IX. | INITIAL APPOINTMENTS (10) | | | |
| | n Tytka, PA-C nal Medicine | Daemen College Master of Science Physician Assistant Studies May 2020 Time gap – May 2020 to October 2020 pending license and credentialing at the start of the COVID pandemic, job search Physician Assistant – Orthopaedic Surgery, Finger Lakes Bone and Joint Center October 2020 to August 2021 Physician Assistant – Medical Oncology, General Physician, PC September 2021 to present Supervising Physician – Dr. Naheed Alam (5) Temporary privileges granted January 16, 2024 for immediate patient need NCCPA certified | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Recommendation, via these minutes, to the Medical Executive Committee for approval. |

| Cristina Varallo-Rodriguez, MD | Universidad Autonoma De | The Committee voted, all in | Recommendation, via |
|--------------------------------|---|-----------------------------|-------------------------|
| Internal Medicine | Guadalajara Facultad De Medicina | favor, to approve the | these minutes, to the |
| | MD June 2012 | appointment with privileges | Medical Executive |
| | • Time gap – July 2012 to June 2016 | granted as requested. | Committee for approval. |
| | raising family | | |
| | St. John's Riverside Hospital | | |
| | Internal Medicine Residency July | | |
| | 2016 to July 2019 | | |
| | Internal Medicine Physician – | | |
| | Mount St. Mary's Hospital | | |
| | November 2019 to October 2020 | | |
| | and Roswell Park Comprehensive | | |
| | Care Center November 2020 to | | |
| | present | | |
| | Joining Apogee Physicians March | | |
| | 2024 | | |
| | American Board of Internal | | |
| | Medicine eligible, sitting August 2024 | | |
| Jamie Schaefer, MD | | The Committee voted, all in | Recommendation, via |
| Ophthalmology | St. George's University MD April 2012 | favor, to approve the | these minutes, to the |
| Ophthamiology | ECFMG issued May 2012 | appointment with privileges | Medical Executive |
| | Glaucoma Center for Vision | granted as requested. | Committee for approval. |
| | Research, University of Florida, | granted as requested. | deminietee for approvan |
| | paid Research Fellowship May | | |
| | 2012 to June 2013 | | |
| | Nassau University Health Center | | |
| | Internal Medicine Internship July | | |
| | 2013 to June 2014 | | |
| | Jacobs School of Medicine | | |
| | Ophthalmology Residency July | | |
| | 2014 to June 2017 | | |
| | West Virginia University | | |
| | Ophthalmic Plastic and | | |
| | Reconstructive Surgery Fellowship | | |
| | July 2017 to June 2019 | | |

| Jascha Teibel, DPM Orthopaedic Surgery | Time gap – June 2019 to August 2019 relocation after Fellowship, vacation, and credentialing at new hospital Oculofacial Plastic Surgeon – Lifespan Physician Group Ophthalmology, Rhode Island, August 2019 to August 2023 Time gap – August 2023 to December 2023 relocation to New York, maternity leave, and establishing private practice Oculofacial Plastic Surgeon – Schaefer Oculofacial Plastic Surgery December 2023 to present, Buffalo VA Medical Center January 2024 to present and Ross Eye Institute January 2024 to present American Board of Ophthalmology certified Rosalind Franklin University of Medicine DPM May 2020 | The Committee voted, all in favor, to approve the | Recommendation, via these minutes, to the |
|---|---|---|--|
| | Advocate Illinois Masonic Medical Center Podiatric Surgery Residency July 2020 to June 2023 Podiatrist – The Foot Doctor July 2023 to present Contracted with TerraceView for podiatric services American Board of Foot and Ankle Surgery eligible | appointment with privileges granted as requested. | Medical Executive Committee for approval. |
| Joseph Yeo, DPM Orthopaedic Surgery | Rosalind Franklin University of Medicine DPM May 2020 Swedish Hospital Northshore University Health System Podiatric | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Recommendation, via these minutes, to the Medical Executive Committee for approval. |

| | Surgery Residency July 2020 to June 2023 Time gap — May 2020 to June 2020 graduated Podiatry then started residency and July 2023 to August 2023 graduated Residency, moved from Chicago, IL to Rochester, NY for work Podiatrist — The Foot Doctor August 2023 to present Contracted with TerraceView for podiatric services Temporary privileges granted January 10, 2024 for immediate patient need American Board of Foot and Ankle Surgery eligible — sat 10/2023 pending results | | |
|---------------------------|--|---|---|
| Brenna Fox, NP Psychiatry | D'Youville College Master of Science Mental Health NP December 2018 Registered Nurse Psychiatry – Erie County Medical Center May 2015 to March 2019, Jamestown Psychiatric March 2019 to August 2019, and Horizon Health Services November 2017 to March 2019 Inpatient Psychiatry Clinical Instructor – D'Youville December 2017 to December 2018 Psychiatric Mental Health Nurse Practitoner – Evergreen Health Services August 2019 to May 2020 and Horizon Health Services May 2020 to present Joining UPP for CPEP moonlighting ANCC certified | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Recommendation, via these minutes, to the Medical Executive Committee for approval. |

| | Collaborating Physician – Dr. John Improta (1) | | |
|--|---|---|---|
| Sara Lowmaster, PhD Psychiatry | Texas A&M University Doctor of Philosophy August 2013 Boston University School of Medicine/VA Boston Healthcare System Postdoctoral Fellow and Research Psychologist July 2013 to July 2014 University of South Dakota, Department of Psychology, Assistant Professor August 2014 to August 2020 and Associate Professor August 2020 to August 2022 University at Buffalo, Jacobs School of Medicine, Department of Psychiatry, Assistant Professor July 2022 to present Joining UPP as Psychologist March 2024 | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Recommendation, via these minutes, to the Medical Executive Committee for approval. |
| Harry Brown, MD Radiology – Teleradiology | University of Illinois College of Medicine MD May 2002 Resurrection Medical Center Transitional Year June 2002 to June 2003 John H. Stroger Jr., Cook County Hospital Radiology Residency July 2003 to June 2007 Indiana University Neuroradiology & Cardiac Imaging Mini Fellowship July 2007 to September 2008 Radiologist – Midwest Imaging Professionals/Radiology Partners September 2008 to July 2022 | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Recommendation, via these minutes, to the Medical Executive Committee for approval. |

| | Teleradiologist – Added Value Radiology, President and Owner, July 2022 to present Joining GLMI to assist with day reads American Board of Diagnostic Radiology certified | | |
|--|--|--|---|
| Lee-Ming Liou, MD Radiology – Teleradiology | University of Illinois College of Medicine Rockford MD May 2003 University of Illinois College of Medicine at Peoria Internal Medicine Preliminary July 2003 to June 2004 and Diagnostic Radiology Residency July 2004 to June 2008 The Ohio State University Musculoskeletal Radiology Fellowship July 2008 to June 2009 Time gaps – May 2003 to July 2003 break between medical school and start of internship and June 2009 to October 2009 completed Fellowship, moved to Chicago and applied for jobs Radiologist – Midwest Imaging Professionals/Radiology Partners October 2009 to September 2022 Teleradiologist – Added Value Radiology September 2022 to present Joining GLMI to assist with day reads American Board of Diagnostic Radiology certified | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. Flags were reviewed and application was endorsed by the Chief of Service. | Recommendation, via these minutes, to the Medical Executive Committee for approval. |
| George Radich, MD Radiology – Teleradiology | Loyola University Stritch School of Medicine MD June 2000 | The Committee voted, all in favor, to approve the | Recommendation, via these minutes, to the |

| X. TEMPORARY PRIVILEGES | to June 2001 Wayne State University Medical Center Radio Residency July 2001 of Rush University Med MRI/Ultrasonograph July 2005 to June 2000 Radiologist — Midwest Professionals/Radiologist — Add Radiology July 2022 to Joining GLMI to assist reads American Board of D Radiology certified Mark Burke, MD Plast Reconstructive Surger — Priv addition | Wayne State University Detroit Medical Center Radiology Residency July 2001 to June 2005 Rush University Medical Center MRI/Ultrasonography Fellowship July 2005 to June 2006 Radiologist – Midwest Imaging Professionals/Radiology Partners September 2006 to July 2022 Teleradiologist – Added Value Radiology July 2022 to present Joining GLMI to assist with day reads American Board of Diagnostic Radiology certified Mark Burke, MD Plastic & Reconstructive Surgery 1/8/2024 – Priv addition Joseph Yeo, DPM Orthopaedic | | Medical Executive Committee for approval. None |
|-------------------------|--|--|---------|---|
| XI. REAPPOINTMENTS (28) | Sarah Thompson, PA Medicine 1/15/2024 Kaitlyn Tytka, PA-C Ir Medicine 1/16/2024 Monica VanSteenbur 1/22/2024 See reappointment summary | Sarah Thompson, PA-C Emergency Medicine 1/15/2024 Kaitlyn Tytka, PA-C Internal Medicine 1/16/2024 Monica VanSteenburg, CRNA 1/22/2024 See reappointment summary (Attachment | | Via these minutes, |
| | B) | В) | | recommendation to Medical Executive Committee for approval. |
| NAME | DEPARTMENT | CATEGORY | PRIVILE | CCEC |
| | | CATEGORY | PKIVILE | :UES |
| Hartman, Erica DDS | Dentistry | Active | | |

| Kapral, Elizabeth DDS | Dentistry | Active | |
|--------------------------------|------------------------------|--------|--------------------------------------|
| Busse, Donald PA-C | Emergency Medicine | AHP | |
| Collaborating MD: J. Bart | | | |
| Holmes, David MD | Family Medicine | Active | |
| Singh, Ranjit MD | Family Medicine | Active | |
| Weissman, Arthur MD | Family Medicine | Active | |
| Calandra, Salvatore MD | Internal Medicine | Active | |
| Farry, James MD | Internal Medicine | Active | |
| Maloney, Michael PA-C | Internal Medicine | AHP | |
| Collaborating MD: S. Yedlapati | | | |
| Orlick, Arthur MD | Internal Medicine | Active | |
| Shehata, MarMD | Internal Medicine | Active | |
| Lin, Diana DMD | Oral & Maxillofacial Surgery | Active | |
| Binkley, Matthew MD | Orthopedic Surgery | Active | |
| Callahan, John MD | Orthopedic Surgery | Active | |
| Gill, Elise PA-C | Orthopedic Surgery | AHP | |
| Collaborating MD: M. Anders | | | |
| Rohrbacher, Bernhard MD | Orthopedic Surgery | Active | |
| Nakhla, Hassan MD | Pathology | Active | |
| Xu, Minlin MD | Pathology | Active | |
| Frank, Tawni MD | Psy & Behavioral Med | Active | |
| Lucaj, Elizabeth MD | Psy & Behavioral Med | Active | |
| Raby, Tatyana PhD | Psy & Behavioral Med | AHP | |
| Engbretson, Jon MD | Radiology | Active | Withdrawing 2 privileges: |
| | | | - In vivo diagnostic interpretation |
| | | | - In vitro diagnostic interpretation |
| | | | Adding 1 Privilege: |
| | | | Neuroradiology |
| Nutty, Christopher FNP | Radiology | AHP | |
| Collaborating MD: J. McGrath | | | |
| Williams, Joseph MD | Radiology | Active | Withdrawing 1 Privilege: |
| | | | - Magnetic Resonance |
| | | | Adding 1 Privilege: |
| | | | Neuroradiology |
| Chopko, Michael MD | Surgery | Active | |
| Kordasiewicz, Lynn ANP | Surgery | AHP | |
| Collaborating MD: W.Flynn | | | |

| Greco, Joseph MD | Urology | Active | |
|----------------------|---------|--------|--|
| Trippy, Shania PA-C | Urology | AHP | |
| Collaborating MD: J. | | | |
| Rutkowski | | | |

| XII. AUTOMATIC CONCLUSION | Reappointment Expiration | | |
|---|---|---|----------------------|
| 1 st Notice | None | For informational purposes. | None necessary. |
| 2 nd Notice | Kristina Christopher, FNP Per Apogee not seeking reappt. Priv. conclude 4-30-2024 Melissa Robb, FNP Per Apogee not seeking reappt. Priv. conclude 4-30-2024 Orthopaedic Surgery Elizabeth Hanretty, PA-C confirmed she wishes to let her privileges conclude 3/31/24 | For informational purposes. | None necessary. |
| 3 rd Notice | Neurosurgery Guterman, Lee MD - Active Did not return his reappointment due 2-29-2024. Certified letter sent and returned with signature. Psychiatry & Behavioral Medicine Cowan, Richard MD Courtesy, Refer & Follow – stated he will not be renewing his privileges and is letting them expire at his reappointment date of Feb. 29, 2024. | For informational purposes. | None necessary. |
| XIII. PROFESSIONAL PRACTICE EVALUATIONS | With the start of Bolaji Anjorin, FPPE and OPPE will be back on track. The | Updates will be given at the February Credentials Meeting | Continue to monitor. |
| XIV. OLD BUSINESS | | | |
| A. Expirables | Expirables will be reviewed and discussed with the Credentials Committee. | For informational purposes. Practice Plans and Chiefs of Service have | None necessary. |

| | | all been notified multiple times. | |
|--|---|--|-----------------|
| B. DEA, License, Boards | January Up to date February DEA- 17 License- 23 Boards- 1 | For informational purposes. | None necessary. |
| C. Follow up on recruitment for Credentials Committee | Dr. Chauhan was invited to observe the Credentials Committee in anticipation of appointment in January 2025. Dr. Panesar will follow up with Dr. Chauhan | For informational purposes. | None necessary. |
| D. Annual Dues | Annual dues were sent out with a due date of April 26, 2024. The MDSO will keep the Committee updated to the progress of payment | For informational purposes. | None necessary. |
| E. Board exception F. Updates on new software- | Dr. Stegemann presented a request for exception from the Board certification requirement for a Podiatrist. The Medical Executive Committee voted to grant the Board exception, based on the medical necessity of the patient population in long term care. The provider is approved to work in the ambulatory capacity at Terrace View only. Awaiting final contract. Initiating internal meetings in preparation for the | For informational purposes. For informational | None necessary. |
| MD Staff | build. | purposes. | None necessary. |
| XIIV. NEW BUSINESS | | | |
| A. Privileging Criteria | For review: Otolaryngology Robotic Privileges. The Credentials Committee had several questions regarding the criteria and what procedures TORS encompasses. Prior to approving the presented criteria, Dr. Michael Nagai has been invited to the February Meeting to discuss further details. In addition, a preceptor/proctoring form will be developed. This is intended to detail the Physicians abilities and allow for any suggestions or concerns to be addressed before the Physician is granted independent privileges. | Dr. Nagai will speak to the Credentials Committee. The form will be presented for approval. | None necessary. |
| XIIIV. ADJOURNMENT | The meeting was adjourned at 3:56pm | | |

Respectfully submitted,

grásakha

Yogesh Bakhai, MD Chair, Credentials Committee

ERIE COUNTY MEDICAL CENTER CORPORATION FEBRUARY 20, 2024 MEETING MINUTES EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS VIRTUAL MEETING

PRESENT: JONATHAN DANDES, SHARON HANSON, THOMAS QUATROCHE, EUGENIO RUSSI

Also

PRESENT: ANDREW DAVIS, JONATHAN SWIATKOWSKI

ABSENT: JENNIFER PERSICO

I. Call to Order

The meeting was called to order at 4:00 p.m. by Committee Vice Chair Eugenio Russi.

II. Minutes

Motion was made by Sharon Hanson, seconded by Jonathan Dandes and unanimously passed to approve the minutes of the Executive Committee meeting of January 16, 2024.

III. <u>Hospital Update</u>

General Overview

Dr. Thomas Quatroche reported that the Foundation hosted the annual gift gathering luncheon with a record-breaking number in attendance. Over 4000 flowers were distributed by the Executive Leadership to patients and nurses on Valentines Day. Operationally, the hospital is beginning to improve though finances continue to be a challenge. Regular discussions with the State Legislature regarding financial assistance remain in place. Dr. Quatroche announced the engagement of consultant Jason Jankowiak to assist with the Strategic Planning for the hospital.

Finances

Jonathan Swiatkowski reported positive results for January. Inpatient volume was up along with outpatient surgeries and the case mix index. Total outpatient visits and total Emergency Room visits were down due to the inclement weather. The average length of stay improved for the month and the prior year. Mr. Swiatkowski stated that Terrace View had its highest census since July 2021. Discussion followed regarding the number of staff at Terrace View, the use of Telemedicine, the impact of the winter storm on the overall numbers for the month and the upcoming Audit.

IV. State Advocacy and Grants

Dr. Quatroche reported on the ongoing efforts to gain state/federal financial assistance. ECMC is working with UB and Kaleida to request a EMR Grant for a system wide upgrade.

V. Strategic Planning

Dr. Quatroche reported that the Executive Team will be having a Strategic Retreat in March.

VI. Governance

Committee members discussed governance.

VII.

Adjourn
There being no other business, the meeting was adjourned at 4:45 p.m.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE FINANCE COMMITTEE MEETING

TUESDAY, JANUARY 16, 2024 – 8:30 AM

BOARD MEMBERS PRESENT OR ATTENDING BY VIDEO

CONFERENCE OR TELEPHONE:

MICHAEL SEAMAN *
RONALD CHAPIN *

DARBY FISHKIN *

BENJAMIN SWANEKAMP *

* ATTENDING BY VIDEO CONFERENCE OR PHONE

BOARD MEMBERS EXCUSED:

ALSO PRESENT:

THOMAS QUATROCHE JONATHAN SWIATKOWSKI ANDREW DAVIS

VANESSA HINDERLITER

I. CALL TO ORDER

The meeting was called to order at 8:31 AM by Chair Michael Seaman.

II. REVIEW AND APPROVAL OF MINUTES

Motion was made by Benjamin Swanekamp, seconded by Darby Fishkin and unanimously passed to approve the minutes of the Finance Committee meeting of December 19, 2023.

III. DECEMBER 2023 OPERATING PERFORMANCE

Mr. Swiatkowski reported that materials sent to Committee members in advance of today's meeting include financial statements for December operations and preliminary financial reports for calendar year 2023.

Mr. Swiatkowski reported that positive trends again continued during the month of December. Inpatient discharges were 5.3% greater than budgeted in the operating plan. Total visits and outpatient surgeries were also greater than the operating plan. Total inpatient surgeries have trended lower than the operating plan for the months of November and December which is typical for the organization during the holiday months.

Acute average length of stay improved to 7.9 days for the month of December, a drop from 8.3 days during the prior month. Acute case mix index was slightly lower than prior month at 1.93 but continues to trend significantly higher than earlier in the year.

Mr. Swiatkowski presented the finance dashboard, reviewing the grant revenues impact on net income, FTE's, and cash flow. Mr. Swiatkowski noted that cash flow was consistent with prior month due to additional cash receipts and other cash management efforts.

Mr. Swiatkowski reviewed December financial performance and advised the Committee that reporting for only the month of December as reported is draft and does not include year-end adjustments for actuarial and other reserve estimates. The year-end adjustments will be included in the year-to-date statements and the 2023 annual financial reports. December operating revenue was greater than budget due to increased volume and rate improvements previously discussed, however operating expenses continued to exceed the operating plan. Other revenue was also greater than the operating plan due to significant growth in ECMCC's specialty pharmacy department.

Mr. Swiatkowski reviewed operating expenses for the month of December and discussed salary and supply expense. Supply expense includes pharmaceutical supply costs related to growth in ECMCC's specialty pharmacy and oncology infusion service. Mr. Swiatkowski also reviewed temporary agency costs for the month of December, noting that agency costs related to temporary coding staff being utilized for a coding project were invoiced in December. Mr. Swiatkowski also discussed the cash receipts assessment payable to New York State.

Mr. Seaman offered comments regarding the operational improvements implemented by the organization during the calendar year. In response to a question from Mr. Seaman, Mr. Swiatkowski presented additional information regarding the coding and billing project which began in September 2023 and discussed results achieved through this initiative.

IV. PRELIMINARY DRAFT 2023 OPERATING PERFORMANCE

Mr. Swiatkowski led a detailed review of preliminary operating results for the calendar year ended December 31, 2023. Mr. Swiatkowski noted that the information presented is unaudited, includes estimates for year-end adjustments and is subject to change.

Mr. Swiatkowski discussed several significant adjustments recorded at year end related to additional reserves for potential DSH reimbursement changes and the impairment of a certain project which are included in the preliminary operating results. Mr. Swiatkowski also reviewed estimated year-end adjustments for actuarially determined liabilities relating to employee pension and other post-employment retiree health benefit expense. Mr. Swiatkowski also reviewed the impact of grant revenue received had on the overall results for the calendar year.

Mr. Swiatkowski discussed operating margin trends for calendar years 2018 through 2023 noting continued improvements year over year and advised that the information presented for 2020 through 2023 includes funding received from the CARES Act, PPP, FEMA and the NYS VAPAP program.

Mr. Swiatkowski reviewed preliminary 2023 year-to-date variances including net patient service revenue, volume, case mix index and DSH/IGT revenue and reserves.

Mr. Swiatkowski reviewed preliminary year-to-date operating expenses noting that the variance in salary expense was the most significant driver. The Corporation incurred additional expenses which exceeded the operating plan in the areas of supplies and other expenses attributed to pharmaceutical supply costs, temporary agency staffing costs, other purchased services and costs related to the EHR project.

Year-to-date trends in FTE's and acute average length of stay were reviewed and discussed with the Committee.

Mr. Swiatkowski led a detailed discussion regarding operational budget variances for ECMCC and Terrace View for calendar year 2023 and provided a high-level summary of the expenses incurred within each category.

V. OTHER UPDATES

Mr. Swiatkowski further discussed cash flow and advised the Committee that in the past three months, focused efforts by Management resulted in a reduction in the number of days in accounts receivable by 10.4 days.

Mr. Swiatkowski reported that the corporation anticipates receiving the 340B settlement by early February. Several updates relating to the pending DSH and IGT payments and the NYS VAPAP program were also presented to the Committee. Mr. Swiatkowski also reported that two payer contracts remain in the negotiation stage and will be finalized in February.

Mr. Swiatkowski and Dr. Quatroche discussed several additional items, including the Medicaid Section 1115 Waiver, upcoming grant opportunities, proposed DSH cuts and a GASB accounting pronouncement related to IT Subscription agreements that was required to be implemented in 2023, which will require reclassification adjustments within the audited financial statements.

Mr. Swiatkowski extended his sincere thanks to Vanessa Hinderliter, Eric Reeners and the accounting team for their efforts this year in finalizing preliminary year-end information for today's meeting considering their significant ongoing involvement with NYS and the VAPAP Program.

VI. ADJOURNMENT

There being no further business, the meeting was adjourned at 9:24 AM by Chair Michael Seaman.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE AUDIT COMMITTEE MEETING

WEDNESDAY, DECEMBER 12, 2023 – 2:00 PM

* ATTENDING VIA VIDEO

CONFERENCE OR PHONE

BOARD MEMBERS PRESENT OR

ATTENDING BY VIDEO

CONFERENCE OR TELEPHONE:

DARBY FISHKIN *
JAMES LAWICKI *

CHRISTOPHER O'BRIEN *

REV. KINZER POINTER *

BOARD MEMBERS EXCUSED:

ALSO PRESENT:

THOMAS J. QUATROCHE

JOSEPH GIGLIA ANDREW DAVIS

JONATHAN SWIATKOWSKI

GUESTS

MATTHEW GARVEY, CPA *

- RSM US, LLP

DAVID L. NESBITT NADINE MUND PATRICK ORLOFF

I. CALL TO ORDER

Chair Darby Fishkin called the Audit Committee meeting to order at 2:00 PM.

II. REVIEW AND APPROVAL OF MINUTES

Motion was made by Rev. Kinzer Pointer, seconded by Christopher O'Brien and unanimously passed to approve the minutes of the Audit Committee meeting of October 11, 2023.

III. INDEPENDENT AUDITOR REPORT OF RSM, LLP (2023 AUDIT PLAN)

Mr. Matthew Garvey, CPA, Audit Partner of RSM, US, LLP presented required pre-audit communications and reviewed RSM's scope of services and auditor responsibilities, noting that the audit will be conducted in accordance with government auditing standards and Uniform Guidance.

Mr. Garvey advised that RSM is required to perform a single audit of Federal program awards and expenditures, pursuant to Uniform Guidance audit requirements. As part of the annual audit, RSM will also issue an investment report as required by New York State Public Authorities Law.

Mr. Garvey led a detailed discussion, reviewing the 2023 audit plan and audit timeline, key areas of focus, the scope of the audit and the risk assessment process. Mr. Garvey reviewed RSM's engagement team and advised the Committee that Mr. Steve McClelland has assumed the secondary partner role due to audit firm rotation requirements. Consistent with prior years, RSM has engaged subject area specialists to assist with specific areas of the independent audit.

Mr. Garvey welcomed input from all Committee members should they have areas for consideration during the audit. Mr. Garvey led further discussion regarding several topics, including shared responsibilities for independence, RSM's audit strategy, development of the audit plan and performance of risk assessment procedures.

Mr. Garvey provided information to the Committee regarding GASB Statement No. 96 (Subscription-Based Information Technology Agreements) which is required to be implemented by the Corporation in 2023.

Mr. Garvey advised the Committee that RSM does not rely upon the work of the internal audit function but holds discussions with Mr. Patrick Orloff, ECMCC's Director of Internal Audit, throughout the course of the year and during the annual audit.

A brief overview of upcoming accounting pronouncements was also presented by Mr. Garvey. Mr. Swiatkowski and Mr. Garvey confirmed that RSM will conduct the annual audit in part on-site and in part virtually. A brief discussion regarding scheduling for the March 2024 Audit Committee meeting was held.

With no further questions from Committee members, Mr. Garvey of RSM was excused at 2:21 PM.

IV. REVIEW & APPROVAL OF 2024 COMPLIANCE PROGRAM WORK PLAN

Mr. David L. Nesbitt, Esq., ECMCC's Chief Compliance Officer and Ms. Nadine Mund, ECMCC's Director of Compliance presented the draft Compliance Program work plan for calendar year 2024.

Ms. Mund reviewed updated compliance plan requirements based on guidance issued by OMIG and OIG. Ms. Mund advised the Committee of updates to the Corporation's Compliance program, including compliance policies and education requirements for employees, medical staff and vendors. The Compliance department is working closely with medical staff and the Revenue Cycle and Purchasing departments to comply with new patient billing reporting requirements. Ms. Mund presented information regarding required disclosure of facility fees that may be charged to patients and internet availability of standard hospital pricing for public awareness.

Several topics were reviewed by Ms. Mund relating to inpatient coding and billing and ongoing compliance monitoring.

Mr. Nesbitt presented information regarding several new regulatory items that are included in the draft 2024 Compliance Program work plan being presented today for the

Committee's review and approval. The new regulatory items were reviewed and discussed amongst the Committee.

In response to a question raised by Ms. Fishkin, Mr. Nesbitt reviewed ongoing compliance education with ECMCC departments and staff.

V. ACTION ITEMS

After review and discussion, Chair Darby Fishkin called for a motion to approve the draft Compliance Program work plan for 2024. Upon motion by Reverend Pointer and seconded by Mr. O'Brien, the Committee voted unanimously to approve the ECMCC Compliance Program work plan as presented.

VI. DRAFT INTERNAL AUDIT PLAN

Mr. Patrick Orloff, CPA, ECMCC's Director of Internal Audit briefly reviewed 2023 internal audit work and presented updates regarding the status of each related project.

Mr. Orloff presented a detailed review of the 2024 draft internal audit plan and discussed the scope of work for each project. Mr. Orloff noted that an initial draft of the internal audit Charter will be presented to management for review and comment before being presented to the Committee for consideration at an upcoming meeting.

Chair Darby Fishkin offered comments regarding the proposed internal audit plan and ongoing internal audit work.

VII. DRAFT LITIGATION REPORT

Mr. Joseph Giglia, Esq., ECMCC's General Counsel presented the Office of General Counsel (OGC) annual report for 2023. Mr. Giglia reminded the Committee that the OGC manages and supervises all litigation for the organization and noted that outside counsel are retained by the Corporation to assist with all matters in litigation.

Mr. Giglia discussed lawsuit and claim activity in the areas of hospital professional liability and general liability for 2023 through the present date. Lawsuit and claim trends for 2023 were reviewed and compared to case activity for several prior years. Mr. Giglia reviewed general information relating to open matters and case resolutions to date.

Mr. Giglia discussed management of case reserves and reported that measurable results were achieved in 2023 allowing the Corporation to achieve a net savings in reserves.

In response to a question from Chair Fishkin, Mr. Giglia and Mr. Nesbitt provided information regarding outside counsel, noting that the Corporation issues RFP's for outside legal services every five years.

VIII. DRAFT RISK MANAGEMENT AND CORPORATE INSURANCE REPORT

Mr. Giglia presented the corporate insurance report and noted that Lawley Insurance has been a valuable partner to the Corporation. Mr. Giglia discussed the current insurance brokerage agreement with Lawley Insurance and advised the Committee that a two-year contract extension is in place. The Corporation completed the annual insurance review process and all insurance policies were recently bound.

Mr. Giglia presented information to the Committee regarding current insurance related matters.

IX. ADJOURN

There being no further business, the meeting was adjourned at 3:05 PM by Chair Darby Fishkin.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE BUILDINGS & GROUNDS COMMITTEE MEETING

JANUARY 23, 2024 – 3:00PM VIA MICROSOFT TEAMS

BOARD MEMBERS PRESENT: RONALD BENNETT DEVI

MICHAEL HOFFERT REVEREND MARK BLUE

EXCUSED: JAMES LAWICKI

ALSO PRESENT:

KEITH AMBROSE ANDREW DAVIS

I. CALL TO ORDER

Chair, Ronald Bennett called the meeting to order at 3:01 p.m.

II. APPROVAL OF BUILDINGS AND GROUNDS MEETING MINUTES

Moved by Michael Hoffert and seconded by Reverend Mark Blue to approve and file the minutes of the Buildings and Grounds Committee of October 24, 2023 as presented.

III. UPDATE - IN PROGRESS INITIATIVES/PROJECTS

Pam Lee provided an overview of the current projects which included the following: Bariatric office expansion at 30 North Union Rd., Main Hospital operating suite surgical light and equipment replacements, and Data Center electrical project. The in-house crew projects included: operating suite and corridor improvements, and hot water recirculation line replacements throughout the Main Hospital. Ms. Lee also applauded the grounds crew for their exceptional snow removal/de-icing efforts during the snowstorm to maintain a safe environment.

IV. UPDATE - PENDING INITIATIVES/PROJECTS

Pam Lee provided an overview of the pending projects which included the following: fire damper redesign, service elevator upgrade, 1st floor Dental Clinic upgrades, MEP (Mechanical, Electrical and Plumbing), and removal of inground fuel oil tanks.

V. OTHER

Ronald Bennett, Michael Hoffert and Reverend Mark Blue welcomed Pam Lee to the Committee and commended her on an excellent Buildings and Grounds presentation.

VI. ADJOURNMENT

Moved by Michael Hoffert and seconded by Reverend Mark Blue to adjourn the Buildings and Grounds Committee meeting at 3:21 p.m.

BOARD OF DIRECTORS MINUTES OF THE HUMAN RESOURCES COMMITTEE MEETING TUESDAY, JANUARY 16, 2024 10:00 - 11:00 A.M.

THIS MEETING WAS HELD VIRTUALLY VIA TEAMS

VOTING BOARD
MEMBERS PRESENT:
MICHAEL SEAMAN

EXCUSED: MICHAEL HOFFERT

ALSO CYNTHIA BASS ANDREW DAVIS
SEAN BEITER HEATHER GALLAGHER

PRESENT: ERIN CONLEY LISA HIGHWAY

I. CALL TO ORDER

Chair, Michael Seaman called the meeting to order at 10:02 a.m.

II. RECEIVE & FILE

Michael Seaman announced the absence of a quorum and deferred any items requiring approval to the next scheduled Human Resources Committee meeting.

III. HOSPITAL UPDATE

Andrew Davis, Chief Operating Officer (COO), reported the hospital volume has improved. Advocacy for the facility continues at the state level. Mr. Davis commended the Human Resources team on continued successful recruitment, employee events and celebrations.

Mr. Davis reported the primary focus within the past 72 hours has been navigating the winter storm operations. The Hospital Command Center, executive and departmental leadership have worked diligently to secure staff and supply levels. Several employees stayed overnight to ensure shift coverage.

IV. <u>EMPLOYEE OF THE MONTH – ECMC AND TERRACE VIEW</u> DECEMBER 2023 & JANUARY 2024

Erin Conley, Training Coordinator, presented the following Employee of the Month honorees:

ECMC

- December 2023 Amanda Farrell, RN, Population Health Clinical Data Analyst
- January 2024 Kristin Pequeen, LPN Behavioral Health, 4 South

Terrace View

- December 2023 Breonna Kirkland, Administrative Control Clerk
- January 2024 Antoinette Olson, Certified Nursing Assistant

V. DIVERSITY, EQUITY, AND INCLUSION

Cynthia Bass, Chief Diversity Officer, reported on the key department highlights and initiatives for Q4 2023 and January 2024.

- The Learning and Organizational Development Center, managed by Dr. Kiera Duckworth, had a very successful year. In 2023, over 700 employees attended 95 various training programs which included diversity and soft skills sessions. The Leadership Academy had 52 employees complete the program, a 47% increase from 2022. Dr. Duckworth will start precept training sessions in January 2024.
- The Diversity, Equity, and Inclusion (DEI) office in collaboration with Terrace View leadership have developed a Diversity Committee to address diversity issues. Ms. Bass will provide an update at the next Human Resources Board Committee meeting.
- Interviews for DEI Task Force members are in progress. Several physicians have expressed interest in joining the DEI Task Force.
- Q4 Cultural Awareness events included:
 - o Hispanic Heritage Parade: August 20, 2023
 - o Native American Heritage month: November 2023
 - o Veterans Day Ceremony: November 9, 2023
 - o Transgender Awareness Week: November 13-19, 2023
 - o Holiday Bazaar: December 14, 2023, hosted over 22 small businesses
- Employee Resource Group: In 2023, we had a 30% membership increase from 2022. A luncheon was held on January 17, 2023 to honor the members.
- Healthcare Equality Index recertified as leader status. We are continuing to build staff education, policies, procedures, and community engagement efforts.
- Ms. Bass hosts a Great Lakes Health WUFO radio program partnering with Ms. Mesiah from Kaleida Health. Topics include mental health awareness, infection prevention, domestic violence, diabetes, and career opportunities at ECMC.

VI. RECRUITMENT AND RETENTION

Lisa Highway, Director of Recruitment and Retention, reported recruitment efforts have continued. Two new employees joined the recruitment team. There are currently four recruiters, including one designated nurse recruiter. The recruitment team hired nurse interns for the spring semester and will be working closely with the May graduates as they pass their boards, so they may transition into clinical positions throughout the hospital.

The recruitment team continues to participate in various events around the community to increase interest for potential employees looking for employment opportunities.

Testing and training efforts continue with the new UKG recruitment system.

Working on decreasing agency hires and positions throughout the hospital.

VII. COMPENSATION, BENEFITS, AND HRIS

Heather Gallagher, Sr. Director of Compensation, Benefits, and HRIS, summarized the key highlights and initiatives.

HRIS

• The new HRIS (HR/Payroll) system launch date was moved from January to early March/April.

Timekeeping

 An RFP was issued for a new timekeeping/scheduling system. The responses will be reviewed and evaluated. We are hoping to provide an update at the next meeting.

Compensation

All union increases and increments were processed on January 1, 2024.

Reorientation

• Completion rate was 93.56% at the end of 2023, which is a significant improvement from 86% in 2022.

Statistics

- HR closed the year with a record high headcount of 4,023 employees.
- In 2023, we hired 768 staff members between ECMC and Terrace View (TV).
 - o Of those new hires, we retained 86% of them for ECMC and 79% at TV.
- Our turnover was down 1% in 2023 from 2022 with a turnover rate of 11.9%.

VIII. EMPLOYEE AND LABOR RELATIONS

Sean Beiter, Director of Labor and Employee Relations reported Amy Blaszczak, HR Business Partner, has joined the team. The HR Business Partner responsibilities have been reorganized for improved communication and collaboration with departments regarding disciplinary processes.

The labor team is finalizing the newly negotiated NYSNA contract book for publication.

The labor team continues to hold regular series of meetings with the three bargaining units to improve communication and address concerns.

IX. <u>CLOSING REMARKS</u>

Andrew Davis thanked the HR team leaders for their exceptional work and dedication. Michael Seaman echoed Mr. Davis's remarks and emphasized the Board understands the importance of developing and training our culture, providing a healthy atmosphere, and negotiating contracts in the best interest of the hospital and our employees.

X. <u>ADJOURNMENT</u>

Michael Seaman moved to adjourn the meeting at 10:30 a.m.

BOARD OF DIRECTORS MINUTES OF THE HUMAN RESOURCES COMMITTEE MEETING THURSDAY, AUGUST 10, 2023 9:30-10:30 A.M.

THIS MEETING WAS HELD VIRTUALLY VIA TEAMS

VOTING BOARD MEMBERS PRESENT OR ATTENDING BY CONFERENCE TELEPHONE:

MICHAEL SEAMAN MICHAEL HOFFERT

CYNTHIA BASS

ALSO ANDREW DAVIS

PRESENT: HEATHER GALLAGHER

LISA HIGHWAY

I. CALL TO ORDER

Chair, Michael Seaman called the meeting to order at 10:00 a.m.

II. RECEIVE & FILE

Moved by Michael Hoffert and Michael Seaman to receive and file the minutes from the June 12th, 2023, Human Resources Committee Meeting of the Board of Directors.

III. INTRODUCTION BY ANDREW L. DAVIS, COO

Andrew Davis, Chief Operating Officer (COO), reported the volume around the hospital is doing well. Trauma season has been busy around the hospital. Advocacy for the facility continues at the state level. Budget talks for 2024 have begun.

Working with NYSNA as the new contract is now implemented throughout the departments around the campus.

There has been a small uptick in COVID-19 cases, but the facility will continue to monitor this situation and discussions will be had about the precautions, if any, that will be taken.

Andrew Davis gave The Board an update on how well the Healthcare Explorers program is going; there has been great feedback on it.

IV. DIVERSITY, EQUITY, AND INCLUSION

Cynthia Bass, Chief Diversity Officer reports that Kiera Duckworth, Training Manager, continues training around the campus on topics such as cultural competencies, communication, conflict resolution, various DEI topics, and team building. A new training course "Across Generational"

has been launched by the department and is helping ECMC staff learn how to effectively handle the generational differences between staff.

ECMC's 3rd annual Pride Walk was held on July 25th, 2023- the LGBTQ+ Resource Group partnered with the DEI office to hold this. Also participated in Buffalo's Annual Pride Walk on June 4th, 2023. On June 17th, 2023, Black & African Employee Resource Group participated in Buffalo's Juneteenth Festival. A few departments that participated: SNUG, BRAVE, and Primary Care. Blood pressure readings were also given out to community members at the tent as well.

Upcoming events: Diversity Vendor Networking Fair (Thursday August 24th, 2023 at 9:30 a.m.) which will include guest speakers and over 50 local businesses. ECMC'S Hispanic Employee Resource Network will participate in the Puerto Rican & Hispanic Day Parade on August 19th, 2023 at 12:00 p.m. at Niagara Square.

V. RECRUITMENT AND RETENTION

Lisa Highway, Director of Recruitment and Retention, reports recruitment efforts continue. The recruitment team is working closely with the May graduates as they pass their boards, so they can transition into clinical positions around the hospital.

The recruitment team continues to go to various events around the community to help increase interest potential employees on looking for employment opportunities.

A new community organization (Harvest House) has started to work with the recruitment team on preparing aspiring CNAs to successfully find employment.

Working on decreasing agency hires and positions around the hospital.

VI. COMPENSATION, BENEFITS, AND HRIS

Heather Gallagher, Sr. Director of Compensation, Benefits, and HRIS, reports the new NYSNA agreement has started to be implemented. The new HRIS system has a tentative launch date of January 1st, 2024.

HR employees has stepped up to help be tour guides to students during the Healthcare Explorers.

VII. EMPLOYEE AND LABOR RELATIONS

Sean Beiter, Director of Labor and Employee Relations, reports the NYSNA negotiations have successfully been completed and it was ratified on July 17th, 2023. This contract is now being implemented around the facility. Labor team is working closely with the nursing departments to ensure all aspects of the agreed upon contract is being done successfully.

The labor team is working closely with staff to have discussions before issues turn into grievances.

The hospital continues to have good connections with all three bargaining unions.

VIII. ADJOURNMENT

Michael Hoffert moved to adjourn the meeting at 10:30 a.m.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE QUALITY IMPROVEMENT/ PATIENT SAFETY COMMITTEE MEETING

TUESDAY, FEBRUARY 13, 2024 MICROSOFT TEAMS PLATFORM

BOARD MEMBERS PRESENT: MICHAEL HOFFERT, BENJAMIN SWANEKAMP, REV KINZER POINTER, JOHN O'DONNELL

PRESENTERS: SAURIN POPAT, MD, MBA, FRCSC, FACS, FSSO, LIISE KAYLER, MD, PHYLLIS MURAWSKI, RN, WILLIAM FLYNN, JR., MD, MEGHAN MULLEN, RN, CHARLENE LUDLOW, RN, CIC

ATTENDANCE:

SERGIO ANILLO, MD

WILLIAM BELLES, MD

Donna Brown

CHARLES CAVARETTA

SAM CLOUD, DO

JOHN CUMBO

PETER CUTLER

ANDY DAVIS

CASSIE DAVIS

BECKY DELPRINCE, RN

JUDY DOBSON, NP

WILLIAM FLYNN, MD

KIZZIE HUNLEY, RN

DONNA JONES, RN, FACHE

JUSTINE KAURICH

KEITH KRABILL, MD

MARC LABELLE, RN

CHARLENE LUDLOW, RN, CIC

PHYLLIS MURAWSKI, RN

YARON PERRY, MD

TOM QUATROCHE, CEO

SIVA YEDLAPATI, MD

CALL TO ORDER

Chair Michael Hoffert, called the meeting to order at 8:00 am.

I. MINUTES

The January 9, 2024, meeting minutes were distributed along with the Quality leadership Council meeting minutes from January 18, 2024, for review. A motion was made and seconded to approve both sets of minutes. They will be forwarded to the Board of Directors for filing.

II. SUMMARY REPORT OF THE QUALITY LEADERSHIP COUNCIL

Donna Jones presented on the Quality Leadership Council meeting that was held January 18, 2024.

New business consisted of quality and patient safety department intranet site. There were no annual QIPS (quality improvement & patient safety) report outs assigned. Ms. Jones reviewed standing business which included 2023 and 2024 QIPS plans. Also reviewed - Insurance quality of care concerns, Univera hospital performance incentive program (HPIP), quality priority focus grid and a Q & A session, new to our standing business for our monthly QLC meetings.

III. COMMISSION ON CANCER - SAURIN POPAT, MD, MBA, FRCSC, FACS, FSSO

Dr. Popat reported on the American College of Surgeons Commission on Cancer. His agenda included a department update, volume and outcomes, QAPI projects and a review of department goals.

The department obtained commission on cancer accreditation in November of 2022 which is for a 3-year period. A review of department volumes and previous year goals and accomplishments took place as well.

In April of 2023 they implemented the 131 treatments of thyroid cancer with the objective of treating 2 patients per month with an eventual goal to treat 70-80 per year.

2023 QAPI projects include synoptic format of OR reports by working with IT through Q3 and Q4 of 2022. The department also set up a series of group and individual education sessions in 2022 and 2023.

2024 Quality improvement goals include working to improve chemotherapy wait times (arrival to start of infusion), establish outpatient palliative care services, and to work on a low dose lung cancer screening CT for current/previous smokers.

IV. TRAUMA PROGRAM - WILLIAM FLYNN, JR., MD AND MEGHAN MULLEN, MSN, RN, CCRN

Dr. Flynn and Meghan Mullen presented on the Trauma Program. The Agenda included current process improvement projects, Trauma Center reverification timeline and what the committee on Trauma (COT) will review for 2024-2025.

Process improvement projects included a discussion on chemical VTE prophylaxis and working on standardizing the drug and frequency along with ongoing education on it.

Other process improvements projects include the topics of blunt cerebrovascular injury and a resuscitation project. A timeline of recertifications include ACS reverification (March 2022), NYS Department of Health recertification (June 2022), Data Collection (Jan - Dec 2024), return for reverification (March 2025), and anticipated NYS Department of Health recertification coming in June of 2025.

Dr. Flynn reviewed opportunities from past visits. This included timely case reviews, demonstrate "loop" closures, and OR access for urgent cases. Dr. Flynn also reviewed the rules in new "gray" book which included response times for consult services, geriatric specific trauma care and pediatric readiness.

The department will continue with current process improvement projects, continue preparations for upcoming survey visits, manage identified opportunities, and address new expectations.

V. TRANSPLANT – LIISE KAYLER, MD AND PHYLLIS MURAWSKI, RN

Dr. Kayler and Phyllis Murawski presented on the Renal Transplant department. A review of department volumes took place showing 151 transplants that occurred in 2023. A department update was shared as well. The department had three surveys that took place during 2023 one of which was the 5-year CMS Survey of Kidney/Pancreas and Living Donor Programs with zero citations. Transplant outcomes along with transplant rates compared to similar size programs was discussed.

QIPS for 2024 were reviewed including safety and resiliency along with equity and engagement.

Current year quality improvement goals include increase preemptive referrals to transplant center, increase transplant evaluations, shorten time from evaluation to waitlist placement, increase live kidney donations and improve post-transplant graft survival.

VI. Environment of Care Management Plan- Charlene Ludlow, RN, CIC

Charlene Ludlow presented an update on the Environment of Care Management plans.

2023 goals and performance along with 2024 goals were reviewed. Ms. Ludlow reviewed the EOC safety goals which included NPSG-15 ligature risk, workplace violence prevention and safe patient handling and mobility. A review of the 2024 EOC safety goals were discussed.

Life safety goals from 2023 included label door frames for areas that have regulated pressure differentials, implement accessibility to fire dampers requiring extensive remedial work and implementation of UV light system for the main HVAC air handler. A review of 2024 EOC life safety goals were discussed.

2023 utilities management goals included IT data center electrical improvements, medical gas regulatory corrections, and utility building systems risks assessment and plan for improvement per NFPA 99 and 101 perform annually. A review of 2024 EOC utilities management goals were discussed.

2023 security management goals were to enhance safety with expansion of camera coverage, key consolidation of pull station fire alarms on behavioral health floors, and new security screening systems for the emergency department. Ms. Ludlow also reviewed the 2024 security management goals.

2023 medical equipment goals included identifying end of life stages of medical equipment to be replaced, begin implementation of an alternative equipment management system, and to continue biomedical staff cross training opportunities. Ms. Ludlow also reviewed the 2024 medical equipment goals.

2023 emergency management goals included two drills or live events each year, continuation of response to SARS and NIMS retraining, and complete all requirements for the current HPP grant by June 30, 2024. Ms. Ludlow reviewed the 2024 emergency management goals.

The last EOC management plan item was the hazardous waste goals for 2023. They were to perform ATP testing within EVS patient care areas throughout the facility, provide CDC's project Firstline onsite training and to maintain 100% of soiled holds in accordance with infection control standards. Ms. Ludlow also reviewed the 2024 hazardous waste goals.

VII. REGULATORY REPORT - CHARLENE LUDLOW, RN, CIC

Charlene Ludlow gave her regulatory report. Last month the Department of Health was onsite for a survey, but we have not received the survey results as of yet. It was a good survey. Final reports seem to be taking longer than usual for some reason.

On February 6th, we received the results from a survey that took place in November of 2023. There were some items on the plan of correction which most have been completed already. We will submit our response this survey this coming Friday.

VIII. ADJOURN

There being no further business, the motion was made and seconded to adjourn the meeting. The next meeting will be held on March 12, 2024.

Dear ECMC Board Members,

As we experienced in January, ECMC's overall operations and patient volumes in February continued to improve. Positive operations growth was reflected in Emergency Department visits (7.0% growth in February 2024 versus February 2023) and our general surgeries increased overall by 7.9% in February 2024 versus February 2023, also exceeding budget by 6.2% with Inpatient Surgeries increasing in that timeframe by 14.4% and Outpatient Surgeries by 4.1%.

On February 22nd, U.S. Senate Majority Leader Charles E. Schumer and U.S. Senator Kirsten Gillibrand announced ECMC will receive \$14,624,938 from the U.S. Department of Homeland Security's Federal Emergency Management Agency (FEMA) to cover costs associated with emergency protective measures and increased staffing taken for their COVID responses dating back to the start of the pandemic in Spring 2020. This funding is provided at a 100% federal cost share. As the Board knows well, contract labor costs were very expensive during the COVID-19 pandemic and necessary to ensure we could support our ECMC caregivers as they worked to save the lives of the most vulnerable patients in our community. We are extremely appreciative of Senator Schumer's and Senator Gillibrand's strong support in our effort to gain hospital reimbursement from FEMA.

ECMC also will receive \$13.6M from FEMA to upgrade and modernize our emergency generators. We applied for this grant in June of 2022. Thanks to the support of our Congressional delegation, this grant will enable ECMC to acquire and install six new state-of-the-art emergency generators that will protect ECMC for many years to come. Special thanks to Jon Swiatkowski and the grants writing team who, as the Board knows, have been very successful recently in securing significant FEMA grant funding, as well as grant funding from other federal, state, and local sources.

We recently successfully completed our 12-week OR lighting modernization project, which now provides significantly enhanced and improved lighting for our dedicated surgical teams. And our Rehabilitation Medicine and Acute Care Services recently held its seventh annual Rehab Symposium, titled "A Multidisciplinary Approach to the Acute Care Patient." For this well-attended conference, many of the region's most experienced clinicians were invited to speak on a variety of topics pertaining to rehabilitation on acute and critical care services. Area therapists, rehab professionals, and therapy students from the community were invited to learn about some of the specialty services that are available at ECMC.

As noted last month, with Governor Hochul earlier this year releasing her recommended state budget for 2024-25, we traveled to Albany a few weeks ago to attend the Healthcare Association of New York State meeting where we met directly with members and staff of our WNY State Legislative Delegation to discuss hospital funding for this year's state budget as well as other legislative matters to be addressed throughout the legislative session that will conclude in June. The state budget negotiations between the Governor and the Legislature are now occurring in earnest and we will keep the Board informed of what transpires in that process as the April 1st deadline draws nearer.

Thank you again to the Board for your continuing confidence in Executive Leadership and for your unwavering support of our remarkable caregivers. We are grateful for the guidance and insight you provide, which strengthens our ability to fulfill our commitment to uphold ECMC's mission.

| \mathbf{r} | | |
|--------------|-----|--|
| ப | ant | |
| п | | |
| | | |

Tom

Erie County Medical Center

Board Report Chief Operating Officer March 26, 2024

Submitted by Andrew Davis

OPERATIONS

Ambulatory Medical Practices

- ECMC's Population Health and Ambulatory Care staff partnered with the ECMC Wellness Warriors and ECMC Office of Diversity Equity & Inclusion to provide targeted health education and blood pressure screenings outside of the cafeteria on February 3, 2024 for "Go Red for Women Day" to bring awareness to cardiovascular disease in women and link participants with necessary services (such as primary care).
- Provided education to the nursing staff on Dexcom diabetic sensors, so the nursing staff will have the ability to empower and educate patients.

Biomedical Services

Department Initiatives/Projects/Updates:

• In March, the Biomedical Engineering department will be working with Phillips and ECMC HIS to implement Philips' Focal Point equipment monitoring tool. This is a web-based system to track patient monitoring health and to provide software updates (OS patches) more easily and centrally. This system is an entitlement under our service agreement and does not have an additional cost associated to start up or use.

Center of Cancer Care Research

February 2024

Monthly Oncology Research Report - Dr. Jennifer Frustino

Team Member & Outreach Updates:

- Dr. Frustino presented a poster at the ASTRO Multidisciplinary Head and Neck Cancer Symposium on February 29 in Phoenix, AZ.
- Completed Sub-Investigator training for MeiraGTx gene therapy clinical trial.
- Devin George is attending ECMC's Manager Enhancement Program.
- Gina Perez and Meghan Sheahan attended FDA inspection training.
- WNY HPV Coalition met at ECMC on February 13 to finalize plans for upcoming 2024 cancer screening and prevention events.

Study Participation:

- Two (2) additional participants were enrolled into NIH grant funded study "R21" which looks for biomarkers that will help predict, prevent, and treat HPV infection in people living with HIV.
- Eight (8) additional participants were enrolled into investigator-initiated study "Liquid Biopsy" which investigates blood draw assays to quantitate effects of therapeutic interventions in patients with HPV mediated head and neck cancer.

- The total CoC accrual for 2024 is (8) participants.
- Total study accrual for 2024 is (22).

Sponsor Updates:

- Merck689 site monitoring visit completed February 1.
- Merck Regional Medical Scientific Director visited on February 13 to invite Dr. Frustino to participate in an invitation-only grant application under Merck Investigators Study Program (MISP).
- MuReva site monitoring visit completed February 26-27.

Sponsored Trials:

- MERCK trails B10: (MERCK) B10 Pembro MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/metastatic Head & Neck squamous cell carcinoma (KNB10): STUDT00005605).
- Merck KEYNOTE-689: Adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. STUDY00004782
- **Chemo Mouthpiece Clinical Trial** STUDY00004783
- **MeiraGTx Gene therapy** study. Salivary gland gene therapy for patients with dry mouth 3 years after radiation therapy for head and neck cancer.
- BMS Celgene Phase 3 Relapsed or Refractory Multiple Myeloma trial
- GBT (Global Blood Therapeutics) STUDY00005955: A randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of *Inclacumab* in participants with sickle cell disease experiencing vaso occlusive crises.
- MuREVA Photobiomodulation for Oral Mucositis Study000040140

Investigator Initiated Studies:

- Incidence of Carotid Artery Stenosis study
- NIH funded HIV-HPV study: HPV and HIV Co-Infection: Clinical, Socio-Behavioral, and Microbiome Implications
- Continue to enroll subjects and study is going well. Established a relationship and successful biospecimen transfer with KSL Diagnostics, Inc. who will assist in HPV analysis for research purposes.
- This study will count towards Commission on Cancer metrics for accruals.

Environmental Services

- Several floor care maintenance projects completed throughout the facility. Main projects included:
 - o Dental Clinic
 - o Ground Level CPEP
 - o Ground Level Physical Therapy, both rooms
 - o 1st floor Orthopedic clinic
- Continued training and development for (5) in-house floor team members.
- Implemented new linen ordering process to include daily par numbers and buffer with CleanCare for Terrace View to prevent linen shortages.
- Continue to work with our partners in bed coordination to improve overall throughput. Identifying areas of opportunity and developing strategies to decrease bed turnaround time. Overall discharge time for February was 74 minutes, a 3-minute improvement from prior month.

Food & Nutrition Services

Initiatives & Projects

- Introduction of new initiatives during the daily huddles in February.
 - Encompassing education on supplements and diets
 - o Highlighting the allergen of the week
 - o Discussing the diet of the week
 - o Emphasizing the importance of PPD education
- Implement structures within operations and improve/implement processes to standardize operations.

Retail Café Enhancements

- Mashgin self-check-out system continues to be successful. Average of 40% gross sales run through Mashgin.
- Implement promotions and new menu items to maximize diversity and menu selections. Working with Diversity Equity & Inclusion Council for special entrees to showcase.

Laboratory Services

Equipment Upgrades/Replacements/Contracts:

- Vendor discussion for replacement of Chemistry front-end automation, chemistry platform upgrade, and long-term consumable pricing. This initiative requires review of long-term space planning to evaluate the feasibility of future extended automation tracks. Final instrumentation space plans are under review.
- Hematology System: 42-month contract extension completed with Sysmex.
 SysmexXN1000 installed on September 7, 2023. Validation of XN1000 is underway.
- Blood Product Supplier: Blood Buy Product Exchange agreement has been executed as a Premier service. Extension of the American Red Cross agreement as secondary supplier is under review.
- Pathology AB&T: Project in partnership with Kaleida Pathology to implement advanced barcode and tracking of Pathology specimens, blocks, and slides. AB&T will improve specimen tracking and traceability of Pathology material.

Outpatient Behavioral Health Services

Program Updates/Initiatives

- Help Center
 - o Identification/attention toward staff recruitment/retainment and potential benefit of per diem staffing
 - Exploration for continued collaboration with Crisis Services as it relates to diversion and crisis response/referrals
- On Track
 - Assessment and planning related to expansion and relocation of On Track from 462 Grider to 1285 Main Street Clinic
 - Increased capacity
 - 2-stage expansion
 - o Census of 40 to 55
 - o Census of 55 to 70
 - Improved engagement through community-based setting
 - Increase use of existing space at 1285 Main Street
 - Increased groups and billables

- Increased hospitality space for participants
- Improved access for participants (train/bus lines)

Adult & Family Clinic (AFC)

- o Perinatal Post Partum Depression Grant received
 - Support staff training and program development for this specific population (i.e. individual, group sessions)
 - Support appropriate accommodations for this specific population
 - Pursue community outreach and coordination with community providers for referral (currently 23 identified Perinatal patients)

1285 Main MICA Clinic

- o OMH Opioid Epidemic Response: A31 Clinic Capacity Building Initiative
 - ECMC OPBH Clinics have implemented 5 best practices required for graduation
 - Final interview date to be determined by OMH

Patient Experience/Satisfaction

 Perception of Care /Patient Satisfaction Surveys were completed December 2023/January 2024 (5-point Likert scale)

Northern Erie Clinical Services: 4.74
Downtown Clinical Services: 4.64
OPBH 1285 Main MICA Clinic: 4.26

Eye Movement Desensitization and Reprocessing (EMDR) Consultation & Training Initiative

- Evidenced based treatment for post-traumatic stress disorder
- Training Completed and increased EMDR therapists within programs by 8 at 1285 Main and 3 at 462 Grider (Total EMDR therapists within both programs = 20)
- Ongoing EMDR Consultation in support of EMDR intervention(s)
- Monitor and target increase EDMR service delivery percentage for appropriate patients with trauma diagnoses within caseloads

Partial Hospitalization Program (PHP) for Early Psychosis – (1st Episode)

- Assessment and program considerations for multidisciplinary service
- Ongoing review of potential program delivery surrounding:
 - Target census
 - Staffing model
 - Potential impact upon inpatient length of stay and decompression of CPEP

Psychology Testing Services

- Exploration, assessment, and consideration surrounding this potential service delivery within ECMC BH OTPT
- CASAC Services ECMC and Erie County Department of Social Services
 - Contract update surrounding this service delivery is complete as of 2/27/2024
- Outpatient Substance Use Treatment (SUT) Certified Recovery Peer Advocate (CRPA)

 ECMCC and WNY Independent Living, INC. D/B/A Mental Health Connection contract fully executed as of 1/31/2024

Plant Operations / Capital Projects

Plant Operations/Facility project updates include the following:

30 North Union - Bariatric Clinic Renovation - Complete

- The expansion project is complete and fully operational. Awaiting delivery of window treatments.
- **To be completed** Delivery and installation of window treatments.

Main Hospital – OR Equipment Surgical Lighting Replacements – In Progress

- **Completed** surgical light replacements for ORs 1, 2, 4, 5, 6, 7, 8, 9, 11 are complete, video integration work, wall-mounted computers, room minor patching/painting, and minor floor repairs in ORs 4, 11 and 12.
- **To be completed** surgical light replacements, video-integration work, wall-mounted computers, room minor patching/painting, and minor floor repairs in OR 3. Final Completion.

Main Hospital - OR Suites Updates for Surgical Light Replacements - In Progress (In-House Crew)

Paint operation suites, replace general room lighting with flat panel LED fixtures, general repairs. Once completed, Steris will perform light replacements. In progress with OR1, OR2, OR5, OR6, OR7, OR8, OR9, OR12. OR11 and OR4 are complete.

Main Hospital - Refresh Former UB Radiology Space - Pending (In-House Crew)

 Replace missing and stained ceiling tiles, demo select equipment, patch/paint walls, replace missing light fixture lamps, clean light fixture lenses. Pending final work scope.

Mammography Suite Creation – Pending (In-House Crew)

 Remove wall and door in registration area, replace ceilings, add flat panel LED light fixtures, abate floors and paint/patch Pain Management rooms. Pending room access and final plans by Capital division.

Radiology

- CCTA's are being performed on a weekly basis. Dr. Glover is the designated provider reading the scans.
- IT is introducing Fuji PACS
- Replacement Caresteam portable imaging units to be delivered in April for Radiology Rooms 35 and 37. Both rooms are expected to be complete by mid to end of June 2024.

Rehabilitation Services

Rehabilitation Services - Medical Rehab Unit (MRU)

 Uniformed Data Systems (UDS) Recertification process initiated and approximately 85% of staff have completed credentialing. This ensures that staff are using the inpatient rehab unit outcome measures appropriately and speaking a common

- language. This is important for accurate data collection, comparisons to other facilities and for maximal reimbursement.
- The The MRU, functioning with one physician had 20 admissions and 18 dishcarges with 411 patient days and a LOS of 22.8 days for the month of February. This is an increase from 2023 when the unit had 15 admissions, 16 discharges, 347 patient days and a LOS of 21.7 with two physicians.
- The Rehabilitation Symposium Committee is planning a symposium in March 2024.

Outpatient Rehabilitation Services

- Documentation project to support why "Skilled Therapist Intervention" is required for daily notes. PDSA cycle #1 for this project completed and adopted. This cycle was to determine current regulatory agency and insurance company documentation standards and staff training for competence. PDSA cycle #2 initiate to revise documentation to support the updates.
- The ECMC outpatient applied for a Dana and Christopher Reeves Grant to improve the quality of life for individuals with paralysis through the expansion of our current wheelchair evaluations and seating program.

PEDS


ECMC PEDS 2024 compared to the same time frame in 2023 increased overall early intervention visits. Ongoing service coordination visits increased by 20%, and basic therapy and education visits increased by 16%. Preschool related service therapy visits increased by 22%. This is due to improved scheduling with local school district universal preschools and an increase in group therapy.

GENERAL REHAB

Rehabilitation Services reported out at Cancer Care Committee related to all of the progress related to building rehab services targeting the Head and Neck population and also the close collaboration with the Kaleida Rehab Subgroup to work towards alignment for future shared accreditation with Great Lakes Health.

Surgical Services

Robotic Volume - February 2024



 Developing a strategic plan for 2024 with focus on increasing volume, P&P efficiencies, and PAT.

Terrace View

Operations

- The average daily census for February was 364.
- Podiatry Services: Dr. Yau provided podiatry services for Terrace View during February. Dr. Jascha Teibel received privileges and is expected to provide podiatry services in March.
- Monthly TV Department Head meetings are ongoing to review 2024 Capital Budget and department needs, review of regulatory testing compliance requirements, and survey preparedness update.
- The facility completed a one-for-one replacements of the dish machines in the café and main kitchen.

COVID/Infection Control

• On February 14, 2024, NYSDOH notified Terrace View the facility qualified for up to \$29,000 worth of infection prevention supplies. The facility placed the order and are awaiting delivery.

PATIENT EXPERIENCE

Press Ganev Scores

We continue to perform at a high level within our organization as it relates to Patient Experience. Our patient experience scores are listed below:

| Patient Experience | YTD (Jan 1 st , 2024- Feb 29, 2024 N= 43(est.) | NYS Jan 1st, 2023- Feb 28, 2023 N= 76(final) | 2024 Benchmark (2024 Benchmarks have not released) |
|--------------------|---|--|--|
| HCAHPS - Nurses | 77(est.) | 79 | 76 |
| HCAHPS – Doctors | 82(est.) | 77 | 77 |
| Discharge | 86(est.) | 94 | 85 |
| Overall # | 65(est.) | 67 | 66 |

Ambulatory Medical Practices

In 2024 the ECMC Ambulatory department is focusing on Health Equity and the Social Determinants of Health (SDOH). Our goal is to increase the connectivity to interventions for patients who documented a need(s) in the Social Determinant of Health Survey from a December 2023 baseline rate of 67%, to a 2024 goal of 80%. The team has started by updating resource guides for staff and patients on who would benefit from resources in the community.





Dialysis

- Eclipse preparations in place for planning staff levels and patient transportation.
- Dialysis Lobby Days will be scheduled in March for patients to increase education of different dialysis and transplant modalities.

Environmental Services

- Continued weekly updates with EVS leadership team and overall Patient Satisfaction scores communicated to frontline staff during Tier 1 shift huddles.
- Reorganization of labor force to strategic units and continued emphasis have had a positive impact and increased overall "cleanliness of hospital environment HCAHP scores by 3.5%.
- Increased workloads for frontline staff have impacted scores. Continuing to work on filling vacant positions with emphasis on service-driven candidates.

Food & Nutrition Services

Press Ganey - Patient Satisfaction Mean Scores (Goal = 50%)

| | 1/1-3 | /1/23 | 1/1-3/1/24 | | |
|-------------|-------------|------------|-------------|------------|--|
| | Survey size | Mean score | Survey size | Mean score | |
| Courtesy | n=164 | 84.06 | n=154 | 83.60 | |
| Temperature | n=160 | 63.39 | n=152 | 66.61 | |
| Quality | n=159 | 61.81 | n=151 | 62.25 | |

Patient Service Initiatives

- Charlene Ludlow, ECMC CNO, is conducting bi-weekly rounds with Nutrition leadership to evaluate patient services.
- Weekly EOC rounds are being conducted with infection control, with no new findings reported.
- Daily tray sweeps in galleys and rooms are being carried out for quality assurance.
- The launch of the new patient menu was successful!

- Rachel Lorek, (AGM) has taken ownership of Patient Services. New workflows have been rolled out for all positions to ensure top patient care.
- AGM developed a new onboarding program implemented to further develop our team.

Quality Improvement Initiatives

- The new admission welcome bags include diet information.
- Our palliative care program continues to offer an enhanced comfort cart.
- Late trays for CPEP have been adjusted to improve satisfaction, increase snack and portion sizes.
- Weekly in-service staff training continues.
- Each leader is assigned a focus unit, to ensure nurse rounding is being conducted
- Additional fridge placed in CPEP to increase our PAR of snack items
- New protocol initiated when in surge to increase our PAR in ED and CPEP.
- Two new policies created with focus on missed meals and incarcerated patients.

Laboratory Services

The following initiatives are underway or completed for improvement of testing turn-around time and patient experience.

- Blood Bank electronic crossmatch implementation completed as of 1/23/24.
- MICU Point of Care Expansion: I-STAT point-of-care testing implemented within the MICUs as of February 2024.
- HbA1c POCT: Capital request submitted for expansion of the Siemens UniPoc middleware for electronic transfer of HbA1c orders and results to mitigate the redundant manual transcription process of results into Altera and Meditech.
- MTP Process: Review of current Massive Transfusion Protocol for possible introduction of Whole Blood MTP packs.
- Thromboplasty Technology Review: In collaboration with the Trauma, ICU, and OR teams' evaluation of point-of-care TEG Thromboplasty testing to improve management of trauma and critical patients for clotting capability.
- Community HCV Screening: Working with Immunodeficiency team to implement community screening for HCV in high-risk populations.
- Chemo Clinic POCT: Evaluation of the feasibility of a POCT test menu to support same day in clinic clearance of patients is in discovery phase.

Surgical Services

- Looking to replace obsolete Perioptimum system with new bed tracking system in 2024. Tele-procedure team in development phase, weekly updates.
- Continue to monitor inpatient surgeries.

Review visitation policy for surgical patients remains the same, but encourage staff to allow visitors to see patients pre-op.

PEOPLE

Ambulatory Medical Practices

The Ambulatory Services Department staff continue to participate in community events, bringing pertinent healthcare information and education to the community. This is an opportunity to provide information about our Primary and Specialty Care Centers, provide pertinent education about various chronic illnesses, and linkage to a PCP at one of our Primary Care Centers. Below are the outreach/in-reach events attended by Ambulatory department staff:

- 2/2/2024: COEM and Employee Health & Safety partnered with Population Health to support the American Heart Association and Go Red for Women Campaign. The teams came together offering educational materials, giveaways, and blood pressure checks.
- 2/7/2024: The YOU Center for Wellness /LBGTQ1A2+ Resource Network tabled outside Great Lakes Café to celebrate "National Black HIV/Aids Awareness Day".
- 2/13/2024: COEM staff attended and presented on the clinic's services at the UAW Erie County February Meeting.
- 2/15/2024: COEM/YOU Center for Wellness attended the Health & Wellness event at the Downtown Buffalo Public Library.
- 2/16/2024: Dr. Claus and Elaine Laskowski participated in a radio interview on the services offered in the YOU Center for Wellness, the recorded aired the following morning.
- 2/21/2024: COEM tables at the Tri-Main Building, providing information on COEM services.
- 2/21/2024: COEM staff attended and presented on the clinic's services at the UAW Niagara -Orleans County February Meeting.
- 2/24/2024 COEM attended "The Good for the Neighborhood" vendor fair providing information on services available at COEM as well as Ambulatory Care.

Outpatient Behavioral Health Services

Staff Updates

- Recognition for enhanced credentials and public awards:
 - Megan Green Credentialed Alcoholism and Substance Abuse Counselor -2 (Northern Erie and Downtown Clinic)
 - Buffalo Spree 2024 Top Doctors Anuradha Mendu, MD Addiction Medicine (Northern Erie Clinical Services)
 - o Sandra Oberkircher Licensed Clinical Social Worker (1285 MICA Clinic)
 - o Matthew McCabe-Licensed Clinical Social Worker (1285 MICA Clinic)
 - o Alexis Pena Licensed Mental Health Counselor (1285 MICA Clinic)

Rehabilitation Services

Rehabilitation Services - MRU

Rehab Quality Coordinator, Angela Jocoy, achieved Certification for inpatient rehab facility prospective payment system (IRF PPS). This is the first time in the history of the Medical Rehabilitation Unit that we have had a certified coordinator in the area of PPS. This allows the appropriate capture of rehab patients for diagnoses, comorbidities, tiered diagnoses, and other data points. This position qualifies patients for rehab stays and provides the ability to obtain the maximal amount of

rehab days allowed along with the maximal payments for each diagnosis. ECMC Rehab typically runs a high CMI as compared to most other facilities and that is why this position and certification highly important to the unit.

PEDS

- PEDS successfully recruited and hired a Coordinator of Youth Services and a Data Management Clerk. The new Coordinator of Youth Services will begin in March, in conjunction with some revenue production via direct care by completing evaluations while training in the new position. These positions are part of an overall restructure and cost savings plan for the PEDS area.
- ECMC PEDS continues to Increase relationships with local school districts to provide services in their UPK (universal preschool programs). Initial meeting conducted with a new school district regarding consultation and direct service provision in their nine UPK classrooms for the upcoming school year.
- A community member, an Erie County Early Intervention Ongoing Service Coordinator, reached out to praise ECMC PEDS' Special Education Itinerant teacher, Neda Hussien, for going above and beyond working with a family who was displaced due to a fire, and maintaining communication with the entire team, providing both continuing services and support.

Outpatient Rehab

The ECMC outpatient department added two certifications: Theresa Liffiton is now Neurodevelopmental Trained (NDT certified) and Sartu Abdukadir is now Modified Barium Swallow Impairment Profile certified. Both certifications support the delivery of evidence-based care.

General Rehab

- At the Foundation's Gift Gathering event, a former rehab patient and family were highlighted as speakers for the event and spoke about the wonderful experience they had at ECMC and throughout Rehabilitation Services.
- Several rehabilitation staff members attended a public meeting for D'Youville University as part of their public meeting with the American speech and hearing association for accreditation. ECMC was asked to take part in the meeting as a stakeholder.

Terrace View

- New Staff (February): (1) FT LPN, (2) FT CNAs, (1) RPT LPN, (1) FT Certified Occupational Therapist (COTA), (1) RPT Respiratory Therapist
- Nursing agencies continue to be utilized to provide temporary supplemental staffing on the evening shift and minimally on the night shift for RNs, LPNs, CNAs, and Respiratory Therapists. The facility goal for 2024 is to increase the average census while continuing to improve staffing and limiting nursing supplemental agency use to the evening shift.

QUALITY

Ambulatory Medical Practices

The National Committee Quality Assurance's (NCQA) **Patient-Centered Medical Home (PCMH) Recognition program** was developed to identify medical practices that have

invested in a model of care that puts patients at the forefront and where continuous quality improvement is a priority.

• ECMC's Internal Medicine Clinic and Family Health Clinic have been reappointed for PCMH Recognition as of 2/22/2024.



Environmental Services

HCAHPS (cleanliness of the hospital environment) dischargedate
 February 2024 Top box score: 66%, n=110

Food & Nutrition Services (Touchworks Rounding Tool)

| Audit Period | Test Tray Audits | | Hospitality Audits | | Patient Rounding Audits | | |
|---------------|------------------|-----|--------------------|------------|----------------------------|-------|--|
| | GOAL = 90% | | GOAI | GOAL = 90% | | = 90% | |
| 2/9 - 2/29/24 | (n=70) | 86% | (n=49) | 98% | (n=333) | 76% | |
| 1/12 - 2/9/24 | (n=30) | 88% | (n=16) | 99% | (n=182) | 76% | |
| 1/1 - 1/11/24 | (n=10) | 91% | (n= 10) | 98% | (n=74) | 78% | |

Our commitment to excellence motivates us to strive for a 90% target across all aspects of our operations. The improvements made in hospitality and Test Tray audits have not only boosted the communication skills of our catering team but also equipped them to address patient inquiries and concerns efficiently. Looking ahead, our unwavering priority to promptly address new admissions through thorough patient rounds highlights our strong dedication to delivering exceptional Patient Services.

Laboratory Services

The Laboratory Medicine department continues to focus on 2024 QIPS Plan Initiatives.

The 2024 Quality Improvement and Patient Safety (QIPS) Plan has the following areas of focus.

- Reduce errors with Pathology Specimen submission from 42 events in 2023 to <30 events in 2024. Errors will be classified as specimen handling or clinical information. Q1 event data will be evaluated for intervention planning.</p>
- Reduce registration errors on outpatient laboratory orders which cause a delay in provider review from 10% in 2023 to 5% in 2024. *Q1 data will be evaluated for intervention planning.*

- Reduce the % Immediate Spin Crossmatch from 95% of total crossmatch testing to 50% in 2024. The Electronic Crossmatch went live on 1/23/24. The immediate spin crossmatch rate was 72% in January and has been reduced to 46% in February. The use of the electronic crossmatch and reduction of immediate spin will be monitored through the remainder of the year.
- * Additional departmental metrics and focused audits continue in accordance with the master Quality plan.

<u>Regulatory</u>: There are no formal regulatory visits anticipated for 2024 and all corrective action plans for the AABB, NYS, and Joint Commission survey have been completed and tracked on-going for continued compliance.

Terrace View

- The facility successfully submitted the quarterly CMS Payroll Based Journaling (PBJ) reports on February 8, 2024 for October-December 2023 reporting period.
- Continue to adhere Environmental Round process/written feedback for neighborhoods to ensure adherence to Life Safety Code and Safety and environmental general safety.
- Nursing Administration: ADON's continue to monitor the neighborhoods that they
 maintain administrative responsibility for, to ensure units are in a state of regulatory
 compliance.

FINANCIAL

Ambulatory Medical Practices

■ In the February 2024, the Ambulatory department saw 12,135 patients, while being budgeted for 12,822 visits (-5% budget). Departments that exceeded budget include You Center for Wellness, Urology, Hertel Dental, ENT, and Wound Care. Additionally, there were 74 visits for Covid testing and/or Covid vaccinations.

Dental/Oral Oncology & Maxillofacial Prosthetics

Patient Visits - February 2024

- Dental/Oral Oncology & Maxillofacial Prosthetics
 - $\circ~730$ visits in 2024, 665 visits in 2023, an increase of 10%
- Dental Clinic Suite 150
 - o 913 visits in 2024, 992 visits in 2023, a decrease of 8%
- Dental Clinic at 800 Hertel Avenue
 - o 423 visits in February 2024, the clinic opened March 2023

<u>Dialysis</u>

Budget and Variance:

- Outpatient (in-center treatments): 2024 Budget 3,957, Variance (-298)
- Home Program: (Home Peritoneal & Home Hemodialysis): YTD Budget 322 treatments, Variance (-169)

Census Volume:

- Outpatient (in-center treatments): February = 1,178 treatments, TYD 2024 total = 3.569
- Home Program: (Home Peritoneal & Home Hemodialysis): February = 85 treatments, 2024 totals = 322

| Dialys | sis | | ± | 2023 | | □ | | 202 | 4 | |
|--------|-------------|---------------------------|----------|--------|----------|-------|-------|-------|--------|----------|
| · | | | YTD | Budget | Variance | Jan | Feb | YTD | Budget | Variance |
| 4555 | AKI | Hemodialysis - AKI | 129 | - | - | 19 | 32 | 51 | - | - |
| | DIALNON | Hemodialysis - Non-ESRD | 0 | - | - | 0 | 0 | 0 | - | - |
| | DIALTRAN | Hemodialysis - Transient | 466 | - | - | 19 | 20 | 39 | - | - |
| | HD | Hemodialysis - Chronic | 23,020 | - | - | 1,791 | 1,778 | 3,569 | - | - |
| | 4555 Totals | | 23,615 | 24,539 | -924 얼 | 1,829 | 1,830 | 3,659 | 3,957 | -298 🖡 |
| 5660 | HOMEHD | Hemodialysis - Home | 20 | - | - | 0 | 0 | 0 | - | - |
| | PD | Hemodialysis - Peritoneal | 1,474 | - | - | 68 | 85 | 153 | - | - |
| | 5660 Totals | | 1,494 | 2,713 | -1,219 👢 | 68 | 85 | 153 | 322 | -169 🦊 |
| Totals | ' | | 25,109 | 27,252 | -2,143 👢 | 1,897 | 1,915 | 3,812 | 4,279 | -467 🦊 |

Environmental Services

- Overall labor and supply budgets for February in line and below budget.
- Overall purchased services above budget for February 2024.
- Continue to focus on transitioning floor team to internal staff members to reduce J&J vendor costs.

Food & Nutritional Services

Retail Sales

| February 2024 Actual | \$157,997 | January 2024 Ac | tual \$137,757 |
|----------------------|------------------|-----------------|-------------------|
| February 2024 Budge | t \$149,070 | January 2024 Bu | ıdget \$149,070 |
| Variance | +\$ 8,926 = 106% | Variance | - \$ 11,313 = 92% |

Laboratory Services

The department budget volumes for January YTD were positive 3.6% to budget target and increased 4.1% in comparison to FY23. The January YTD operating expense has a negative variance of 4.3% to budget target and a negative variance of 2.2% to FY23. The personnel expense has a positive variance of 1.9% to budget target and postive 1.3% to FY23 actual. Non-personnel expenses January YTD demonstrated a negative variance of 6.8% to budget target and a negative variance of 3.9% to FY23. The negative non-personnel variance was impacted by some delayed 2023 expense postings. The department will continue to monitor expense in alignment with overall volume. (February data not available at time of report).

Radiology

• The Radiology department is up 5.4% YTD over budget.

Rehabilitation Services

<u>Acute Care</u>

Acute therapy volumes continue to grow as the demand for acute therapy is growing in the emergency department, overflow units, observation, orthopedic services, critical care, acute geriatrics, behavioral health and for bedside wound care treatments.

- Acute PT was 168 treatments over budget (+5 %).
- Acute OT was 157 over treatments over budget (+ 7%).

Supportive Care & Palliative Medicine

■ Total Inpatient Consults for February: 102

Transitions of Care: 12 (home services)

Sloan Comfort Home: 1

Terrace View: 7

Surgical Services

2023 surgical volume exceeded budget.

• OR Surgical Light Replacment project near completion, OR #3 remains.

Transplant

 2024 started out slow in Transplant. With zero (0) Living Donors or KP's, we are one (1) less deceased Transplant from last year.


• Living Donor transplant will be performed on March 11.

• Pre-Transplant Clinic is below budget by -76 we did increase budget significantly in 2024 based on our 2023 volume.

Post-Transplant has exceeded the 2024 budget YTD by 69.

| <u>Transplant / Vascular</u> | | ± | 2023 | | | | 2024 | 1 | | |
|------------------------------|-------------|-------------------|-------|--------|----------|-----|------|-----|--------|----------|
| | ` | | YTD | Budget | Variance | Jan | Feb | YTD | Budget | Variance |
| 6430 | TRANPRE | Transplant Clinic | 661 | - | - | 37 | 49 | 86 | - | - |
| | TRANPREPRC | Transplant Clinic | 2 | - | - | 0 | 1 | 1 | - | - |
| | 6430 Totals | <u> </u> | 663 | 563 | 100 👚 | 37 | 50 | 87 | 163 | -76 👢 |
| 6431 | TRANPOSPRC | Transplant Clinic | 1 | - | - | 0 | 0 | 0 | - | - |
| | TRANPOST | Transplant Clinic | 4,258 | - | - | 369 | 352 | 721 | - | - |
| | 6431 Totals | | 4,259 | 4,411 | -152 🐿 | 369 | 352 | 721 | 652 | 69 👚 |
| Totals | | | 4,922 | 4,974 | -52 🖢 | 406 | 402 | 808 | 815 | -7 |

| | DD-K | LD-K | KP | Pancreas | Total |
|------|------|------|----|----------|-------|
| 2009 | 16 | 7 | 0 | 0 | 23 |
| 2010 | 8 | 11 | 0 | 0 | 19 |
| 2011 | 11 | 2 | 2 | 0 | 15 |
| 2012 | 7 | 3 | 0 | 1 | 11 |
| 2013 | 15 | 4 | 0 | 0 | 19 |
| 2014 | 12 | 5 | 0 | 0 | 17 |
| 2015 | 3 | 1 | 0 | 0 | 4 |
| 2016 | 24 | 2 | 3 | 1 | 30 |
| 2017 | 23 | 6 | 0 | 0 | 29 |
| 2018 | 29 | 2 | 0 | 0 | 31 |
| 2019 | 23 | 2 | 2 | 0 | 27 |
| 2020 | 31 | 1 | 2 | 0 | 34 |
| 2021 | 35 | 0 | 0 | 0 | 35 |
| 2022 | 18 | 5 | 0 | 0 | 23 |
| 2023 | 19 | 1 | 2 | 0 | 22 |
| 2024 | 18 | 0 | 0 | 0 | 18 |



The difference between healthcare and true $care^{TM}$



Internal Financial Reports For the month ended February 29, 2024

Financial Dashboard February 29, 2024

| Statement of Operations: | <u>Month</u> | Year-to-Date (YTD) | YTD Budget | Cash Flow Summary: | | <u>Month</u> | | <u>YTD</u> |
|--|-------------------------------|---|---------------------------------|--|---|---|---|---|
| Net patient revenue Other Total revenue | \$ 52,838 14,707 67,545 | \$ 107,552 \$ 29,557 137,109 | \$ 103,684 28,862 132,546 | Net cash provided by (| , | \$ (17,540) | | \$ 58,198 |
| Salary & benefits Physician fees Purchased services | 36,402 9,806 6,058 | 75,808 19,692 12,910 | 73,540 19,305 11,861 | Investing activities Financing activities | | (2,161) | | (3,837) |
| Supplies & other Depreciation and amortization Interest | 13,589 4,133 977 | 27,318 8,257 1,972 | 26,459 7,921 1,758 | | cash and cash equivalents | | | 51,292 |
| Total expenses | 70,965 | 145,957 | 140,844 | Cash and cash equival | ents - beginning | 92,244 | | 19,771 |
| Operating Income/(Loss) Before Other Items | (3,420) | (8,848) | (8,298) | Cash and cash equ | uivalents - ending | \$ 71,063 | | \$ 71,063 |
| Grant revenue | 609 | 609 | <u> </u> | | | | | |
| Income/(Loss) from Operations With Other Items | (2,811) | (8,239) | (8,298) | | | | | |
| Other Non-operating gain/(loss) | 1,272 | 1,074 | 200 | | | | | |
| Change in net assets | \$ (1,539) | \$ (7,165) | \$ (8,098) | | | | | |
| Operating margin | -4.2% | -6.0% | -6.3% | | | | | |
| | | | | | | | | |
| Balance Sheet: | | | | Key Statistics: | | Month | YTD | YTD Budget |
| Assets: Cash & short-term investments | | \$ 82,909 99,303 | | Key Statistics: Discharges: | - Acute - Exempt units | Month 1,039 399 | <u>YTD</u> 2,105 805 | <u>YTD Budget</u> 1,893 890 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited | | 99,303 172,958 | | | | 1,039 | 2,105 | 1,893 890 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets | | 99,303 | | Discharges: | | 1,039 399 | 2,105 805 | 1,893 890 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets Liabilities & Net Assets: Accounts payable & accrued expenses | | 99,303 172,958 504,485 \$ 859,655 \$ 324,891 | | Discharges: Observation Cases: | - Exempt units - Acute - Exempt units | 1,039 399 262 8,213 | 2,105 805 566 17,041 | 1,893 890 428 15,261 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets Liabilities & Net Assets: Accounts payable & accrued expenses Estimate self-insurance reserves Other liabilities | | 99,303 172,958 504,485 \$ 859,655 \$ 324,891 58,809 498,631 | | Discharges: Observation Cases: Patient days: | - Exempt units - Acute - Exempt units | 1,039 399 262 8,213 4,717 | 2,105 805 566 17,041 9,552 | 1,893 890 428 15,261 10,210 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets Liabilities & Net Assets: Accounts payable & accrued expenses Estimate self-insurance reserves Other liabilities Long-term debt, including current portion Lease liability, including current portion | | 99,303 172,958 504,485 \$ 859,655 \$ 324,891 58,809 498,631 200,538 26,632 | | Discharges: Observation Cases: Patient days: Average length of stay, | - Exempt units - Acute - Exempt units acute Blended | 1,039 399 262 8,213 4,717 7.9 | 2,105 805 566 17,041 9,552 8.1 | 1,893 890 428 15,261 10,210 8.1 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets Liabilities & Net Assets: Accounts payable & accrued expenses Estimate self-insurance reserves Other liabilities Long-term debt, including current portion Lease liability, including current portion Subscription liability, including current portion Line of credit | | \$ 859,655 \$ 324,891 58,809 498,631 200,538 26,632 23,486 10,000 | | Discharges: Observation Cases: Patient days: Average length of stay, Case mix index | - Exempt units - Acute - Exempt units acute Blended | 1,039 399 262 8,213 4,717 7.9 | 2,105 805 566 17,041 9,552 8.1 1.82 | 1,893 890 428 15,261 10,210 8.1 1.84 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets Liabilities & Net Assets: Accounts payable & accrued expenses Estimate self-insurance reserves Other liabilities Long-term debt, including current portion Lease liability, including current portion Subscription liability, including current portion | | \$ 859,655 \$ 324,891 58,609 498,631 200,538 26,632 23,486 10,000 (283,332) | | Discharges: Observation Cases: Patient days: Average length of stay, Case mix index | - Exempt units - Acute - Exempt units acute Blended Medical Center Terrace View LTC | 1,039 399 262 8,213 4,717 7.9 1.76 | 2,105 805 566 17,041 9,552 8.1 1.82 443 | 1,893 890 428 15,261 10,210 8.1 1.84 425 |
| Assets: Cash & short-term investments Patient receivables Assets whose use is limited Other assets Liabilities & Net Assets: Accounts payable & accrued expenses Estimate self-insurance reserves Other liabilities Long-term debt, including current portion Lease liability, including current portion Subscription liability, including current portion Line of credit | | \$ 859,655 \$ 324,891 58,809 498,631 200,538 26,632 23,486 10,000 | | Discharges: Observation Cases: Patient days: Average length of stay, Case mix index Average daily census: | - Exempt units - Acute - Exempt units acute Blended Medical Center Terrace View LTC | 1,039 399 262 8,213 4,717 7.9 1.76 446 | 2,105 805 566 17,041 9,552 8.1 1.82 443 369 | 1,893 890 428 15,261 10,210 8.1 1.84 425 |

The difference between healthcare and true care $^{\text{\tiny{M}}}$



Management Discussion and Analysis For the month ended February 29, 2024 (Amounts in Thousands)

February 2024 Operating Performance

During February 2024, ECMCC experienced strong operating volume and revenue overall, representing positive trends continuing from 2023. ECMCC outperformed budget in inpatient cases during the month, especially within the acute medical and surgical service areas. ECMCC fell behind plan in total outpatient visits during the month primarily driven by certain clinic growth planned but only partially achieved. Total surgeries for the month far exceeded the operating plan leading to additional revenue for the month as well. The additional revenue derived from these volume trends during February were partially offset by additional expenses primarily within benefits and purchased services, which drove an operating loss for the month of (\$3,420). This operating loss however was favorable to the month's budgeted loss of (\$3,754) and significantly better than the operating loss during February 2022 of (\$7,327).

Inpatient discharges for the month exceeded the budgeted cases of 1,320 by 118 cases (or 8.97%), driven by favorable variances in acute, behavioral health and medical rehab services offset by unfavorable variances in chemical dependency services. Acute discharges of 1,039 exceeded the budget by 16.3%, bolstered by inpatient surgery variance of 41 surgeries. During February management was able to stabilize the acute length of stay after the winter storm event experienced in January. ECMCC managed to an acute length of stay of 7.9 days in February as compared to an expected length of stay of 7.9 days, which also represents a reduction from January 2024's acute length of stay of 8.3 days. Net patient service revenue however was unfavorably impacted during the month with an acute case mix index of 1.76 as compared to a budgeted case mix of 1.86. This was driven in large part by a reduction in severity of respiratory cases in the community.

Additionally, during February, ECMCC's Terrace View skilled nursing facility has nearly returned to 95% occupancy due to significant and successful recruitment efforts to address the staffing challenges experienced at that facility over the last several years.

Outpatient volume fell below budget for the month by 1,409 visits, a 5.6% shortfall. This was driven primarily by lower clinic visit volume during the month. However, during the month ECMCC experienced a significant increase in outpatient surgeries, resulting in a total of 617 total cases for February. This represents a favorable variance of 64 cases over the budget of 553, or 11.6%. Certain clinic growth has been delayed slightly due to the timing of construction and staffing challenges but are temporary in nature and are expected to be achieved throughout the rest of the year.

Total FTEs during February were essentially in line with budgeted targets for the month, which represents a decrease from the FTEs reported during January. Lower usage of vacation time, sick time and other leave time influenced the overall variance favorably during the month. Management does continue to experience costs related to premium time including overtime, shift differential, and additional worked time bonus rates per hour. These increases were necessary to ensure staff availability during a period of significant staffing challenges as well as to meet minimum staffing standards imposed by New York State both for the Hospital and Terrace View.

Expenses were also seen during the month in temporary nursing staff in both the hospital and Terrace View to meet minimum standards. Management has planned for a certain number of agency staff to remain throughout the year, however, ECMCC is still ramping down, but not yet to the level within the plan for February.

Management Discussion and Analysis For the month ended February 29, 2024 (Amounts in Thousands)

Balance Sheet

ECMCC saw a significant increase in cash from December 2023 resulting in 38 days operating cash as compared to 16 days operating cash at the end of 2023. Cash levels have increased during the two-month period as a result of the receipt of the 2023 initial disproportionate share (DSH/IGT) payment, along with the retrospective reimbursement settlement related to the 340b drug pricing program. Partially offsetting those receipts, management paid the New York State Pension Plan contribution timely as required as well as ongoing operating vendor payments. Lastly, the ongoing efforts to accelerate and increase collections as a result of ongoing cash management efforts as well as the billing and collection project implemented in September 2023 have favorably impacted the overall cash balance. It is important to note as well that there remains a delay in receipt of the Nursing Home Upper Payment Limit (UPL) payment for 2023, which is not expected until June of 2024.

Patient receivables decreased over \$3 million from December 31, 2023 due to management implementing initiatives to increase cash collections and reduce delays. Total Days in Patient Receivables has decreased another 7.8 days from the end of December 31, 2023, driven by additional cash receipts during the month.

The decrease in prepaid expenses, inventories and other receivables from December 31, 2023 is related to receipt of the DSH/IGT payments for prior periods during January partially offset by the additional receivable recorded related to the 2024 DSH/IGT.

The change in other accrued expenses reflects the recognition of the deferred revenue received in January of 2024 resulting from the receipt of the current year initial payment for DSH/IGT.

The change in other liabilities is the result of the net activity related to the payment of contribution required by the NYS pension plan.

Vendor Related Cyber Incident

On February 21, 2024, Change Healthcare, a third-party service provider to ECMCC and several of its vendors, became aware of a cybersecurity incident (the "Incident") causing a disruption across the health care industry. ECMCC uses Change Healthcare for various revenue cycle related services including professional billing, claims processing, and eligibility authorizations. As a result of the Incident, as of March 15, 2024, ECMCC is not aware of any company data including personally identifiable information (PII) and/or protected health information (PHI), that has been compromised because of the incident. ECMCC will continue to monitor the overall response by Change to the incident but cannot predict at this point whether it will have a significant adverse impact on the organization or whether PII or PHI will be identified in the future as being compromised. Additionally, ECMCC is in constant contact with Change Healthcare, the various vendors and payers impacted and has implemented cash management strategies in order to ensure that any unfavorable cash flow impacts have been mitigated.

Balance Sheet February 29, 2024 and December 31, 2023

(Dollars in Thousands)

| | F.b | | D | | | nge from |
|---|-------|---------------------------------------|----------|---------------|-------|-----------|
| Assets | Febru | ıary 29, 2024 | Decei | mber 31, 2023 | Decei | mber 31st |
| Current Assets: | | | | | | |
| Cash and cash equivalents | \$ | 71,063 | \$ | 19,771 | \$ | 51,292 |
| Investments | Ψ | 11,846 | Ψ | 10,646 | Ψ | 1,200 |
| Patient receivables, net | | 99,303 | | 102,389 | | (3,086) |
| Prepaid expenses, inventories and other receivables | | 36,008 | | 62,528 | | (26,520) |
| | | · · · · · · · · · · · · · · · · · · · | | | | |
| Total Current Assets | - | 218,220 | | 195,334 | | 22,886 |
| Assets Whose Use is Limited: | | | | | | |
| Designated under self-Insurance programs | | 57,904 | | 57,904 | | - |
| Restricted under third party agreements | | 109,919 | | 107,627 | | 2,292 |
| Designated for long-term investments | | 5,135 | | 5,091 | | 44 |
| Total Assets Whose Use is Limited | | 172,958 | | 170,622 | | 2,336 |
| Property and equipment, net | | 300,454 | | 307,343 | | (6,889) |
| Other assets | | 168,023 | | 168,809 | | (786) |
| Total Assets | \$ | 859,655 | \$ | 842,108 | \$ | 17,547 |
| Liabilities & Net Position | | | | | | |
| Current Liabilities: | | | | | | |
| Current portion of long-term debt | \$ | 12,805 | \$ | 12,869 | \$ | (64) |
| Current portion of lease liability | · | 6,926 | · | 6,944 | · | (18) |
| Current portion of subscription liability | | 8,964 | | 8,724 | | 240 |
| Line of credit | | 10,000 | | 10,000 | | - |
| Accounts payable | | 57,730 | | 59,922 | | (2,192) |
| Accrued salaries and benefits | | 79,332 | | 73,734 | | 5,598 |
| Other accrued expenses | | 182,992 | | 125,936 | | 57,056 |
| Estimated third party payer settlements | | 4,837 | | 4,486 | | 351 |
| Total Current Liabilities | | 363,586 | | 302,615 | | 60,971 |
| Long-term debt | | 187,733 | | 188,940 | | (1,207) |
| Long-term lease liability | | 19,706 | | 20,521 | | (815) |
| Long-term subscription liability | | 14,522 | | 15,727 | | (1,205) |
| Estimated self-insurance reserves | | 58,809 | | 59,340 | | (531) |
| Other liabilities | | 498,631 | | 531,132 | | (32,501) |
| Total Liabilities | | 1,142,987 | | 1,118,275 | | 24,712 |
| Total Net Position | | (283,332) | | (276,167) | | (7,165) |
| Total Liabilities and Net Position | \$ | 859,655 | \$ | 842,108 | \$ | 17,547 |

The difference between healthcare and true $care^{TM}$



Statement of Operations

For the month ended February 29, 2024

(Dollars in Thousands)

| | Actual | Budget | Favorable/ (Unfavorable) | Prior Year |
|--|------------|------------|-----------------------------|------------|
| On anoting a Bassansas | 710000 | | (0.110.101.01.07) | 11101 1001 |
| Operating Revenue: Net patient revenue | 53,688 | 51,075 | 2,613 | 44,845 |
| Less: Provision for uncollectable accounts | (850) | (993) | 143 | (983) |
| Adjusted Net Patient Revenue | 52,838 | 50,082 | 2,756 | 43,862 |
| Disproportionate share / IGT revenue | 10,273 | 10,273 | 2,700 | 9,571 |
| Other revenue | 4,434 | 4,158 | 276 | 2,323 |
| Total Operating Revenue | 67,545 | 64,513 | 3,032 | 55,756 |
| Operating Expenses: | | | | |
| Salaries & wages | 27,673 | 27,623 | (50) | 24,944 |
| Employee benefits | 8,729 | 7,726 | (1,003) | 7,960 |
| Physician fees | 9,806 | 9,652 | (154) | 9,082 |
| Purchased services | 6,058 | 5,652 | (406) | 6,299 |
| Supplies | 11,078 | 10,062 | (1,016) | 8,092 |
| Other expenses | 1,880 | 1,967 | 87 | 1,717 |
| Utilities | 631 | 656 | 25 | 699 |
| Depreciation & amortization | 4,133 | 4,050 | (83) | 3,353 |
| Interest | 977 | 879 | (98) | 937 |
| Total Operating Expenses | 70,965 | 68,267 | (2,698) | 63,083 |
| Operating Income/(Loss) Before Other Items | (3,420) | (3,754) | 334 | (7,327) |
| Other Gains/(Losses) | | | | |
| Grant revenue | 609 | | 609 | 4,228 |
| Income/(Loss) from Operations | (2,811) | (3,754) | 943 | (3,099) |
| Other Non-operating Gain/(Loss): | | | | |
| Interest and dividends | 485 | 180 | 305 | 203 |
| Unrealized gain/(loss) on investments | 787 | (80) | 867 | (2,305) |
| Non-operating Gain/(Loss) | 1,272 | 100 | 1,172 | (2,102) |
| Excess of Revenue/(Deficiency) Over Expenses | \$ (1,539) | \$ (3,654) | \$ 2,115 | \$ (5,201) |

Statement of Operations

For the two months ended February 29, 2024

(Dollars in Thousands)

| | Actual | Budget | Favorable/ (Unfavorable) | Prior Year |
|--|------------|------------|-----------------------------|-------------|
| Operating Revenue | Aotuai | Buaget | (Ginavorabic) | 11101 1001 |
| Operating Revenue: Net patient revenue | 109,442 | 105,763 | 3,679 | 94,179 |
| Less: Provision for uncollectable accounts | (1,890) | (2,079) | 189 | (2,339) |
| Adjusted Net Patient Revenue | 107,552 | 103,684 | 3,868 | 91,840 |
| Disproportionate share / IGT revenue | 20,547 | 20,547 | - | 19,142 |
| Other revenue | 9,010 | 8,315 | 695 | 5,070 |
| Total Operating Revenue | 137,109 | 132,546 | 4,563 | 116,052 |
| Operating Expenses: | | | | |
| Salaries & wages | 58,415 | 57,693 | (722) | 54,211 |
| Employee benefits | 17,393 | 15,847 | (1,546) | 16,718 |
| Physician fees | 19,692 | 19,305 | (387) | 18,451 |
| Purchased services | 12,910 | 11,861 | (1,049) | 12,813 |
| Supplies | 22,481 | 21,338 | (1,143) | 17,961 |
| Other expenses | 3,837 | 3,931 | 94 | 3,764 |
| Utilities | 1,000 | 1,190 | 190 | 1,314 |
| Depreciation & amortization | 8,257 | 7,921 | (336) | 6,706 |
| Interest | 1,972 | 1,758 | (214) | 1,874 |
| Total Operating Expenses | 145,957 | 140,844 | (5,113) | 133,812 |
| Operating Income/(Loss) Before Other Items | (8,848) | (8,298) | (550) | (17,760) |
| Other Gains/(Losses) | | | | |
| Grant revenue | 609 | | 609 | 6,478 |
| Income/(Loss) from Operations | (8,239) | (8,298) | 59 | (11,282) |
| Other Non-operating Gain/(Loss): | | | | |
| Interest and dividends | 793 | 360 | 433 | 347 |
| Unrealized gain/(loss) on investments | 281 | (160) | 441 | 605 |
| Non-operating Gain/(Loss) | 1,074 | 200 | 874 | 952 |
| Excess of Revenue/(Deficiency) Over Expenses | \$ (7,165) | \$ (8,098) | \$ 933 | \$ (10,330) |

Statement of Changes in Net Position For the month and two months ended February 29, 2024

(Dollars in Thousands)

| | Month | | Year-to-Date | |
|---|-----------------|----|--------------|--|
| Unrestricted Net Assets: | | | | |
| Excess/(Deficiency) of revenue over expenses | \$ (1,539) | \$ | (7,165) | |
| Other transfers, net | - | | | |
| Contributions for capital acquisitions | - | | - | |
| Change in accounting principle | - | | - | |
| Net assets released from restrictions for capital acquisition | | | | |
| Change in Unrestricted Net Assets | (1,539) | | (7,165) | |
| Temporarily Restricted Net Assets: | | | | |
| Contributions, bequests, and grants | - | | - | |
| Other transfers, net | - | | - | |
| Net assets released from restrictions for operations | - | | - | |
| Net assets released from restrictions for capital acquisition | | | | |
| Change in Temporarily Restricted Net Assets | | | | |
| Change in Net Position | (1,539) | | (7,165) | |
| Net Position, beginning of period | (281,793) | | (276,167) | |
| Net Position, end of period | \$ (283,332) | \$ | (283,332) | |

The difference between healthcare and true $care^{tm}$



Statement of Cash Flows

For the month and two months ended February 29, 2024

(Dollars in Thousands)

| | Month | | Year-to-Date | |
|--|-------|----------|--------------|----------|
| Cash Flows from Operating Activities: | | | | |
| Change in net assets | \$ | (1,539) | \$ | (7,165) |
| Adjustments to Reconcile Changes in Net Assets to Net Cash Provided by/(Used in) Operating Activities: | | | | |
| Depreciation and amortization | | 4,133 | | 8,257 |
| Provision for bad debt expense | | 850 | | 1,890 |
| Net change in unrealized (gain)/loss on Investments | | (787) | | (281) |
| Changes in Operating Assets and Liabilities: | | | | |
| Patient receivables | | (3,709) | | 1,196 |
| Prepaid expenses, inventories and other receivables | | (1,942) | | 26,520 |
| Accounts payable | | (8,941) | | (2,192) |
| Accrued salaries and benefits | | 10,520 | | 5,598 |
| Estimated third party payer settlements | | 180 | | 351 |
| Other accrued expenses | | (15,098) | | 57,056 |
| Self Insurance reserves | | 300 | | (531) |
| Other liabilities | | (1,507) | | (32,501) |
| Net Cash Provided by/(Used in) Operating Activities | | (17,540) | | 58,198 |
| Cash Flows from Investing Activities: | | | | |
| Additions to Property and Equipment, net | | (94) | | (1,368) |
| Decrease/(increase) in assets whose use is limited | | (3,117) | | (2,336) |
| Sale/(Purchase) of investments, net | | 1,408 | | (919) |
| Investment in component units | | , - | | - |
| Change in other assets | | (358) | | 786 |
| Net Cash Provided by/(Used in) Investing Activities | | (2,161) | | (3,837) |
| Cash Flows from Financing Activities: | | | | |
| Principal payments on / proceeds from long-term debt, net | | (632) | | (1,271) |
| Principal payments on / additions to long-term lease liability, net | | (551) | | (833) |
| Principal payments on / additions to long-term subscription, net | | (297) | | (965) |
| Proceeds from line of credit | | - | | - |
| Increase/(Decrease) in Cash and Cash Equivalents | | (21,181) | | 51,292 |
| Cash and Cash Equivalents, beginning of period | | 92,244 | | 19,771 |
| Cash and Cash Equivalents, end of period | \$ | 71,063 | \$ | 71,063 |

Statistical and Ratio Summary

| | Febru | ary 29, 2024 | December 31, 2023 | | ECMCC 3 Year Avg. 2020 - 2022 | |
|--|-------|--|-------------------|---|-------------------------------------|---|
| Liquidity Ratios: Current Ratio Days in Operating Cash & Investments Days in Patient Receivables Days Expenses in Accounts Payable Days Expenses in Current Liabilities Cash to Debt Working Capital Deficit | \$ | 0.6 38 55.4 60.3 144.9 70.2% (145,366) | \$ | 0.7 16 63.2 53.6 129.2 43.0% (89,919) | \$ | 0.8 29.5 55.5 61.2 144.5 52.8% (72,929) |
| Capital Ratios: Long-Term Debt to Fixed Assets Assets Financed by Liabilities Debt Service Coverage (Covenant > 1.1) Capital Expense Average Age of Plant Debt Service as % of NPSR Capital as a % of Depreciation | | 62.5% 133.0% 1.7 9.7% 6.7 3.8% 16.6% | | 67.7% 133.6% 2.3 3.0% 7.6 4.2% 13.1% | | 68.4% 127.9% 1.6 3.0% 9.4 4.0% 34.3% |
| Profitability Ratios: Operating Margin Net Profit Margin Return on Total Assets Return on Equity | | -6.5% -6.5% -5.0% 15.2% | | -13.2% -1.0% -0.8% 2.3% | | -14.1% -3.5% -2.1% 7.9% |
| Productivity and Cost Ratios: Total Asset Turnover Total Operating Revenue per FTE Personnel Costs as % of Total Revenue | \$ | 1.0 245,581 54.5% | \$ | 0.9 224,619 57.5% | \$ | 0.8 216,505 57.0% |

The difference between healthcare and true $care^{tm}$



Key Statistics Period Ended February 29, 2024

| | Currer | nt Period | | • | Year to Date | | | | |
|-----------------|-----------------|-----------------|--|---|----------------|-----------|------------------|-----------------|-----------------|
| Actual | Budget | % to Budget | Prior Year | | Actual | | Budget | % to Budget | Prior Year |
| | | | <u>, </u> | Discharges: | | | | | <u> </u> |
| 1,039 | 893 | 16.3% | 895 | Med/Surg (M/S) - Acute | 2,10 | | 1,893 | | 1,900 |
| 228 | 211 | 8.2% | 201 | Behavioral Health | 44 | | 463 | | 436 |
| 153 18 | 200 16 | -23.4% 12.6% | 177 16 | Chemical Dependency (CD) - Detox Medical Rehab | 32 | 28 37 | 398 29 | | 365 28 |
| • | | | | | | | | | |
| 1,438 | 1,320 | 8.97% | 1,289 | Total Discharges | 2,9 | 10 | 2,783 | 4.6% | 2,729 |
| | | | | Patient Days: | | | | | |
| 8,213 | 7,040 | 16.7% | 8,166 | M/S - Acute | 17,04 | | 15,261 | 11.7% | 17,757 |
| 3,693 613 | 3,714 852 | -0.6% -28.1% | 3,877 703 | Behavioral Health CD - Detox | 7,44 1,30 | | 8,001 1,652 | -7.0% -21.1% | 8,052 1,523 |
| 411 | 280 | 46.8% | 347 | Medical Rehab | 8(| | 557 | 44.9% | 709 |
| 12,930 | 11,886 | 8.8% | 13,093 | Total Patient Days | 26,59 | | 25,471 | 4.4% | 28,041 |
| 12,000 | 11,000 | 0.070 | 10,000 | · | 20,00 | | 20,471 | 7.770 | 20,041 |
| 283 | 243 | 16.7% | 292 | Average Daily Census (ADC): M/S - Acute | 28 | 24 | 254 | 11.7% | 301 |
| 127 | 128 | -0.6% | 138 | Behavioral Health | 12 | | 133 | | 136 |
| 21 | 29 | -28.1% | 25 | CD - Detox | | 22 | 28 | | 26 |
| 14 | 10 | 46.8% | 12 | Medical Rehab | | 13 | 9 | 44.9% | 12 |
| 446 | 410 | 8.8% | 468 | Total ADC | 4 | 13 | 425 | 4.4% | 475 |
| | | | | Average Length of Stay: | | | | | |
| 7.9 | 7.9 | 0.3% | 9.1 | M/S - Acute | | .1 | 8.1 | 0.4% | 9.3 |
| 16.2 | 17.6 | -8.1% | 19.3 | Behavioral Health | 16 | | 17.3 | | 18.5 |
| 4.0 22.8 | 4.3 17.5 | -6.0% 30.4% | 4.0 21.7 | CD - Detox Medical Rehab | 4 21 | .0 8 | 4.1 19.5 | -4.1% 11.7% | 4.2 25.3 |
| 9.0 | 9.0 | -0.2% | 10.2 | Average Length of Stay | - | .1 | 9.2 | | 10.3 |
| | 0.0 | 0.270 | 10.2 | Occupancy: | | · · · · · | 0.2 | 0.270 | 10.0 |
| 82.4% | 79.7% | 3.4% | 86.4% | % of M/S Acute staffed beds | 82.4 | 1% | 79.7% | 3.4% | 86.4% |
| | | | | Case Mix Index: | | | | | |
| 1.76 | 1.86 | -5.5% | 1.7057 | Blended (Acute) | 1.8 | 32 | 1.84 | -1.0% | 1.72 |
| 262 | 204 | 28.4% | 195 | Observation Status | 56 | 66 | 428 | 32.2% | 414 |
| 398 | 357 | 11.5% | 322 | Inpatient General Surgeries | 8 | 18 | 755 | 8.3% | 715 |
| 617 | 553 | 11.6% | 557 | Outpatient General Surgeries | 1,27 | 73 | 1,214 | 4.9% | 1,223 |
| 26 | 43 | -39.5% | 48 | Inpatient Ancillary Surgeries | | 16 | 92 | | 117 |
| 29 | 27 | 7.4% | 23 | Outpatient Ancillary Surgeries | | 71 | 56 | | 48 |
| 23,682 5,039 | 25,091 5,162 | -5.6% -2.4% | 23,708 4,662 | Outpatient Visits Emergency Visits Including Admits | 46,47 10,12 | | 50,085 10,683 | | 48,286 9,455 |
| 55.4 | 44.2 | 25.3% | 60.6 | Days in A/R | 55 | | 44.2 | | 60.6 |
| 1.4% | 2.0% | | 2.6% | Bad Debt as a % of Net Revenue | 1.6 | | 2.0% | | 2.9% |
| 3,232 | 3,181 | 1.6% | 3,208 | FTE's | 3,24 | 13 | 3,204 | 1.2% | 3,207 |
| 4.27 | 4.43 | -3.6% | 4.27 | FTE's per Adjusted Occupied Bed | 4. | | 4.34 | | 4.09 |
| \$ 20,053 | \$ 20,040 | 0.1% | \$ 18,744 | Net Revenue per Adjusted Discharge | \$ 19,56 | 3 3 | 1,581 | 1137.8% | \$ 18,351 |
| \$ 27,090 | \$ 27,144 | -0.2% | \$ 27,042 | Cost per Adjusted Discharge | \$ 26,47 | 74 \$ | 2,127 | 1144.9% | \$ 26,778 |
| Terrace View | Long Terr | m Care: | | | | | | | |
| 10,780 | 10,891 | -1.0% | 10,190 | Patient Days | 22,1 | 13 | 22,529 | -1.8% | 21,513 |
| 372 | 376 | -1.0% | 364 | Average Daily Census | 36 | 69 | 375 | -1.8% | 365 |
| 95.3% | 96.3% | -1.0% | 93.3% | Occupancy - % of Staffed beds | 94.5 | 5% | 96.3% | -1.8% | 93.5% |
| 457 | 504 | -9.4% | 405 | FTE's | 46 | 64 | 509 | -8.9% | 409 |
| 6.8 | 7.4 | -8.5% | 6.4 | Hours Paid per Patient Day | 6 | .7 | 7.2 | -7.2% | 6.1 |

Medical Executive Committee CMO Report to the ECMC Board of Directors March 2024

University at Buffalo Update

- The Chair of Medicine has been selected. We are waiting for the announcement.
- Psychiatry Chair search is underway as well as the Anesthesia Chair search.

Current hospital operations

| • | Admissions YTD: | 2,462 | (2,234) |
|---|-----------------------|--------|---------|
| • | ED visits YTD: | 10,192 | (9,316) |
| • | CPEP visits: | 1,797 | (1,825) |
| • | Observation: | 648 | (470) |
| • | Inpatient Surgeries: | 957 | (839) |
| • | Outpatient Surgeries: | | (1,484) |
| • | ALC days YTD: | 1,681 | (2,729) |

The average length of stay MTD 7.8 (7.6). CMI 1.8474 (1.7565)

CMO Update

- Preparing for the 2024 eclipse on April 8, 2024. Upwards of a million additional people are expected in the city of Buffalo, as we are in the direct path of the eclipse.
 - o Infrastructure concerns
 - Volume of traffic on the road
 - o Schools will be closed, childcare issues with call-ins
 - Road congestion
 - o Patient discharging concerns
 - o Expecting a state of emergency being declared prior to the event

OR Lighting Update

• The lighting project will be complete by the end of this week. They are working on room eleven, our final OR room. Thank you to Marc Labelle and Cassie Davis for making this project happen on time and on budget.

Communications and External Affairs Report Submitted by Peter K. Cutler Vice President of Communications and External Affairs March 26, 2024

Marketing

Continued advertising marketing support of Orthopedic services, Help Center and nursing
recruitment through placement of TV, radio, and print advertisements. Also maintained ECMC's
long secured billboard just east of Grider Street on the outbound side of NYS Route 33 with
graphics highlighting ECMC's nationally ranked Orthopedic services.

Media Report

 Continue coordination of media interviews related to ECMC service lines including coverage of transplantation, orthopedics, behavioral health, surgical services, physical therapy and emergency services.

Community and Government Relations

• With Governor Hochul's delivery of her annual State of the State address and then the subsequent release one week later of her recommended 2024-25 Executive Budget, the NYS 2024 Legislative Session has commenced. We are engaged in our advocacy in the State Capitol between the Executive Chamber and each house of the State Legislature for programs, policies and funding opportunities to reinforce and strengthen ECMC's position as our region's leading healthcare institution for trauma/emergency, behavioral health, transplantation services, as well as enhance our position as our region's safety net hospital, providing high-quality healthcare services for the most vulnerable residents of our community.

Medical Executive Committee Meeting Monday, February 26, 2024 <u>Meeting held by Microsoft</u> Teams Platform

Attendance (Voting Members):

| Sergio Anillo, MD | Jeffrey Brewer, MD | Anthony DePlato, MD | Douglas Drumsta, MD |
|----------------------|------------------------|-----------------------|----------------------------|
| Richard Ferguson, MD | Wiliam Flynn, Jr., MD | Sandra Sieminski, MD | Richard Hall, MD, DDS, PhD |
| Joseph Izzo, JR., MD | Elizabeth Kapral, DDS | Keith Krabill, MD | Michael Manka, MD |
| Ellen Rich, MD | Parveen Minhas, ANP | Yaron Perry, MD | Jennifer Pugh, MD |
| Matthew Ruggieri, MD | Yousef Soofi, MD | Kimberly Wilkins, MD | |
| Mary Welch, MD | Cassandra Williams, MD | Siva Yedlapati | |
| Yogesh Bakhai, MD | William Belles, MD | Rebecca Buttaccio, PA | |

Non-Voting Members and Guests:

| Thomas Quatroche, PhD | Andy Davis, COO | Samuel Cloud, DO | Arthur Orlick, MD |
|-----------------------|---------------------------|----------------------|-----------------------|
| William Flynn, MD | Mandip Panesar, MD | Charlene Ludlow, RN | Dean Allison Brashear |
| Cheryl Carpenter | Jon Swiatkowski | Donna Jones | Cassie Davis |
| Michael Ott, Pharm D | John Cumbo | Becky DelPrince | Peter Cutler |
| Charles Cavaretta | Ashley Halloran, Pharmacy | John Tomaszewski, MD | Melissa Gomez |

CALL TO ORDER

A. Dr. Jennifer Pugh, President, called the meeting to order at 11:31 am.

B. PRESIDENT'S REPORT:

- 1. Doctor's Day Breakfast will be held on Wednesday, March 27, 2024 beginning at 7:30 am in the overflow café.
- 2. The next Wellness Welcome will take place on Thursday, April 18, 2024. We are currently working on our invite list of new Medical Dental Staff members so if you have anyone in your department that you would recommend attending, please let us know.
- 3. We are finalizing our plan for in-house leadership training to be held over 2 years in Buffalo. We are looking for those currently in leadership to nominate rising leaders within your department who would benefit from coursework in resolving conflict, communication, and healthcare strategy.
- 4. Dr. Pugh took a moment to recognize Residents Week and to thank the Residents for all they do.

II. ADMINISTRTIVE REPORTS

- A. CEO/COO/CFO REPORT –Tom Quatroche, CEO, Andrew Davis, COO, Jon Swiatkowski, CFO
 - 1. CEO Dr. Tom Quatroche, PhD.
 - a. The hospital has recently received IGT operational funding.
 - b. Thank you to Jon Swiatkowski and his team who assisted with the process of retrieving FEMA funding.
 - c. We continue to work with state legislators reviewing the state budget.

Erie County Medical Center - Medical Executive Committee February 26, 2024 Minutes of Record 1 | P a g e d. Operationally, Dr. Quatroche thanked all for their continued efforts as the hospital becomes busier.

2. COO REPORT - Andrew Davis

- a. Mr. Davis thanked the Synergy team as they reopened the bariatric center.
- b. The OR lighting project continues and should be completed by the end of March. Mr. Davis thanked all assisting with this project.

3. CFO REPORT – Jon Swiatkowski

- a. Mr. Swiatkowski began with a recap of January 2024 progress. There is a continuation of positive trends with the inpatient status and inpatient surgeries. The January snowstorm did have a slight impact on our overall numbers, as some clinics had to close due to the storm with travel restrictions in place.
- b. We continue to work with the state and the federal government for future reimbursement for the hospital.
- c. Mr. Swiatkowski and John Cumbo spoke on the recent Charge Healthcare cyber-attack. This was a widespread issue impacting thousands of providers.

III. CHIEF NURSING OFFICER REPORT – Charlene Ludlow, RN, CIC

- a. Reminder that Doctor's Day is March 27, 2024, with breakfast in the overflow café from 7:30 10:00 am.
- b. Recruitment continues in the nursing department working with several universities. We are currently experiencing the highest volume of students inhouse.
- c. Bed huddles continue seven days a week. Working on earlier discharges (by noon each day) if possible. This will assist with throughput for the rest of the day.
- d. Congratulations to Karen Konikoff as she prepares for retirement. There will be a luncheon taking place Wednesday this week.

IV. UNIVERSITY REPORT – Dean Allison Brashear, MD, MBA

- a. Dr. Brashear spoke on the Learning Environment.
- b. The Student Graduation questionnaire went out on February 14, 2024 and is completed by the medical students. These students graduate on April 26th and the 4th year students are asked to fill out this questionnaire. A response rate of 80-90% is typically received.
- c. 'Beyond The Knife' program took place last week. This program was about the neighborhoods, their configurations, and the impact on the community.
- d. 'Changing the East Side of Buffalo' program will be taking place later today. We have over 400 people registered for this event.
- e. On March 15, 2024, at noon the Powerhouse will host 'The Match'. This event has every 4th year medical students open their envelope for their match.

V. CHIEF MEDICAL OFFICER REPORT – Samuel D. Cloud, DO

- a. Dr. Cloud took a moment to congratulate Michael Cummings, MD and Jillian Sauer, RN for achieving the distinguished Physician Honoree award and the distinguished Nursing Honoree award, respectively.
- b. Dr. Cloud shared an operation update which included ED volumes, CPEP volumes, admissions, observation, average length of stay, ALC days, along with inpatient and outpatient surgeries.

Erie County Medical Center - Medical Executive Committee February 26, 2024 Minutes of Record 2 | Page


- c. An updated on the OR lightening project was shared. The project is on schedule and on budget.
- d. Dr. Cloud shared an update on the COVID trends in Western New York along with trends on Influenza.
- e. The University is reaching an end to the interview process for the Chair of Medicine with the Chair of Psychiatry and the Chair of Anesthesia search getting underway.

VI. ASSOCIATE MEDICAL DIRECTORS REPORT – Dr Arthur Orlick, Dr. Michael Cummings, Dr. Tadakamalla and Dr. William Flynn

- a. Dr. Flynn stated that the Surgical Executive Committee is working on process performance indicators to improve efficiencies in the OR.
- b. The Trauma program is preparing for the March 2025 re-certification.

VII. CHIEF MEDICAL INFORMATION OFFICER REPORT – Mandip Panesar, MD

- a. Dr. Panesar spoke on the CDS Query Intervention process through Meditech.
 This is a revised process which should be more streamlined. We anticipate a GO LIVE date beginning early next week.
- b. Dr. Panesar and John Cumbo reviewed HYPERCARE. Cortext is being decommissioned at the end of July 2024. Onsite training for HYPERCARE begins March 18, 2024. Complete support for current Cortext will end July 30, 2024.



VIII. CONSENT CALENDAR

| Reappointments Resignations Dual Reappointment Applications New Business / Extractions Appointment Approval Appointment Approval Appointment Approval Committee Assignments Particular Manua Dietary Manua OPPE Metrics Ambulatory Care Informed Consent of Treatment Downtime Forms: Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks PRN Medication Admin Reassessment Record Med Surg Line Assessment Neurovascular Flap Graft Check Approvascular Flap Graft Check University GME Committee — Minutes of January 2024 Linaclotide (Linzess) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Review and Approvascular Glacks Review and Approvascular Flap Graft Checks Approvascular Flap Graft Check Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Eaceive and File Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | MEETING MINUTES/MOTIONS | PAGE# | |
|--|----------|---|---------|---|
| 2. CREDENTIALS COMMITTEE: February 1, 2024 Appointments Reappointments Resignations Dual Reappointment Applications New Business / Extractions Appointment Approval Committee Assignments Radiology Job Description Pictary Manua OPPE Metrics 3. HIM – Minutes of January, 2024 Ambulatory Care Informed Consent of Treatment Downtime Forms: Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks PRN Medication Admin Reassessment Record Med Surg Line Assessment Neuro Checks DT Neuro | 1. | MINUTES of the Previous MEC Meeting: January 22, 2024 | 7-11 | Receive and File |
| Review and Approval Reappointments Resignations Review and Approval Review and Approva | 2. | | | Receive and File |
| Resignations Resignations Dual Reappointment Applications New Business / Extractions Appointment Approval Committee Assignments Review and Approval Pareire Approval Appointment Approval Review and Approval Pareire Assignments Review and Approval Review and Approval Review and Approval Review and Approval Pareire Assignments Review and Approval Pareire Assignments Review and Approval Pareire Approval Review and Approval Pareire Approval Review and Approval Review and Approval Ambulatory Care Informed Consent of Treatment Pareire Ambulatory Care Informed Consent of Treatment Downtime Forms: Blood Transfusion Pareire Assessment Review and Approval Neurovascular Checks Review and Approval Review and Approva | | | 42.25 | Review and Approve |
| Dual Reappointment Applications New Business / Extractions Appointment Approval Appointment Approval Appointment Approval Review and Approval Dietary Manua 107 Review and Approval Review and | | Reappointments | 13-25 | Review and Approve |
| New Business / Extractions Appointment Approval 90-91 Review and Approval 99-96 Review and Approval 99-96 Review and Approval 99-96 Review and Approval 99-96 Review and Approval 99-97 Review and Approval 99-97 Review and Approval 107 Review and Approval 109-126 Review and Approval 129-126 Review and Approval | | Resignations | | Review and Approve |
| Appointment Approval Committee Assignments 93-96 Review and Approval Radiology Job Description Period Dietary Manua OPPE Metrics Interview and Approval Ambulatory Care Informed Consent of Treatment Downtime Forms: Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks PRM Medication Admin Reassessment Record Med Surg Line Assessment Neuro Checks DT Od Int RN Consents OBS Verification Vascular Flap Graft Check An Review and Approval Approvation of Treatment Review and Approvation of Treatment Approvation of Treatment Downtime Forms: Blood Transfusion 29-30 Review and Approvation of Treatment Review and Approvation of Treatment 31-32 Review and Approvation of Treatment Review and Approvation of Treatment 34-35 Review and Approvation of Treatment Approvation of Treatment 36-37 Review and Approvation of Treatment Review and Approvation of Treatment Approvation of Treatment Approvation of Treatment 40 Review and Approvation of Treatment Approvation of Treatment Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | Dual Reappointment Applications | | Review and Approve |
| Committee Assignments 93-96 Review and Approversity | | New Business / Extractions | | |
| Radiology Job Description Dietary Manua 107 Review and Approv OPPE Metrics 109-126 Review and Approv 3. HIM — Minutes of January, 2024 Ambulatory Care Informed Consent of Treatment 28 Review and Approv Downtime Forms: Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks 31 Review and Approv Neurovascular Checks 33 Review and Approv Med Surg Line Assessment Record Med Surg Line Assessment Q4 hr RN Consents OBS Verification Q4 hr RN Consents OBS Verification Vascular Flap Graft Check 40 Review and Approv Wound Pressure Injury 41-42 Review and Approv Wound Pressure Injury 41-42 Review and Approv 41-42 Review and Approv 42 44-49 Receive and Approv 43 Review and Approv 44 Review and Approv 45 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | Appointment Approval | 90-91 | Review and Approve |
| Radiology Job Description Dietary Manua 107 Review and Approv OPPE Metrics 109-126 Review and Approv 3. HIM — Minutes of January, 2024 Ambulatory Care Informed Consent of Treatment 28 Review and Approv Downtime Forms: Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks 31 Review and Approv Neurovascular Checks 33 Review and Approv Med Surg Line Assessment Record Med Surg Line Assessment Q4 hr RN Consents OBS Verification Q4 hr RN Consents OBS Verification Vascular Flap Graft Check 40 Review and Approv Wound Pressure Injury 41-42 Review and Approv Wound Pressure Injury 41-42 Review and Approv 41-42 Review and Approv 42 44-49 Receive and Approv 43 Review and Approv 44 Review and Approv 45 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | Committee Assignments | 93-96 | Review and Approve |
| Dietary Manua 107 Review and Approv OPPE Metrics 109-126 Review and Approv 3. HIM – Minutes of January, 2024 27-42 Receive and file Ambulatory Care Informed Consent of Treatment 28 Review and Approv Downtime Forms: Blood Transfusion 29-30 Review and Approv Wound Pressure Injury Assessment 31-32 Review and Approv Neurovascular Checks 33 Review and Approv Med Surg Line Assessment Record 34-35 Review and Approv Neuro Checks DT 38 Review and Approv Neuro Checks DT 38 Review and Approv Vascular Flap Graft Check 40 Review and Approv Vascular Flap Graft Check 40 Review and Approv Wound Pressure Injury 41-42 Review and Approv Wound Pressure Injury 41-42 Review and Approv Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy 56-60 Receive and File Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 53 Receive and File Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | | 98-105 | Review and Approve |
| OPPE Metrics 109-126 Review and Approv 27-42 Receive and file Ambulatory Care Informed Consent of Treatment 28 Review and Approv Downtime Forms: Blood Transfusion 29-30 Review and Approv Wound Pressure Injury Assessment 31-32 Review and Approv Neurovascular Checks 33 Review and Approv Med Surg Line Assessment Record 34-35 Review and Approv Med Surg Line Assessment 36-37 Review and Approv Neuro Checks DT 38 Review and Approv Q4 hr RN Consents OBS Verification Vascular Flap Graft Check 40 Review and Approv Wound Pressure Injury 41-42 Review and Approv 4. University GME Committee – Minutes of January 2024 44-49 Receive and File Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | 5.7 | 107 | • |
| 3. HIM – Minutes of January, 2024 Ambulatory Care Informed Consent of Treatment Downtime Forms: Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks PRN Medication Admin Reassessment Record Med Surg Line Assessment Active And Approvate App | | · · · · · · · · · · · · · · · · · · · | 109-126 | · · |
| Ambulatory Care Informed Consent of Treatment Downtime Forms: Blood Transfusion Blood Transfusion Wound Pressure Injury Assessment Review and Approx Neurovascular Checks Review and Approx PRN Medication Admin Reassessment Record Med Surg Line Assessment Neuro Checks DT Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Wound Pressure Injury University GME Committee – Minutes of January 2024 Medition to Formulary Linaclotide (Linzess) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Review and Approx 28 Review and Approx 29-30 Review and Approx 31-32 Review and Approx 31-32 Review and Approx 34-35 Review and Approx 36-37 Review and Approx 38 Review and Approx 40 Review and Approx 40 Review and Approx 41-42 Review and Approx 41-42 Review and Approx 42-49 Receive and File Addition to Formulary Linaclotide (Linzess) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet | 3. | | 27-42 | • • • |
| Downtime Forms: Blood Transfusion 29-30 Review and Approx | <u> </u> | Ambulatory Care Informed Consent of Treatment | | |
| Blood Transfusion Wound Pressure Injury Assessment Neurovascular Checks PRN Medication Admin Reassessment Record Med Surg Line Assessment Neuro Checks DT Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Wound Pressure Injury Linaclotide (Linzess) – restricted to prior therapy Abacavir 300 mg tablet Review and Approx Review and Approx 36-37 Review and Approx 38 Review and Approx 39 Review and Approx 40 Review and Approx 41-42 Review and Approx 41-42 Review and Approx 41-42 Review and Approx 42-49 Receive and File 43-49 Receive and File 44-49 Receive and File 45-65 Receive and File 46-65 Receive and File 47-65 Receive and File 48-61-65 Receive and File 49 Receive and File 40 Review and Approx 40 Review and Approx 40 Review and Approx 41-42 Review and Approx 41-42 Review and Approx 41-49 Receive and File 40 Receive and File 40 Receive and File 40 Receive and File 41-49 Receive and File | | | 20 | Torion and Approve |
| Wound Pressure Injury Assessment Neurovascular Checks PRN Medication Admin Reassessment Record Med Surg Line Assessment Neuro Checks DT Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Wound Pressure Injury 41-42 Review and Approv 42 44-49 Receive and Approv 45 P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Ageview and Approv 31-32 Review and Approv 32-37 Review and Approv 33-37 Review and Approv 34-49 Review and Approv 40 Review and Approv 41-42 Review and Approv 44-49 Receive and File 51-78 Receive and File 61-65 Receive and File 61-65 Receive and File | | | 29-30 | Review and Approve |
| Neurovascular Checks PRN Medication Admin Reassessment Record Advanced Surg Line Assessment Neuro Checks DT Neuro Checks DT Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Wound Pressure Injury Linaclotide (Linzess) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Review and Approv 33 Review and Approv 34 Review and Approv 44 Review and Approv 45 Receive and File 51 Receive and File 61 Receive and File 53 Receive and File | | | | Review and Approve |
| Med Surg Line Assessment Neuro Checks DT Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Wound Pressure Injury 4. University GME Committee – Minutes of January 2024 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 36-37 Review and Approvate 4 40 Review and Approvative a | | , , | 33 | Review and Approve |
| Neuro Checks DT Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Wound Pressure Injury 4. University GME Committee – Minutes of January 2024 4. University GME Committee – Minutes of January 2024 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Review and Approvative an | | PRN Medication Admin Reassessment Record | 34-35 | Review and Approve |
| Q4 hr RN Consents OBS Verification Vascular Flap Graft Check Vound Pressure Injury 4. University GME Committee – Minutes of January 2024 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Review and Approvative 41-42 Review and Approvative 41-42 Receive and File 51-78 Receive and File 61-65 Receive and File Fransplant Removal from formulary Abacavir 300 mg tablet | | Med Surg Line Assessment | 36-37 | Review and Approve |
| Vascular Flap Graft Check Wound Pressure Injury 4. University GME Committee – Minutes of January 2024 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Acceive and File Review and Approvative and File 51-78 Receive and File 61-65 Receive and File 61-65 Receive and File | | | 38 | Review and Approve |
| Wound Pressure Injury 4. University GME Committee – Minutes of January 2024 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Review and Approvative Approval 41-42 Review and Approvative Approval 41-42 Receive and File 51-78 Receive and File 61-65 Receive and File File Transplant Removal from formulary Abacavir 300 mg tablet | | | 39 | Review and Approve |
| 4. University GME Committee – Minutes of January 2024 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Receive and File 61-65 Receive and File 61-65 Receive and File | | | | |
| 5. P & T Committee – Minutes of February 6, 2024 Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet 51-78 Receive and File 56-60 Receive and File 61-65 Receive and File 53 Receive and File | | , , | | |
| Addition to Formulary Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Addition to Formulary 56-60 Receive and File 61-65 Receive and File 53 Receive and File | | | | |
| Linaclotide (Linzess) – restricted to prior therapy Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Seceive and File Transplant Receive and File | 5. | | 51-78 | Receive and File |
| Letermovir (prevymis) – restricted to infectious diseases and/or Transplant Removal from formulary Abacavir 300 mg tablet Receive and File | | • | | |
| Transplant Removal from formulary Abacavir 300 mg tablet 53 Receive and File | | | 56-60 | Receive and File |
| Abacavir 300 mg tablet 53 Receive and File | | | 61-65 | Receive and File |
| | | Removal from formulary | | |
| | | Abacavir 300 mg tablet | 53 | Receive and File |
| I rizivir (Abacavir, Lamivudine, Zidovudine) 53 Receive and File | | Trizivir (Abacavir, Lamivudine, Zidovudine) | 53 | Receive and File |
| Combivir (Lamvudine, Zidovudine) 53 Receive and File | | Combivir (Lamvudine, Zidovudine) | 53 | Receive and File |
| Epzicom (Abacavir Sulfate, Lamivudine) 53 Receive and File | | Epzicom (Abacavir Sulfate, Lamivudine) | 53 | Receive and File |
| Guideline Updates | | , | | |
| Look Alike-Sound Alike List 68 Receive and File | | · | 68 | Receive and File |
| High Alert Medications 66-67 Receive and File | | | 66-67 | |
| 6. Professional Dev. & Wellness Committee – Minutes of January 18, 2024 80 Receive and File | 6. | | | |
| 7. Resource Management Committee – Minutes of January 10, 2024 82-84 Receive and File | | • | | |

MOTION to APPROVE all items in the CONSENT CALENDAR was made and seconded. Motion to approve all items in the Consent Calendar is carried.

UNANIMOUSLY APPROVED.

Erie County Medical Center - Medical Executive Committee February 26, 2024 Minutes of Record 4 | Page

IX. APPROVALS – Jennifer Pugh, MD

- a. Dr. Pugh discussed the following items for review and approval:
 - 1. Appointment Approval
 - 2. Committee Assignment, 2024
 - 3. Radiology Job Descriptions
 - 4. Dietary Manual
 - 5. OPPE Metrics

MOTION to APPROVE all items was made and seconded. Motion to approve all items is carried.

UNANIMOUSLY APPROVED.

X. APPOINTMENT APPROVALS – Jennifer Pugh, MD

a. Dr. Pugh presented the appointment of Siva Yedlapati, MD as the Associate Chief of Service (Hospitalist) Internal Medicine.

MOTION to APPROVE the appointment was made and seconded. Motion to approve is carried.

UNANIMOUSLY APPROVED

XI. EXECUTIVE SESSION

The Medical Executive meeting was adjourned at 12:39pm to Executive Session for the purpose of receiving and filing minutes from the January 2024 Chiefs of Service meetings and the January 2024 Board Patient Safety & Quality Assurance meetings along with discussing the Leadership Council Report, Quality Patient Safety report and the Regulatory report.

The following Executive Session agenda items were discussed and motion(s) were made:

A. <u>MOTION</u>: Receive and file Board Quality PI meeting minutes from January 2024 and Chiefs of Service meeting minutes from January 2024.

Motion, Seconded and MOTION APPROVED

XII. ADJOURNMENT

There was no further business conducted. Motion to adjourn the meeting was made and seconded. The next meeting will be Monday, March 25, 2024, at 11:30 am. via Teams/Hybrid in the Dr. Zizzi conference room at ECMC. Meeting was adjourned at 12:49 pm.

Page 73 of 330

Respectfully submitted,

Wirke Marker, MD

Michael Manka, MD President-Elect

On behalf of James Lukan, MD, FACS Secretary, ECMCC, Medical/Dental Staff

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Financial Report December 31, 2023

PRELIMINARY DRAFT
PRELIMINARY DRAFT
Purposes Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PREPROSES
OMINY
PRELIMINARY
PRELIMINARY
PREPROSES
OMINY
PREPROSES
OMINY
PREPROSES
OMINY

Contents

| Independent auditor's report | 1-3 |
|---|-------|
| Management's discussion and analysis | 4-13 |
| Basic financial statements | |
| Statements of net position | 14 |
| Statements of revenues, expenses and changes in net position | 15 |
| Statements of cash flows | 16-17 |
| Statements of net position—discretely presented component units | 18 |
| Statements of revenues, expenses and changes in net position—discretely presented component units | 19 |
| Notes to the financial statements | 20-54 |
| Required supplementary information | |
| Schedule of corporation's contributions NYSLRS pension plan | 55 |
| Schedule of corporation's proportionate share of net pension liability NYSLRS pension plan | 56 |
| Schedule of corporation's changes in total OPEB liability and related ratios | 57 |
| Uniform guidance audit requirements | |
| Schedule of expenditures of federal awards | 58 |
| Notes to schedule of expenditures of federal awards | 59 |
| Report on internal control over financial reporting and on compliance and other matters based on an audit of financial statements performed in accordance with <i>Government Auditing Standards</i> | 60-61 |
| Report on compliance for each major federal program; report on internal control over compliance; and report on schedule of expenditures of federal awards required by the uniform guidance | 62-64 |
| Schedule of findings and questioned costs | 65-66 |
| Summary schedule of prior year findings and questioned costs | 67 |

Independent Auditor's Report

Board of Directors
Erie County Medical Center Corporation

Report on the Audit of the Financial Statements

Opinions

We have audited the financial statements of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation (the Corporation), a component unit of the County of Erie, as of and for the years ended December 31, 2023 and 2022, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements as listed in the table of contents.

In our opinion, the accompanying financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation, as of December 31, 2023 and 2022, and the respective changes in financial position, and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinions

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions. The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc., and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*.

Emphasis of Matter

As discussed in Note 8 to the financial statements, the Corporation restated the December 31, 2022 financial statements. The restatement was required to be made for the implementation of the Governmental Accounting Standards Board (GASB) Statement No. 96, Subscription-Based Information Technology Arrangements. Our opinion is not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for twelve months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that management's discussion and analysis on pages 4 to 13 as well as the required supplementary information for certain pension and other postemployment benefits (OPEB) related data on pages 55 to 57 be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the GASB who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated **DATE** on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

DATE

FOR REVIEW Subject to Change Aproduced Not to be Reproduced

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Management's Discussion and Analysis

Erie County Medical Center Corporation (the Corporation or ECMCC) is a state public benefit corporation dedicated to provide every patient the highest quality of care delivered with compassion. The Corporation fully embraces its position as a safety net provider for the eight-county region of Western New York State (encompassing over 1.5 million residents), supporting persons in need who lack the ability to pay.

To assist the reader in understanding the operations of the Corporation, this annual report has been organized into three parts that should be read together:

- Management's discussion and analysis
- Financial statements and notes to the financial statements and
- Supplemental schedules

The purpose of the discussion and analysis is to provide the reader with objective data to evaluate the financial position and the activities of the Corporation for the year ended December 31, 2023. This narrative and the financial statements and footnotes are the responsibility of the Corporation's management.

The financial statements (the statements of net position, the statements of revenues, expenses and changes in net position and the statements of cash flows) present financial information in a form similar to that used by other government hospitals and have been prepared in accordance with accounting principles generally accepted in the United States of America.

In 2023, the Corporation implemented GASB Statement No. 96, Subscription-Based Information Technology Arrangements. This standard extends the right-of-use accounting concepts introduced in GASB Statement No. 87 to subscription-based information technology arrangements (SBITAs). Under GASB 96, governments are required to identify arrangements that qualify as SBITAs and recognize a right-to-use subscription asset, initially measured as the sum of the initial subscription liability amount, payments made to the vendor before commencement of the subscription term, and capitalizable implementation costs. The subscription asset is then amortized over the subscription term. The accompanying financial statements and management discussion and analysis information for the year ended December 31, 2022 have been restated to reflect the new accounting standard.

The accompanying financial statements of the Corporation include financial data of the Corporation's discretely presented component units: (i) ECMC Foundation, Inc., and (ii) The Grider Initiative, Inc. however, Management's Discussion and Analysis focuses on the Corporation.

Introduction

During 2023, the Corporation persevered through it's fourth consecutive year of significant financial challenges, while continuing to provide high quality, compassionate care to the tens of thousands of Western New Yorkers who depend on ECMCC, serving as the region's community hospital, helping patients from the most influential to the most vulnerable. ECMCC's dedicated caregivers, support staff, executive leadership, as well as an involved and supportive Board of Directors, continue to advance the mission of the Corporation and its service to the greater Western New York area. The Corporation continues to be a provider of choice in our community as a result of its continual focus on high quality healthcare services, the patient experience and physician engagement.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis

The Corporation began a period of operational recovery through growth during 2023, providing a higher volume of services within inpatient and outpatient services to Western New York residents and as well as many others beyond this region. Patient volume encounters (not expressed in thousands) are as follows:

| | | | | | | % Growth |
|-------------|---------|---------|---------|---------|---------|-----------|
| | 2019 | 2020 | 2021 | 2022 | 2023 | 2022-2023 |
| | | | | | | |
| Inpatients | 19,996 | 19,110 | 18,903 | 17,412 | 17,643 | 1.3% |
| Surgeries | 15,606 | 12,481 | 13,803 | 12,478 | 13,321 | 6.8% |
| Emergency | 69,391 | 65,261 | 68,384 | 59,064 | 63,715 | 7.9% |
| Outpatients | 306,891 | 299,297 | 280,611 | 274,402 | 297,168 | 8.3% |
| Dialysis | 27,549 | 27,973 | 26,116 | 24,961 | 25,159 | 0.8% |
| Transplants | 127 | 134 | 146 | 148 | 151 | 2.0% |

The healthcare industry nationally and within this market continued to face challenges during 2023 and the Corporation was not immune to these headwinds. However, the Corporation worked hard to begin to address them and recover. In 2023, ECMCC inpatient volumes ended the year higher than prior year by 1.3% in terms of patient discharges and by 6.3% for inpatient surgeries while length of stay improved by 12.1%. Outpatient surgeries were 7.1% ahead of prior year with emergency department visits exceeding 2022 by 7.9%, leading to a growth in total outpatient visits from the prior year of 8.3%. As the Regional Center of Excellence for Transplantation and Kidney Care, continued growth in this program has been experienced over the last two years, providing life saving procedures to the residents of Western New York and beyond. 2023 saw the most transplants (kidney and pancreas) ECMCC has performed in it's history, with 151 transplant surgeries, an increase of 2.0% and 18.9% over 2022 and 2019 (pre-COVID levels), respectively.

The global outbreak of COVID-19, a new strain of coronavirus that can result in severe respiratory disease, was declared a pandemic by the World Health Organization in March of 2020. After three unprecedented years of managing COVID-19, the Department of Health and Human Services (HHS) declared an end to the public emergency on May 11, 2023, thus ending the pandemic. With a lot of time, energy, and unyielding teamwork during the pandemic, the Corporation was able to effectively manage through the pandemic by implementing operational improvements, successfully recruiting staff, and entering into partnerships to provide funding assistance in addition to the COVID Relief funding. ECMCC management took on all additional measures during the pandemic to protect the health of the community and promote the continuity of its mission and will continue to monitor the course of COVID-19 beyond the pandemic.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis (Continued)

In response to the impact on the healthcare environment from COVID-19, the Coronavirus Aid, Relief, and Economic Security (CARES) Act and the American Rescue Plan (ARP) Act (Acts) were enacted by Congress during 2020 and 2021, respectively. These Acts included, among other things, support for healthcare providers and patients in the form of grants, payments for uninsured patients, and changes to Medicare and Medicaid payments. The Corporation to date has received \$72.4 million of Provider Relief Fund distributions provided under the CARES and ARP Acts. During 2020, the Corporation also received \$39.1 million and \$10 million in loans under the Medicare Accelerated and Advance Payment Program and the Paycheck Protection Program (PPP), respectively. During 2021, the PPP loan forgiveness application was approved by the U.S. Small Business Administration and, as such, the \$10 million loan was forgiven in full. As of December 31, 2022, the Medicare Accelerated and Advance Payments had been fully recouped.

The CARES Act also includes financial relief through the Federal Emergency Management Agency's (FEMA) Disaster Relief Fund. As of December 31, 2023, the Corporation has been awarded and received \$6.6 million from FEMA to reimburse eligible incremental expenses as a result of COVID-19. The Corporation will continue to submit for grant reimbursement for remaining eligible COVID-19 expenses under this program.

During 2022 and 2023, the industry and more specifically, the Western New York health care market experienced a cost inflation crisis. This crisis was driven nationally and locally by the lingering effects of staffing challenges across all healthcare industry stakeholders including suppliers, manufacturers, postacute settings as well as providers. As costs continued to escalate to operate the business and care for the patients within the community, in order to maintain mission critical services, ECMCC has worked closely with the New York State Department of Health's various grant and operating assistance programs to bridge cash flow funding gaps. Simultaneously, ECMCC has implemented several operational improvement actions in an effort to mitigate as much of the cost escalation as possible. Although significant improvements have been made operationally, the New York State Department of Health has provided supplemental funding to the Corporation as well as many hospitals and nursing homes across New York State. As a result, the Corporation received \$51,998 for the year ended December 31, 2022. This benefit has been recorded as non-operating revenue within the statements of revenue, expenses and changes in net position. An additional \$27,000 was received in December 2022 for the year ended December 31, 2023, and was recorded as unearned revenue in the statements of net position as of December 31, 2022 and recorded as non-operating revenue within the statements of revenue, expenses and changes in net position for the year ended December 31, 2023. Two additional awards totaling \$76,368 were received and recognized as non-operating revenue during the year ended December 31, 2023.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis (Continued)

The continued volume and visit trends reflect the trust that the Western New York community has placed in ECMCC. Notable achievements in 2023 include:

- ECMCC earned its full hospital accreditation The Joint Commission's Gold Seal of Approval Accreditation by demonstrating continuous compliance with performance standards.
- Successful reaccreditation by The Centers for Medicare and Medicaid Services (CMS), part of the Department of Health and Human Services (HHS) of Transplant program, housed in ECMCC's Regional Center of Excellence for Transplantation and Kidney Care.
- Commission on Accreditation of Rehabilitation Facilities (CARF) issued three-year accreditation to ECMCC's Acute Inpatient Rehabilitation Programs (through June 30, 2026) stating that this "achievement is an indication of ECMCC's dedication to improving the quality of the lives of the persons served."
- ECMCC's Laboratory Services received the two-year accreditation for ECMCC's Transfusion Services following bi-annual on-site assessment by the Association for the Advancement of Blood and Biotherapies (AABB)
- Terrace View Long-Term Care Facility was named to Newsweek's 2024 Best Nursing Homes List for performance on key measures on health inspections, quality measures and staffing. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. Only four percent of nursing homes nationwide received this distinction. Of the 600 skilled nursing facilities state-wide that operate, 42 received this recognition. It is a distinct honor to be ranked amongst the best nursing homes within both the state and the nation. This is the fourth consecutive year Terrace View has received this recognition.
- ECMCC has been recognized by the Lown Institute for outstanding social responsibility, receiving an
 "A" grade on the 2023-24 Lown Institute Hospitals Index. ECMCC achieved this honor through strong
 performance across metrics of health equity, patient outcomes, and value of care, out of more than
 3,600 hospitals nationwide. In 2021, ECMCC was ranked among the top 100 hospitals in the United
 States for racial inclusivity by the Lown Institute; in 2022 ECMCC was ranked in the top 50 hospitals
 in the country for racial inclusivity.
- ECMCC was recognized by the Buffalo Purchasing Initiative for superseding its goal in 2023 for spending with businesses owned by people of color.
- ECMCC's hip replacement surgery service ranked in the nation's top 7% by US News & World Report. ECMCC earned the highly respected publication's High Performing ranking, placing it among 437 hospitals out of 6,000 evaluated for the service.
- ECMCC earned platinum recognition for its efforts to increase organ and tissue donor registrations across the country, through the DoNation Campaign. DoNation is a national initiative sponsored by the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA), to educate our community about the crucial need for organ and tissue donation and to encourage people to sign up as organ and tissue donors. Between October 2022 and September 2023, ECMCC has actively participated in this campaign to earn this federal recognition.
- The American College of Emergency Physicians, implemented the Geriatric Emergency Department Accreditation (GEDA) program to recognize those emergency departments that provide excellent care for older adults. ECMCC's Emergency Department has achieved the bronze standard – Level 3 GEDA accreditation. ECMCC named among one of America's 100 Best Hospitals for Orthopedic Surgery. This achievement reflects ECMCC's outstanding clinical outcomes for Orthopedic Surgery and puts ECMCC in the top 5% of hospitals nationwide for overall Orthopedic services.
- ECMCC was awarded the 2023 Orthopedic Surgery Excellence Award™, a Five-Star rating in Total Knee Replacement for two years in a row (2022-2023), a Five-Star rating for Hip Fracture Treatment for 13 years in a row (2011-2023) and a 2023 Five-Star Distinction in Total Hip Replacement.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis (Continued)

Financial Metric Analysis

The Corporation's total net position decreased in 2023 primarily due to the significant non-cash expenses related to the actuarial liability adjustments related to the New York State Pension Plan benefits and the unfavorable results from operations which were offset by grant funding assistance provided by New York State, recorded as non-operating revenue. Additional drivers of performance are discussed in further detail below.

Comparative financial ratios for the Corporation to the 2022 (most recent publicly available audited data) averages of other comparable New York State (NYS) Public Benefit Corporation (PBC) hospitals are presented in the following table. The financial statements used for the calculation of the following ratios, where appropriate, have been reclassified to conform to the presentation used in the development of the benchmarks, consistent with generally accepted accounting principles (U.S. GAAP) for entities not subject to the Governmental Accounting Standards Board (GASB) standards.

| | | ECMCC | | PBC Average |
|--------------------------------|--------|--------|-------|----------------|
| | 2023 | 2022 | 2021 | 2022 |
| Operating margin | -14.2% | -10.8% | -3.6% | -16.1% |
| Operating cash flow margin | -6.0% | 4.6% | 4.0% | -10.0% |
| Debt service coverage | 2.7 | 1.5 | 1.1 | -0.5 |
| Unrestricted days cash on hand | 14.1 | 29.2 | 48.7 | 48.9 |
| Days cash on hand | 90.5 | 118.7 | 140.2 | 65.1 |
| Days in accounts receivable | 66.0 | 53.9 | 49.5 | 34.1 |
| Average age of plant | 15.4 | 13.0 | 12.5 | 20.4 |

The operational performance ratios for 2023 generally represent unfavorable changes from the Corporation's 2022 performance ratios and favorable comparisons to the NYS Healthcare Public Benefit Corporations' ratios. Driving these unfavorable shifts during 2023 in large part is the large swing in the amortization component of the pension expense, shifting from a reduction in expense in 2022 of \$32.5 million to an increase in expense of \$39.8 million in 2023. Although these changes have no cash flows associated with them, the changes to the liabilities associated with them are included within the operating margin. The operating margin before the impact of the amortization components of the pension benefit and postemployment benefit is 11.6% and 20.3% for 2023 and 2022, respectively. This change before those actuarial impacts reflects a favorable movement in operating margin which is representative of the operational improvements and growth experienced during 2023. Additionally, grants received from the New York State Department of Health (NYSDOH) and FEMA have been recognized as non-operating revenue and are excluded from the operating ratio calculations as required under GASB accounting standards. Unrestricted days cash on hand decreased 15.1 days (51.7%) due to overall operating losses and the delay in the receipt of annual Disproportionate Share Hospital (DSH) Revenue to the first quarter of 2024. Days in accounts receivable increased by 12.1 days (22.5%) due to a delay in collections and an increase in unbilled accounts as a result of staffing shortages during the year. Average age of plant increased by 2.4 years (16.5%) as a result of reduced capital investment in an effort to manage ongoing operations and cash flow needs to maintain the services provided to the community while incurring operating losses.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Summary Financial Statements with Analysis

Management is providing the following summary financial statements and variance analysis for certain financial statement lines where it believes the readers understanding of the financial statements is enhanced.

Statements of Net Position

Net position is categorized as follows:

Net investment in capital assets: Consists of capital assets, net of accumulated depreciation and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets.

Restricted: Result when constraints placed on the use of the net position are either externally imposed by creditors, grantors, contributors, or imposed by law through constitutional provisions or enabling legislation.

Unrestricted: Represents the resources derived primarily from services rendered to patients and other operating revenues and not meeting the previously listed criteria. These resources are used for transactions related to the general healthcare and academic operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Condensed Statements of Net Position are as follows:

| | | | (| Restated) | 2023-2022 | | | | |
|--|----|-----------|----|-----------|-----------|-----------|----------|--|--|
| | me | 2023 | | 2022 | | \$ Change | % Change | | |
| Assets | 1 | | | | | | | | |
| Current assets, excluding assets whose | | | | | | | | | |
| use is limited | \$ | 189,816 | \$ | 210,427 | \$ | (20,611) | (9.8) | | |
| Assets whose use is limited | | 170,621 | | 157,516 | | 13,105 | 8.3 | | |
| Capital assets, net | | 313,039 | | 359,386 | | (46,347) | (12.9) | | |
| Net pension asset | | - | | 77,538 | | (77,538) | 100.0 | | |
| Other assets | | 8,906 | | 7,780 | | 1,126 | 14.5 | | |
| Total assets | | 682,382 | | 812,647 | | (130,265) | (16.0) | | |
| Deferred outflows of resources | | 159,464 | | 178,411 | | (18,947) | (10.6) | | |
| Total assets and deferred | | | | | | | | | |
| outflows of resources | \$ | 841,846 | \$ | 991,058 | \$ | (149,212) | (15.1) | | |
| Liabilities | | | | | | | | | |
| Current liabilities | \$ | 302,347 | \$ | 303,848 | \$ | (1,501) | (0.5) | | |
| Noncurrent liabilities | | 730,926 | | 560,724 | | 170,202 | 30.4 | | |
| Total liabilities | | 1,033,273 | | 864,572 | | 168,701 | 19.5 | | |
| Deferred inflows of resources | | 84,740 | | 396,441 | | (311,701) | (78.6) | | |
| Net Position | | | | | | | | | |
| Net investment in capital assets | | 58,654 | | 85,013 | | (26,359) | (31.0) | | |
| Restricted | | 95,555 | | 80,719 | | 14,836 | 18.4 | | |
| Unrestricted | | (430,376) | | (435,687) | | 5,311 | 1.2 | | |
| Total net position | | (276,167) | | (269,955) | | (6,212) | (2.3) | | |
| Total liabilities, deferred inflows | | | | | | | | | |
| of resources and net position | \$ | 841,846 | \$ | 991,058 | \$ | (149,212) | (15.1) | | |

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Statements of Net Position (Continued)

Overall, total assets and deferred outflows of resources decreased \$149,212 from 2022 to 2023. The following variances in total assets are noteworthy:

Total current assets, excluding the current portion of assets whose use is limited, decreased by \$20,611 due to the following:

- Cash, cash equivalents and investments decreased by \$20,029 due to losses from operations and the timing of the annual DSH and Upper Payment Limit (UPL) cash receipts offset by earnings on investments.
- Patient accounts receivable, net, increased by \$18,820 as a result of current year decreases in collections due to an increase in unbilled accounts as a result of staffing shortages and increased patient volumes.
- Other receivables decreased by \$21,822 which is due to a \$21,856 decrease in Medicaid DSH and UPL program receivables, a decrease of \$286 in due from third party payors and a \$320 increase in other receivables.

The following variances in non-current assets are noteworthy:

- Assets whose use is limited, including current portion, increased by a net of \$13,105, which is due to
 a required deposit of collateral of \$11,015 related to a new line of credit agreement, unrealized gains
 on investments of \$3,786 and an increase in reserve account funding for actuarial liabilities and other
 limited use assets of \$2,311, offset by a decrease in assets designated for long-term investment of
 \$4,007.
- Capital assets, net, decreased by \$46,347 due to the shortfall in capital asset investments during 2023 as compared to the ongoing depreciation expense on all capital assets, which is a continued result of reduced cash flow availability driven by operating losses. Investments in capital assets are summarized in a following section.
- Net pension asset decreased \$77,538 and was eliminated due to changes in actuarial assumptions, which increased the liability thus creating a net pension liability, which is further discussed in the section below.

Overall, total liabilities and deferred inflows decreased \$143,000 and net position decreased \$6,212 from 2022.

The following variances in total liabilities are noteworthy:

- Accounts payable and accrued salaries and benefits decreased by \$17,339 due to timing of payments to vendors and employees at year-end.
- Accrued other liabilities increased by \$1,908 largely as a result of increases in amounts due to Erie County and third-party payors.
- Unearned revenue decreased by \$22,517 due to a decrease of \$27,000 related to the New York State grant received in late December 2022 for the calendar year 2023, thus recognized during 2023. Other unearned revenue increased \$4,483.
- The line of credit liability remained unchanged due to borrowings that remain outstanding at December 31, 2023.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Statements of Net Position (Continued)

- The long-term portion of self-insured obligations increased by \$3,238 due to changes in actuarial
 estimates for self-insured retentions for malpractice and workers' compensation claims greater than
 payments made on those claims. The current portion of these self-insured obligations decreased by
 \$148.
- Net pension liability, including current portion, was established at \$198,936 due to changes in actuarial assumptions used to value the plan as of December 31, 2023. As noted above, at December 31, 2022, the Corporation had recorded a net pension asset of \$77,538.
- The liability for Other Post-Employment Benefits (OPEB) increased by \$22,516 primarily as a result of the unfavorable impact of a change in actuarial assumptions related to unfavorable healthcare trend rates and a decrease in the discount rate used to measure the obligation.
- Net position decreased by \$6,212 due to unfavorable financial performance related to inflationary pressures on operating expenses continuing to outpace increases in patient volume and payor reimbursement rates.

Statements of Revenues, Expenses and Changes in Net Position

Condensed Statements of Revenues, Expenses and Changes in Net Position are as follows:

| | | (Restated) | 2023-2022 | | | | | |
|--|--------------|--------------|------------|----------|--|--|--|--|
| | 2023 | 2022 | \$ Change | % Change | | | | |
| Net patient service revenue | \$ 603,720 | \$ 566,389 | \$ 37,331 | 6.6 | | | | |
| Disproportionate share (DSH) revenue | 107,105 | 68,295 | 38.810 | 56.8 | | | | |
| Other operating revenue | 46,639 | 26,095 | 20,544 | 78.7 | | | | |
| Total operating revenues | 757,464 | 660,779 | 96,685 | 14.6 | | | | |
| Operating expenses: | | | | | | | | |
| Payroll and employee benefits | 440,770 | 410,664 | 30,106 | 7.3 | | | | |
| Professional fees | 110,577 | 109,113 | 1,464 | 1.3 | | | | |
| Purchased services | 81,712 | 78,037 | 3,675 | 4.7 | | | | |
| Supplies | 132,197 | 117,877 | 14,320 | 12.1 | | | | |
| Other operating expenses | 30,529 | 29,185 | 1,344 | 4.6 | | | | |
| Depreciation and amortization | 49,812 | 49,872 | (60) | (0.1) | | | | |
| Total operating expenses | 845,597 | 794,748 | 50,849 | 6.4 | | | | |
| Operating loss before pension | | | | | | | | |
| and other post employment | | | | | | | | |
| benefits amortization components | (88,133) | (133,969) | 45,836 | 34.2 | | | | |
| Pension (expense) benefit, amortization component Other post employment benefits, | (39,752) | 32,537 | (72,289) | (222.2) | | | | |
| amortization component | 20,424 | 29,861 | (9,437) | (31.6) | | | | |
| Operating loss | (107,461) | (71,571) | (35,890) | (50.1) | | | | |
| Non-operating revenues (expenses): | | | | | | | | |
| Investment gain (loss) | 6,283 | (13,966) | 20,249 | (145.0) | | | | |
| Grant revenue | 107,230 | 63,151 | 44,079 | 69.8 | | | | |
| Interest expense | (12,264) | (12,028) | (236) | (2.0) | | | | |
| Total change in net position | (6,212) | (34,414) | 28,202 | 81.9 | | | | |
| Net position—beginning of year | (269,955) | (235,541) | (34,414) | (14.6) | | | | |
| Net position—end of year | \$ (276,167) | \$ (269,955) | \$ (6,212) | (2.3) | | | | |

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position (Continued)

Overall, total operating revenues increased by \$96,685 or 14.6% in 2023 with changes attributable to the following:

- Net patient service revenue increased \$37,331, or 6.6%, in 2023 as a result of a combination of overall increased patient volumes, an increase in contracted reimbursement rates, improvements in bad debt write-offs and improvements in ECMCC's ability to discharge patients into the community.
- DSH revenue increased by \$38,810, or 56.8%, in 2023 as a result of an increase in the nursing home upper payment limit of \$5,885 due to a significant increase in the pool size in the State Plan Amendment and a \$32,925 increase in federal DSH due to an increase in uncompensated care net of anticipated formula changes in the Medicaid DSH cap calculation enacted through legislation but not yet implemented which will exclude costs from services provided to Medicaid-eligible beneficiaries who are dually eligible for Medicare or any other coverage.
- Other operating revenue increased \$20,544, or 78.7% due to an increase in specialty pharmacy operations of \$20,777.

Total operating expenses including pension expense/benefit and other post-employment benefit expenses increased \$132,575 or 18.1% in 2023. Expense changes are attributable to the following:

- Payroll and employee benefit expenses have increased by \$30,106 or 7.3% as a result of increases in salaries due to new collective bargaining agreements' market rate adjustments and additional pay incentives offered to fill open shifts to meet New York State minimum staffing standards for both the hospital and the skilled nursing facility. Salaries and employee benefit expense as a percent of net patient service revenue increased by 0.5%, from 72.5% in 2022 to 73.0% in 2023.
- Pension expense increased by \$65,834 as a result of changes in actuarial assumptions used to value the plan including investment returns, discount rates and other demographic assumptions.
- Supplies expense increased by \$14,320 or 12.1% as a result of increased surgical volume, increased volume within the specialty pharmacy operations and pharmaceutical cost increases related to drug shortages.
- OPEB benefit decreased \$11,976 or 38.2% as a result of unfavorable differences between projected and actual experience of net claims cost and benefit payment made to current employees.

Capital Assets, Net

At December 31, 2023, the Corporation had capital assets, including lease and subscription-based information technology arrangement assets, net of accumulated depreciation of \$313,039 compared to \$359,386 at December 31, 2022, representing a decrease of \$46,347 or 12.9%.

During 2023, the Corporation invested \$15,047 in various capital assets (\$6,030), leases (\$4,668) and SBITAs (\$4,349). Noteworthy investments in capital assets include continued investment into the building exterior improvements of \$455 and purchases of other medical and non-medical equipment, furniture and fixtures, and information systems infrastructure investments. Noteworthy additions to capital leases include printers and copiers (\$2,552) and other various leased medical and non-medical equipment. Noteworthy additions to SBITAs includes MRI software (\$1,755) and other medical and non-medical software. GASB Statement No. 87, *Leases*, establishes the foundational principle that leases are financing of the right-to-use an underlying asset for a period of time. The Corporation recorded lease assets, net of accumulated depreciation, in the amount of \$26,371 and \$30,054 in 2023 and 2022, respectively. GASB Statement No. 96, *Subscription-Based Information Technology Arrangements*, extends the right-of-use accounting concepts introduced in GASB Statement No. 87, *Leases*, to SBITAs. The Corporation recorded SBITA assets in the amount of \$25,761 in 2023 and \$31,216 in 2022.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Forward-Looking Factors

Management has prepared the following forward-looking factors to assist the reader in understanding the financial, economic and market factors impacting the Corporation:

Collective Bargaining Agreements

The Corporation operates under three collective bargaining agreements that cover substantially all employees. Corporation employees of the Civil Service Employee Association (CSEA) are covered by a contract negotiated in concert with Erie County, New York, which contains a sub-bargaining unit representing only Corporation employees. The previous agreement ended in 2022, while a new agreement began January 1, 2023 and runs through December 31, 2027. Registered Nurses (RNs) are covered under an agreement with the New York State Nurses Association (NYSNA). This agreement began in 2019 and ran through December 31, 2022. The parties have mutually agreed to a new contract effective January 1, 2023 that runs through December 31, 2027. The Corporation's agreement with the American Federation of State, County and Municipal Employees (AFSCME), a contract negotiated in concert with the County of Erie, New York, and ratified with AFSCME employees in 2022 runs through December 31, 2026.

Transactions with the County of Erie

The Corporation is a component unit of the County of Erie, New York. The County has ongoing contractual and legal obligations to the Corporation and the Corporation has ongoing contractual and legal obligations to the County.

Medicare and Medicaid Reimbursement

The future state of both reimbursement levels and reimbursement methods related to the Medicare and Medicaid programs remains uncertain. Unimplemented formulaic changes as well as budget proposals related to both of these programs for the upcoming year and beyond may significantly alter reimbursements or methodologies, thus changing the environment in which we conduct business as the Corporation relies heavily on these programs for reimbursement for services. The impact of these state and federal rule changes and budget proposals are unknown at this time but could materially impact the Corporation.

Contacting the Corporation's Financial Management

This financial report is designed to provide our community and creditors with a general overview of Erie County Medical Center Corporation's finances and to demonstrate the Corporation's accountability for the resources it receives. If you have any questions about this report or need additional financial information, contact the Chief Financial Officer, Erie County Medical Center Corporation, 462 Grider Street, Buffalo, New York 14215.

Statements of Net Position December 31, 2023 and 2022 (Dollars in Thousands)

| • | | | (Restated) |
|--|----------|----------------|-------------------|
| | 2023 | | 2022 |
| Assets and Deferred Outflows of Resources | | | |
| Current assets: | | | |
| Cash and cash equivalents | | 0,773 \$ | 44,195 |
| Investments | | 0,646 | 7,253 |
| Assets whose use is limited | | 3,986 | 99,078 |
| Patient accounts receivable, net | | 2,389 | 83,569 |
| Other receivables | | 0,608 | 62,430 |
| Supplies, prepaids and other Total current assets | | 5,400 3,802 | 12,980 309,505 |
| Assets whose use is limited | - | 6,635 | 58,438 |
| Capital assets, net | | 3,039 | 359,386 |
| Net pension asset | 31 | 3,039 | 77,538 |
| Other assets, net | | 8,906 | |
| other assets, net | | 8,580 | 7,780 503,142 |
| Total courts | |) 0 | |
| Total assets | | 2,382 | 812,647 |
| Deferred outflows of resources: Pension | 12 | 3,115 | 142 602 |
| Other post employment benefits | | .5,670 | 143,693 22,684 |
| Other post employment benefits Other | | 0,679 | 12,034 |
| Total deferred outflows of resources | | 9,464 | 178,411 |
| | 100 m | | |
| Total assets and deferred outflows of resources | 3 84 | 1,846 \$ | 991,058 |
| Liabilities, Deferred Inflows of Resources and Net Position | | | |
| Current liabilities: | - MO CO | | |
| Current portion of long-term debt | | 2,128 \$ | 11,716 |
| Line of credit | | 0,000 | 10,000 |
| Current portion of lease and SBITA liability Accounts payable Accrued salaries, wages and employee benefits Net pension liability Other post employment benefits | | 6,409 | 14,770 |
| Accounts payable | | 9,927 | 73,650 |
| Accrued salaries, wages and employee benefits | | 9,603 | 43,219 |
| Net pension liability | | 4,131 | - |
| Other post employment benefits | | 2,326 | 12,061 |
| Accrued other liabilities | | 2,021 | 40,113 |
| Unearned revenue | | 5,802 | 98,319 |
| Total current liabilities | 30 | 2,347 | 303,848 |
| Long-term debt, net | 19 | 0,515 | 202,641 |
| Long-term lease and SBITA liability, net | 3 | 4,682 | 44,409 |
| Net pension liability, net of current portion | 16 | 4,805 | - |
| Self-insured obligations | 5 | 2,121 | 48,883 |
| Other post employment benefits, net of current portion | 28 | 1,585 | 259,334 |
| Other | | 7,218 | 5,457 |
| Total liabilities | 1,03 | 3,273 | 864,572 |
| Deferred inflows of resources: | | | |
| Pension | 2 | 3,737 | 280,189 |
| Other post employment benefits | | 9,337 | 114,812 |
| Leases | | 1,666 | 1,440 |
| Total deferred inflows of resources | 8 | 4,740 | 396,441 |
| Net Position: | | | |
| Net investment in capital assets | 5 | 8,654 | 85,013 |
| Restricted: | | | |
| Expendable | 9 | 5,555 | 80,719 |
| Jnrestricted | (43 | 0,376) | (435,687) |
| Total net position | (27 | (6,167) | (269,955) |
| Total liabilities, deferred inflows of resources and net position | | 1,846 \$ | 991,058 |
| . c.a | <u>-</u> | <u>.,</u> | 001,000 |

Statements of Revenues, Expenses and Changes in Net Position Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | | 0000 | | (Restated) 2022 |
|--|----|-----------|----|--------------------|
| Operating revenues: | | 2023 | | 2022 |
| Net patient service revenue, net of provision for | \$ | 603,720 | \$ | 566,389 |
| bad debts of \$4,596 and \$15,474 for 2023 and 2022, respectively | Ψ | 603,720 | φ | 300,309 |
| Disproportionate share revenue (DSH) | | 107,105 | | 68,295 |
| Other operating revenue | | 46,639 | | 26,095 |
| Total operating revenues | | 757,464 | | 660,779 |
| Total operating revenues | | 151,464 | | 000,779 |
| Operating expenses: | | | | |
| Payroll and employee benefits | | 440,770 | | 410,664 |
| Professional fees | | 110,577 | | 109,113 |
| Purchased services | | 81,712 | | 78,037 |
| Supplies | | 132,197 | | 117,877 |
| Other operating expenses | | 30,529 | | 29,185 |
| Depreciation and amortization | | 49,812 | | 49,872 |
| Total operating expenses | | 845,597 | | 794,748 |
| Operating loss before pension benefit and other post employment benefits amortization components | | (88,133) | | (133,969) |
| Pension (expense) benefit, amortization component | | (39,752) | | 32,537 |
| Other post employment benefits, amortization component | | 20,424 | | 29,861 |
| Operating loss | | (107,461) | | (71,571) |
| Nonoperating revenues (expenses): | | | | |
| Investment gain (loss) | | 6,283 | | (13,966) |
| Grant revenue | | 107,230 | | 63,151 |
| Interest expense | | (12,264) | | (12,028) |
| Total nonoperating revenues (expenses) | | 101,249 | | 37,157 |
| Total change in net position | | (6,212) | | (34,414) |
| Net position—beginning of year | | (269,955) | | (235,541) |
| Net position—end of year | \$ | (276,167) | \$ | (269,955) |

Statements of Cash Flows Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | | 2023 | 2022 |
|---|----|-----------|---------------|
| Cash flows from operating activities: | | | _ |
| Receipts from patients and third-party payors | \$ | 608,472 | \$ 585,894 |
| Payments to Medicare Advance Payment Program | | - | (20,879) |
| Payments to employees for salaries and benefits | | (415,584) | (389,561) |
| Payments to vendors for supplies and other | | (369,364) | (293,557) |
| Other receipts | | 119,572 | 31,591 |
| Net cash used in operating activities | | (56,904) | (86,512) |
| Cash flows from capital and related financing activities: | | | |
| Purchases of capital assets | | (12,554) | (26,855) |
| Borrowings on line of credit | | Olan S | 10,000 |
| Payments on long-term debt | | (11,714) | (11,317) |
| Interest paid on long-term debt | | (12,264) | (10,928) |
| Net cash used in capital and related financing activities | 6 | (36,532) | (39,100) |
| Cash flows from noncapital financing activities: | | | |
| Grant funding | | 80,229 | 90,151 |
| Net cash provided by noncapital financing activities | Ca | 80,229 | 90,151 |
| Cash flows from investing activities: | | | |
| (Purchases) sales of assets whose use is limited, net | | (13,105) | 11,047 |
| Investment gain (loss) | | 6,283 | (13,966) |
| (Purchases) sales of investments, net | | (3,393) | 13,111 |
| Net cash (used in) provided by investing activities | | (10,215) | 10,192 |
| Net change in cash and cash equivalents | | (23,422) | (25,269) |
| Cash and cash equivalents: | | | |
| Beginning | | 44,195 | 69,464 |
| Ending | \$ | 20,773 | \$ 44,195 |

Noncash capital and related financing activities:

Included in accounts payable at December 31, 2023 and 2022, was \$1,357 and \$2,737, respectively, of invoices related to capital asset acquisitions.

(Continued)

Statements of Cash Flows (Continued) Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | | 2023 | 2022 |
|---|-----------|--------------|-----------|
| Reconciliation of operating loss to net cash | | | |
| used in operating activities: | | | |
| Operating loss | \$ | (107,461) \$ | (71,571) |
| Adjustments to reconcile operating loss to net cash | | | |
| used in operating activities: | | | |
| Depreciation and amortization | | 49,812 | 49,872 |
| Provision for bad debts | | 4,596 | 15,474 |
| Changes in assets, deferred outflows, liabilities and deferred inflows: | | | |
| Patient accounts receivable | | (23,416) | (22,328) |
| Medicare Advance Payment Program | | -100 | (20,879) |
| Other receivables | | 21,822 | 26,070 |
| Supplies, prepaids and other | | (3,546) | 17,218 |
| Deferred outflows of resources | | 18,947 | 100,984 |
| Accounts payable | | (4,634) | 21,955 |
| Accrued liabilities | | (9,785) | 13,176 |
| Unearned revenue | | 4,484 | (62,799) |
| Estimated third-party payor settlements | | 1,750 | 289 |
| Self-insured obligations | | 3,238 | 1,322 |
| Net pension liability (asset) | | 276,474 | (78,453) |
| OPEB AND | | 22,516 | (107,711) |
| Deferred inflows of resources | | (311,701) | 38,689 |
| | | | |
| Net cash used in operating activities | <u>\$</u> | (56,904) \$ | (86,512) |

Statements of Net Position—Discretely Presented Component Units December 31, 2023 and 2022 (Dollars in Thousands)

| | | | | 20 | 23 | | | | 2022 | | | | | | | |
|---|-----|---|---------|---------------|--------|--------------|--------------------|---------------|--------------------------|----------------|-----------------------------------|--------------|--|--------------|-------------------|-----------------|
| | Fou | The Research ECMC Grider Health ir oundation, Inc. Initiative, Inc. Erie County | | | | , | Aggregate Total | Four | ECMC Foundation, Inc. | | The Grider Initiative, Inc. | | Research for Health in Erie County, Inc. | | ggregate Total | |
| Assets | 100 | iluation, inc. | IIIILIC | ative, iiic. | Lile C | ounty, mc. | | IOtal | i oui | idation, inc. | 11110 | lative, inc. | LIIC | County, Inc. | | TOtal |
| Current assets: Cash and cash equivalents Investments | \$ | 2,365 | \$ | 270 | \$ | - | \$ | 2,635 | \$ | 2,337 | \$ | 271 | \$ | 2 1,092 | \$ | 2,610 1,092 |
| Other receivables Supplies, prepaids and other | | 938 259 | | - | | - | Ţ. | 938 259 | | 1,634 408 | | - - | | - - | | 1,597 408 |
| Total current assets | | 3,562 | | 270 | | 11.4 SQ | | 3,832 | | 4,379 | | 271 | | 1,094 | | 5,707 |
| Other receivables Endowment and other investments | | 887 3,129 | | - 9,962 | | ion - Dar | | 887 13,091 | | 1,030 2,298 | | - 9,576 | | - - | | 1,030 11,874 |
| Equipment and vehicles, net | | - | | a a a Million | | | 3 | <u> </u> | | 1 | | | | - | | 1 |
| | | 4,016 | | 9,962 | 3601 | Chor | A NO | 13,978 | | 3,329 | | 9,576 | | - | | 12,905 |
| Total assets | _\$ | 7,578 | \$ | 10,232 | \$1,40 | | \$ | 17,810 | \$ | 7,708 | \$ | 9,847 | \$ | 1,094 | \$ | 18,612 |
| Liabilities and Net Position Current liabilities: | | | | | | | | | | | | | | | | |
| Accounts payable Funds held in custody for others | \$ | 11 596 | \$ | Moji | \$ | - | \$ | 11 596 | \$ | 22 596 | \$ | - | \$ | - | \$ | 22 596 |
| Total current liabilities | | 607 | | - | | - | | 607 | | 618 | | - | | - | | 618 |
| Long-term liabilities: | | | | | | | | | | | | | | | | |
| Related party Unearned revenue | | 969 335 | | - | | - | | 969 335 | | 2,522 509 | | - | | - - | | 2,522 509 |
| Total liabilities | | 1,911 | | - | | - | | 1,911 | | 3,649 | | - | | - | | 3,649 |
| Net Position Restricted: | | | | | | | | | | | | | | | | |
| Nonexpendable | | 50 | | 10,000 | | - | | 10,050 | | 50 | | 10,000 | | _ | | 10,050 |
| Expendable | | 2,634 | | 232 | | - | | 2,866 | | 1,510 | | (153) | | = | | 1,357 |
| Unrestricted | | 2,983 | | | | - | | 2,983 | | 2,499 | | <u> </u> | | 1,094 | | 3,556 |
| Total net position | | 5,667 | | 10,232 | | - | | 15,899 | | 4,059 | | 9,847 | | 1,094 | | 14,963 |
| Total liabilities and net position | _\$ | 7,578 | \$ | 10,232 | \$ | - | \$ | 17,810 | \$ | 7,708 | \$ | 9,847 | \$ | 1,094 | \$ | 18,612 |

Statements of Revenues, Expenses and Changes in Net Position—Discretely Presented Component Units Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | | | | 20 |)23 | | | | | 2022 | | | | | | | | |
|--|------|---------------|------------|------------------|---------------|--------------|------|-----------|------------------|----------------|--------|-------------|-------------------|-------|---------|-----------|--|--|
| | | | | The Research for | | | | | The Research for | | | | | | | | | |
| | | ECMC | CMC Grider | | der Health in | | | Aggregate | ECMC | | Grider | | Health in | | Αç | ggregate | | |
| | Four | ndation, Inc. | Initia | tive, Inc. | Erie | County, Inc. | | Total | Fo | undation, Inc. | Initi | ative, Inc. | Erie County, Inc. | | . Total | | | |
| Operating revenues: | | | | | | | | | | | | | | | | | | |
| Grants, contributions and special events | \$ | 4,732 | \$ | - | \$ | - | \$ | 4,732 | \$ | 3,425 | \$ | - | \$ | - | \$ | 3,396 | | |
| Total operating revenues | | 4,732 | | - | | - | | 4,732 | | 3,425 | | - | | - | | 3,396 | | |
| Operating expenses: | | | | | | | | | | | | | | | | | | |
| Program services and grants | | 970 | | _ | | 1,107 | | 2,077 | | 875 | | _ | | 5 | | 880 | | |
| Fundraising | | 1,640 | | - | | a Olyana | | 1,640 | | 1,562 | | - | | _ | | 1,562 | | |
| Other operating expenses | | 641 | | - | | 100 | | 641 | | 357 | | - | | 1 | | 358 | | |
| Total operating expenses | | 3,251 | | Altra. | Alban. | 1,107 | a1(9 | 4,358 | | 2,794 | | - | | 6 | | 2,800 | | |
| | | | | O UMAIA. | 200 | SS, Tall | 112 | | | | | | | | | | | |
| Operating income (loss) | | 1,481 | | | | (1,107) | | 374 | | 631 | | - | | (6) | | 596 | | |
| | | | | | | | | | | | | | | | | | | |
| Nonoperating revenue: | | | | | | | | | | | | | | | | | | |
| Investment income (loss) | | 127 | ROUN , | 385 | 1 | 13 | | 525 | | (145) | | (347) | | (31) | | (531) | | |
| O I | | CON. | | on-fi | | (4.004) | | | | 400 | | (0.47) | | (07) | | 0.5 | | |
| Change in net position | | 1,608 | | 385 | | (1,094) | | 899 | | 486 | | (347) | | (37) | | 65 | | |
| Net position—beginning of year | | 4,059 | | 9,847 | | 1,094 | | 15,000 | | 3,573 | | 10,194 | | 1,131 | | 14,898 | | |
| Net position—end of year | \$ | 5,667 | \$ | 10,232 | \$ | _ | \$ | 15,899 | \$ | 4,059 | \$ | 9,847 | \$ | 1,094 | \$ | 14,963 | | |
| , | | -1 | • | - 1 | _ | | | -, | | ,,,,, | _ | - , + | • | , | _ | , , , , , | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 1. Organization

The Corporation: Erie County Medical Center Corporation (referred to as the Corporation or ECMCC) is a public benefit corporation created by the Erie County Medical Center Corporation Act, Chapter 143 of the Laws of New York State, 2003 (Title 6 of Article 10-C of the Public Authorities Law) (the Act) as amended in 2016. The Corporation was created under the Act to secure a form of governance which permits the Corporation to have the legal, financial, and managerial flexibility to operate its health care facilities for the benefit of the residents of New York State (the State), the County of Erie (the County), and Western New York, including persons in need who lack the ability to pay.

The Corporation's "Health Care Facilities" consist of the Medical Center, a 573-bed acute tertiary care facility providing inpatient, emergency, outpatient, primary care and specialty clinic services (Medical Center), a 390-bed residential health care facility (Terrace View) both located on Grider Street in the City of Buffalo and three chemical dependency and alcohol rehabilitation clinics located throughout the County. The Corporation serves as the region's only Level 1 Adult Trauma Center, burn center, comprehensive traumatic brain injury and spinal cord injury rehabilitative center, Comprehensive Psychiatric Emergency Program provider for acute psychiatric emergencies, Regional Center of Excellence for Transplantation and Kidney Care.

The Corporation has the power under the Act to acquire, operate, and manage its facilities and to issue bonds and notes to finance the costs of providing such facilities. The Act specifically provides that the Corporation's existence shall continue until terminated by law; provided, however, that no such termination shall take effect so long as the Corporation shall have bonds or other obligations outstanding unless adequate provision has been made for the payment or satisfaction thereof. The Corporation's primary purpose is the operation of the Medical Center and Terrace View, and its powers, duties and functions are as set forth in the Act, as amended, and other applicable laws.

The Corporation qualifies as a governmental entity and, accordingly, is exempt from federal income tax pursuant to Section 115 of the Internal Revenue Code of 1986.

In accordance with Governmental Accounting Standards Board (GASB) Statement No. 14, *The Financial Reporting Entity*, as amended, the Corporation's financial statements are included, as a discretely presented component unit, in the County's Annual Comprehensive Financial Report (ACFR). A copy of the ACFR can be obtained from the Erie County Comptroller's Office, 95 Franklin Street, Room 1100, Buffalo, New York 14202. The Corporation is subject to New York civil service law.

Governance: The Corporation is governed by its Board of Directors (the Board) consisting of fifteen (15) voting directors, eight (8) of whom are appointed by the Governor of the State of New York and seven (7) of whom are appointed by the Erie County Executive with the advice and consent of the Erie County Legislature. There are four non-voting representatives, as well. The directors and non-voting members serve staggered terms and continue to hold office until their successors are appointed. Directors have experience in the fields of health care services, quality and patient safety, human resources, strategic growth, law, and financial management and reflect a broad representation of the community served by the Corporation. Regular meetings of the Board are scheduled eleven (11) times per year. Board leaders are appointed by the Board.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 1. Organization (Continued)

Great Lakes Heath System: The Corporation is a member of Great Lakes Health System of Western New York (Great Lakes). Great Lakes is a not-for-profit, community-based corporation comprised of unified partners whose objective is to provide the highest quality of healthcare to the residents of Western New York. Great Lakes is comprised of the Corporation, Kaleida Health (KH), The Center for Hospice and Palliative Care and the State University of New York at Buffalo (the University).

Great Lakes Health Integrated Network: The Corporation, together with KH has formed Great Lakes Health Integrated Network (GLIN) with each maintaining a 50% ownership interest. As of December 31, 2023 and 2022, capital contributions due to GLIN totaled \$326 and \$767, respectively. Contributions are used to pay for care coordination services, information systems infrastructure and routine operating expenses to support community population health management.

Medical School Collaboration: The Corporation serves as a primary teaching hospital for the Jacobs School of Medicine and Biomedical Sciences of the State University of New York at Buffalo (the Medical School). An agreement governs the relationship between the Corporation and the Medical School. The Corporation serves as an integral part of the education and research mission of the Medical School by providing the clinical settings for the Medical School's public mission to educate and train physicians, nurses and other healthcare professionals, conduct clinical research programs and deliver healthcare services to patients. There are currently 187 full-time equivalent medical residents assigned to the Corporation in various Academic College of Graduate Medical Education accredited residency programs.

Component Units: Accounting principles generally accepted in the United States of America (U.S. GAAP) require the inclusion within the Corporation's financial statements of certain organizations as component units. The component units discussed below are included because the nature and significance of their relationship to the Corporation are such that exclusion would cause the reporting entity's financial statements to be misleading or incomplete under criteria set forth by the GASB.

The component unit information in the accompanying basic financial statements includes the financial data of the Corporation's three discretely presented component units. The three discretely presented component units are discussed in more detail below:

ECMC Foundation, Inc.: The ECMC Foundation, Inc. (the Foundation) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC). The Foundation was formed for the purpose of supporting Corporation programs. The financial statements of the Foundation have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Executive Director, ECMC Foundation, Inc., 462 Grider Street, Buffalo, NY 14215.

The Grider Initiative, Inc.: The Grider Initiative, Inc. (the Physician Endowment) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the IRC. The Physician Endowment was funded in 2010, for the purpose of recruiting physicians who shall practice on the Grider Street campus of the Corporation. The entity was funded with an initial transfer of \$10,000 from the Corporation. Earnings from the investment of the initial transfer may be used only for physician recruitment and retention and necessary expenses of the entity. The financial statements of The Grider Initiative, Inc. have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Chair, The Grider Initiative, Inc. 462 Grider Street, Buffalo, NY 14215.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 1. Organization (Continued)

Research for Health in Erie County, Inc.: Research for Health in Erie County, Inc. (RHEC) was a not-for-profit organization dedicated to supporting research activities relating to the causes, nature, and treatment of diseases, disorders, and defects of particular importance to the public health in areas served by the Corporation. During 2023, RHEC was dissolved and the remaining net assets were contributed to the ECMC Foundation in order for ECMC Foundation to carry out the original RHEC mission.

In addition, the financial statements of the Corporation include the operations of the following component units, which are blended with the accounts of the Corporation:

PPC Strategic Services LLC (PPC): The Corporation is the sole owner of this enterprise, which was established to enable the Corporation to enter into various other business relationships.

Grider Support Services, LLC: The Corporation is the sole owner of this enterprise, which was formed to act as an MSO for physician practice services, which includes providing employees, management and administrative services.

Grider Community Gardens, LLC: This entity is wholly-owned and controlled by the Corporation and was formed for the purpose of purchasing and holding properties in proximity to the Corporation's Grider Street Campus.

1827 Fillmore, LLC: This entity is controlled by the Corporation and was formed for the purchase and development of property immediately adjacent to the Corporation's Grider Street campus.

Note 2. Summary of Significant Accounting Policies

Basis of accounting: The Corporation uses the accrual basis of accounting. Revenue is recognized in the period it is earned and expenses are recognized in the period incurred. Under this basis of accounting, all assets, deferred outflows of resources, liabilities and deferred inflows of resources associated with the operation of the Corporation are included in the statements of net position.

For financial accounting and reporting purposes, the Corporation follows all pronouncements of the GASB. All references to relevant authoritative literature issued by the GASB with which the Corporation must comply are hereinafter referred to generally as U.S. GAAP. The discretely presented component units, as previously described, report under Financial Accounting Standards Board (FASB) standards. As such, certain revenue recognition criteria and presentation features are different from GASB revenue recognition criteria and presentation features.

Use of estimates: The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The reserve for uncollectible accounts, contractual allowances, estimated third-party payor settlements, workers compensation reserves, malpractice reserves, net pension assets/obligations, other post-employment benefit obligations, self-insured obligations, as well as, Disproportionate Share (DSH) revenue and certain other accounts, require the use of estimates. Actual results could differ from those estimates.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Included in net patient service revenue are adjustments to prior year estimated third-party payor settlements, and their related estimated receivables and payables that were originally recorded in the period the related services were rendered, as well as adjustments to the net realization rate for collections on patient accounts receivable. These adjustments are made in the normal course of operations and amounts reported are consistent with the approach in prior years. The adjustments to prior year estimates and other third-party reimbursement or recoveries that relate to prior years also impact DSH revenues as discussed in Note 5. The combined effect of changes related to prior years' estimates resulted in an increase of \$5,472 and \$196 in total operating revenues for the years ended December 31, 2023 and 2022, respectively.

Cash and cash equivalents: The Corporation's cash and cash equivalents include cash on hand and cash in checking and money market accounts as well as investments with a maturity of three months or less when purchased. Cash and cash equivalents designated for long-term purposes or received with donor-imposed restrictions limiting their use to long-term purposes are not considered cash and cash equivalents for purposes of the statements of cash flows. Monies deposited in Federal Deposit Insurance Corporation (FDIC) insured commercial banks are collateralized with specifically designated securities held by a pledging financial institution, as required by State regulations.

Patient accounts receivable: Patient accounts receivable are reported net of both an estimated allowance for contractual adjustments and an estimated allowance for uncollectible accounts. The contractual adjustments represent the difference between established billing rates and estimated reimbursement from Medicare, Medicaid and other third-party payor programs. Current operations are charged with an estimated provision for bad debts estimated based on the age of the account, prior experience and any other circumstances which affect collectability. The Corporation's policy does not require collateral or other security for patient accounts receivable and the Corporation routinely accepts assignment of, or is otherwise entitled to receive, patient benefits payable under health insurance programs, plans or policies. The allowance for estimated doubtful accounts at December 31, 2023 and 2022 was approximately \$64,577 and \$63,414, respectively.

Investments and assets whose use is limited: The Corporation generally records its investments at fair value. Such assets are comprised of cash and cash equivalents, including money market funds, fixed income securities, commercial paper and equity funds. Assets classified as investments are unrestricted. Assets classified as limited as to use are restricted under Board designation or terms of agreements with third parties and include debt service funds, funds for self-insured workers' compensation costs and medical malpractice costs, collateral for insured workers' compensation programs, patient and resident monies, funding for future retiree health costs, and funds limited as to use for the acquisition of property, plant and equipment.

Investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is at least possible that changes in risks in the near term could materially affect the net position of ECMCC.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other receivables: The composition of other receivables, as of December 31 is as follows:

| | 2023 | 2022 |
|--|-----------------------|-----------------------|
| DSH and Upper Payment Limit (UPL) (Note 5) Due from affiliated organizations and joint ventures | \$ 28,473 1,233 | \$ 50,330 1.928 |
| Due from third-party payors Other | 6,980 3,922 | 7,524 2.648 |
| outor | \$ 40,608 | \$ 62,430 |

Capital assets: Capital assets are stated at cost. Depreciation is computed under the straight-line method over the estimated useful life of the asset. Estimated useful lives of assets have been established as follows:

| Land and land improvements | Bull L | 5-25 years |
|----------------------------|--------|-------------|
| Buildings and improvements | | 10-40 years |
| Fixed equipment | | 10-20 years |
| Major movable equipment | | 3-20 years |

When assets are retired, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected for the period. Maintenance and repairs are charged to expense as incurred with significant renewals and betterments being capitalized.

Capital assets that are donated (without restriction) are recorded at their fair market values as a direct increase to the component of net investment in capital assets.

Deferred outflows of resources: Deferred outflows of resources represent a consumption of net position that applies to a future period(s) and therefore will not be recognized as an outflow of resources (expense) until that time. Deferred outflows of resources consist primarily of unrecognized items not yet charged to pension expense and retiree health expense related to the net pension (asset)/liability and post-employment benefit obligations, and items related to the 2017 financing transaction as described below, amongst other deferred resources.

The 2017 financing transaction included the payment of points, in the amount of \$17,040 to Erie County associated with the differential in interest rate on the 2017 financing using the credit rating of Erie County and the rate that the Corporation was projected to pay independent of a relationship with Erie County. The points are being amortized on the interest method over the term of the 2017 financing. The unamortized amount of points at December 31, 2023 and 2022, is \$8,712 and \$9,836, respectively. The 2017 financing transaction also included the advance refunding of the 2011 financing, the proceeds of which were used to finance the construction of the Terrace View Nursing Home on the Corporation's campus. The deposit required to the advance refunding escrow was greater than the balance outstanding on the 2011 financing in the amount of \$2,038 and is being amortized on the interest method over the life of the advance refunding component of the transaction. The unamortized portion of this advance refunding at December 31, 2023 and 2022 is \$652 and \$834, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other assets: Amounts due from the County, as noted in Note 14, as well as ownership interests in various business enterprises are included in other assets.

Collaborative Care Ventures, LLC (Collaborative Care) was formed in 2014 by ECMCC and KH. Collaborative Care was created as a vehicle for ECMCC and KH to participate in various investments in the future consistent with their missions. At December 31, 2023 and 2022, the Corporation's share of the net assets of Collaborative Care amounted to \$1,022 and \$1,060, respectively.

Great Lakes Health Integrated Network (GLIN) was formed in 2018 by ECMCC and KH. GLIN was formed to support, manage and negotiate value-based contracts and/or risk-based contracts with third-party payors for the purpose of managing population health and anticipated payment reform. The Corporation's share of contributed capital supports organizational development and ongoing operations. The Corporation's share of GLIN's profit or loss is recognized as non-operating revenue. At December 31, 2023 and 2022, the Corporation's share of the net assets of GLIN amounted to \$4,324 and \$2,179, respectively.

Leases: The Corporation is a lessee for noncancellable leases of real estate and equipment. The Corporation recognizes a lease liability and an intangible right-to-use lease asset in the financial statements for leases. At the commencement of a lease, the Corporation measures the lease liability at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate. The lease assets are amortized over the shorter of the lease term or the underlying asset useful life.

The Corporation is also a lessor for noncancellable leases of real estate. The Corporation recognizes a lease receivable and deferred inflow of resources in the financial statements for these leases. At the commencement of the lease, the Corporation measures the lease receivable at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate.

Subscription Based Information Technology Arrangements (SBITAs): The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its SBITAs. The subscription asset is measured as the subscription liability plus direct costs incurred in implementing the subscription asset. The subscription asset is amortized on a straight-line basis over the shorter of the subscription term or the useful life of the underlying subscription asset. At the subscription commencement, the subscription liability is measured at the present value of payments expected to be made during the subscription term and utilizes the interest rate charged in the SBITA, if available, or otherwise discounted using the Corporation's incremental borrowing rate to calculate the present value of the payments.

Unearned revenue: Unearned revenue represents funds received by the Corporation for the DSRIP Program and health care transformation funds received that have not yet been earned.

Compensated absences: The Corporation has accrued liabilities for certain compensated absences earned by its employees, to include vacation, sick, and compensatory time. The Corporation's employees are permitted to accumulate unused vacation and sick leave time up to certain maximum limits. The Corporation accrues the estimated obligation related to vacation pay based on pay rates currently in effect. Sick leave credits, if accumulated above certain prescribed levels, may be the basis of a supplemental payment to employees upon retirement. The Corporation accrues an estimated liability for these estimated terminal payments. These amounts have been included in the statements of net position at December 31, 2023 and 2022, within the caption accrued salaries, wages and employee benefits in the amounts of \$17,496 and \$15,295, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Deferred inflows of resources: Deferred inflows of resources represent an acquisition of net position that applies to a future period(s) and therefore will not be recognized as an inflow of resources (revenue) until that time. Deferred inflows of resources consist primarily of the unamortized portion of certain items related to the Corporation's pension, other post-employment benefits and the value of leases receivable plus any payments received at or before the commencement of the lease term that relates to future periods.

Net position: Net position is classified into three categories according to external donor restrictions or availability of assets for satisfaction of the Corporation's obligations. The Corporation's net position is described as follows:

Net investment in capital assets: This represents the Corporation's total investment in capital assets, net of accumulated depreciation and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets. To the extent debt has been incurred but not yet expended for capital assets, such amounts are not included as a component of net investment in capital assets.

Restricted: The restricted expendable component of net position consists of constraints placed on net position through external constraints imposed by creditors (such as through debt covenants), grantors, contributors, or laws or regulations of other governments or constraints imposed by law through constitutional provisions or enabling legislation. The restricted nonexpendable component of net position is permanently unavailable for use. The earnings on the nonexpendable net position are classified as restricted expendable.

Unrestricted: This component of net position consists of net position that does not meet the definition of other components of net position described above. These resources are used for transactions relating to the general health care operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Net patient service revenue: Net patient service revenue is reported as services are rendered at estimated net realizable amounts, including estimated retroactive revenue adjustments under reimbursement agreements with third-party payors. Estimated settlements under third-party reimbursement agreements are accrued in the period the related services are rendered and adjusted in future periods as final settlements are determined. An estimated provision for bad debts is included in net patient service revenue.

Charity care: The Corporation provides care to patients who meet certain criteria under its charity care policy, without charge or at amounts less than established rates. Because the Corporation does not pursue collection of amounts determined to qualify as charity care, they are not reported as net patient service revenue in the accompanying statements of revenues, expenses and changes in net position. The estimated costs of caring for charity care patients were \$4,459 and \$4,602 for the years ended December 31, 2023 and 2022, respectively. Additionally, the Corporation provided approximately \$2,397 and \$2,517 in discounts to self-pay patients for the years ended December 31, 2023 and 2022, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Contributions: The Foundation reports gifts of cash or promises to give as restricted contributions when they are received with donor stipulations that limit the use of the donated assets. When the intent of the donor is that the assets are to remain in perpetuity and the Foundation does not have the right to invade the original principal, the assets are reported as with donor restrictions. When a donor restriction expires, restricted-expendable net positions are released to unrestricted net position. The Foundation conducted a capital campaign to raise funds to support the construction of a new Level 1 Adult Trauma Center, Emergency Department and other capital needs in support of the mission of the Corporation. Receivables for pledges associated with this campaign are recorded net of a reserve for uncollectible pledges and are discounted to present value using a 4.79% discount rate, over the expected collection period of the pledges.

Classification of revenues: The Corporation has classified its revenues as either operating or non-operating revenues according to the following criteria:

Operating revenues: Operating revenues include activities that have the characteristics of exchange transactions, such as payments for providing services and payments for goods and services received, for health care services provided to patients, net of contractual adjustments and provisions for bad debts.

Nonoperating revenues: Nonoperating revenues include activities that have the characteristics of nonexchange transactions, such as gifts and contributions, CARES Act funding, NYSDOH grant funding, Federal Emergency Management Agency (FEMA) funding, income from investments and contributions.

Income taxes: The Corporation is a Public Benefit Corporation of the State of New York and is exempt from federal income taxes under Section 115 of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements.

Contributed services: RHEC receives contributions from the Corporation consisting primarily of donated space, equipment, and personnel support. During 2023 and 2022, the value of contributed services meeting the requirements for recognition in the financial statements was not material and has not been recorded.

Certain immaterial amounts related to contributed rents have been reflected in the Foundation's financial statements as contribution revenue. The Foundation generally pays for services requiring specific expertise. However, many individuals volunteer their time and perform a variety of tasks that assist the Foundation in meeting its goals and objectives. Such services are not recognized in the Foundation financial statements.

No amounts have been reflected in the Physician Endowment financial statements for contributed services, as the value of contributed services meeting the requirements for recognition in the financial statements was not material.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Recent and pending accounting pronouncements: Effective January 1, 2022, the Corporation adopted GASB issued Statement No. 96, Subscription-Based Information Technology Arrangements. This Statement provides guidance on the accounting and financial reporting for subscription-based information technology arrangements (SBITAs) for government end users. This Statement: (1) defines a SBITA; (2) establishes that a SBITA results in a right-to-use subscription asset—an intangible asset—and a corresponding subscription liability; (3) provides the capitalization criteria for outlays other than subscription payments, including implementation costs of a SBITA; and (4) requires note disclosures regarding a SBITA. To the extent relevant, the standards for SBITAs are based on the standards established in Statement No. 87, Leases. A SBITA is defined as a contract that conveys control of the right to use another party's information technology software alone or in combination with tangible capital assets as specified in the contract for a period of time in an exchange or exchange-like transaction. See Note 8, for further details regarding the implementation of this Standard.

Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 99, *Omnibus 2022*. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing (1) practice issues that have been identified during implementation and application of certain GASB Statements and (2) accounting and financial reporting for financial guarantees. The requirements of this Statement are effective at various dates as outlined in the Statement. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

In June 2022, GASB issued Statement No. 100, Accounting Changes and Error Corrections-An Amendment of GASB No. 62. This Statement defines accounting changes as changes in accounting principles, changes in accounting estimates, and changes to or within the financial reporting entity and describes the transactions or other events that constitute those changes. As part of those descriptions, for (1) certain changes in accounting principles and (2) certain changes in accounting estimates that result from a change in measurement methodology, a new principle or methodology should be justified on the basis that it is preferable to the principle or methodology used before the change. That preferability should be based on the qualitative characteristics of financial reporting-understandability, reliability, relevance, timeliness, consistency, and comparability. This Statement also addresses corrections of errors in previously issued financial statements. The requirements of this Statement are effective for accounting changes and error corrections made in fiscal years beginning after June 15, 2023, and all reporting periods thereafter. Earlier application is encouraged. The Corporation does not anticipate the adoption of this standard will have a significant impact on the financial statements.

In June 2022, GASB issued Statement No. 101, *Compensated Absences*. The objective of this Statement is to better meet the information needs of financial statement users by updating the recognition and measurement guidance for compensated absences. That objective is achieved by aligning the recognition and measurement guidance under a unified model and by amending certain previously required disclosures. The requirements of this Statement are effective for fiscal years beginning after December 15, 2023, and all reporting periods thereafter. Earlier application is encouraged. The Corporation does not anticipate adopting this standard will have a material impact on the financial statements.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

In December 2023, GASB issued Statement No. 102, *Certain Risk Disclosures*. The objective of this Statement is to provide users of government financial statements with essential information about risks related to a government's vulnerabilities due to certain concentrations or constraints. This Statement defines a *concentration* as a lack of diversity related to an aspect of a significant inflow of resources or outflow of resources. A *constraint* is a limitation imposed on a government by an external party or by formal action of the government's highest level of decision-making authority. Concentrations and constraints may limit a government's ability to acquire resources or control spending. This Statement requires a government to assess whether a concentration or constraint makes the primary government reporting unit or other reporting units that report a liability for revenue debt vulnerable to the risk of a substantial impact. Additionally, this Statement requires a government to assess whether an event or events associated with a concentration or constraint that could cause the substantial impact have occurred, have begun to occur, or are more likely than not to begin to occur within 12 months of the date the financial statements are issued. The requirements of this Statement are effective for fiscal years beginning after June 15, 2024, and all reporting periods thereafter. Earlier application is encouraged. The Corporation has not yet determined the impact this statement will have on the financial statements

Reclassifications: Certain prior-year amounts have been reclassified to conform to the current-year presentation. Such reclassifications had no effect on previously reported operating loss/income or changes in net position.

Subsequent events: The Corporation has evaluated subsequent events for potential recognition and/or disclosure through DATE, the date the financial statements were issued.

Note 3. Coronavirus Pandemic (COVID-19)

Under certain provisions in the CARES and American Rescue Plan (ARP) Acts, the Corporation recognized benefits totaling \$8,395, in its statements of revenues, expenses and changes in net position, for the year ended December 31, 2022 (\$0 in 2023). The benefit is entirely comprised of distributions from the Provider Relief Fund established under these Acts and is recognized as non-operating revenue. During 2020, the Corporation also deferred payment of \$10,926 for the employer portion of the Social Security payroll taxes as allowed by the CARES Act. In accordance with the CARES Act, 50% of the deferred payroll tax was paid on January 3, 2022, with the remainder paid on January 3, 2023.

Under the CARES Act, the Centers for Medicare & Medicaid Services (CMS) expanded the Medicare Accelerated and Advance Payment Program to provide necessary funds to Medicare providers to assist with the disruption in claims submission and claims processing. During 2020, the Corporation received advance payments under this program totaling \$39,101. As of December 31, 2022, Medicare had recouped the advance in its entirety with \$20,879 recouped during 2022 and \$18,222 recouped in prior years.

The CARES Act also includes financial relief through FEMA's Disaster Relief Fund. The Corporation has received \$3,829 and \$2,757 from FEMA to reimburse eligible incremental expenses as a result of COVID-19 during the years ended December 31, 2023 and 2022, respectively. The Corporation will continue to submit for grant reimbursement for any remaining eligible COVID-19 expenses under this program. Costs claimed under FEMA may not be reimbursed by any other funding source or payor, and may not be claimed though Provider Relief Funds (PRF) or other grants.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable

The Corporation has agreements with third-party payors that provide for payment to the Corporation at amounts different from its established rates. A summary of the payment arrangements for hospital services with major third-party payors is as follows:

Medicare: Inpatient acute care services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge and per patient day depending on the service. Acute care rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Certain inpatient and outpatient services, as well as defined organ acquisition, capital and medical education costs related to Medicare beneficiaries are paid based on regulatory proscribed formulae. The Corporation is reimbursed for such items at a tentative rate with final settlement determined after submission of annual cost reports by the Corporation and audits thereof by the Medicare fiscal intermediary. The Corporation's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Corporation. Most outpatient reimbursements are based on an Ambulatory Payment Classification weighting by acuity system, although some outpatient cost reimbursement still exists.

Medicaid: Inpatient services rendered to Medicaid program beneficiaries are reimbursed at prospectively determined rates in accordance with Part 86 of the New York Codes, Rules and Regulations and New York State Law which are promulgated by the New York State Department of Health (DOH). Outpatient services are similarly paid at either prospective rates or fee schedule amounts.

Under the New York Health Care Reform Act, the Corporation also enters into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Corporation under these agreements includes prospectively determined rates, discounts from charges, and prospectively determined per diem rates. Medicaid, Workers' Compensation and No-fault continue to have reimbursement rates determined based on New York's Prospective Reimbursement Methodology.

Terrace View provides services to residents under agreements with third-party payors (Medicaid, Medicare and HMO's) under provisions of their respective cost reimbursement formulas or contractually negotiated rates. If amounts received are less than established billing rates, the difference is accounted for as a reduction of revenue. Final determination of the reimbursement rates are subject to review by appropriate third-party payors. Provisions are made in the financial statements for anticipated adjustments that may result from such reviews. The difference between the estimated amounts accrued and final settlements are reported in operations in the year of settlement.

Net patient service revenue, as reported on the statements of revenues, expenses and changes in net position, is comprised of the following for the years ended December 31:

| | 2023 | 2022 |
|--------------------------|--------------|--------------|
| Gross charges | \$ 1,673,523 | \$ 1,514,854 |
| Less: | | |
| Discounts and allowances | 1,064,847 | 932,991 |
| Provision for bad debts | 4,956 | 15,474 |
| | \$ 603,720 | \$ 566,389 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable (Continued)

Net patient service revenue by payor for the years ended December 31 is as follows:

| | 2023 | | | 2022 | | | |
|---|------|---------|--|--------|---------------|--|--------|
| | | Amount | | % | Amount | | % |
| Medicare* | \$ | 247,282 | | 41.0% | \$ 229,412 | | 40.5% |
| Medicaid* | | 164,815 | | 27.3% | 156,183 | | 27.6% |
| Commercial and other third-party payors | | 164,704 | | 27.3% | 153,322 | | 27.1% |
| No-fault | | 20,452 | | 3.4% | 23,968 | | 4.2% |
| Self-pay | | 6,467 | | 1.0% | 3,504 | | 0.6% |
| | \$ | 603,720 | | 100.0% | \$ 566,389 | | 100.0% |

^{*}Medicare and Medicaid include Managed Care plans.

Laws and regulations governing Medicare, Medicaid, and other third-party payor programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in future periods. The Corporation believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs.

Patient accounts receivable consist of the following at December 31:

| | 2023 | 2022 |
|--|-------------------|-------------------|
| Gross accounts receivable Less: | \$ 295,805 | \$ 271,115 |
| Discounts and allowances Allowance for bad debts | 128,839 64,577 | 124,132 63,414 |
| | \$ 102,389 | \$ 83,569 |

Concentration of credit risk: The Corporation grants credit without collateral to its patients, most of whom are insured under third-party payor arrangements. The mix of net receivables from patients and third-party payors at December 31 is as follows:

| | 2023 | 2022 |
|---|--------|--------|
| NA 11 ** | 00.00/ | 05.00/ |
| Medicare* | 33.2% | 35.6% |
| Commercial and other third party payors | 32.7% | 27.7% |
| Medicaid* | 27.8% | 32.1% |
| No-fault | 5.5% | 3.7% |
| Self-pay | 0.8% | 0.9% |
| Total | 100.0% | 100.0% |

^{*}Medicare and Medicaid include Managed Care plans.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 5. Disproportionate Share (DSH) Revenue

The Medicaid DSH program is designed to provide funds to certain hospitals to help offset the cost of uncompensated care provided to the uninsured. Each state has a specified Federal DSH allotment. In addition, New York State law authorizes the New York State Department of Health (DOH) to make supplemental DSH medical assistance payments to public hospitals located in Erie County, Nassau County, and Westchester County. For long term care facilities, DSH revenue is recognized in accordance with Upper Payment Limit (UPL) regulations promulgated by the Centers for Medicare and Medicaid Services (CMS).

In 2023 and 2022, DSH funding recorded by the Corporation totaled \$107,105 and \$68,295, respectively. The DSH funding process is complex and includes both tentative and final settlements for various state fiscal years which are subject to the availability of state and federal funding among other factors. As a result, DSH revenue is estimated and final settlements may vary significantly from the initial estimates.

For hospital services, DSH revenue of \$91,220 and \$58,295 was recognized in 2023 and 2022, respectively. In addition, during 2023 and 2022, the Corporation recognized \$15,885 and \$10,000, respectively, of UPL revenue for Terrace View. UPL revenue has been recognized based off New York State fiscal year 2023-2024, as determined by the DOH, using cost report year 2021 data.

CMS has indicated that cost reports dating back to the 2021 reporting year and the methodology employed to calculate DSH revenue are subject to audit for those years. Additionally, on February 24, 2024 CMS published the final rule addressing recent legislative changes to the Social Security Act, which changed hospital specific Medicaid DSH payment formulas. At this time, the impact of the CMS audit activity, and any DSH payment formula changes including implementation timing are not certain. Management has taken what it believes to be reasonable and appropriate steps to assure compliance with the CMS methodology.

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited

Cash and cash equivalents and investments: The Corporation's investments are made in accordance with State regulations and its own investment policy. The investment policy is regularly reviewed by an investment committee of the Board which evaluates the performance of investment managers and monitors compliance with the investment policy.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

The Corporation's investments are generally reported at fair value, as discussed in Note 2. The carrying amounts of cash and cash equivalents, investments and assets whose use is limited are included in the Corporation's statements of net position as follows:

| | 2023 | | | 2022 |
|--|----------|---------------------------------------|-----------|-------------------------------------|
| Cash and cash equivalents Investments Assets whose use is limited—current Assets whose use is limited—noncurrent | \$ | 20,773 10,646 113,986 56,635 | \$ | 44,195 7,253 99,078 58,438 |
| Assets whose use is inflited—Horiculterit | \$ | 202,040 | \$ | 208,964 |
| Current portion of assets whose use is limited: Patient and residents trust cash Restricted for debt service (a) | \$ | 726 13,570 | \$ | 362 2,360 |
| Designated for self-insurance obligations (b) | | 8,998 | | 9,356 |
| Designated for retiree health obligations (b) | | 12,326 | | 12,061 |
| Designated for DSRIP program (b) | | 71,684 | | 68,534 |
| NYS voluntary defined contribution plan escrow Medical and dental staff funds | | 49 | | 129 |
| Restricted—self-insured workers' compensation collateral ^(d) | | 1,121 5,512 | | 1,004 5,272 |
| Total current portion of assets whose use is limited | \$ | 113,986 | \$ | 99,078 |
| MON NOR | <u> </u> | 110,000 | Ψ | 00,010 |
| Noncurrent portion of assets whose use is limited: Restricted for debt service (a) | \$ | 10,302 | \$ | 9,825 |
| Designated for long-term investment (b) | | 5,091 | | 9,099 |
| Designated for retiree health obligations (b) | | 12,505 | | 12,770 |
| Designated for self-insurance obligations (b) | | 24,075 | | 21,808 |
| Restricted—insured workers' compensation collateral (c) | | 4,662 | | 4,936 |
| Total noncurrent portion of assets whose use is limited | \$ | 56,635 | <u>\$</u> | 58,438 |

⁽a) Funds restricted by operation of indenture agreement

⁽b) Funds internally designated by operation of Board authority

⁽c) Funds restricted—insured workers' compensation collateral agreement

⁽d) Funds restricted—self-insured workers' compensation collateral agreements

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

The Corporation's cash and cash equivalents, as well as investments, are exposed to various risks, including credit, custodial credit, interest rate and market risks, as discussed in more detail below:

Deposits

All monies are deposited with banks or trust companies designated by the Corporation's investment committee of the Board of Directors. Funds not needed for immediate expenditure may be deposited in interest or non-interest-bearing accounts or invested in various marketable securities and bonds.

Custodial credit risk: Custodial credit risk is the risk that, in the event of bank failure, the Corporation's deposits might not be recovered. FDIC insurance through December 31, 2023 for funds held in interest bearing accounts is \$250 per depositor per category of legal ownership. New York law requires that deposits in excess of FDIC insured amounts are collateralized. The Corporation's bank deposits at December 31, 2023 and 2022, totaled \$27,068 and \$50,760, of which \$1,030 and \$1,043, respectively, were insured. Amounts over FDIC insured limits were fully collateralized with securities held by the pledging financial institution.

Investments

The Corporation's investment policy authorizes the Corporation to invest in accordance with New York State Finance Law Section 8(14), Section 201 and Public Authorities Law Article 9 Section 2800 to 2985, as well as the relevant provisions of the ECMCC Act. Compliance with the policy is monitored by the Corporation's investment committee and reported on regularly throughout the year by the Corporation's investment advisor.

Credit risk: Credit risk is the risk that the issuer or other counterparty to an investment will not fulfill its obligation, causing the Corporation to experience a loss of principal. The Corporation's investment policy limits investments in equity and fixed income securities with ratings only in the highest category. ECMCC's investments in government bonds carry the explicit guarantee of the U.S. government. The corporate bonds, short-term fixed income and government bonds are all rated AA+ or better by the Standards & Poor's rating agency.

Interest rate risk: Interest rate risk is the risk that changes in interest rates will adversely affect the fair value of an investment. The Corporation's cash equivalent securities are limited to maturities of no greater than eighteen months; short-term fixed income securities are limited to maturities of no greater than five years; and long-term fixed income securities are limited to maturities to no more than ten years. Substantially all of the Corporation's investments and assets whose use is limited have stated maturities of less than one year.

Custodial credit risk: For an investment, custodial credit risk is the risk that, in the event of the failure of the counterparty, the Corporation will not be able to recover the value of its investments or collateral securities that are in the possession of an outside party. The Corporation's investment policy does not address custodial credit risk.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

Concentration of credit risk: Concentration of credit risk is the risk of loss attributable to the magnitude of investments in any single issuer. The Corporation's investment policy indicates the combined holdings of securities from one issuer shall not constitute more than 5.0% of the fund except for issues guaranteed directly or indirectly by the U.S. Government. The Corporation had no holdings in Federal National Mortgage Association (Fannie Mae) or Federal Home Loan Mortgage Corporation (Freddie Mac) issues at December 31, 2023 and 2022.

Fair value of financial instruments: Fair value is defined in the accounting standards as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy established by GASB. Assets carried at fair value are required to be classified and disclosed in one of the following three categories:

- **Level 1:** Valuations based on quoted prices in active markets for identical assets that the Corporation has the ability to access.
- **Level 2:** Valuations based on quoted prices in active markets for similar assets, quoted prices in markets that are not active or for which all significant inputs are observable, directly or indirectly. The Corporation has no Level 2 assets.
- **Level 3:** Valuations based on inputs that are unobservable and significant to the overall fair value measurement. These are generally company generated inputs and are not market-based inputs. The Corporation has no Level 3 assets.

| | Level 1 | | Level 2 | | Level 3 | Total |
|--|---------------|----|---------|----|---------|---------------|
| Cash and cash equivalents | \$ 20,773 | \$ | - | \$ | - | \$ 20,773 |
| Investments and assets whose use is limited: | | | | | | |
| Cash and cash equivalents Marketable equity securities: | 115,448 | | - | | - | 115,448 |
| Small/Mid cap equities | 4,423 | | - | | - | 4,423 |
| Growth equities | 1,447 | | - | | - | 1,447 |
| Core equities | 9,921 | | - | | - | 9,921 |
| International equities | 10,190 | | - | | - | 10,190 |
| U.S. fixed income | 39,838 | | - | | - | 39,838 |
| Total investments and assets | | | | | | |
| whose use is limited | 181,267 | | - | | - | 181,267 |
| Total | \$ 202,040 | \$ | - | \$ | - | \$ 202,040 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

| | 2022 | | | | | | | | |
|--|--------|---------|-------|---|------|----------|----|---------|--|
| | | Level 1 | Le | evel 2 | Leve | l 3 | | Total | |
| Cash and cash equivalents | \$ | 44,195 | \$ | - | \$ | - | \$ | 44,195 | |
| Investments and assets whose use is limited: | | | | | | | | | |
| Cash and cash equivalents Marketable equity securities: | | 96,213 | | - | | <u>-</u> | | 96,213 | |
| Small/Mid cap equities | | 4,117 | | <u>-</u> | | MILENI | | 4,117 | |
| Growth equities | | 1,459 | | - | | _ | | 1,459 | |
| Core equities | | 9,070 | | - 6 | | - | | 9,070 | |
| International equities | | 10,330 | | WALE OF THE PARTY | | - | | 10,330 | |
| U.S. fixed income | | 43,580 | | Ma ñ | 3 | - | | 43,580 | |
| Total investments and assets | M | ALL RE | M. P. | 10 | | | | | |
| whose use is limited | 11110. | 164,769 | | 10/2 | | - | | 164,769 | |
| Total | \$ | 208,964 | \$ 3 | | \$ | - | \$ | 208,964 | |

Note 7. Capital Assets, Net

Capital asset activity for the years ended December 31 is as follows:

| | | | | 20 |)23 | | |
|--|------|-------------|-------|------------|-----|------------|---------------|
| | E | Beginning | | | | Disposals/ | Ending |
| | | Balance | | Additions | - | Transfers | Balance |
| Capital assets—being depreciated: | | | | | | | |
| Land and land improvements | \$ | 41,166 | \$ | 31 | \$ | - | \$ 41,197 |
| Buildings and improvements | | 545,092 | | 2,882 | | - | 547,974 |
| Fixed/major moveable equipment | | 151,523 | | 5,096 | | (165) | 156,454 |
| Total capital assets—being depreciated | | 737,781 | | 8,009 | | (165) | 745,625 |
| deprediated | | 737,701 | | 0,003 | | (100) | 740,020 |
| Less accumulated depreciation | | (461,308) | | (32,001) | | 165 | (493,144) |
| Total capital assets—being depreciated, net | | 276,473 | | (23,992) | | - | 252,481 |
| Capital assets—not being depreciated: | | | | | | | |
| Construction in progress | | 21,643 | | 3,165 | | (16,382) | 8,426 |
| Capital assets, net, excluding lease and SBITA assets | \$ | 298,116 | \$ | (20,827) | \$ | (16,382) | \$ 260,907 |
| Lease and SBITA assets, net (Note 8) | | | | | | | \$ 52,132 |
| Total capital assets, net, as reported | in s | tatements o | of ne | t position | | | \$ 313,039 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 7. Capital Assets, Net (Continued)

| | 2022 | | | | | | | |
|--|------|------------------------------|-----------|-----------------------|------------|------------------------------|----|------------------------------|
| | | Beginning | | | Disposals/ | | | Ending |
| | | Balance | Additions | | Transfers | | | Balance |
| Capital assets—being depreciated: Land and land improvements Buildings and improvements Fixed/major moveable equipment | \$ | 41,624 547,713 160,780 | \$ | 525 4,763 5,632 | \$ | (983) (7,384) (14,889) | \$ | 41,166 545,092 151,523 |
| Total capital assets—being depreciated | | 750,117 | | 10,920 | | (23,256) | | 737,781 |
| Less accumulated depreciation | | (448,779) | | (34,911) | | 22,382 | 1 | (461,308) |
| Total capital assets—being depreciated, net | | 301,338 | | (23,991) | æ (§ | (874) | | 276,473 |
| Capital assets—not being depreciated: | | | | | | | | |
| Construction in progress | | 19,699 | | 8,216 | | (6,272) | | 21,643 |
| Capital assets, net, excluding lease and SBITA assets | \$ | 321,037 | \$ | (15,775) | \$ | (7,146) | \$ | 298,116 |
| Lease and SBITA assets, net (Note 8) | | | | | | : | \$ | 61,270 |
| Total capital assets, net, as reported in statements of net position | | | | | | | | 359,386 |

Construction in progress at December 31, 2023 and 2022, includes costs associated with various mechanical, electrical and information-technology security projects. The costs associated with an ambulatory electronic medical records system project of \$11,239 were written off during the year ended December 31, 2023 and recorded within purchased services expenses within the statements of revenues, expenses and changes in net position.

Depreciation expense amounted to \$32,001 and \$34,911 for the years ended December 31, 2023 and 2022, respectively.

Note 8. Leases and Subscription-Based Information Technology Arrangements

The Corporation is a lessee for various noncancellable leases of real estate and equipment. The expected lease payments are discounted using the interest rate charged on the lease, if available, and are otherwise discounted using the Corporation's incremental borrowing rate. The right-to-use assets are amortized over the shorter of the lease term or the underlying asset useful life. Lease assets are reported within capital assets and lease and SBITA liabilities are reported separately in the statements of net position.

Effective January 1, 2022, the Corporation adopted GASB Statement No. 96, *Subscription-Based Information Technology Arrangements (SBITAs)*. This Statement provides guidance on the accounting and financial reporting for SBITAs for government end users. The implementation of this Statement required the restatement of certain expenses and the change in net position in the December 31, 2022 financial statements.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its subscription-based information technology agreements with others. These arrangements have terms requiring monthly, quarterly or annual payments. The expected payments are discounted using the interest rate charged on the arrangement, if available, or are otherwise discounted using the Corporation's incremental borrowing rate.

Right-to-use assets by major class and the related accumulated amortization for the years ended December 31 is summarized as follows:

| | | | | | | 2023 | | |
|---|-----------|----------------------|----|-----------|-----|-------------|-------------|-------------------|
| | | Beginning Balance | | Additions | Rem | easurements | Retirements | Ending Balance |
| Lease assets being amortized: | | | | | 1 | | 0,0 | |
| Real estate | \$ | 13,969 | \$ | 718 | \$ | | \$ 2,760 | \$ 11,927 |
| Equipment | | 34,696 | | 3,950 | | 1,413 | - | 40,059 |
| Total lease assets being amortized | | 48,665 | 1 | 4,668 | 252 | 1,413 | 2,760 | 51,986 |
| | | | | | | | | |
| Less accumulated amortization: | | | | | | | | |
| Real estate | | 2,603 | | 1,156 | | <u>-</u> | 1,069 | 2,690 |
| Equipment | MAL | 16,008 | 30 | 6,917 | | <u></u> | - | 22,925 |
| Total accumulated amortization | TIL | 18,611 | | 8,073 | | | 1,069 | 25,615 |
| Lease assets, net | | 30,054 | | (3,405) | lnn | 1,413 | 1,691 | 26,371 |
| | | | | | | | | |
| Subscription-based information technology assets | | 39,473 | | 4,349 | | - | - | 43,822 |
| Accumulated amortization | N | 8,257 | 1 | 9,804 | | - | - | 18,061 |
| Subscription-based information technology assets, net | Ull | 31,216 | \ | (5,455) | | - | - | 25,761 |
| Lease and SBITA assets, | | | | | | | | |
| net of accumulated amortization | \$ | 61,270 | \$ | (8,860) | \$ | 1,413 | \$ 1,691 | \$ 52,132 |
| | | | | | | | | |
| | | | | | | 202 | 2 | |
| | Beginning | | | | | Ending | | |
| | | Balance | | Additions | Rem | easurements | Retirements | Balance |
| Lease assets being amortized: | | | | | | | | |
| Real estate | \$ | 13,541 | \$ | 428 | \$ | - ; | \$ - | \$ 13,969 |
| Equipment | | 26,194 | | 8,502 | | - | _ | 34,696 |
| Total lease assets being amortized | | 39,735 | | 8,930 | | - | - | 48,665 |
| · · | | · | | · | | | | |
| Less accumulated amortization: | | | | | | | | |
| Real estate | | 1,410 | | 1,193 | | - | - | 2,603 |
| Equipment | | 10,546 | | 5,462 | | - | - | 16,008 |
| Total accumulated amortization | | 11,956 | | 6,655 | | - | - | 18,611 |
| Lease assets, net | | 27,779 | | 2,275 | | - | - | 30,054 |
| | | | | | | | | _ |
| Subscription-based information technology assets | | 34,370 | | 5,103 | | - | - | 39,473 |
| Accumulated amortization | | - | | 8,257 | | - | - | 8,257 |
| Subscription-based information technology assets, net | | 34,370 | | (3,154) | | - | - | 31,216 |
| Lease and SBITA assets, | | | | | | | | |
| net of accumulated amortization | _\$ | 62,149 | \$ | (879) | \$ | - ; | \$ - | \$ 61,270 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

As of December 31, 2023, the principal and interest requirements to maturity for the lease liability are as follows:

| | Principal | Interest | | Total |
|-----------|-----------|--------------|----|--------|
| 0004 | Φ 7.005 | Φ 000 | Φ. | 0.000 |
| 2024 | \$ 7,685 | \$ 923 | \$ | 8,608 |
| 2025 | 5,794 | 655 | | 6,449 |
| 2026 | 3,916 | 447 | | 4,363 |
| 2027 | 2,549 | 303 | | 2,852 |
| 2028 | 1,543 | 205 | | 1,748 |
| 2029-2033 | 3,669 | 538 | | 4,207 |
| 2034-2038 | 1,484 | 59 | | 1,543 |
| | \$ 26,640 | 3,130 | \$ | 29,770 |

As of December 31, 2023, the principal and interest requirements to maturity for the SBITA liability are as follows:

| | N. | Principal | nterest | Total |
|--------------|----|----------------|-------------|----------------|
| 2024 | \$ | 8,724 | \$ 800 | \$ 9,524 |
| 2025 2026 | | 7,129 5,568 | 475 218 | 7,604 5,786 |
| 2027 | | 2,846 | 49 | 2,895 |
| 2028 | | 135 | 3 | 138 |
| 2029-2033 | | 49 | 1 | 50 |
| | \$ | 24,451 | \$ 1,546 | \$ 25,997 |

Lessor: The Corporation leases real estate to external parties. In accordance with GASB Statement No. 87, *Leases*, the Corporation records lease receivables and deferred inflows of resources based on the present value of expected receipts over the term of the respective leases. The Corporation recognized lease receivables (reported within other assets in the statements of net position) of \$753 and \$501 at December 31, 2023 and 2022, respectively, deferred inflows of resources of \$1,666 and \$1,440 at December 31, 2023 and 2022, respectively, and lease revenue of \$632 and \$931 during the years ended December 31, 2023 and 2022, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 9. Accrued Other Liabilities

The composition of accrued other liabilities as of December 31 is as follows:

| | _ | 2023 | | | 2022 |
|---|-------|------|--------|-----|--------|
| Due to Erie County | | \$ | 12,767 | \$ | 11,880 |
| Due to joint venture | | | 326 | | 767 |
| Medical malpractice claims | | | 1,792 | | 1,800 |
| Estimated third-party payor settlements | | | 4,486 | | 2,736 |
| Asset retirement obligations | | | 2,167 | | 2,118 |
| Workers compensation claims | | | 7,416 | | 7,556 |
| Other | 757 | | 13,067 | 705 | 13,256 |
| Total | - AFI | \$ | 42,021 | \$ | 40,113 |

GASB Statement No. 83, Certain Asset Retirement Obligations, establishes criteria for determining the timing and pattern of recognition of a liability and a corresponding deferred outflow of resources for asset retirement obligations (AROs). An ARO is a legally enforceable liability associated with the retirement of a tangible capital asset. In accordance with this Statement, the Corporation completes an analysis of assets meeting the criteria of an ARO for specific types of medical equipment such as medical imaging equipment (e.g., MRIs, CT scanners, and PET scanners), X-Rays, and ultrasounds as well as computers containing information protected by HIPAA laws, and certain types of laboratory equipment. In addition, the Corporation evaluates the requirements for disposal of underground fuel and lab acid tanks. The Corporation determined, based on industry standards for disposition of similar assets, the total asset retirement obligation totaled \$2,167 and \$2,118 at December 31, 2023 and 2022, respectively. The assets have a remaining useful life ranging from 0 to 30 years. This obligation is discounted using a rate of 4.0% and an inflation factor of 3.0% at December 31, 2023 and 2022.

Note 10. Indebtedness

Long-term debt consisted of the following at December 31:

| Erie County—Guaranteed Senior |
|--------------------------------|
| Revenue Bonds, Series 2004 |
| Erie County—2017 loan payable |
| Erie County—2017 loan payable |
| Erie County—2017 capitalized |
| interest assumption obligation |
| Finance obligations |
| Total debt |

| | | | | | 2023 | | | | |
|----|----------|---------|---------|----------------|----------|---------|---------|---------|-----------|
| В | eginning | ginning | | Pa | ayments/ | | Ending | | ue Within |
| E | Balance | Ad | ditions | Forgiveness Ba | | Balance | C | ne Year | |
| | | | | | | | | | |
| \$ | 61,135 | \$ | - | \$ | (4,165) | \$ | 56,970 | \$ | 4,390 |
| | 90,154 | | - | | (2,780) | | 87,374 | | 2,849 |
| | 53,235 | | - | | (4,159) | | 49,076 | | 4,271 |
| | | | | | | | | | |
| | 7,505 | | - | | (231) | | 7,274 | | 237 |
| | 2,328 | | - | | (379) | | 1,949 | | 381 |
| \$ | 214,357 | \$ | - | \$ | (11,714) | \$ | 202,643 | \$ | 12,128 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

| | | | 2022 | | |
|--------------------------------|------------|-----------|-------------|------------|------------|
| | Beginning | | Payments/ | Ending | Due Within |
| | Balance | Additions | Forgiveness | Balance | One Year |
| Erie County—Guaranteed Senior | | | | | |
| Revenue Bonds, Series 2004 | \$ 65,080 | \$ - | \$ (3,945) | \$ 61,135 | \$ 4,165 |
| Erie County—2017 loan payable | 92,867 | - | (2,713) | 90,154 | 2,780 |
| Erie County—2017 loan payable | 57,286 | - | (4,051) | 53,235 | 4,159 |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | 7,731 | - | (226) | 7,505 | 231 |
| Finance obligations | 2,710 | - | (382) | 2,328 | 381 |
| Total debt | \$ 225,674 | \$ - | \$ (11,317) | \$ 214,357 | \$ 11,716 |

Future annual principal payments applicable to long-term debt for the years subsequent to December 31, 2023 are as follows:

| 2024 2025 2026 2027 2028 2029-2033 2034-2038 | \$ 12,128 12,565 13,025 13,507 14,008 76,818 54,603 |
|--|--|
| 2039-2042 | 5,989 |
| Total | \$ 202,643 |

The Series 2004 Bonds are secured by a pledge of the gross receipts of the Corporation and amounts on deposit in certain debt service reserve funds. Interest rates on the bonds range from 5.5% to 5.7%, with principal payments ranging from \$4,165 to \$7,220 due annually on November 1 with interest payments due semi-annually on May 1 and November 1.

Pursuant to a Guaranty Agreement, the County has unconditionally guaranteed to the Corporation, the punctual payment of the principal, interest, and redemption premium, if any, on the Series 2004 Bonds, as the same shall become due and payable, and has pledged the faith and credit of the County for the performance of such guaranty. A municipal bond insurance policy has been purchased by the Corporation to guarantee all debt service payments in case of default by the Corporation and the County.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie, with the assistance of the Erie County Fiscal Stability Authority. The proceeds of the loan were used to finance the construction of a new Level 1 Adult Trauma Center and Emergency Department, fund various other capital projects on the Corporation's campus as well as refinance a 2011 loan. The loan has an interest rate of 3.377% with monthly principal and interest payments ranging from \$474 to \$930 during the term of the loan. In addition to the loan, the Corporation assumed the liability related to funds borrowed to pay capitalized interest during construction on the various projects noted above. The capitalized interest liability assumption has an interest rate of 3.377% with monthly principal and interest payments ranging from \$40 to \$77 during the term of the loan. The new money portion of the loan and the capitalized interest assumption agreement is fully amortized and matures in 2039. The refinancing component of the loan has an interest rate of 2.649% with monthly principal and interest payments ranging from \$300 to \$460 during the term of the loan and is fully amortized and maturing in 2034.

During 2018, the Corporation entered into a finance obligation agreement in the amount of \$2,044, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$29 and matures September 2025.

During 2018, the Corporation entered into a second finance obligation agreement in the amount of \$409, the proceeds of which were used to purchase various suite improvements. The agreement required principal and interest payments (cost of capital is estimated at 3.8%) of \$4 and was paid in full during 2023.

During 2019, the Corporation entered into a finance obligation agreement in the amount of \$1,805, the proceeds of which were used to finance various cafeteria improvements. The agreement requires principal and interest payments (cost of capital ranges from 0% to 9.0%) of \$17 and matures March 2029.

During 2020, the Corporation entered into a finance obligation agreement in the amount of \$2,555, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$39 and matures July 2026.

During 2021, the Corporation entered into a finance obligation agreement in the amount of \$1,552, the proceeds of which were used to finance a new food service line. The agreement requires principal and interest payments (cost of capital is 4.0%) of \$19 and matures in December 2028.

During 2021, the Corporation signed an agreement for an unsecured revolving line of credit with an original maturity date of November 2022 and was amended and extended to May 2024. The Corporation has available \$10,000 with interest payable at a variable rate of daily Secured Overnight Financing Rate (SOFR) plus 183 basis points. There was \$10,000 of outstanding borrowings against the line at December 31, 2023 and 2022, respectively. Management is currently negotiating an extension for the maturity date of this agreement.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan

Retirement plan: The Corporation participates in the New York State and Local Retirement System (NYSLRS or the System), which is a cost-sharing, multiple-employer public employees' retirement system. There are more than 515,000 pensioners and beneficiaries in the System with over 1.2 million participants.

For purposes of measuring the net pension liability (asset), deferred outflows of resources and deferred inflows of resources related to pensions, and pension expense/benefit, information about the fiduciary net position of the NYSLRS and additions to/deductions from NYSLRS' fiduciary net position have been determined on the same basis as they are reported by NYSLRS. For this purpose, benefit payments (including refunds of employee contributions) are recognized when due and payable in accordance with the benefit terms. The net pension liability (asset) is measured as the portion of the present value of projected benefit payments to be provided through the pension plan to current active and inactive employees that is attributed to those employees' past periods of service (total pension liability), less the amount of the pension plan's fiduciary net position. The net pension liability (asset) should be measured as of a date (measurement date) no earlier than the end of the employer's prior fiscal year, consistently applied from period to period.

Obligations of employers and employees to contribute and benefits to employees are governed by the New York State Retirement and Social Security Law (RSSL). As set forth in the RSSL, the Comptroller of the State of New York (the Comptroller) serves as sole trustee and administrative head of the System. The Comptroller shall adopt and may amend rules and regulations for the administration and transaction of the business of the System and for custody and control of its funds. The System issues a publicly available financial report that includes financial statements and required supplementary information. That report may be obtained by writing to the New York State and Local Retirement System, 110 State Street, Albany, NY 12244.

NYSLRS provides three main types of retirement benefits: service retirements, ordinary disability retirements (non-job-related disabilities), and accident disability retirements (job-related disabilities) to members who are in different Tiers. The members' Tier is determined by the date of membership. Subject to certain conditions, members generally become fully vested as to benefits upon the completion of five years of service depending on their Tier. Employees may be required to contribute a percentage of their salary to the pension plan based on their Tier, determined by their date of membership in the plan. Annual pension benefits can be calculated as a percentage of final average salary times number of years of service and changes with the number of years of membership within the plan.

At December 31, 2023 and 2022, the Corporation reported a liability of \$198,936 and an asset of \$77,538, respectively, for its proportionate share of the NYSLRS net pension liability (asset). The total pension liability (asset) used to calculate the net pension liability (asset) is determined by an actuarial valuation as of April 1st each year and rolled forward to March 31st. The Corporation's proportion for the net pension liability (asset) for each fiscal year was based on the Corporation's indexed present value of future compensation to NYSLRS of all participating employers for 2023 and 2022, which was 0.9277% and 0.9485%, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(a) Actuarial Assumptions

The total pension liability for the March 31, 2023 measurement date was determined using an actuarial valuation as of April 1, 2022, with update procedures used to roll-forward the total pension liability to March 31, 2023. The actuarial valuations used the following actuarial assumptions:

Inflation 2.9% Salary increases 4.4%, including inflation Investment rate of return 5.9%, net of pension plan investment expense

Cost of living adjustments 1.5%

Mortality improvement Society of Actuaries Scale MP-2021

The total pension asset for the March 31, 2022, measurement date was determined using an actuarial valuation as of April 1, 2021, with update procedures used to roll-forward the total pension liability to March 31, 2022. The actuarial valuations used the following actuarial assumptions:

Inflation 2.7%

Salary increases
4.4%, including inflation
Investment rate of return
5.9%, net of pension plan investment expense

Cost of living adjustments 1.4%

Mortality improvement Society of Actuaries Scale MP-2020

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(b) Expected Rate of Return on Investments

The long-term expected rate of return on pension plan investments was determined using a building-block method in which best-estimate ranges of expected future real rates of return (expected return, net of investment expenses and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target allocation and best estimates of arithmetic real rates of return for each major asset class are summarized in the following tables at December 31:

| | 2023 | | | |
|---|---|--|--|--|
| | Target | Long-Term | | |
| | Asset | Expected Real | | |
| Asset class | Allocation | Rate of Return | | |
| Demostic equity | 22.00/ | 4.20/ | | |
| Domestic equity International equity | 32.0% 15.0% | 4.3% 6.9% | | |
| Private equity | 10.0% | 7.5% | | |
| Real estate | 9.0% | 4.6% | | |
| Fixed income | 23.0% | 1.5% | | |
| Credit | 4.0% | 5.4% | | |
| Real assets | 3.0% | 5.8% | | |
| Opportunistic/absolute return strategy | 3.0% | 5.4% | | |
| Cash | 1.0% | 0.0% | | |
| | 100.0% | | | |
| | | | | |
| | 20 | 22 | | |
| | 20 Target | 22 Long-Term | | |
| | Target Asset | Long-Term Expected Real | | |
| Asset class | Target | Long-Term | | |
| | Target Asset Allocation | Long-Term Expected Real Rate of Return | | |
| Domestic equity | Target Asset Allocation 32.0% | Long-Term Expected Real Rate of Return | | |
| Domestic equity International equity | Target Asset Allocation 32.0% 15.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% | | |
| Domestic equity International equity Private equity | Target Asset Allocation 32.0% 15.0% 10.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% 6.5% | | |
| Domestic equity International equity | Target Asset Allocation 32.0% 15.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% | | |
| Domestic equity International equity Private equity Real estate | Target Asset Allocation 32.0% 15.0% 10.0% 9.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% 6.5% 5.0% | | |
| Domestic equity International equity Private equity Real estate Fixed income | Target Asset Allocation 32.0% 15.0% 10.0% 9.0% 23.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% 6.5% 5.0% 0.0% | | |
| Domestic equity International equity Private equity Real estate Fixed income Credit | Target Asset Allocation 32.0% 15.0% 10.0% 9.0% 23.0% 4.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% 6.5% 5.0% 0.0% 3.8% | | |
| Domestic equity International equity Private equity Real estate Fixed income Credit Real assets | Target Asset Allocation 32.0% 15.0% 10.0% 9.0% 23.0% 4.0% 3.0% | Long-Term Expected Real Rate of Return 3.3% 5.9% 6.5% 5.0% 0.0% 3.8% 5.6% | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(c) Discount Rate

The discount rate used to measure the total pension liability (asset) as of December 31, 2023 and 2022 was 5.9%. The projection of cash flows used to determine the discount rate assumes that contributions from plan members will be made at the current contribution rates and that contributions from employers will be made at statutorily required rates, actuarially determined. Based on those assumptions, the NYSLRS fiduciary net position was projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on NYSLRS investments was applied to all periods of projected benefit payments to determine the total pension liability (asset).

Sensitivity of the Net Pension Liability (Asset) to the Discount Rate

The following presents the Corporation's proportionate share of the net pension liability (asset) calculated using the discount rate of 5.9% at December 31, 2023 and 2022, as well as what the Corporation's proportionate share of the net pension liability (asset) would be if it were calculated using a discount rate that is one percentage point lower or one percentage point higher than the current rate:

| | | | | 2023 | | |
|--|----|------------|-----|-------------|----|------------|
| | 19 | 6 Decrease | Dis | scount Rate | 19 | % Increase |
| | 6 | (4.9%) | | (5.9%) | | (6.9%) |
| Corporation's proportionate share of the | | No II | | | | |
| net pension liability (asset) | \$ | 480,743 | \$ | 198,936 | \$ | (36,546) |
| | | | | | | |
| | | | | 2022 | | |
| | 1% | 6 Decrease | Dis | scount Rate | 19 | % Increase |
| | | (4.9%) | | (5.9%) | | (6.9%) |
| Corporation's proportionate share of the net pension (asset) liability | \$ | 199,582 | \$ | (77,538) | \$ | (309,335) |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(d) Deferred Outflows and Inflows of Resources

At December 31, 2023 and 2022, the Corporation reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

| | | 2023 | 2022 |
|--|----|---------|---------------|
| Deferred outflows of resources: | | | |
| Differences between expected and actual actuarial experience | \$ | 21,188 | \$ 5,872 |
| Changes in assumptions | | 96,616 | 129,402 |
| Other | | 5,311 | 8,419 |
| Total | \$ | 123,115 | \$ 143,693 |
| Deferred inflows of resources: | | | |
| Difference between expected and actual experience | \$ | 5,587 | \$ 7,616 |
| Change in assumptions | | 1,068 | 2,184 |
| Difference between projected and actual investment earnings | | | |
| on pension plan investments | | 1,168 | 253,904 |
| Changes in proportion and differences between Corporation | | | |
| contributions and proportionate share of contributions | 06 | 15,914 | 16,485 |
| Total OF TOTAL | \$ | 23,737 | \$ 280,189 |

The change in employer proportionate share is the difference between the employer proportionate share of net pension liability (asset) in the prior year compared to the current year. Changes in these amounts are amortized over a five-year closed period, reflecting the average remaining service life of plan members.

The net deferred outflows and inflows of resources of resources related to pensions, excluding contributions made subsequent to the measurement date, will be recognized in pension expense as follows:

| | | Amount |
|---------------------------|----|----------|
| Years ending December 31: | | |
| 2024 | \$ | 22,475 |
| 2025 | | (13,480) |
| 2026 | | 37,621 |
| 2027 | | 52,762 |
| | \$ | 99,378 |

Annual Pension Expense (Benefit)

The Corporation's annual pension expense (benefit) for calendar years ended 2023 and 2022, which includes contributions toward the actuarially determined asset or liability and the amortization of deferred outflows and inflows of resources, was approximately \$65,509 and \$(47), respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB)

Plan description: The Corporation provides OPEB that include basic medical and hospitalization plan coverage to eligible retirees. Eligible retirees may only be covered under the indemnified plan of the Corporation. To qualify, a retiree must meet various eligibility requirements as agreed to in collective bargaining agreements. The Corporation pays varying amounts based on specific union agreements.

Funding the plan: Currently, there is no New York State statute that expressly authorizes local governments to create a trust for OPEB purposes. Additionally, New York State's General Municipal Law does not allow for a reserve fund to accumulate funds for OPEB obligations. The Corporation's Board of Directors and management believe it is prudent to reserve funds for the Plan and have therefore internally designated \$24,831 in 2023 and 2022, for purposes of funding future post-employment benefits. These internally designated funds are included within assets whose use is limited in the statements of net position. In addition to the funding for future post-employment benefits, the Corporation continues to finance current benefits on a pay-as-you-go basis.

Annual OPEB cost and net OPEB obligation: The Corporation's total OPEB liability measured at December 31, 2023 and 2022, of \$293,911 and \$271,395, was determined by an actuarial valuation as of January 1, 2023 and 2022, respectively. The measurement date of the obligation is December 31, 2023 and 2022.

(a) Actuarial Assumptions

The total OPEB liability in the December 31, 2023, actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

| Inflation | 2.5% |
|--------------------------------|---|
| Salary increases | 3.3% per annum |
| Pre-Medicare Plans | 7.8% for 2023, 4.0% ultimate trend rate in 2075 |
| Medicare Plans | 4.6% for 2023, 4.0% ultimate trend rate in 2075 |
| Pre-Medicare Prescription Plan | 7.8% for 2023, 4.0% ultimate trend rate in 2075 |
| Medicare Prescription Plan | 7.0% for 2023, 4.0% ultimate trend rate in 2075 |
| Mortality | Society of Actuaries Scale MP-2021 |

The total OPEB liability in the December 31, 2022 actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

| Inflation | 2.5% |
|--------------------------------|---|
| Salary increases | 3.7% per annum |
| Pre-Medicare Plans | 7.8% for 2022, 4.0% ultimate trend rate in 2075 |
| Medicare Plans | 4.5% for 2022, 4.0% ultimate trend rate in 2075 |
| Pre-Medicare Prescription Plan | 7.8% for 2022, 4.0% ultimate trend rate in 2075 |
| Medicare Prescription Plan | 6.5% for 2022, 4.0% ultimate trend rate in 2075 |
| Mortality | Society of Actuaries Scale MP-2021 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

(b) Changes in the OPEB Liability

| | 2023 | 2022 |
|--|------------------|----------|
| Changes in the OPEB obligation: | | |
| Projected OPEB obligation at the beginning of year | \$ 271,395 \$ | 379,106 |
| Service cost | 2,620 | 4,528 |
| Interest cost | 9,722 | 6,959 |
| Difference between expected and actual experience | 232 | (34,085) |
| Change in assumptions | 26,546 | (69,430) |
| Actual benefit payments | (16,604) | (15,683) |
| Projected OPEB obligation at the end of year | \$ 293,911 \$ | 271,395 |

(c) Discount Rate

The discount rate used to measure the total OPEB liability was 3.3% and 3.7%, based on the Bond Buyer 20-year Bond GO index rate as of December 31, 2023 and 2022, respectively.

Sensitivity of the OPEB Liability to the Discount Rate

The following presents the Corporation's total OPEB liability calculated using the discount rate of 3.3%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (2.3%) or one percentage point higher (4.3%) than the current rate.

| | | | | 2023 | | |
|--|----|------------|-----|------------|----|------------|
| | 1% | 6 Decrease | Dis | count Rate | 1% | 6 Increase |
| | | (2.3%) | | (3.3%) | | (4.3%) |
| The Corporation's total OPEB liability | \$ | 337,382 | \$ | 293,911 | \$ | 258,462 |

The discount rate used to measure the total OPEB liability as of December 31, 2022, was 3.7%, based on the Bond Buyer 20-year Bond GO index rate.

The following presents the Corporation's total OPEB liability calculated using the discount rate of 3.7%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (2.7%) or one percentage point higher (4.7%) than the current rate.

| | | | | 2022 | | |
|--|----|----------|-----|------------|----|------------|
| | 1% | Decrease | Dis | count Rate | 19 | % Increase |
| | | (2.7%) | | (3.7%) | | (4.7%) |
| The Corporation's total OPEB liability | \$ | 310,620 | \$ | 271,395 | \$ | 239,334 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

Sensitivity of the OPEB Liability to the Healthcare Cost Trend Rates

The following presents the Corporation's total OPEB liability calculated using healthcare cost trend rates that are one percentage point lower or one percentage point higher than the current healthcare cost trend rates.

| thcare |
|-----------------------|
| 15 4 40/ 1 |
| end Rates 1% Increase |
| 293,911 \$ 341,658 |
| 22 |
| ncare |
| nd Rates 1% Increase |
| 71,395 \$ 314,630 |
| |

(d) Deferred Outflows and Inflows of Resources

The following are components of deferred outflows and inflows at December 31, 2023 and 2022:

| | 2023 | | | |
|---|------|-------------------|-----|----------------------|
| | | Deferred Deferred | | |
| | | Outflows Inflows | | |
| Differences between expected and actual actuarial experience Changes in assumptions | \$ | 544 25,126 | \$ | (27,754) (31,583) |
| Total | \$ | 25,670 | \$ | (59,337) |
| | | 20 | 022 | |
| | | eferred | | Deferred |
| | | Outflows | | Inflows |
| Differences between expected and actual actuarial experience Changes in assumptions | \$ | 96 22,588 | \$ | (58,636) (56,176) |
| Total | \$ | 22,684 | \$ | (114,812) |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

The net deferred outflows and inflows of resources at December 31, 2023, will be recognized as follows:

| | Amount |
|------|-------------|
| 2024 | \$ (24,297) |
| 2025 | (12,810) |
| 2026 | 3,440 |
| | \$ (33,667) |

(e) Annual OPEB Benefit

The Corporation's annual OPEB benefit for the years ended December 31, 2023 and 2022, was \$19,343 and \$31,319, respectively.

Note 13. New York State Department of Health (NYSDOH) Grant Programs

The NYSDOH offers the Vital Access Provider Assurance Program (VAPAP) program. Funding under this program is made to public or safety net hospitals and health systems that meet certain criteria or that have been designated as critical access or sole community hospitals and is awarded to enable these facilities to maintain operations and provision of vital services while they implement longer-term solutions to achieve sustainable health care service delivery. During the years ended December 31, 2023 and 2022, the Corporation received grant payments under this program in the amount of \$76,838 and \$78,998, respectively. Specifically related to these grants, during the years ended December 31, 2023 and 2022, \$103,838 and \$51,998, respectively, was recognized in the statement of revenues, expenses and changes in net position as non-operating revenue.

Note 14. Transactions With the County of Erie

On December 30, 2009, the Corporation and the County entered into a Settlement Agreement. The Settlement Agreement resulted in the Corporation and the County entering into a number of transactions to resolve litigation and prepare for implementing the Corporation's master facility plan.

In October 2012, the Corporation and the County signed an amendment to the 2009 Settlement Agreement (the Amendment). The terms of the Amendment provide for the County to be reimbursed from the Corporation for certain workers' compensation claims incurred by Corporation employees that were paid by the County. The Amendment also provides for the County to reimburse the Corporation, over time, for post-retirement health expenses that the Corporation incurred for Corporation employees with service time at the County.

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie. A component of the loan agreement included the payment of points by the Corporation to the County of Erie in the amount of \$17,040 as further described in Note 2 and 10.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 14. Transactions With the County of Erie (Continued)

Other transactions: Amounts that are included in operating revenues and expenses in the statements of revenues, expenses and changes in net position, which represent related-party transactions that occurred between the Corporation and the County during the years ended December 31, 2023 and 2022, are as follows:

The Corporation earned revenue totaling \$3,902 and \$3,856 for the years ended December 31, 2023 and 2022, respectively, from the County. Revenue earned relates to services provided to School 84, mental health services and various other charges related to County departments located within the Corporation's physical plant.

The net amount due to the County of approximately \$12,661 and \$11,393 at December 31, 2023 and 2022, respectively, is non-interest bearing and reflect the Corporation's net amount owed to the County as a result of various transactions and services between parties. This balance is reported as a component of accounts payable and accrued other liabilities in the statements of net position at December 31, 2023 and 2022, respectively.

Note 15. Self-Insured Obligations

The Corporation is self-insured for all medical malpractice claims for occurrences on or after January 1, 2004. Additionally, the Corporation began purchasing excess stop-loss insurance on a claims made basis for medical malpractice effective November 2008. The current policy provides \$35,000 of coverage in excess of a self-insured retention (SIR) of \$4,000 of individual claims or \$12,000 in aggregate claims effective November 19, 2018. Immediately previously, the policy provided \$35,000 of coverage in excess of a SIR \$3,000 of individual claims or \$10,000 in aggregate claims.

Effective April 1, 2016, the Corporation became self-insured for workers' compensation claims through a combination of self-insurance and a high-deductible plan for certain periods as follows: The Corporation maintains a stop-loss insurance policy for the claims in excess of \$750. As required by the NYS Workers' Compensation Board, ECMCC maintains a security deposit on its self-insured workers' compensation obligations. The value of the security deposit was \$30,689 and \$26,128 as of December 31, 2023 and 2022, respectively. The deposit is maintained through a surety bond. The surety requires a collateral deposit to maintain the bond. The value of the collateral held by the surety was \$5,512 and \$5,272 as of December 31, 2023 and 2022, respectively. Effective January 1, 2012, the Corporation insured a portion of its workers' compensation exposure through an occurrence basis high-deductible plan. The Corporation remains responsible for the first \$750 of an individual claim payment after December 31, 2021 and 2022, \$4,662 and \$4,936, respectively, has been designated to service workers' compensation claims and included as part of assets whose use is limited. The Corporation remains self-insured for workers' compensation claims prior to January 1, 2012. The County has assumed a portion of liabilities for all occurrences originating prior to 2004.

Losses from asserted and unasserted medical malpractice and workers' compensation claims are accrued based on actuarial estimates that incorporate the Corporation's past experience, the nature of each claim or incident, relevant trend factors, and estimated recoveries, if any, on unsettled claims.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 15. Self-Insured Obligations (Continued)

The Corporation has accrued \$33,407 and \$30,975 at December 31, 2023 and 2022, respectively, for medical malpractice related exposures. Such amounts have been discounted at 2.0% for 2023 and 2022 and the accrued liabilities are included within the accrued other liabilities and self-insured obligations caption of the accompanying statements of net position. Charges to expense for medical malpractice costs are included within the other operating expenses caption of the accompanying statements of revenues, expenses and changes in net position.

The Corporation has accrued \$27,922 and \$27,264 at December 31, 2023 and 2022, respectively, for workers' compensation related exposures. Such amounts have been discounted at 1.75% for 2023 and 2022, and the liabilities are included within the accrued other liabilities and self-insured obligations captions of the accompanying statements of net position. Charges to expense for workers' compensation costs approximated \$7,376 and \$7,884 in 2023 and 2022, respectively, and are included within the payroll, employee benefits and contract labor caption of the accompanying statements of revenues, expenses and changes in net position.

Eligible retirees are provided basic medical and hospitalization coverage by the Corporation as more fully described in Note 12.

The composition of self-insured obligations as of December 31, is as follows:

| 2023 | | | | | | | | | | |
|-----------------------|------|-----------|-------|-------------|-----|---------|----|---------|----|----------|
| • | 10. | Ell 1 | TO Y | Actuarial |),, | | | | | |
| | ME | Beginning |))) E | stimate of | | Claims | | Ending | Du | e Within |
| | | Balance | Clai | ms Incurred | | Paid | E | Balance | Or | ne Year |
| | (| For- | Re | | | | | | | |
| Medical malpractice | \$ | 30,975 | \$ | 4,750 | \$ | (2,318) | \$ | 33,407 | \$ | 1,792 |
| Workers' compensation | | 27,264 | | 6,145 | | (5,487) | | 27,922 | | 7,416 |
| | \$ | 58,239 | \$ | 10,895 | \$ | (7,805) | \$ | 61,329 | \$ | 9,208 |
| | 2022 | | | | | | | | | |
| | | | - | Actuarial | | | | | | |
| | Е | Beginning | Ε | stimate of | | Claims | | Ending | Du | e Within |
| | | Balance | Clai | ms Incurred | | Paid | E | 3alance | Or | ne Year |
| | | | | | | | | | | |
| Medical malpractice | \$ | 28,159 | \$ | 3,797 | \$ | (981) | \$ | 30,975 | \$ | 1,800 |
| Workers' compensation | | 28,348 | | 6,378 | | (7,462) | | 27,264 | | 7,556 |
| | \$ | 56,507 | \$ | 10,175 | \$ | (8,443) | \$ | 58,239 | \$ | 9,356 |

Medical malpractice and workers' compensation amounts due within one year are management's estimates based on historical claims.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 16. Commitments and Contingencies

The health care industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations is subject to future government review and interpretation as well as regulatory actions unknown or unasserted at the time. Government activity, in recent years, has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse statutes and regulations, which could result in the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. While no regulatory allegations have been made against the Corporation, compliance with such laws and regulations can be subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time. Management and its counsel are not aware of any such actions that will have a material adverse effect on the Corporation's financial statements.

Loss contingency liabilities are recorded in accordance with U.S. GAAP, which requires recognition of a loss when it is deemed probable that an asset has been impaired or a liability has been incurred, and the amount of the loss can be reasonably estimated. As of December 31, 2023 and 2022, the Corporation has recorded no loss contingencies except as disclosed in Note 15.

The Corporation formed 1827 Fillmore, LLC (1827) for the purpose of acquiring and developing land immediately adjacent to its Grider Street campus. A condition of the acquisition was that 1827 demolish a building on the site with known asbestos abatement requirements. This condition was met in 2018. The Corporation has undertaken a community planning process to determine the future use(s) of the site. The site requires the environmental remediation expenditures; however, the amount of such expenditures is dependent on the ultimate use of the site and requirements from regulators. Through December 31, 2023, approximately \$4,600 has been spent on remediating and improving the land.

Required Supplementary Information

Required Supplementary Information Schedule of Corporation's Contributions NYSLRS Pension Plan December 31, 2023 (Dollars in Thousands)

| | 2023 | | 2022 | | 2021 | | 2020 | 2019 | 2018 | | 2017 | | 2016 | 2015 | 2014 |
|---|---------------|--------|---------|----|---------|------|---------|---------------|---------------|----|---------|--------|---------|---------------|---------------|
| Contractually required contribution | \$ 25,153 | \$ | 31,946 | \$ | 30,167 | \$ | 27,343 | \$ 26,447 | \$ 25,803 | \$ | 25,235 | \$ | 26,722 | \$ 29,771 | \$ 29,835 |
| Contributions in relation to the contractually required contribution Contribution deficiency | \$ 25,153 | \$ | 31,946 | \$ | 30,167 | \$ | 27,343 | \$ 26,447 | \$ 25,803 | \$ | 25,235 | \$ | 26,722 | \$ 29,771 | \$ 29,835 |
| ECMCC covered-employee payroll | \$ 245,606 | \$ | 244,519 | \$ | 235,767 | \$ | 216,871 | \$ 204,007 | \$ 193,386 | \$ | 183,540 | \$ | 166,691 | \$ 175,409 | \$ 163,395 |
| Contributions as a percentage of covered-employee payroll | 10.2% | , D | 13.1% | 6 | 12.8% | e of | 12.6% | 13.0% | 13.3% |) | 13.7% | , 6 | 16.0% | 17.0% | 18.3% |

Required Supplementary Information Schedule of Corporation's Proportionate Share of Net Pension Liability (Asset) NYSLRS Pension Plan December 31, 2023 (Dollars in Thousands)

| | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|--|------------|-------------|---------|------------|-----------|-----------|-----------|------------|-----------|
| ECMCC proportion of the net pension (asset) liability | 0.9277% | 0.9485% | 0.9187% | 0.8504% | 0.8079% | 0.7646% | 0.7614% | 0.7228% | 0.7137% |
| ECMCC proportionate share of the net pension (asset) liability | \$ 198,936 | \$ (77,538) | \$ 915 | \$ 225,197 | \$ 57,240 | \$ 24,677 | \$ 71,544 | \$ 116,006 | \$ 24,112 |
| ECMCC covered-employee payroll | 245,606 | 273,555 | 249,490 | 246,772 | 235,284 | 216,044 | 183,540 | 166,691 | 175,409 |
| ECMCC proportionate share of the net pension liability | | | | | | | | | |
| as a percentage of its covered-employee payroll | 81.0% | -28.3% | 0.4% | 91.3% | 24.3% | 11.4% | 39.0% | 69.6% | 13.7% |
| Plan fiduciary net position as a percentage of the | | | | | | | | | |
| total pension liability | 90.8% | 103.7% | 100.0% | 86.4% | 96.3% | 98.2% | 94.7% | 90.7% | 97.9% |

Note: GASB requires 10 years of information to be presented in this table. However, until a full 10-year trend is compiled, the Corporation will present information for those year for which information is available.

Change in Benefit Terms

The New York State Legislature lowered the vesting requirement for Tier 5 and Tier 6 from ten years to five years (Chapter 56 0f the Laws of 2022), prior to the April 1, 2022 actuarial valuation.

Changes of Assumptions

2023: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2021, inflation was updated to 2.9%, cost-of-living updated to 1.5%, for the April 1, 2022 actuarial valuation.

2022: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2020, inflation was updated to 2.7%, cost-of-living updated to 1.4%, and the interest rate assumption was reduced to 5.9% for the April 1, 2021 actuarial valuation.

Required Supplementary Information Schedule of Corporation's Changes in Total OPEB Liability and Related Ratios December 31, 2023 and 2022 (Dollars in Thousands)

| | 2023 | | 2022 |
|--|-----------|----|-----------|
| Total OPEB liability: | | | |
| Service cost | 2,620 | \$ | 4,528 |
| Interest cost | 9,722 | | 6,959 |
| Differences between expected and actual experience | 232 | | (34,085) |
| Changes of assumptions | 26,546 | | (69,430) |
| Benefit payments | (16,604) | | (15,683) |
| Net change in total OPEB liability | 22,516 | | (107,711) |
| Total OPEB liability—beginning | 271,395 | | 379,106 |
| Total OPEB liability—ending | § 293,911 | \$ | 271,395 |
| Covered employee payroll | 87,249 | \$ | 87,719 |
| Total OPEB liability as a percentage of covered employee payroll | 336.86% | 6 | 309.39% |
| Discount rate | 3.3% | 6 | 3.7% |

Change in Benefit Terms

There were no significant changes in benefits during 2023 and 2022.

Changes of Assumptions

2023: The discount rate was decreased from 3.7% to 3.3%, while salary increases were adjusted from 3.7% to 3.3% as well as an update to the medical and prescription trend rates.

2022: The annual rate of increase in healthcare costs were revised to better reflect future expectations.

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Uniform Guidance Audit Requirements December 31, 2023

PRELIMINARY DRAFT
PUMPOSES Omly
PREVIOUS DRAFT
PUMPOSES OMLY

Schedule of Expenditures of Federal Awards For the Year Ended December 31, 2023

| Federal Grantor/Pass-Through Grantor/Program or Cluster Title | Federal Assistance Listing Number | Pass-Through Entity Identifying Number | Provided to Subrecipient | s | Total Federal Expenditures |
|--|--------------------------------------|---|-----------------------------|---|-------------------------------|
| U.S. Department of Health and Human Services Health Resources and Services Administration Direct Programs COVID-19: Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution | 93.498 | N/A | \$ - | ; | 8,394,858 |
| Training in General, Pediatric, and Public Health Dentistry | 93.059 | N/A | - | | 370,983 |
| Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants | 93.924 | N/A | - | | 50,607 |
| Oral Diseases and Disorders Research | 93.121 | N/A | | | 186,894 |
| Total U.S. Department of Health and Human Services Health Resources and Services Administration Direct Programs | | | | | 9,003,342 |
| U.S. Department of Health and Human Services pass-through program from: Health Research Inc. | | | | | |
| National Bioterrorism Hospital Preparedness Program | 93.889 | 2430-18 | - | | 40,000 |
| New York State Office of Mental Health COVID-19: Block Grants for Community Mental Health Services | 93.958 | C21661GG | <u>y</u> - | | 373,988 |
| Total U.S. Department of Health and Human Services Pass-Through Programs | | | | | 413,988 |
| U.S. Department of Justice Pass-Through Program From: New York State Office of Victim Crime Services Crime Victim Assistance | 16.575 | OVS01-C10952GG-1080200 | - | | 390,981 |
| New York State Division Criminal Justice Services Crime Victim Assistance | 16.575 | OVS01-T11152GG-1080200 | - | | 212,673 |
| New York State Division Criminal Justice Services Crime Victim Assistance | 16.575 | N/A | | | 426,815 1.030,469 |
| New York State Office of Victim Crime Services Crime Victim Assistance/Discretionary Grants | 16.582 | 15POVC-22-GK-01799-NONF | - | | 159,983 |
| New York State Division Criminal Justice Services Violence Against Women Formula Grants | 16.588 | C00256GG-1090000 | - | | 50,000 |
| Total U.S. Department of Justice Pass-Through Program | | | | | 1,240,452 |
| U.S. Department of Homeland Security (Federal Emergency Management Agency) COVID-19: Disaster Grants - Public Assistance (Presidentially Declared Disasters) | 97.036 | N/A | | | 3,861,791 |
| Total Expenditures of Federal Awards | | | \$ - | , | 14,519,573 |

See notes to the schedule of expenditures of federal awards.

Notes to Schedule of Expenditures of Federal Awards Year Ended December 31, 2023

Note 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of the Erie County Medical Center Corporation (the Corporation) under programs of the federal government for the year ended December 31, 2023. The information on this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).

For purposes of the Schedule, federal awards include all federal assistance entered into directly between the Corporation and the federal government and sub-awards from nonfederal organizations made under federally sponsored agreements. The Schedule does not include payments received under Medicare and Medicaid reimbursement programs. Because the Schedule presents only a selected portion of the activities of the Corporation, it is not intended to, and does not, present the financial position, changes in net position and cash flows of the Corporation.

Note 2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Corporation has elected to not exercise its option to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 3. Other Federal Awards

There were no federal awards expended for noncash assistance, insurance, or any loans, loan guarantees, or interest subsidies outstanding at December 31, 2023.

Note 4. Subrecipients

The Corporation did not provide federal awards to any subrecipients during the year ended December 31, 2023.

Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

Independent Auditor's Report

Board of Directors
Erie County Medical Center Corporation

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of the business-type activities and the aggregate discretely presented component units of Erie Medical Center Corporation (the Corporation), as of and for the year ended December 31, 2023, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements, and have issued our report thereon dated DATE.

The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*, and accordingly, this report does not include reporting on internal controls over financial reporting or instances of reportable noncompliance associated with ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.


Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Corporation's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the basic financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.





Report on Compliance For Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

Independent Auditor's Report

Board of Directors
Erie County Medical Center Corporation

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Erie County Medical Center Corporation's (the Corporation) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Corporation's major federal programs for the year ended December 31, 2023. The Corporation's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Corporation complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Corporation's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Corporation's federal programs.

Auditor's Responsibility for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Corporation's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Corporation's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design
 and perform audit procedures responsive to those risks. Such procedures include examining, on a
 test basis, evidence regarding the Corporation's compliance with the compliance requirements
 referred to above and performing such other procedures as we considered necessary in the
 circumstances.
- obtain an understanding of the Corporation's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the Corporation's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance We have audited the financial statements of the Corporation as of and for the year ended December 31, 2023 and have issued our report thereon dated DATE, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the basic financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditure of federal awards is fairly stated in all material respects in relation to the basic financial statements as a whole.

Firm Signature DATE

Schedule of Findings and Questioned Costs Year Ended December 31, 2023

Section I—Summary of Auditor's Results

| Financial Statements | | | | |
|--|-----------------|----------------|---------------------------------------|---------------------|
| Type of auditor's report issued on whether the financial statements audited were prepared in accordance with GAAP: | | Unmodifie | ed | - |
| Internal control over financial reporting: Material weakness(es) identified? Significant deficiency(ies) identified? | | _ yes _ yes | X | no none reported |
| Noncompliance material to financial statements noted? | AFT | _ yes | X | _ no |
| Federal Awards | | | | |
| Internal control over major programs: Material weakness(es) identified? Significant deficiency(ies) identified? | Shawall On n | yes yes | X | no none reported |
| Type of auditor's report issued on compliance for major programs: | | Unmodifie | ed | _ |
| Any audit findings disclosed that are required to be reported in accordance with 2 CFR Section 200.516(a)? | | _ yes | X | no |
| Identification of major federal programs: | | | | |
| Federal Assistance Listing Number(s) | Name of Fe | ederal Prog | gram or Cluste | <u>er</u> |
| 93.498 | | | Relief Fund an | |
| 93.059 | | | ural Distribution Pediatric, and F | |
| Dollar threshold used to distinguish between Type A and Type B programs: | | | \$ 750,000 | = |
| Auditee qualified as a low risk auditee? | X | _ yes | | no |

(Continued)

Schedule of Findings and Questioned Costs (Continued) Year Ended December 31, 2023

Section II—Financial Statement Findings

No findings noted.

Section III—Findings and Questioned Costs for Federal Awards

No findings noted.



Erie County Medical Center Corporation(A Component Unit of the County of Erie)

Summary Schedule of Prior Year Findings and Questioned Costs Year Ended December 31, 2023

Section I—Financial Statement Findings

No findings noted.

Section II—Findings and Questioned Costs for Federal Awards

No findings noted.



2023 ANNUAL REPORT OF

ERIE COUNTY MEDICAL CENTER CORPORATION

(AS REQUIRED BY N.Y. PUBLIC AUTHORITIES LAW)



Respectfully Submitted by the Corporation March 31, 2024

TABLE OF CONTENTS

| Message from the Leadership of ECMC Corporation | Pages 3-6 |
|---|-------------|
| Certification | Page 7 |
| Mission Statement | Page 8 |
| Accomplishments | Pages 9-11 |
| Performance Goals – 2022 | Pages 11-14 |
| Capital Projects | Page 15 |
| Real Property & Property Acquisitions | Page 15 |
| Code of Conduct | Page 16 |
| Internal Control Structure and Procedures | Page 16 |
| Pending Litigation | Page 16 |
| Corporation and Board Structure | Pages 17-27 |
| Subsidiary Information | Pages 28-29 |
| | |

APPENDIX A

Financial Reports Four-Year Financial Plan Outstanding Bonds and Notes

APPENDIX B

Compensation Schedule

APPENDIX C

Corporation Expenditures in Excess of \$100,000

APPENDIX D

Enabling Legislation Charter or By-Laws

MESSAGE FROM THE LEADERSHIP OF ECMC CORPORATION

2023 was a year for ECMC that marked growth in services, improvement in quality, success with accreditation, efforts to support our caring and inclusive culture, and operational improvements from the lingering effects of the COVID-19 pandemic.

In almost every measurable category, increases demonstrated a sustainable positive trend in patient volumes. Positive operations growth were reflected in our outpatient services (8.2%), Emergency Department visits (7.9%) and general surgeries (6.7%). And total acute average length of stay dropped by 12.1%, which is very beneficial to our patients and overall hospital operations. While these increases have not mitigated our financial challenges, they are helping us significantly as we, like all hospitals across New York, recover from the effects of responding to the COVID pandemic.

We often speak about ECMC's unique culture and the dedication and resilience of our caregivers. They are the cornerstone of our institution. Their accomplishments and nationally recognized clinical excellence supports and strengthens our recruitment efforts. ECMC has had tremendous success recruiting nurses in the past year, eliminating almost all agency nurses. Since the beginning of 2023, we brought on 768 new hires that includes 176 new RNs and 72 LPNs and 90 CNAs. We hear routinely that many of our new employees are attracted to ECMC based on their knowledge of our inclusive, diverse and talented workforce and supportive culture. Also, ECMC worked with our private and academic partners to recruit and onboard 118 new physicians during the year.

In 2023, our nurses ratified a five-year contract that runs to December 31, 2027. In addition to ensuring our ECMC nurses get competitively compensated for their complex nursing care, the new contract further acknowledged their steadfast determination over the past three years to provide hope and healing to the residents of Western New York during the most challenging periods of the COVID-19 pandemic. This contract also keeps ECMC registered nurses competitive in the market and will help support our successful recruitment and retention efforts. We also continue to recognize and support our nurses, and this year the ECMC Foundation Nursing Education and Professional Development Fund supported 43 nursing scholarships and 24 nursing certifications. From 2017 through 2023, over \$650,000 has been awarded from the Fund, resulting in 416 nursing scholarships and 264 nursing certifications.

In January 2023, ECMC earned full hospital accreditation – The Joint Commission's Gold Seal of Approval® Accreditation – by demonstrating continuous compliance with its performance standards. The Gold Seal is a symbol of quality that reflects a healthcare organization's commitment to providing safe and quality patient care. This accreditation surveys many clinical areas from behavioral health and ambulatory services to surgical services, inpatient care, and many others. It is a complete assessment of ECMC services and quality of care. ECMC underwent a rigorous, unannounced onsite survey in November 2022. During the review, a team of Joint Commission expert surveyors evaluated compliance with hospital standards related to several areas, including emergency management, environment of care, infection prevention and control, leadership, and medication management. Surveyors also conducted onsite observations and interviews. Throughout our nation's network of healthcare institutions, Joint Commission accreditation is universally regarded as the national standard of excellence.

The surveyors highlighted the inclusive, collaborative culture at ECMC and the kindness of our caregivers, while also stating on many occasions how we had very few findings for an organization as large and complex as ECMC. The survey team was extremely complimentary about the "passion" and "engagement" of everyone they encountered from clinical to non-clinical staff in the care of our patients.

Among our many clinical accomplishments, accreditations and national recognition in 2023, the Centers for Medicare and Medicaid Services (CMS), part of the U.S. Department of Health and Human Services (HHS), reaccredited ECMC's Transplant program, housed in our Regional Center of Excellence for Transplantation and Kidney Care. Under the leadership of the Center's Program Director Dr. Liise Kayler and her dedicated team of providers and support staff, the Center set a record this past year for the most transplants ever conducted at ECMC, performing a total of 151 kidney transplants, exceeding the previous annual record established last year (148).

ECMC Orthopedics was reported in Becker's Hospital Review as only one of four orthopedic surgical services in New York State to be ranked as one of America's 100 Best Hospitals for Orthopedic Surgery by Healthgrades, the nation's leading marketplace connecting doctors and patients. This achievement reflected ECMC's outstanding clinical outcomes for Orthopedic Surgery and put ECMC in the top 5% of hospitals nationwide for overall Orthopedic services. In addition, ECMC continues to provide new technology for all of its surgical programs and this year added Mako and DaVinci robotic surgery capabilities to provide state-of-the-art care for our patients.

In 2023, ECMC expanded and strengthened several off-campus outpatient facilities to provide greater healthcare services to the residents of our region, including: the ECMC Northtown Center for Specialty Care at 30 North Union Road in Amherst co-locates multiple specialty practices (e.g., Bariatric Surgery & Medical Weight Loss Management, Gastroenterology and Inflammatory Bowel Disease, Interventional Pain Management, & Plastic and Reconstructive Surgery) in a recently fully renovated facility. In March 2023, the ECMC Center for Dental Care opened at 800 Hertel in North Buffalo. This Center is the result of years of collaboration between Erie County Medical Center, the Health Resources and Services Administration, People Inc. and Evergreen Health.

For the fourth consecutive year, Terrace View Long-Term Care Facility was recognized on Newsweek's Best Nursing Homes 2024 list. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. Only four percent of nursing homes nationwide received this distinction. Of the 600 skilled nursing facilities statewide that operate, 42 received this recognition. It is a distinct honor to be ranked amongst the best nursing homes within both the state and the nation.

The Commission on Accreditation of Rehabilitation Facilities (CARF) issued three-year accreditation to ECMC's Acute Inpatient Rehabilitation Programs. And ECMC's Laboratory Services received another two-year accreditation for ECMC's Transfusion Services following bi-annual on-site assessment by the Association for the Advancement of Blood and Biotherapies (AABB). The American College of Emergency Physicians implemented the Geriatric Emergency Department Accreditation (GEDA) program to recognize those emergency departments that provide excellent care for older adults.

BRAVE (Buffalo Rising Against Violence at ECMC) achieved designation/certification as Western New York's only Trauma Recovery Center. Our program is only the second NYS Office of Victims Services(OVS)-funded program in the state to attain that distinction from the National Alliance of Trauma Recovery Centers; the other is located across the state in Brooklyn. The goal is to meet people where they are and ensure they have basic needs met (stable housing, food, healthcare), so they can

move from surviving the trauma to healing. Developed in 2001, the evidence-based Trauma Recovery Center (TRC) model is designed to provide emergency support, clinical care, and wraparound case management to help survivors in communities most impacted by violence stabilize in moments of crisis, heal from trauma, and address their needs in the wake of victimization.

Announced December 14, 2023 by Governor Kathy Hochul, ECMC's SNUG program was awarded a \$2.8M state grant. ECMC's SNUG program was one of 16 different community-based organizations and hospitals funded across NYS. Administered and supported by the state Division of Criminal Justice Services, the SNUG Street Outreach program employs outreach workers, social workers, case managers and hospital responders who work in neighborhoods experiencing elevated levels of gun violence.

Further highlighting our successful commitment to broad-based Diversity, Equity and Inclusion efforts throughout our institution, ECMC was recognized by the Lown Institute, a highly regarded Boston-based national think tank, for outstanding social responsibility, receiving an "A" grade on the 2023-24 Lown Institute Hospitals Index. ECMC achieved this honor through strong performance across metrics of health equity, patient outcomes, and value of care, out of more than 3,600 hospitals nationwide. ECMC ranked 8 out of 138 hospitals in New York State and 350 of 3,637 hospitals nationally on the Social Responsibility metric.

And for the second time in three years, ECMC was honored by New York State for our continuing success in the procurement of goods and services from MWBEs, always exceeding the state's goals. We transformed our MWBE program under the leadership of our Executive Management leadership and VP of Materials Management by integrating it into our institution's procurement process. Our team received New York State's MWBE Champions Award in 2021 and again just a few months ago in Albany at the 2023 New York State MWBE Forum. Since 2020, ECMC has utilized over \$44 million in MWBE services on a variety of projects throughout our institution. In the state's fiscal year 2022-23, ECMC reached 47.05% utilization, well exceeding the NYS goal of 30%.

The dynamic culture of ECMC may be best reflected in the success of our Annual Giving Campaign. Because of our ECMC Family's generosity in 2023, we achieved the highest level of support from staff throughout our institution. By exceeding 50% participation in charitable giving, we realized the highest percentage ever (50.86%) for contributions to the Annual Giving Campaign. With \$472,390 in total support in 2023, the Foundation reinvests those proceeds back into the care our staff deliver through a variety of programs that support professional development for staff, equipment and technology to enhance our high-quality healthcare services and other initiatives to ensure they have all of the support and resources they need to provide lifesaving care to our patients.

As the one year anniversary of the May 14th tragedy approached in 2023, and to express our support and remembrance for the victims and survivors of the 5/14 racist attack at Tops on Jefferson Avenue, hundreds of our ECMC Family participated in a walk on Friday, May 12th on the ECMC health campus followed immediately by a brief memorial tree and plaque dedication at our Remembrance Garden. Mark Talley, son of victim Geraldine Talley and once a member of our Behavioral Health staff, and who since 5/14 has founded Agents for Advocacy, a not-for-profit organization dedicated to "... improving the lives of low-income communities by providing access to essential resources and services," joined us for this solemn ceremony. As we had done in 2022 days after this unspeakable act of hate and racism, our ECMC Family gathered in prayer and in solidarity against racism, bigotry, and hatred, showing our collective commitment to stand together and promote diversity, defend equity and ensure inclusivity. We have been and will continue to be committed to these principles, as we work to make ECMC and our community a place of belonging for all. This tragedy sadly reinforced that much work is left to be done,

but our commitment to these efforts and our fight against racism and discrimination has only been strengthened.

We continue to meet all of the challenges and opportunities we face with our partners at Kaleida Health and the University at Buffalo as we collaborate to strengthen our services to patients and support our mission as an academic hospital. These challenges of the past several years are well documented and widely acknowledged, but what the experiences throughout that time proved was how dedicated and resilient our ECMC caregivers are and how committed they are to fulfilling our institution's mission. As we navigated through circumstances that tested the most experienced among us, our caregivers' resolve and determination never wavered, helping ECMC to achieve success in 2023. As we continue to move forward and strengthen our capabilities to provide world-class healthcare services to the residents of Western New York, we will continue to build on the successes of 2023 to help ensure an even better future for our community and our institution.

Sincerely,

Thomas J. Quatroche Jr., PhD President & Chief Executive Officer

Jennifer C. Persico, Esq. Jennifer Pugh, MD, MBA, FACEP Chair, Board of Directors President, Medical Executive Committee

CERTIFICATION

The financial reports submitted in this Annual Report have been approved by the Board of Directors of the Erie County Medical Center Corporation and are hereby certified, as indicated by signatures below, by the Chief Executive Officer and Chief Financial Officer. Specifically, the undersigned certify, based on knowledge and information provided to us that the financial reports and the information provided therein (1) are accurate, correct and do not contain any untrue statement of material fact; (2) do not omit any material fact which, if omitted, would cause the financial statements to be misleading in light of the circumstances under which such statements are made; and (3) fairly present, in all material respects, the financial condition and results of operations of the Erie County Medical Center Corporation as of, and for, the year ended December 31, 2023.

Respectfully submitted,

Thomas J. Quatroche, Ph.D.

President and Chief Executive Officer

Jonathan T. Swiatkowski, CPA

Chief Financial Officer

MISSION

To provide every patient the highest quality of care delivered with compassion.

VISION

ECMC WILL BE A LEADER IN AND RECOGNIZED FOR:

- High quality family centered care resulting in exceptional patient experiences.
- Superior clinical outcomes.
- The hospital of choice for physicians, nurses, and staff.
- Strong collaboration with community partners to improve access to healthcare and the quality of life and vitality of the region.
- Academic affiliations that provide the best education for physicians, dentists, nurses, and other clinical staff.

CORE VALUES

ACCES!

All patients get equal care regardless of their ability to pay or source of payment. We address the healthcare needs of each patient that we can appropriately serve, without bias or pre-judgment.

EXCELLENCE

Excellence is a standard that will never be lowered; there is an expectation of excellence in all areas.

DIVERSITY

We recognize the importance and value of diversity and the enrichment that diversity can bring to ECMCC.

FULFILLING POTENTIAL

We respect the value and potential of each individual as offering a significant contribution to the good of the whole organization. Personal growth and development is important for organizational success.

DIGNITY

Each individual, no matter his or her limitations, background or situation, has intrinsic dignity and unique capabilities.

PRIVACY

We honor each person's right to privacy and confidentiality.

FAIRNESS and INTEGRITY

Equity and fairness are guidelines for all decision-making. We demand personal and institutional integrity.

COMMUNITY

In accomplishing our mission we remain mindful of the public's trust and are always responsive to the immediate surrounding community and our natural environment. This commitment represents both our organization and us as individuals.

A successful future for ECMCC depends on a vibrant community and a healthy environment.

COLLABORATION

Collaboration with other organizations is beneficial within the context of our mission and is fundamental to achieving our goals.

COMPASSION

All involved with ECMCC's service delivery demonstrate caring, compassion, and understanding for patients, employees, volunteers, and families.

STEWARDSHIP

We can only be successful in carrying out our mission through solid financial performance and by assuring that resources provided to us are used effectively, in the way they were intended, and for the benefit of our patients and community.



The difference between healthcare and true care™



<u>Highlights ECMC – 2023</u>

January

• The **Joint Commission** granted ECMC three-year Comprehensive Accreditation.

February

- The New York State Division of Homeland Security and Emergency Services (DHSES) has processed a payment in the amount of \$1,640,522.39 from FEMA. This payment is related to Disaster 4480 COVID-19 declared on Mar 20, 2020.
- Successful reaccreditation by The Centers for Medicare and Medicaid Services (CMS), part of the Department of Health and Human Services (HHS) of Transplant program, housed in ECMC's Regional Center of Excellence for Transplantation and Kidney Care.
- NYSDOH survey of ECMC Laboratory services successfully completed.

March

- Opened the new **ECMC Center for Dental Care** at the People Inc. Health Services Building on Hertel Avenue in North Buffalo. The new dental office was built with advanced equipment to support the complex dental health of special needs patients, from throughout Western New York. This practice will provide adult and pediatric dental care to the local community as well. The Division is the only large, accredited hospital-based dental residency program in Western New York.
- Joint Commission survey of ECMC Laboratory services successfully completed

April

• NYSDOH survey of ECMC Radiology successfully completed.

July

- Commission on Accreditation of Rehabilitation Facilities (CARF) issued three-year accreditation to ECMC's Acute Inpatient Rehabilitation Programs (through June 30, 2026) stating that this "achievement is an indication of [ECMC's] dedication to improving the quality of the lives of the persons served."
- ECMC's Laboratory Services received another two-year accreditation for ECMC's
 Transfusion Services following bi-annual on-site assessment by the Association for the
 Advancement of Blood
 and Biotherapies (AABB).
- Erie County Medical Center has again been recognized by the Lown Institute for outstanding social responsibility, receiving an "A" grade on the **2023-24 Lown Institute Hospitals Index**. ECMC achieved this honor through strong performance across metrics of health equity, patient outcomes, and value of care, out of more than 3,600 hospitals nationwide. In 2021, ECMC was ranked among the top 100 hospitals in the United States for racial inclusivity by the Lown Institute; in 2022 ECMC was ranked in the top 50 hospitals in the country for racial inclusivity.

• ECMC launched a new summer internship opportunity for high school students in 10th, 11th and 12th grades called "Healthcare Explorers." This immersive summer internship experience allows students to have hands-on learning opportunities across the ECMC health campus. Students explore such health system areas as: ambulatory services, critical care, emergency services, hospital public safety, inpatient pharmacy, IT security, laboratory medicine, medical/surgical nursing, radiology, surgical services, and transplantation services.

September

- Terrace View Long-Term Care Facility has been recognized on **Newsweek's Best Nursing Homes** 2024 list. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. Only four percent of nursing homes nationwide received this distinction. Of the 600 skilled nursing facilities state-wide that operate, 42 received this recognition. It is a distinct honor to be ranked amongst the best nursing homes within both the state and the nation. This is the fourth consecutive year Terrace View has received this recognition.
- Erie County Medical Center has been awarded the **Antimicrobial Stewardship Center of Excellence** (CoE) designation by the Infectious Diseases Society of America. The designation recognizes institutions that have created stewardship programs led by infectious disease-trained clinicians that advance science in antimicrobial resistance. The core criteria for the CoE program place emphasis on an institution's ability to implement stewardship protocols by integrating best practices to slow the emergence of resistance, optimize the treatment of infections, reduce adverse events associated with antibiotic use and to address other challenging areas related to antimicrobial stewardship. A total of 179 programs nationwide have received the designation since the program's launch.

October

- ECMC earned platinum recognition for its efforts to increase organ and tissue donor registrations across the country, through **the DoNation Campaign**. DoNation is a national initiative sponsored by the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA), to educate our community about the crucial need for organ and tissue donation and to encourage people to sign up as organ and tissue donors. Since 2011, this campaign has encouraged more than 60,000 donor registrations nationwide. Between October 2022 and September 2023, ECMC has actively participated in this campaign to earn this federal recognition.
- ECMC announced it has again achieved numerous five-star ratings for specialty care, according to new research released by **Healthgrades**, the leading resource consumers use to find a hospital or doctor. ECMC was honored with a Five-Star rating in Total Knee Replacement for 3 years in a row (2022-2024), a Five-Star rating for Hip Fracture Treatment for 14 years in a row (2011-2024) and a Five-Star Distinction in Total Hip Replacement (2023-24).

November

• The American College of Emergency Physicians, implemented the Geriatric Emergency Department Accreditation (GEDA) program to recognize those emergency departments that provide excellent care for older adults. Communicating with our institution, representatives of GEDA stated, "...we are excited to announce that Erie County Medical Center's Emergency Department has achieved the bronze standard – Level 3 GEDA accreditation.

• BRAVE (Buffalo Rising Against Violence at ECMC) achieved designation/certification as Western New York's only Trauma Recovery Center. Our program is only the second NYS Office of Victims Services(OVS)-funded program in the state to attain that distinction from the National Alliance of Trauma Recovery Centers; the other is located across the state in Brooklyn. It's a successful model that treats victims of violence holistically and proactively through comprehensive case management and assertive outreach. The goal is to meet people where they are and ensure they have basic needs met (stable housing, food, healthcare), so they can move from surviving the trauma to healing. Developed in 2001, the evidence-based Trauma Recovery Center (TRC) model is designed to provide emergency support, clinical care, and wraparound case management to help survivors in communities most impacted by violence stabilize in moments of crisis, heal from trauma, and address their needs in the wake of victimization.

December

Announced December 14, 2023 by Governor Kathy Hochul, ECMC's SNUG program
was awarded a \$2.8M state grant. ECMC's SNUG program was one of 16 different
community-based organizations and hospitals funded across NYS. Administered and
supported by the state Division of Criminal Justice Services, the SNUG Street Outreach
program employs outreach workers, social workers, case managers and hospital
responders who work in neighborhoods experiencing elevated

2023 PERFORMANCE GOALS/OUTCOMES

ECMC Strategic Plan Priorities and Goals

- 1. Exceptional Quality and Experience Raise the standard of clinical care to improve quality, patient safety, and patient experience in the acute care and ambulatory environments.
- **2. Cultural Identity** Preserve ECMC's strong cultural identity while further instilling a sense of urgency and genuine stewardship to achieve our organizational objectives.
- **3.** Campus Transformation Address our deferred maintenance issues, expand capacity, and integrate the development of Kensington Heights and the surrounding community.
- **4. Performance Improvement** Generate the margin necessary to meet our budgetary goals by lowering ECMC's overall cost position, enhancing revenue cycle performance, and targeted growth.
- **5. Population Health Capabilities** Take greater responsibility for managing the overall health of our patient populations through a shift from fee-for-service to risk-based arrangements.
- **6. Community Needs** Through partnerships and targeted investments, be a leading corporate citizen by addressing socioeconomic challenges that impact our communities.
- **7. Great Lakes Health Collaboration** Further increase interconnectivity between ECMC, Kaleida and our partners through clinical and operational collaborations.
- **8. Strengthen Relationship with Academic Partners** Partner with the University at Buffaloand other local professional training programs to enhance our impact across the tripartite academic mission.

Progress Against Strategic Plan Priorities and Goals

1. Exceptional Quality and Experience

- Joint Commission granted ECMC three-year Comprehensive Accreditation.
- Medical Intensive Care, Trauma Intensive Care and Burn Units maintained American Association of Critical Care Nurses silver-level Beacon Award for Excellence.
- Maintained ANCC Pathway to Excellence designation.
- Launched Maxillofacial Prosthetics Fellowship, a CODA-accredited 12-month postgraduate certificate program devoted to maxillofacial prosthetics and dental oncology.
- ECMC selected as a study site for a new Phase 2 clinical trial to administer a novel gene therapy with the potential to help with dry mouth symptoms after radiation therapy for head and neck cancer.
- Presented ECMC's "Primary Care's Hypertension Remote Patient Monitoring Program," highlighting the 47% increase in controlling enrolled participates blood pressure at the America's Essential Hospitals Annual Conference, VITAL 2023.
- Named Top 5 percent in nation for Orthopedic Services by Healthgrades.

2. Cultural Identity

- Continued focus on Diversity, Equity & Inclusion across the organization.
- ECMC earned LGBTQ+ Healthcare Equality High Performer under the Human Rights Campaign Foundation.
- ECMC's Office of Diversity, Equity and Inclusion oversees six Employee Resource Groups, which facilitate a cultural awareness initiative to promote inclusion and belonging across our organization.

3. Campus Transformation

- Completion of OR lighting modernization program.
- Kensington Heights and Grider Street development initiatives.

4. Performance Improvement

- Continued expansion of Accelerating Excellence programs and projects.
- Oral Oncology & Maxillofacial Prosthetics acquired Artec Space Spider 3D Scanner and SprintRay Pro 95 S Printer, which is leading to more comfortable visits for patients, greater speed and accuracy in our laboratory work, and greater patient satisfaction.
- Daily bed huddles 7 days per week.
- Growth in both DaVinci and Mako robotic surgery systems.
- ECMC Center for Cardiovascular Care in collaboration with the ECMC Radiology Department added a new diagnostic service of Coronary CTA's.
- Expanded Intensive Outpatient Program and Help Center operations.
- Developed new patient tracking system called TeleProcedure.
- Added 768 new hires that includes 176 new RNs and 72 LPNs and 90 CNAs.
- Recruited 118 new physicians to the ECMC Medical Staff, including new surgeons in surgeons in Ortho, Neuro, GI, Urology.

5. Population Health Capabilities

- Conducted multiple lung cancer and head and neck cancer screening clinics in vulnerable communities throughout the city.
- Opened ECMC Northtown Center for Specialty Care that co-locates multiple specialty practices (e.g., Bariatric Surgery & Medical Weight Loss Management, Gastroenterology and Inflammatory Bowel Disease, Interventional Pain Management, & Plastic and Reconstructive Surgery).
- Opened ECMC Center for Dental Care at 800 Hertel in North Buffalo that meets the needs of our patients with intellectual and developmental disabilities.
- Accelerated the growth and infrastructure development for Great Lakes Integrated Network

6. Community Needs

- Exceeded MWBE goal for 2023, reaching 47.05% utilization.
- Received NYS MWBE Champions Award for second time in three years.
- Recognized by the Lown Institute, for outstanding social responsibility, receiving an "A" grade on the 2023-24.

- Maintained partnership with the Buffalo City Mission focused on its Recuperative Care Unit.
- Received over \$2.8 million dollars in state funding for ECMC's SNUG program, which, along with ECMC's BRAVE program, provides services to victims of all forms of violence and for those who have been impacted trauma.

7. Great Lakes Health Collaboration

- Continued growth of Great Lakes Cancer Care.
- Continued partnership and investment in Great Lakes Integrated Network
- Further expansion of collaborative value-analysis program.

8. Strengthen Relationship with Academic Partners

- Strengthened Neurological surgery with UB Neurosurgery. Dr. Hanna Algattas performing skulled-based neurosurgery for tumors, which is only procedure of this kind currently in WNY.
- In 2023, 1,490 Nursing students rotated through ECMC as part of their clinicals.

CAPITAL PROJECTS IN PROCESS IN 2023

| Mechanical, Electrical, Plumbing and Elevator Improvements | Began November 2018 |
|--|---------------------|
| Data Center Renovations | Began August 2019 |
| Information Technology Disaster Recovery | Began November 2021 |

REAL PROPERTY ACQUISTIONS

| Address of Location Purchased | Name of Seller | Purchase Price |
|----------------------------------|--------------------------|----------------|
| 465 Grider Street Buffalo | Corinda Larkins Mayberry | \$285,000.00 |
| NY 14215 | & Willie J. Mayberry | |

CODE OF ETHICS

See Appendix D. Article XI; Sections 1-8

INTERNAL CONTROL STRUCTURE AND PROCEDURES

Assessment of Effectiveness of Internal Controls

New York State Public Authority Reporting System (PARIS)

Erie County Medical Center Corporation

At and For the Year Ended December 31, 2023

The evaluation of the system of internal control is an ongoing process conducted throughout the year by myself in the capacity as the Chief Financial Officer of Erie County Medical Center Corporation. In this ongoing process there is engagement and oversight by the Audit Committee of the Board of Directors with support, advice and assistance provided by the Chief Executive Officer, the Chief Operating Officer, the General Counsel and a robust internal audit function.

The conclusions of the ongoing assessment were that no control deficiencies, significant deficiencies or material weaknesses, collectively as defined in generally accepted auditing standards, in internal controls were identified, however, performance improvement opportunities to enhance internal control were identified and implemented.

Based on my ongoing assessment, the work of the internal audit function and the work of the independent audit firm for ECMC there is an effective system of internal control to safeguard assets and to assure that transactions are properly authorized.

Respectfully submitted,

Jonathan T. Swiatkowski, CPA Chief Financial Officer

PENDING LITIGATION

The corporation is involved in several matters related to medical malpractice, workers' compensation, and business disputes as discussed in Note 15 in the enclosed audited financial statements beginning on page 49. There are no other material matters pending litigation at this time.

CORPORATION AND BOARD STRUCTURE

ECMC Corporation's Board of Directors is comprised of 15 voting Directors, drawn from institutions and occupations across Western New York. Of these directors, eight are appointed by the Governor of New York – via the recommendations of the County Executive (3), County Legislature (3), the Temporary President of the NYS Senate (1) and the Speaker of the NYS Assembly (1) – and seven are appointed by the County Executive with the advice and consent of the Erie County legislature. In addition, the Board has four non-voting members: (1) appointed by Erie County Executive; (1) appointed by Erie County Legislature Majority; (1) appointed by Erie County Legislature Minority; (1) ECMCC President and CEO via Public Authorities Law.

ECMC CORPORATION BOARD OF DIRECTORS

OFFICERS

Jennifer C. Persico, Esq. *Chair*

Eugenio Russi Vice Chair

Sharon L. Hanson Secretary

Darby Fishkin, CPA *Treasurer*

Thomas J. Quatroche Jr., PhD *President & CEO*

BOARD MEMBERS

Ronald P. Bennett, Esq.

Reverend Mark E. Blue

Ronald A. Chapin

Jonathan A. Dandes

Michael H. Hoffert

Christian Johnson

James L. Lawicki, II

Christopher J. O'Brien, Esq.

The Honorable John O'Donnell, J.S.C.

Reverend Kinzer M. Pointer

Michael A. Seaman

Philip Stegemann, MD

Benjamin Swanekamp

BOARD OF DIRECTORS REGULAR AND ANNUAL MEETINGS

Tuesday, January 24, 2023 (Annual and Regular Meeting)

Present: Reverend Mark Blue, Ronald A Chapin (virtual), Darby Fishkin, Sharon Hanson, Michael

Hoffert (virtual), James Lawicki, Christopher O'Brien, Hon. John O'Donnell, Jennifer Persico, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman,

Benjamin Swanekamp

Excused: Ronald Bennett, Jonathan Dandes, Christian Johnson

Also

Present: Samuel Cloud, MD, Anthony J. Colucci, III (virtual), Peter Cutler, Andrew Davis,

Cassandra Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene

Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski, James Turner,

Tuesday, February 28, 2023

Present: Ronald Bennett*, Reverend Mark Blue, Ronald A Chapin*, Jonathan Dandes*, Darby

Fishkin*, Sharon Hanson, Michael Hoffert*, Christian Johnson*, James Lawicki*, Christopher O'Brien, Hon. John O'Donnell, Jennifer Persico, Reverend Kinzer Pointer,

Thomas J. Quatroche*, Michael Seaman

Excused: Eugenio Russi, Benjamin Swanekamp

Also

Present: Samuel Cloud, MD, Anthony J. Colucci, III*, Peter Cutler*, Andrew Davis, Cassandra

Davis*, Joseph Giglia, Vanessa Hinderliter, Susan Gonzalez*, Pamela Lee*, Charlene

Ludlow, Jennifer Pugh, MD, James Turner*

Tuesday, March 28, 2023

Present: Ronald Bennett*, Reverend Mark Blue*, Ronald A Chapin*, Jonathan Dandes, Sharon

Hanson, Michael Hoffert*, James Lawicki*, Christopher O'Brien*, Jennifer Persico, Reverend Kinzer Pointer*, Thomas J. Quatroche, Eugenio Russi*, Michael Seaman*,

Benjamin Swanekamp

Excused: Darby Fishkin, Christian Johnson, Hon. John O'Donnell

Also

Present: Samuel Cloud, MD, Anthony J. Colucci, III*, Peter Cutler*, Andrew Davis, Cassandra

Davis*, Joseph Giglia, Susan Gonzalez*, Vanessa Hinderliter*, Donna Jones*, Pamela

Lee*, Charlene Ludlow, Jennifer Pugh, MD, James Turner*

Tuesday, April 25, 2023

Present: Ronald Bennett*, Reverend Mark Blue, Ronald A Chapin*, Jonathan Dandes, Darby

Fishkin*, Michael Hoffert*, Christian Johnson*, James Lawicki*, Hon. John

Tuesday, April 25, 2023 (cont.)

O'Donnell*, Jennifer Persico, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Benjamin Swanekamp

Excused:

Sharon Hanson, Christopher O'Brien*

Also

Present: Samuel Cloud, MD, Anthony J. Colucci, III*, Peter Cutler, Andrew Davis, Cassandra

Davis*, Joseph Giglia, Susan Gonzalez*, Vanessa Hinderliter*, Donna Jones*, Pamela

Lee*, Charlene Ludlow, Jennifer Pugh, MD, James Turner*

Tuesday, May 23, 2023

Present: Ronald Bennett*, Reverend Mark Blue*, Ronald A Chapin*, Jonathan Dandes, Darby

Fishkin*, Sharon Hanson, Michael Hoffert*, Christian Johnson*, James Lawicki*, Christopher O'Brien, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Dr. Philip Stegemann, Benjamin Swanekamp

Excused:

Jennifer Persico

Also

Present: Samuel Cloud, MD, Anthony J. Colucci, III*, Peter Cutler, Andrew Davis, Cassandra

Davis, Joseph Giglia, Susan Gonzalez, Vanessa Hinderliter*, Donna Jones, Pamela Lee,

Charlene Ludlow, Jennifer Pugh, MD, James Turner

Tuesday, June 27, 2023

Present: Reverend Mark Blue, Darby Fishkin, Sharon Hanson, Michael Hoffert*, Christian

Johnson*, James Lawicki*, Christopher O'Brien*, Hon. John O'Donnell, Jennifer Persico, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman,

Benjamin Swanekamp

Excused: Ronald Bennett, Ronald A Chapin, Jonathan Dandes, Dr. Philip Stegemann,

Also

Present: Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Vanessa

Hinderliter*, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, James

Turner

Tuesday, July 25, 2023

Present: Reverend Mark Blue*, Ronald A Chapin*, Darby Fishkin*, Sharon Hanson, Michael

Hoffert*, James Lawicki*, Hon. John O'Donnell, Jennifer Persico, Reverend Kinzer

Pointer, Thomas J. Quatroche, Dr. Philip Stegemann, Benjamin Swanekamp

Tuesday, July 25, 2023 (cont.)

Excused: Ronald Bennett, Jonathan Dandes, Christian Johnson, Christopher O'Brien, Eugenio Russi,

Michael Seaman

Also

Present: Samuel Cloud, MD, Antony J. Colucci, III*, Peter Cutler, Andrew Davis, Cassandra Davis,

Joseph Giglia, Donna Jones, Pamela Lee*, Charlene Ludlow, Jennifer Pugh, MD, James

Turner

Tuesday, September 26, 2023

Present: Ronald Bennett*, Reverend Mark Blue*, Ronald A Chapin*, Jonathan Dandes, Sharon

Hanson, Michael Hoffert*, Christian Johnson*, James Lawicki*, Hon. John O'Donnell, Jennifer Persico, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael

Seaman, Dr. Philip Stegemann, Benjamin Swanekamp

Excused: Darby Fishkin, Christopher O'Brien

Also

Present: Donna Brown, Samuel Cloud, MD, Antony J. Colucci, III*, Peter Cutler, Andrew Davis,

Cassandra Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene

Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski, James Turner

Tuesday, October 24, 2023

Present: Ronald Bennett, Reverend Mark Blue, Jonathan Dandes, Sharon Hanson, Michael

Hoffert*, Christian Johnson*, James Lawicki, Christopher O'Brien, Reverend Kinzer

Pointer, Thomas J. Quatroche, Eugenio Russi*, Michael Seaman

Excused: Ronald Chapin, Darby Fishkin, Christian Johnson, Hon. John O'Donnell, Jennifer Persico,

Dr. Philip Stegemann, Benjamin Swanekamp

Also

Present: Donna Brown, Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph

Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD,

Jonathan Swiatkowski*, James Turner

Tuesday, November 28, 2023

Present: Ronald Bennett*, Ronald Chapin*, Jonathan Dandes, James Lawicki*, Hon. John

O'Donnell, Jennifer Persico, Reverend Kinzer Pointer*, Thomas J. Quatroche, Eugenio

Russi, Michael Seaman, Dr. Philip Stegemann, Benjamin Swanekamp

Tuesday, November 28, 2023 (cont.)

Excused: Rev. Mark Blue, Sharon Hanson, Michael Hoffert, Christian Johnson, Christopher O'Brien

Also

Present: Donna Brown, Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski

ERIE COUNTY MEDICAL CENTER BOARD OF DIRECTORS STANDING COMMITTEE APPOINTMENTS 2023

| | | 2023 | |
|--|-----------------|--|--|
| STANDING COMMITTEE | # OF MEMBERS | BOARD MEMBERSHIP | STAFF |
| EXECUTIVE Call of Chair | 5 | Jennifer Persico - Chair Jonathan Dandes Darby Fishkin Sharon L. Hanson Eugenio Russi | A.J. Colucci Andrew L. Davis Jonathan Swiatkowski Samuel D Cloud, MD Thomas Quatroche Joseph Giglia Jeffra Wilson (Asst.) x4823 |
| QUALITY IMPROVEMENT/ PATIENT SAFETY Meets Monthly | 5 | MICHAEL HOFFERT - Chair Kinzer Pointer Judge John O'Donnell Benjamin Swanekamp Christian Johnson | Andrew Davis Thomas Quatroche Donna Jones Samuel D. Cloud, MD Charlene Ludlow Pam Lee James Turner Jackie Wilson (Asst.) x5888 |
| FINANCE Meets Monthly | 4 | MICHAEL A. SEAMAN - Chair Ronald A. Chapin Darby Fishkin Benjamin Swanekamp | A.J. Colucci, III Andrew Davis Jonathan Swiatkowski Thomas Quatroche Lynn Sacha (Asst.) x6331 |
| AUDIT & COMPLIANCE Call of Chair | 4 | DARBY FISHKIN - Chair James Lawicki Christopher O'Brien Reverend Kinzer Pointer Joseph Giglia, ex-officio | A.J. Colucci, III Andrew Davis Jonathan Swiatkowski Thomas Quatroche Lynn Sacha (Asst.) x6331 |
| EXECUTIVE COMPENSATION Call of Chair | 3 | JONATHAN DANDES - Chair Sharon Hanson Christopher O'Brien | A.J. Colucci, III Thomas Quatroche Joseph Giglia |

04 04 23 Page 1

ERIE COUNTY MEDICAL CENTER BOARD OF DIRECTORS STANDING COMMITTEE APPOINTMENTS 2023

| | | 2023 | |
|---|-----------------|---|---|
| STANDING COMMITTEE | # OF MEMBERS | BOARD MEMBERSHIP | STAFF |
| GOVERNANCE Call of Chair | 3 | SHARON HANSON - Chair Ronald Chapin Jennifer Persico Thomas Quatroche, Jr., ex officio Joseph Giglia, ex officio | A.J. Colucci, III Lori Hoffman (Asst.) x5684 |
| HUMAN RESOURCES Call of Chair | 3 | MICHAEL SEAMAN - Chair Michael Hoffert Kinzer Pointer | She'Bria Gordon(Asst.) (shuh-bry-yuh) x 3266 |
| INVESTMENT Call of Chair | 3 | EUGENIO RUSSI - Chair Sharon L. Hanson Judge John O'Donnell | Jonathan Swiatkowski Thomas Quatroche Lynn Sacha (Asst.) x6331 |
| BUILDINGS & GROUNDS Ad-Hoc Committee Call of Chair | 3 | RONALD BENNETT - Chair Michael Hoffert Mark Blue James Lawicki | Andrew Davis Thomas Quatroche James Turner Michelle Kroupa(Asst.)x5273 |
| WBE/MBE SUBCOMMITTEE Call of Chair | 3 | REVEREND MARK BLUE - Chair Ronald A. Chapin Christian Johnson | Diane Artieri Sarina Rohloff Joseph Giglia Thomas Quatroche Patty Chase (Asst.) x7595 |
| POST-ACUTE QI Call of Chair | 3 | RONALD CHAPIN - Chair Michael Seaman Christophher O'Brien | Andrew Davis Stephen Woodruff Monica Hunjan (Asst.) x7279 |
| CONTRACTS COMMITTEE | 3 | CHRISTOPHER O'BRIEN - Chair Ronald Bennett Jennifer Persico | Lori Hoffman (Asst.) x6584 |

04 04 23 Page 2

Erie County Medical Center Corporation Confidential Evaluation of Board Performance

| Criteria Agree Disagree Disagree Disagree Otherwission and purpose of ECMCC. The policies, practices and decisions of the Board are always consistent with this mission. Board members comprehend their role and flduciary responsibilities and hold themselves and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members ele empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and vision and work respectfully with each other. | | | Somewhat | Somewhat | |
|--|---|-------|----------|----------|----------|
| of the mission and purpose of ECMCC. The policies, practices and decisions of the Board are always consistent with this mission. Board members comprehend their role and fiduciary responsibilities and hold themselves and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and through discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board services appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. | Criteria | Agree | | | Disagree |
| The policies, practices and decisions of the Board are always consistent with this mission. Board members comprehend their role and fiduciary responsibilities and hold themselves and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table active participation of members. Board members have sufficient opportunity to research, discuss, substitutional information or discussion is required. The Board exercises appropriate | | | | | |
| Board are always consistent with this mission. Board members comprehend their role and fiduciary responsibilities and hold themselves and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board acvercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance expectations and reviewing performance expectations and reviewing performance expectations and reports before problems occur. | | | | | |
| Board members comprehend their role and flduciary responsibilities and hold themselves and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board has identified the areas of most risk to ECMCC and other executive staff, including setting performance expectations and reviewing performance annually. The Board members demonstrate leadership and | | | | | |
| iduciary responsibilities and hold themselves and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC in in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| and each other to these principles. The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| The Board has adopted policies, by-laws, and practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| practices for the effective governance, management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| management and operations of ECMCC and reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. | | | | | |
| reviews these annually. The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| The Board sets clear and measurable performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| performance goals for ECMCC that contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| contribute to accomplishing its mission. The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| The decisions made by Board members are arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| arrived at through independent judgment and deliberation, free of political influence or self-interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| deliberation, free of political influence or self- interest. Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| Individual Board members communicate effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| effectively with executive staff so as to be well informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| informed on the status of all important issues. Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| Board members are knowledgeable about ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| ECMCC's programs, financial statements, reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| reporting requirements, and other transactions. The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | 1 | | | | |
| The Board meets to review and approve all documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| documents and reports prior to public release and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| and is confident that the information being presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | 1 | | | | |
| presented is accurate and complete. The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| The Board knows the statutory obligations of ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| ECMCC and if ECMCC is in compliance with state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| state law. Board and committee meetings facilitate open, deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| deliberate and thorough discussion, and the active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| active participation of members. Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | Board and committee meetings facilitate open, | | | | |
| Board members have sufficient opportunity to research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | deliberate and thorough discussion, and the | | | | |
| research, discuss, question and prepare before decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | active participation of members. | | | | |
| decisions are made and votes taken. Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| Individual Board members feel empowered to delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | _ · · · · · · · · · · · · · · · · · · · | | | | |
| delay votes, defer agenda items, or table actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| actions if they feel additional information or discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | <u> </u> | | | | |
| discussion is required. The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| The Board exercises appropriate oversight of the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| the CEO and other executive staff, including setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| setting performance expectations and reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| reviewing performance annually. The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| The Board has identified the areas of most risk to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| to ECMCC and works with management to implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| implement risk mitigation strategies before problems occur. Board members demonstrate leadership and | | | | | |
| problems occur. Board members demonstrate leadership and | 1 | | | | |
| Board members demonstrate leadership and | | | | | |
| | | | | | |
| | | | | | |

| Date | Completed: | | |
|------|------------|--|--|
| Dale | Completed | | |

ECMC CORPORATION EXECUTIVE ADMINISTRATION

Thomas J. Quatroche Jr., PhD President and Chief Executive Officer

Andrew L. Davis, MBA Chief Operating Officer

Samuel D. Cloud, MD Chief Medical Officer

Jonathan T. Swiatkowski, CPA Chief Financial Officer

Charlene Ludlow, MHA, RN, CIC Senior Vice President of Nursing

James Turner, RN, BSN Senior Vice President of Operations

Cassandra Davis Senior Vice President, Ambulatory Services and Population Health

Pamela Lee, MBA, MS, RN Senior Vice President of Operations

Joseph T. Giglia, II, Esq. General Counsel

Anthony J. Colucci, III, Esq. *Executive Vice President*

Donna M. Brown
Associate Hospital Administrator

Peter K. Cutler Vice President of Communications and External Affairs

Donna Jones, MHA, MSN, RN, FACHE, CPHQ *Chief Quality Officer*

Susan M. Gonzalez
Executive Director, ECMC Foundation

ECMC CORPORATION MEDICAL-DENTAL STAFF OFFICERS

Jennifer Pugh, MD, MBA, FACEP President

Michael Cummings, MD Immediate Past President

Michael A. Manka Jr., MD President-Elect

Ashvin Tadakamalla, MD *Treasurer*

James Lukan, MD, FACS Secretary

PRIMARY CORPORATION

Erie County Medical Center Corporation

ECMC Corporation was established as a New York State Public Benefit Corporation and since 2004 has included an advanced academic medical center with 573 inpatient beds, on- and off-campus health centers, more than 30 outpatient specialty care services and Terrace View, a 390-bed long-term care facility. ECMC is Western New York's only Level 1 Adult Trauma Center, as well as a regional center for burn care, behavioral health services, transplantation, medical oncology and head & neck cancer care, rehabilitation and a major teaching facility for the University at Buffalo. Most ECMC physicians, dentists and pharmacists are dedicated faculty members of the university and/or members of a private practice plan. More Western New York residents are choosing ECMC for exceptional patient care and patient experiences – the difference between healthcare and true care™.

ECMC Corporation Employees: 3,919

ACTIVE SUBSIDIARY INFORMATION

PPC Strategic Services, LLC

ECMC Corporation is the sole owner of this enterprise, which was established to enable the Corporation to enter into various other business relationships, and to provide management services to them, as needed. The accounts of PPC Strategic Services LLC are consolidated into the accounts of the Corporation as of, and for the years ended, December 31, 2023 and 2022, respectively.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

PPC Strategic Services LLC (formerly named ECMCC Strategic Services, LLC) owns Greater Buffalo Niagara SC Venture, LLC, a presently inactive entity. The ownership interest is accounted for utilizing the equity method of accounting.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

Grider Community Gardens, LLC

This entity is wholly owned and controlled by the Corporation. The Corporation's net investment as of December 31, 2023 and 2022 is approximately \$1 million and \$748 thousand, respectively, and is reflected in other non-current assets of the parent company's financial statements.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

Grider Support Services, LLC

This entity was formed to act as a Management Services Organization ("MSO") for physician services for ECMC Hospital. The entity acts as a pass-through entity, and has no substantial assets or liabilities, or significant operating results. Its activity is consolidated into ECMC Corporation operations.

The sole member of this entity is Erie County Medical Center Corporation. Employees: 29

1827 Fillmore, LLC

This entity was formed in order to purchase real estate adjacent to the current health campus for the purpose of future development. Its activities to date consist of remediating and improving land adjacent to the ECMC campus and is consolidated into ECMC Corporation.

Net position as of December 31, 2023 and 2022 is \$144 and \$491 thousand, respectively.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Financial Report December 31, 2023

PRELIMINARY DRAFT
PRELIMINARY DRAFT
Purposes Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY DRAFT
Purposes
Ominy
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PREPROSES
OMINY
PRELIMINARY
PRELIMINARY
PREPROSES
OMINY
PREPROSES
OMINY
PREPROSES
OMINY

Contents

| Independent auditor's report | 1-3 |
|---|-------|
| Management's discussion and analysis | 4-13 |
| Basic financial statements | |
| Statements of net position | 14 |
| Statements of revenues, expenses and changes in net position | 15 |
| Statements of cash flows | 16-17 |
| Statements of net position—discretely presented component units | 18 |
| Statements of revenues, expenses and changes in net position—discretely presented component units | 19 |
| Notes to the financial statements | 20-54 |
| Required supplementary information | |
| Schedule of corporation's contributions NYSLRS pension plan | 55 |
| Schedule of corporation's proportionate share of net pension liability NYSLRS pension plan | 56 |
| Schedule of corporation's changes in total OPEB liability and related ratios | 57 |
| Uniform guidance audit requirements | |
| Schedule of expenditures of federal awards | 58 |
| Notes to schedule of expenditures of federal awards | 59 |
| Report on internal control over financial reporting and on compliance and other matters based on an audit of financial statements performed in accordance with <i>Government Auditing Standards</i> | 60-61 |
| Report on compliance for each major federal program; report on internal control over compliance; and report on schedule of expenditures of federal awards required by the uniform guidance | 62-64 |
| Schedule of findings and questioned costs | 65-66 |
| Summary schedule of prior year findings and questioned costs | 67 |

Independent Auditor's Report

Board of Directors
Erie County Medical Center Corporation

Report on the Audit of the Financial Statements

Opinions

We have audited the financial statements of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation (the Corporation), a component unit of the County of Erie, as of and for the years ended December 31, 2023 and 2022, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements as listed in the table of contents.

In our opinion, the accompanying financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation, as of December 31, 2023 and 2022, and the respective changes in financial position, and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinions

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions. The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc., and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*.

Emphasis of Matter

As discussed in Note 8 to the financial statements, the Corporation restated the December 31, 2022 financial statements. The restatement was required to be made for the implementation of the Governmental Accounting Standards Board (GASB) Statement No. 96, Subscription-Based Information Technology Arrangements. Our opinion is not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for twelve months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that management's discussion and analysis on pages 4 to 13 as well as the required supplementary information for certain pension and other postemployment benefits (OPEB) related data on pages 55 to 57 be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the GASB who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated **DATE** on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

DATE

FRELIMINARY DRAFT
Purposes Only
PRELIMINARY DRAFT
Purposes
Change
Change
Sulbject to be Reproduced

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Management's Discussion and Analysis

Erie County Medical Center Corporation (the Corporation or ECMCC) is a state public benefit corporation dedicated to provide every patient the highest quality of care delivered with compassion. The Corporation fully embraces its position as a safety net provider for the eight-county region of Western New York State (encompassing over 1.5 million residents), supporting persons in need who lack the ability to pay.

To assist the reader in understanding the operations of the Corporation, this annual report has been organized into three parts that should be read together:

- Management's discussion and analysis
- Financial statements and notes to the financial statements and
- Supplemental schedules

The purpose of the discussion and analysis is to provide the reader with objective data to evaluate the financial position and the activities of the Corporation for the year ended December 31, 2023. This narrative and the financial statements and footnotes are the responsibility of the Corporation's management.

The financial statements (the statements of net position, the statements of revenues, expenses and changes in net position and the statements of cash flows) present financial information in a form similar to that used by other government hospitals and have been prepared in accordance with accounting principles generally accepted in the United States of America.

In 2023, the Corporation implemented GASB Statement No. 96, Subscription-Based Information Technology Arrangements. This standard extends the right-of-use accounting concepts introduced in GASB Statement No. 87 to subscription-based information technology arrangements (SBITAs). Under GASB 96, governments are required to identify arrangements that qualify as SBITAs and recognize a right-to-use subscription asset, initially measured as the sum of the initial subscription liability amount, payments made to the vendor before commencement of the subscription term, and capitalizable implementation costs. The subscription asset is then amortized over the subscription term. The accompanying financial statements and management discussion and analysis information for the year ended December 31, 2022 have been restated to reflect the new accounting standard.

The accompanying financial statements of the Corporation include financial data of the Corporation's discretely presented component units: (i) ECMC Foundation, Inc., and (ii) The Grider Initiative, Inc. however, Management's Discussion and Analysis focuses on the Corporation.

Introduction

During 2023, the Corporation persevered through it's fourth consecutive year of significant financial challenges, while continuing to provide high quality, compassionate care to the tens of thousands of Western New Yorkers who depend on ECMCC, serving as the region's community hospital, helping patients from the most influential to the most vulnerable. ECMCC's dedicated caregivers, support staff, executive leadership, as well as an involved and supportive Board of Directors, continue to advance the mission of the Corporation and its service to the greater Western New York area. The Corporation continues to be a provider of choice in our community as a result of its continual focus on high quality healthcare services, the patient experience and physician engagement.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis

The Corporation began a period of operational recovery through growth during 2023, providing a higher volume of services within inpatient and outpatient services to Western New York residents and as well as many others beyond this region. Patient volume encounters (not expressed in thousands) are as follows:

| | | | | | | % Growth |
|-------------|---------|---------|---------|---------|---------|-----------|
| | 2019 | 2020 | 2021 | 2022 | 2023 | 2022-2023 |
| | | | | | | |
| Inpatients | 19,996 | 19,110 | 18,903 | 17,412 | 17,643 | 1.3% |
| Surgeries | 15,606 | 12,481 | 13,803 | 12,478 | 13,321 | 6.8% |
| Emergency | 69,391 | 65,261 | 68,384 | 59,064 | 63,715 | 7.9% |
| Outpatients | 306,891 | 299,297 | 280,611 | 274,402 | 297,168 | 8.3% |
| Dialysis | 27,549 | 27,973 | 26,116 | 24,961 | 25,159 | 0.8% |
| Transplants | 127 | 134 | 146 | 148 | 151 | 2.0% |

The healthcare industry nationally and within this market continued to face challenges during 2023 and the Corporation was not immune to these headwinds. However, the Corporation worked hard to begin to address them and recover. In 2023, ECMCC inpatient volumes ended the year higher than prior year by 1.3% in terms of patient discharges and by 6.3% for inpatient surgeries while length of stay improved by 12.1%. Outpatient surgeries were 7.1% ahead of prior year with emergency department visits exceeding 2022 by 7.9%, leading to a growth in total outpatient visits from the prior year of 8.3%. As the Regional Center of Excellence for Transplantation and Kidney Care, continued growth in this program has been experienced over the last two years, providing life saving procedures to the residents of Western New York and beyond. 2023 saw the most transplants (kidney and pancreas) ECMCC has performed in it's history, with 151 transplant surgeries, an increase of 2.0% and 18.9% over 2022 and 2019 (pre-COVID levels), respectively.

The global outbreak of COVID-19, a new strain of coronavirus that can result in severe respiratory disease, was declared a pandemic by the World Health Organization in March of 2020. After three unprecedented years of managing COVID-19, the Department of Health and Human Services (HHS) declared an end to the public emergency on May 11, 2023, thus ending the pandemic. With a lot of time, energy, and unyielding teamwork during the pandemic, the Corporation was able to effectively manage through the pandemic by implementing operational improvements, successfully recruiting staff, and entering into partnerships to provide funding assistance in addition to the COVID Relief funding. ECMCC management took on all additional measures during the pandemic to protect the health of the community and promote the continuity of its mission and will continue to monitor the course of COVID-19 beyond the pandemic.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis (Continued)

In response to the impact on the healthcare environment from COVID-19, the Coronavirus Aid, Relief, and Economic Security (CARES) Act and the American Rescue Plan (ARP) Act (Acts) were enacted by Congress during 2020 and 2021, respectively. These Acts included, among other things, support for healthcare providers and patients in the form of grants, payments for uninsured patients, and changes to Medicare and Medicaid payments. The Corporation to date has received \$72.4 million of Provider Relief Fund distributions provided under the CARES and ARP Acts. During 2020, the Corporation also received \$39.1 million and \$10 million in loans under the Medicare Accelerated and Advance Payment Program and the Paycheck Protection Program (PPP), respectively. During 2021, the PPP loan forgiveness application was approved by the U.S. Small Business Administration and, as such, the \$10 million loan was forgiven in full. As of December 31, 2022, the Medicare Accelerated and Advance Payments had been fully recouped.

The CARES Act also includes financial relief through the Federal Emergency Management Agency's (FEMA) Disaster Relief Fund. As of December 31, 2023, the Corporation has been awarded and received \$6.6 million from FEMA to reimburse eligible incremental expenses as a result of COVID-19. The Corporation will continue to submit for grant reimbursement for remaining eligible COVID-19 expenses under this program.

During 2022 and 2023, the industry and more specifically, the Western New York health care market experienced a cost inflation crisis. This crisis was driven nationally and locally by the lingering effects of staffing challenges across all healthcare industry stakeholders including suppliers, manufacturers, postacute settings as well as providers. As costs continued to escalate to operate the business and care for the patients within the community, in order to maintain mission critical services, ECMCC has worked closely with the New York State Department of Health's various grant and operating assistance programs to bridge cash flow funding gaps. Simultaneously, ECMCC has implemented several operational improvement actions in an effort to mitigate as much of the cost escalation as possible. Although significant improvements have been made operationally, the New York State Department of Health has provided supplemental funding to the Corporation as well as many hospitals and nursing homes across New York State. As a result, the Corporation received \$51,998 for the year ended December 31, 2022. This benefit has been recorded as non-operating revenue within the statements of revenue, expenses and changes in net position. An additional \$27,000 was received in December 2022 for the year ended December 31, 2023, and was recorded as unearned revenue in the statements of net position as of December 31, 2022 and recorded as non-operating revenue within the statements of revenue, expenses and changes in net position for the year ended December 31, 2023. Two additional awards totaling \$76,368 were received and recognized as non-operating revenue during the year ended December 31, 2023.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis (Continued)

The continued volume and visit trends reflect the trust that the Western New York community has placed in ECMCC. Notable achievements in 2023 include:

- ECMCC earned its full hospital accreditation The Joint Commission's Gold Seal of Approval Accreditation by demonstrating continuous compliance with performance standards.
- Successful reaccreditation by The Centers for Medicare and Medicaid Services (CMS), part of the Department of Health and Human Services (HHS) of Transplant program, housed in ECMCC's Regional Center of Excellence for Transplantation and Kidney Care.
- Commission on Accreditation of Rehabilitation Facilities (CARF) issued three-year accreditation to ECMCC's Acute Inpatient Rehabilitation Programs (through June 30, 2026) stating that this "achievement is an indication of ECMCC's dedication to improving the quality of the lives of the persons served."
- ECMCC's Laboratory Services received the two-year accreditation for ECMCC's Transfusion Services following bi-annual on-site assessment by the Association for the Advancement of Blood and Biotherapies (AABB)
- Terrace View Long-Term Care Facility was named to Newsweek's 2024 Best Nursing Homes List for performance on key measures on health inspections, quality measures and staffing. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. Only four percent of nursing homes nationwide received this distinction. Of the 600 skilled nursing facilities state-wide that operate, 42 received this recognition. It is a distinct honor to be ranked amongst the best nursing homes within both the state and the nation. This is the fourth consecutive year Terrace View has received this recognition.
- ECMCC has been recognized by the Lown Institute for outstanding social responsibility, receiving an
 "A" grade on the 2023-24 Lown Institute Hospitals Index. ECMCC achieved this honor through strong
 performance across metrics of health equity, patient outcomes, and value of care, out of more than
 3,600 hospitals nationwide. In 2021, ECMCC was ranked among the top 100 hospitals in the United
 States for racial inclusivity by the Lown Institute; in 2022 ECMCC was ranked in the top 50 hospitals
 in the country for racial inclusivity.
- ECMCC was recognized by the Buffalo Purchasing Initiative for superseding its goal in 2023 for spending with businesses owned by people of color.
- ECMCC's hip replacement surgery service ranked in the nation's top 7% by US News & World Report. ECMCC earned the highly respected publication's High Performing ranking, placing it among 437 hospitals out of 6,000 evaluated for the service.
- ECMCC earned platinum recognition for its efforts to increase organ and tissue donor registrations across the country, through the DoNation Campaign. DoNation is a national initiative sponsored by the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA), to educate our community about the crucial need for organ and tissue donation and to encourage people to sign up as organ and tissue donors. Between October 2022 and September 2023, ECMCC has actively participated in this campaign to earn this federal recognition.
- The American College of Emergency Physicians, implemented the Geriatric Emergency Department Accreditation (GEDA) program to recognize those emergency departments that provide excellent care for older adults. ECMCC's Emergency Department has achieved the bronze standard Level 3 GEDA accreditation. ECMCC named among one of America's 100 Best Hospitals for Orthopedic Surgery. This achievement reflects ECMCC's outstanding clinical outcomes for Orthopedic Surgery and puts ECMCC in the top 5% of hospitals nationwide for overall Orthopedic services.
- ECMCC was awarded the 2023 Orthopedic Surgery Excellence Award™, a Five-Star rating in Total Knee Replacement for two years in a row (2022-2023), a Five-Star rating for Hip Fracture Treatment for 13 years in a row (2011-2023) and a 2023 Five-Star Distinction in Total Hip Replacement.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Operations Analysis (Continued)

Financial Metric Analysis

The Corporation's total net position decreased in 2023 primarily due to the significant non-cash expenses related to the actuarial liability adjustments related to the New York State Pension Plan benefits and the unfavorable results from operations which were offset by grant funding assistance provided by New York State, recorded as non-operating revenue. Additional drivers of performance are discussed in further detail below.

Comparative financial ratios for the Corporation to the 2022 (most recent publicly available audited data) averages of other comparable New York State (NYS) Public Benefit Corporation (PBC) hospitals are presented in the following table. The financial statements used for the calculation of the following ratios, where appropriate, have been reclassified to conform to the presentation used in the development of the benchmarks, consistent with generally accepted accounting principles (U.S. GAAP) for entities not subject to the Governmental Accounting Standards Board (GASB) standards.

| | | PBC Average | | |
|--------------------------------|--------|----------------|-------|--------|
| | 2023 | 2022 | 2021 | 2022 |
| Operating margin | -14.2% | -10.8% | -3.6% | -16.1% |
| Operating cash flow margin | -6.0% | 4.6% | 4.0% | -10.0% |
| Debt service coverage | 2.7 | 1.5 | 1.1 | -0.5 |
| Unrestricted days cash on hand | 14.1 | 29.2 | 48.7 | 48.9 |
| Days cash on hand | 90.5 | 118.7 | 140.2 | 65.1 |
| Days in accounts receivable | 66.0 | 53.9 | 49.5 | 34.1 |
| Average age of plant | 15.4 | 13.0 | 12.5 | 20.4 |

The operational performance ratios for 2023 generally represent unfavorable changes from the Corporation's 2022 performance ratios and favorable comparisons to the NYS Healthcare Public Benefit Corporations' ratios. Driving these unfavorable shifts during 2023 in large part is the large swing in the amortization component of the pension expense, shifting from a reduction in expense in 2022 of \$32.5 million to an increase in expense of \$39.8 million in 2023. Although these changes have no cash flows associated with them, the changes to the liabilities associated with them are included within the operating margin. The operating margin before the impact of the amortization components of the pension benefit and postemployment benefit is 11.6% and 20.3% for 2023 and 2022, respectively. This change before those actuarial impacts reflects a favorable movement in operating margin which is representative of the operational improvements and growth experienced during 2023. Additionally, grants received from the New York State Department of Health (NYSDOH) and FEMA have been recognized as non-operating revenue and are excluded from the operating ratio calculations as required under GASB accounting standards. Unrestricted days cash on hand decreased 15.1 days (51.7%) due to overall operating losses and the delay in the receipt of annual Disproportionate Share Hospital (DSH) Revenue to the first quarter of 2024. Days in accounts receivable increased by 12.1 days (22.5%) due to a delay in collections and an increase in unbilled accounts as a result of staffing shortages during the year. Average age of plant increased by 2.4 years (16.5%) as a result of reduced capital investment in an effort to manage ongoing operations and cash flow needs to maintain the services provided to the community while incurring operating losses.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Summary Financial Statements with Analysis

Management is providing the following summary financial statements and variance analysis for certain financial statement lines where it believes the readers understanding of the financial statements is enhanced.

Statements of Net Position

Net position is categorized as follows:

Net investment in capital assets: Consists of capital assets, net of accumulated depreciation and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets.

Restricted: Result when constraints placed on the use of the net position are either externally imposed by creditors, grantors, contributors, or imposed by law through constitutional provisions or enabling legislation.

Unrestricted: Represents the resources derived primarily from services rendered to patients and other operating revenues and not meeting the previously listed criteria. These resources are used for transactions related to the general healthcare and academic operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Condensed Statements of Net Position are as follows:

| | | | (| Restated) | 2023-2022 | | | | |
|--|----|-----------|----|-----------|-----------|-----------|----------|--|--|
| | me | 2023 | | 2022 | | \$ Change | % Change | | |
| Assets | 1 | | | | | | | | |
| Current assets, excluding assets whose | | | | | | | | | |
| use is limited | \$ | 189,816 | \$ | 210,427 | \$ | (20,611) | (9.8) | | |
| Assets whose use is limited | | 170,621 | | 157,516 | | 13,105 | 8.3 | | |
| Capital assets, net | | 313,039 | | 359,386 | | (46,347) | (12.9) | | |
| Net pension asset | | - | | 77,538 | | (77,538) | 100.0 | | |
| Other assets | | 8,906 | | 7,780 | | 1,126 | 14.5 | | |
| Total assets | | 682,382 | | 812,647 | | (130,265) | (16.0) | | |
| Deferred outflows of resources | | 159,464 | | 178,411 | | (18,947) | (10.6) | | |
| Total assets and deferred | | | | | | | | | |
| outflows of resources | \$ | 841,846 | \$ | 991,058 | \$ | (149,212) | (15.1) | | |
| Liabilities | | | | | | | | | |
| Current liabilities | \$ | 302,347 | \$ | 303,848 | \$ | (1,501) | (0.5) | | |
| Noncurrent liabilities | | 730,926 | | 560,724 | | 170,202 | 30.4 | | |
| Total liabilities | | 1,033,273 | | 864,572 | | 168,701 | 19.5 | | |
| Deferred inflows of resources | | 84,740 | | 396,441 | | (311,701) | (78.6) | | |
| Net Position | | | | | | | | | |
| Net investment in capital assets | | 58,654 | | 85,013 | | (26,359) | (31.0) | | |
| Restricted | | 95,555 | | 80,719 | | 14,836 | 18.4 | | |
| Unrestricted | | (430,376) | | (435,687) | | 5,311 | 1.2 | | |
| Total net position | | (276,167) | | (269,955) | | (6,212) | (2.3) | | |
| Total liabilities, deferred inflows | | | | | | | | | |
| of resources and net position | \$ | 841,846 | \$ | 991,058 | \$ | (149,212) | (15.1) | | |

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Statements of Net Position (Continued)

Overall, total assets and deferred outflows of resources decreased \$149,212 from 2022 to 2023. The following variances in total assets are noteworthy:

Total current assets, excluding the current portion of assets whose use is limited, decreased by \$20,611 due to the following:

- Cash, cash equivalents and investments decreased by \$20,029 due to losses from operations and the timing of the annual DSH and Upper Payment Limit (UPL) cash receipts offset by earnings on investments.
- Patient accounts receivable, net, increased by \$18,820 as a result of current year decreases in collections due to an increase in unbilled accounts as a result of staffing shortages and increased patient volumes.
- Other receivables decreased by \$21,822 which is due to a \$21,856 decrease in Medicaid DSH and UPL program receivables, a decrease of \$286 in due from third party payors and a \$320 increase in other receivables.

The following variances in non-current assets are noteworthy:

- Assets whose use is limited, including current portion, increased by a net of \$13,105, which is due to
 a required deposit of collateral of \$11,015 related to a new line of credit agreement, unrealized gains
 on investments of \$3,786 and an increase in reserve account funding for actuarial liabilities and other
 limited use assets of \$2,311, offset by a decrease in assets designated for long-term investment of
 \$4.007.
- Capital assets, net, decreased by \$46,347 due to the shortfall in capital asset investments during 2023 as compared to the ongoing depreciation expense on all capital assets, which is a continued result of reduced cash flow availability driven by operating losses. Investments in capital assets are summarized in a following section.
- Net pension asset decreased \$77,538 and was eliminated due to changes in actuarial assumptions, which increased the liability thus creating a net pension liability, which is further discussed in the section below.

Overall, total liabilities and deferred inflows decreased \$143,000 and net position decreased \$6,212 from 2022.

The following variances in total liabilities are noteworthy:

- Accounts payable and accrued salaries and benefits decreased by \$17,339 due to timing of payments to vendors and employees at year-end.
- Accrued other liabilities increased by \$1,908 largely as a result of increases in amounts due to Erie County and third-party payors.
- Unearned revenue decreased by \$22,517 due to a decrease of \$27,000 related to the New York State grant received in late December 2022 for the calendar year 2023, thus recognized during 2023. Other unearned revenue increased \$4,483.
- The line of credit liability remained unchanged due to borrowings that remain outstanding at December 31, 2023.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Statements of Net Position (Continued)

- The long-term portion of self-insured obligations increased by \$3,238 due to changes in actuarial
 estimates for self-insured retentions for malpractice and workers' compensation claims greater than
 payments made on those claims. The current portion of these self-insured obligations decreased by
 \$148.
- Net pension liability, including current portion, was established at \$198,936 due to changes in actuarial assumptions used to value the plan as of December 31, 2023. As noted above, at December 31, 2022, the Corporation had recorded a net pension asset of \$77,538.
- The liability for Other Post-Employment Benefits (OPEB) increased by \$22,516 primarily as a result of the unfavorable impact of a change in actuarial assumptions related to unfavorable healthcare trend rates and a decrease in the discount rate used to measure the obligation.
- Net position decreased by \$6,212 due to unfavorable financial performance related to inflationary pressures on operating expenses continuing to outpace increases in patient volume and payor reimbursement rates.

Statements of Revenues, Expenses and Changes in Net Position

Condensed Statements of Revenues, Expenses and Changes in Net Position are as follows:

| | | (Restated) | 2023-2022 | | | |
|--|--------------|--------------|------------|----------|--|--|
| | 2023 | 2022 | \$ Change | % Change | | |
| Net patient service revenue | \$ 603,720 | \$ 566,389 | \$ 37,331 | 6.6 | | |
| Disproportionate share (DSH) revenue | 107,105 | 68,295 | 38,810 | 56.8 | | |
| Other operating revenue | 46,639 | 26,095 | 20,544 | 78.7 | | |
| Total operating revenues | 757,464 | 660,779 | 96,685 | 14.6 | | |
| Operating expenses: | | | | | | |
| Payroll and employee benefits | 440,770 | 410,664 | 30,106 | 7.3 | | |
| Professional fees | 110,577 | 109,113 | 1,464 | 1.3 | | |
| Purchased services | 81,712 | 78,037 | 3,675 | 4.7 | | |
| Supplies | 132,197 | 117,877 | 14,320 | 12.1 | | |
| Other operating expenses | 30,529 | 29,185 | 1,344 | 4.6 | | |
| Depreciation and amortization | 49,812 | 49,872 | (60) | (0.1) | | |
| Total operating expenses | 845,597 | 794,748 | 50,849 | 6.4 | | |
| Operating loss before pension | - | | | | | |
| and other post employment | | | | | | |
| benefits amortization components | (88,133) | (133,969) | 45,836 | 34.2 | | |
| Pension (expense) benefit, amortization component Other post employment benefits, | (39,752) | 32,537 | (72,289) | (222.2) | | |
| amortization component | 20,424 | 29,861 | (9,437) | (31.6) | | |
| Operating loss | (107,461) | (71,571) | (35,890) | (50.1) | | |
| Non-operating revenues (expenses): | | | | | | |
| Investment gain (loss) | 6,283 | (13,966) | 20,249 | (145.0) | | |
| Grant revenue | 107,230 | 63,151 | 44,079 | 69.8 | | |
| Interest expense | (12,264) | (12,028) | (236) | (2.0) | | |
| Total change in net position | (6,212) | (34,414) | 28,202 | 81.9 | | |
| Net position—beginning of year | (269,955) | (235,541) | (34,414) | (14.6) | | |
| Net position—end of year | \$ (276,167) | \$ (269,955) | \$ (6,212) | (2.3) | | |

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position (Continued)

Overall, total operating revenues increased by \$96,685 or 14.6% in 2023 with changes attributable to the following:

- Net patient service revenue increased \$37,331, or 6.6%, in 2023 as a result of a combination of overall increased patient volumes, an increase in contracted reimbursement rates, improvements in bad debt write-offs and improvements in ECMCC's ability to discharge patients into the community.
- DSH revenue increased by \$38,810, or 56.8%, in 2023 as a result of an increase in the nursing home upper payment limit of \$5,885 due to a significant increase in the pool size in the State Plan Amendment and a \$32,925 increase in federal DSH due to an increase in uncompensated care net of anticipated formula changes in the Medicaid DSH cap calculation enacted through legislation but not yet implemented which will exclude costs from services provided to Medicaid-eligible beneficiaries who are dually eligible for Medicare or any other coverage.
- Other operating revenue increased \$20,544, or 78.7% due to an increase in specialty pharmacy operations of \$20,777.

Total operating expenses including pension expense/benefit and other post-employment benefit expenses increased \$132,575 or 18.1% in 2023. Expense changes are attributable to the following:

- Payroll and employee benefit expenses have increased by \$30,106 or 7.3% as a result of increases in salaries due to new collective bargaining agreements' market rate adjustments and additional pay incentives offered to fill open shifts to meet New York State minimum staffing standards for both the hospital and the skilled nursing facility. Salaries and employee benefit expense as a percent of net patient service revenue increased by 0.5%, from 72.5% in 2022 to 73.0% in 2023.
- Pension expense increased by \$65,834 as a result of changes in actuarial assumptions used to value the plan including investment returns, discount rates and other demographic assumptions.
- Supplies expense increased by \$14,320 or 12.1% as a result of increased surgical volume, increased volume within the specialty pharmacy operations and pharmaceutical cost increases related to drug shortages.
- OPEB benefit decreased \$11,976 or 38.2% as a result of unfavorable differences between projected and actual experience of net claims cost and benefit payment made to current employees.

Capital Assets, Net

At December 31, 2023, the Corporation had capital assets, including lease and subscription-based information technology arrangement assets, net of accumulated depreciation of \$313,039 compared to \$359,386 at December 31, 2022, representing a decrease of \$46,347 or 12.9%.

During 2023, the Corporation invested \$15,047 in various capital assets (\$6,030), leases (\$4,668) and SBITAs (\$4,349). Noteworthy investments in capital assets include continued investment into the building exterior improvements of \$455 and purchases of other medical and non-medical equipment, furniture and fixtures, and information systems infrastructure investments. Noteworthy additions to capital leases include printers and copiers (\$2,552) and other various leased medical and non-medical equipment. Noteworthy additions to SBITAs includes MRI software (\$1,755) and other medical and non-medical software. GASB Statement No. 87, *Leases*, establishes the foundational principle that leases are financing of the right-to-use an underlying asset for a period of time. The Corporation recorded lease assets, net of accumulated depreciation, in the amount of \$26,371 and \$30,054 in 2023 and 2022, respectively. GASB Statement No. 96, *Subscription-Based Information Technology Arrangements*, extends the right-of-use accounting concepts introduced in GASB Statement No. 87, *Leases*, to SBITAs. The Corporation recorded SBITA assets in the amount of \$25,761 in 2023 and \$31,216 in 2022.

Management's Discussion and Analysis December 31, 2023 (Dollars in Thousands)

Forward-Looking Factors

Management has prepared the following forward-looking factors to assist the reader in understanding the financial, economic and market factors impacting the Corporation:

Collective Bargaining Agreements

The Corporation operates under three collective bargaining agreements that cover substantially all employees. Corporation employees of the Civil Service Employee Association (CSEA) are covered by a contract negotiated in concert with Erie County, New York, which contains a sub-bargaining unit representing only Corporation employees. The previous agreement ended in 2022, while a new agreement began January 1, 2023 and runs through December 31, 2027. Registered Nurses (RNs) are covered under an agreement with the New York State Nurses Association (NYSNA). This agreement began in 2019 and ran through December 31, 2022. The parties have mutually agreed to a new contract effective January 1, 2023 that runs through December 31, 2027. The Corporation's agreement with the American Federation of State, County and Municipal Employees (AFSCME), a contract negotiated in concert with the County of Erie, New York, and ratified with AFSCME employees in 2022 runs through December 31, 2026.

Transactions with the County of Erie

The Corporation is a component unit of the County of Erie, New York. The County has ongoing contractual and legal obligations to the Corporation and the Corporation has ongoing contractual and legal obligations to the County.

Medicare and Medicaid Reimbursement

The future state of both reimbursement levels and reimbursement methods related to the Medicare and Medicaid programs remains uncertain. Unimplemented formulaic changes as well as budget proposals related to both of these programs for the upcoming year and beyond may significantly alter reimbursements or methodologies, thus changing the environment in which we conduct business as the Corporation relies heavily on these programs for reimbursement for services. The impact of these state and federal rule changes and budget proposals are unknown at this time but could materially impact the Corporation.

Contacting the Corporation's Financial Management

This financial report is designed to provide our community and creditors with a general overview of Erie County Medical Center Corporation's finances and to demonstrate the Corporation's accountability for the resources it receives. If you have any questions about this report or need additional financial information, contact the Chief Financial Officer, Erie County Medical Center Corporation, 462 Grider Street, Buffalo, New York 14215.

Statements of Net Position December 31, 2023 and 2022 (Dollars in Thousands)

| • | | | (Restated) |
|--|----------|----------------|-------------------|
| | 2023 | | 2022 |
| Assets and Deferred Outflows of Resources | | | |
| Current assets: | | | |
| Cash and cash equivalents | | 0,773 \$ | 44,195 |
| Investments | | 0,646 | 7,253 |
| Assets whose use is limited | | 3,986 | 99,078 |
| Patient accounts receivable, net | | 2,389 | 83,569 |
| Other receivables | | 0,608 | 62,430 |
| Supplies, prepaids and other Total current assets | | 5,400 3,802 | 12,980 309,505 |
| Assets whose use is limited | - | 6,635 | 58,438 |
| Capital assets, net | | 3,039 | 359,386 |
| Net pension asset | 31 | 3,039 | 77,538 |
| Other assets, net | | 8,906 | |
| other assets, net | | 8,580 | 7,780 503,142 |
| Total courts | |) 0 | |
| Total assets | | 2,382 | 812,647 |
| Deferred outflows of resources: Pension | 12 | 3,115 | 142 602 |
| Other post employment benefits | | .5,670 | 143,693 22,684 |
| Other post employment benefits Other | | 0,679 | 12,034 |
| Total deferred outflows of resources | | 9,464 | 178,411 |
| | 100 | | |
| Total assets and deferred outflows of resources | 3 84 | 1,846 \$ | 991,058 |
| Liabilities, Deferred Inflows of Resources and Net Position | | | |
| Current liabilities: | - MO CO | | |
| Current portion of long-term debt | | 2,128 \$ | 11,716 |
| Line of credit | | 0,000 | 10,000 |
| Current portion of lease and SBITA liability Accounts payable Accrued salaries, wages and employee benefits Net pension liability Other post employment benefits | | 6,409 | 14,770 |
| Accounts payable | | 9,927 | 73,650 |
| Accrued salaries, wages and employee benefits | | 9,603 | 43,219 |
| Net pension liability | | 4,131 | - |
| Other post employment benefits | | 2,326 | 12,061 |
| Accrued other liabilities | | 2,021 | 40,113 |
| Unearned revenue | | 5,802 | 98,319 |
| Total current liabilities | 30 | 2,347 | 303,848 |
| Long-term debt, net | 19 | 0,515 | 202,641 |
| Long-term lease and SBITA liability, net | 3 | 4,682 | 44,409 |
| Net pension liability, net of current portion | 16 | 4,805 | - |
| Self-insured obligations | 5 | 2,121 | 48,883 |
| Other post employment benefits, net of current portion | 28 | 1,585 | 259,334 |
| Other | | 7,218 | 5,457 |
| Total liabilities | 1,03 | 3,273 | 864,572 |
| Deferred inflows of resources: | | | |
| Pension | 2 | 3,737 | 280,189 |
| Other post employment benefits | | 9,337 | 114,812 |
| Leases | | 1,666 | 1,440 |
| Total deferred inflows of resources | 8 | 4,740 | 396,441 |
| Net Position: | | | |
| Net investment in capital assets | 5 | 8,654 | 85,013 |
| Restricted: | | | |
| Expendable | 9 | 5,555 | 80,719 |
| Jnrestricted | (43 | 0,376) | (435,687) |
| Total net position | (27 | (6,167) | (269,955) |
| Total liabilities, deferred inflows of resources and net position | | 1,846 \$ | 991,058 |
| . c.a | <u>-</u> | <u>.,</u> | 001,000 |

Statements of Revenues, Expenses and Changes in Net Position Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| (Dollars in Thousands) | 2023 | (Restated) 2022 |
|---|-----------------|--------------------|
| Operating revenues: | 2023 | 2022 |
| Net patient service revenue, net of provision for bad debts of \$4,596 and \$15,474 for 2023 and 2022, respectively | \$ 603,720 | \$ 566,389 |
| Disproportionate share revenue (DSH) | 107,105 | 68,295 |
| Other operating revenue | 46,639 | 26,095 |
| Total operating revenues | 757,464 | 660,779 |
| Operating expenses: | | |
| Payroll and employee benefits | 440,770 | 410,664 |
| Professional fees | 110,577 | 109,113 |
| Purchased services | 81,712 | 78,037 |
| Supplies | 132,197 | 117,877 |
| Other operating expenses | 30,529 | 29,185 |
| Depreciation and amortization | 49,812 | 49,872 |
| Total operating expenses | 845,597 | 794,748 |
| Operating loss before pension benefit and other post employment benefits amortization components | (88,133) | (133,969) |
| Pension (expense) benefit, amortization component | (39,752) | 32,537 |
| Other post employment benefits, amortization component | 20,424 | 29,861 |
| Operating loss | (107,461) | (71,571) |
| Nonoperating revenues (expenses): | | |
| Investment gain (loss) | 6,283 | (13,966) |
| Grant revenue | 107,230 | 63,151 |
| Interest expense | (12,264) | (12,028) |
| Total nonoperating revenues (expenses) | 101,249 | 37,157 |
| Total change in net position | (6,212) | (34,414) |
| Net position—beginning of year | (269,955) | (235,541) |
| Net position—end of year | \$ (276,167) | \$ (269,955) |

Statements of Cash Flows Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | | 2023 | 2022 |
|---|----|-----------|---------------|
| Cash flows from operating activities: | | | _ |
| Receipts from patients and third-party payors | \$ | 608,472 | \$ 585,894 |
| Payments to Medicare Advance Payment Program | | - | (20,879) |
| Payments to employees for salaries and benefits | | (415,584) | (389,561) |
| Payments to vendors for supplies and other | | (369,364) | (293,557) |
| Other receipts | | 119,572 | 31,591 |
| Net cash used in operating activities | | (56,904) | (86,512) |
| Cash flows from capital and related financing activities: | | | |
| Purchases of capital assets | | (12,554) | (26,855) |
| Borrowings on line of credit | | Olan S | 10,000 |
| Payments on long-term debt | | (11,714) | (11,317) |
| Interest paid on long-term debt | | (12,264) | (10,928) |
| Net cash used in capital and related financing activities | 6 | (36,532) | (39,100) |
| Cash flows from noncapital financing activities: | | | |
| Grant funding | | 80,229 | 90,151 |
| Net cash provided by noncapital financing activities | Ca | 80,229 | 90,151 |
| Cash flows from investing activities: | | | |
| (Purchases) sales of assets whose use is limited, net | | (13,105) | 11,047 |
| Investment gain (loss) | | 6,283 | (13,966) |
| (Purchases) sales of investments, net | | (3,393) | 13,111 |
| Net cash (used in) provided by investing activities | | (10,215) | 10,192 |
| Net change in cash and cash equivalents | | (23,422) | (25,269) |
| Cash and cash equivalents: | | | |
| Beginning | | 44,195 | 69,464 |
| Ending | \$ | 20,773 | \$ 44,195 |

Noncash capital and related financing activities:

Included in accounts payable at December 31, 2023 and 2022, was \$1,357 and \$2,737, respectively, of invoices related to capital asset acquisitions.

(Continued)

Statements of Cash Flows (Continued) Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | 2023 | 2022 |
|---|--------------------|-----------|
| Reconciliation of operating loss to net cash | | _ |
| used in operating activities: | | |
| Operating loss | \$ (107,461) \$ | (71,571) |
| Adjustments to reconcile operating loss to net cash | | |
| used in operating activities: | | |
| Depreciation and amortization | 49,812 | 49,872 |
| Provision for bad debts | 4,596 | 15,474 |
| Changes in assets, deferred outflows, liabilities and deferred inflows: | | |
| Patient accounts receivable | (23,416) | (22,328) |
| Medicare Advance Payment Program | <u>-</u> [W] - | (20,879) |
| Other receivables | 21,822 | 26,070 |
| Supplies, prepaids and other | (3,546) | 17,218 |
| Deferred outflows of resources | 18,947 | 100,984 |
| Accounts payable | (4,634) | 21,955 |
| Accrued liabilities | (9,785) | 13,176 |
| Unearned revenue | 4,484 | (62,799) |
| Estimated third-party payor settlements | 1,750 | 289 |
| Self-insured obligations | 3,238 | 1,322 |
| Net pension liability (asset) | 276,474 | (78,453) |
| OPEB and the control of the control | 22,516 | (107,711) |
| Deferred inflows of resources | (311,701) | 38,689 |
| Net cash used in operating activities | \$ (56,904) \$ | (86,512) |

Statements of Net Position—Discretely Presented Component Units December 31, 2023 and 2022 (Dollars in Thousands)

| | | | | 20 | 023 | | | | | 2022 | | | | | | |
|------------------------------------|-----------|----------------|--------|-------------|---------|-----------------|----------|-----------------|-----|------------------|------|--------------|------|---------------|----|-----------------|
| | The | | | The | Res | earch for | | | | The Research for | | | | | | |
| | | ECMC | (| Grider | H | ealth in | A | Aggregate | | ECMC | | Grider | | lealth in | A | ggregate |
| | Fou | ındation, Inc. | Initia | ative, Inc. | Erie (| County, Inc. | | Total | Fou | ndation, Inc. | Init | iative, Inc. | Erie | County, Inc. | | Total |
| Assets | | | | | | | | | | | | | | | | |
| Current assets: | | | | | | | | | _ | | _ | | _ | | | |
| Cash and cash equivalents | \$ | 2,365 | \$ | 270 | \$ | - | \$ | 2,635 | \$ | 2,337 | \$ | 271 | \$ | 2 | \$ | 2,610 |
| Investments | | - | | - | | - | | | | . . | | - | | 1,092 | | 1,092 |
| Other receivables | | 938 | | - | | - | | 938 | | 1,634 | | - | | - | | 1,597 |
| Supplies, prepaids and other | | 259 | | | | | // | 259 | | 408 | | | | . | | 408 |
| Total current assets | | 3,562 | | 270 | | | 2016 | 3,832 | | 4,379 | | 271 | | 1,094 | | 5,707 |
| | | | | | | | | | | | | | | | | |
| Other receivables | | 887 | | - | | | | 887 | | 1,030 | | - | | - | | 1,030 |
| Endowment and other investments | | 3,129 | | 9,962 | | 3 - 11 Oll 11 - | | 13,091 | | 2,298 | | 9,576 | | - | | 11,874 |
| Equipment and vehicles, net | | - | | UNITED A | | 5110 | <u>J</u> | - | | 1 | | - | | - | | 1 |
| | | 4,016 | | 9,962 | Con | Children . | ~ nO! | 13,978 | | 3,329 | | 9,576 | | - | | 12,905 |
| | | | Blu | TO DIE | .m. 870 | | MA | | | | | | | | | |
| Total assets | <u>\$</u> | 7,578 | \$ | 10,232 | \$ | | \$ | 17,810 | \$ | 7,708 | \$ | 9,847 | \$ | 1,094 | \$ | 18,612 |
| Liabilities and Net Position | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Current liabilities: | • | Rev | | | 3) | | • | 44 | | | • | | • | | • | |
| Accounts payable | \$ | 401 11 | \$ | WOF . | \$ | - | \$ | 11 | \$ | 22 | \$ | - | \$ | - | \$ | 22 |
| Funds held in custody for others | | 596 | | 11/2 - | | - | | 596 | | 596 | | - | | - | | 596 |
| Total current liabilities | | 607 | | | | - | | 607 | | 618 | | - | | - | | 618 |
| Lang tame liabilities. | | | | | | | | | | | | | | | | |
| Long-term liabilities: | | 969 | | | | | | 969 | | 0.500 | | | | | | 0.500 |
| Related party Unearned revenue | | 335 | | - | | - | | 335 | | 2,522 509 | | - | | - | | 2,522 509 |
| Onearned revenue | | 335 | | | | | | 335 | | 509 | | - | | | | 509 |
| Total liabilities | | 1,911 | | - | | - | | 1,911 | | 3,649 | | - | | = | | 3,649 |
| Net Position | | | | | | | | | | | | | | | | |
| Restricted: | | | | | | | | | | | | | | | | |
| | | 50 | | 10,000 | | | | 40.050 | | 50 | | 10,000 | | | | 10.050 |
| Nonexpendable Expendable | | | | 232 | | - | | 10,050 2,866 | | | | , | | - | | 10,050 1,357 |
| Unrestricted | | 2,634 | | 232 | | - | | , | | 1,510 | | (153) | | 4.004 | | , |
| | | 2,983 5,667 | | 10,232 | | - | | 2,983 15,899 | | 2,499 | | 0.047 | | 1,094 | | 3,556 |
| Total net position | | 5,667 | | 10,232 | | - | | 15,899 | | 4,059 | | 9,847 | | 1,094 | | 14,963 |
| Total liabilities and net position | \$ | 7,578 | \$ | 10,232 | \$ | _ | \$ | 17,810 | \$ | 7,708 | \$ | 9.847 | \$ | 1,094 | \$ | 18,612 |

Statements of Revenues, Expenses and Changes in Net Position—Discretely Presented Component Units Years Ended December 31, 2023 and 2022 (Dollars in Thousands)

| | | | | 20 |)23 | | | | | 2022 | | | | | | | |
|--|------|---------------|--------|------------|--------|--------------|------|-----------|------------------|----------------|-------|-------------|-------------------|-------|-----------|-----------|--|
| | | | | The | Re | esearch for | | | The Research for | | | | | | | | |
| | ECMC | | G | Grider | | Health in | | Aggregate | | ECMC | | Grider | Health in | | Aggregate | | |
| | Four | ndation, Inc. | Initia | tive, Inc. | Erie | County, Inc. | | Total | Fo | undation, Inc. | Initi | ative, Inc. | Erie County, Inc. | | . Total | | |
| Operating revenues: | | | | | | | | | | | | | | | | | |
| Grants, contributions and special events | \$ | 4,732 | \$ | - | \$ | - | \$ | 4,732 | \$ | 3,425 | \$ | - | \$ | - | \$ | 3,396 | |
| Total operating revenues | | 4,732 | | - | | - | | 4,732 | | 3,425 | | - | | - | | 3,396 | |
| Operating expenses: | | | | | | | | | | | | | | | | | |
| Program services and grants | | 970 | | _ | | 1,107 | | 2,077 | | 875 | | _ | | 5 | | 880 | |
| Fundraising | | 1,640 | | - | | a Olyana | | 1,640 | | 1,562 | | - | | _ | | 1,562 | |
| Other operating expenses | | 641 | | - | | 100 | | 641 | | 357 | | - | | 1 | | 358 | |
| Total operating expenses | | 3,251 | | Altra. | Alban. | 1,107 | a1(9 | 4,358 | | 2,794 | | - | | 6 | | 2,800 | |
| | | | | O UMAIA. | 200 | SS, Tall | 112 | | | | | | | | | | |
| Operating income (loss) | | 1,481 | | | | (1,107) | | 374 | | 631 | | - | | (6) | | 596 | |
| | | | | | | | | | | | | | | | | | |
| Nonoperating revenue: | | | | | | | | | | | | | | | | | |
| Investment income (loss) | | 127 | ROUN , | 385 | 1 | 13 | | 525 | | (145) | | (347) | | (31) | | (531) | |
| O I | | CON. | | on-fi | | (4.004) | | | | 400 | | (0.47) | | (07) | | 0.5 | |
| Change in net position | | 1,608 | | 385 | | (1,094) | | 899 | | 486 | | (347) | | (37) | | 65 | |
| Net position—beginning of year | | 4,059 | | 9,847 | | 1,094 | | 15,000 | | 3,573 | | 10,194 | | 1,131 | | 14,898 | |
| Net position—end of year | \$ | 5,667 | \$ | 10,232 | \$ | _ | \$ | 15,899 | \$ | 4,059 | \$ | 9,847 | \$ | 1,094 | \$ | 14,963 | |
| , | | -1 | • | - 1 | _ | | | -, | | ,,,,, | _ | - , + | • | , | _ | , , , , , | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 1. Organization

The Corporation: Erie County Medical Center Corporation (referred to as the Corporation or ECMCC) is a public benefit corporation created by the Erie County Medical Center Corporation Act, Chapter 143 of the Laws of New York State, 2003 (Title 6 of Article 10-C of the Public Authorities Law) (the Act) as amended in 2016. The Corporation was created under the Act to secure a form of governance which permits the Corporation to have the legal, financial, and managerial flexibility to operate its health care facilities for the benefit of the residents of New York State (the State), the County of Erie (the County), and Western New York, including persons in need who lack the ability to pay.

The Corporation's "Health Care Facilities" consist of the Medical Center, a 573-bed acute tertiary care facility providing inpatient, emergency, outpatient, primary care and specialty clinic services (Medical Center), a 390-bed residential health care facility (Terrace View) both located on Grider Street in the City of Buffalo and three chemical dependency and alcohol rehabilitation clinics located throughout the County. The Corporation serves as the region's only Level 1 Adult Trauma Center, burn center, comprehensive traumatic brain injury and spinal cord injury rehabilitative center, Comprehensive Psychiatric Emergency Program provider for acute psychiatric emergencies, Regional Center of Excellence for Transplantation and Kidney Care.

The Corporation has the power under the Act to acquire, operate, and manage its facilities and to issue bonds and notes to finance the costs of providing such facilities. The Act specifically provides that the Corporation's existence shall continue until terminated by law; provided, however, that no such termination shall take effect so long as the Corporation shall have bonds or other obligations outstanding unless adequate provision has been made for the payment or satisfaction thereof. The Corporation's primary purpose is the operation of the Medical Center and Terrace View, and its powers, duties and functions are as set forth in the Act, as amended, and other applicable laws.

The Corporation qualifies as a governmental entity and, accordingly, is exempt from federal income tax pursuant to Section 115 of the Internal Revenue Code of 1986.

In accordance with Governmental Accounting Standards Board (GASB) Statement No. 14, *The Financial Reporting Entity*, as amended, the Corporation's financial statements are included, as a discretely presented component unit, in the County's Annual Comprehensive Financial Report (ACFR). A copy of the ACFR can be obtained from the Erie County Comptroller's Office, 95 Franklin Street, Room 1100, Buffalo, New York 14202. The Corporation is subject to New York civil service law.

Governance: The Corporation is governed by its Board of Directors (the Board) consisting of fifteen (15) voting directors, eight (8) of whom are appointed by the Governor of the State of New York and seven (7) of whom are appointed by the Erie County Executive with the advice and consent of the Erie County Legislature. There are four non-voting representatives, as well. The directors and non-voting members serve staggered terms and continue to hold office until their successors are appointed. Directors have experience in the fields of health care services, quality and patient safety, human resources, strategic growth, law, and financial management and reflect a broad representation of the community served by the Corporation. Regular meetings of the Board are scheduled eleven (11) times per year. Board leaders are appointed by the Board.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 1. Organization (Continued)

Great Lakes Heath System: The Corporation is a member of Great Lakes Health System of Western New York (Great Lakes). Great Lakes is a not-for-profit, community-based corporation comprised of unified partners whose objective is to provide the highest quality of healthcare to the residents of Western New York. Great Lakes is comprised of the Corporation, Kaleida Health (KH), The Center for Hospice and Palliative Care and the State University of New York at Buffalo (the University).

Great Lakes Health Integrated Network: The Corporation, together with KH has formed Great Lakes Health Integrated Network (GLIN) with each maintaining a 50% ownership interest. As of December 31, 2023 and 2022, capital contributions due to GLIN totaled \$326 and \$767, respectively. Contributions are used to pay for care coordination services, information systems infrastructure and routine operating expenses to support community population health management.

Medical School Collaboration: The Corporation serves as a primary teaching hospital for the Jacobs School of Medicine and Biomedical Sciences of the State University of New York at Buffalo (the Medical School). An agreement governs the relationship between the Corporation and the Medical School. The Corporation serves as an integral part of the education and research mission of the Medical School by providing the clinical settings for the Medical School's public mission to educate and train physicians, nurses and other healthcare professionals, conduct clinical research programs and deliver healthcare services to patients. There are currently 187 full-time equivalent medical residents assigned to the Corporation in various Academic College of Graduate Medical Education accredited residency programs.

Component Units: Accounting principles generally accepted in the United States of America (U.S. GAAP) require the inclusion within the Corporation's financial statements of certain organizations as component units. The component units discussed below are included because the nature and significance of their relationship to the Corporation are such that exclusion would cause the reporting entity's financial statements to be misleading or incomplete under criteria set forth by the GASB.

The component unit information in the accompanying basic financial statements includes the financial data of the Corporation's three discretely presented component units. The three discretely presented component units are discussed in more detail below:

ECMC Foundation, Inc.: The ECMC Foundation, Inc. (the Foundation) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC). The Foundation was formed for the purpose of supporting Corporation programs. The financial statements of the Foundation have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Executive Director, ECMC Foundation, Inc., 462 Grider Street, Buffalo, NY 14215.

The Grider Initiative, Inc.: The Grider Initiative, Inc. (the Physician Endowment) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the IRC. The Physician Endowment was funded in 2010, for the purpose of recruiting physicians who shall practice on the Grider Street campus of the Corporation. The entity was funded with an initial transfer of \$10,000 from the Corporation. Earnings from the investment of the initial transfer may be used only for physician recruitment and retention and necessary expenses of the entity. The financial statements of The Grider Initiative, Inc. have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Chair, The Grider Initiative, Inc. 462 Grider Street, Buffalo, NY 14215.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 1. Organization (Continued)

Research for Health in Erie County, Inc.: Research for Health in Erie County, Inc. (RHEC) was a not-for-profit organization dedicated to supporting research activities relating to the causes, nature, and treatment of diseases, disorders, and defects of particular importance to the public health in areas served by the Corporation. During 2023, RHEC was dissolved and the remaining net assets were contributed to the ECMC Foundation in order for ECMC Foundation to carry out the original RHEC mission.

In addition, the financial statements of the Corporation include the operations of the following component units, which are blended with the accounts of the Corporation:

PPC Strategic Services LLC (PPC): The Corporation is the sole owner of this enterprise, which was established to enable the Corporation to enter into various other business relationships.

Grider Support Services, LLC: The Corporation is the sole owner of this enterprise, which was formed to act as an MSO for physician practice services, which includes providing employees, management and administrative services.

Grider Community Gardens, LLC: This entity is wholly-owned and controlled by the Corporation and was formed for the purpose of purchasing and holding properties in proximity to the Corporation's Grider Street Campus.

1827 Fillmore, **LLC**: This entity is controlled by the Corporation and was formed for the purchase and development of property immediately adjacent to the Corporation's Grider Street campus.

Note 2. Summary of Significant Accounting Policies

Basis of accounting: The Corporation uses the accrual basis of accounting. Revenue is recognized in the period it is earned and expenses are recognized in the period incurred. Under this basis of accounting, all assets, deferred outflows of resources, liabilities and deferred inflows of resources associated with the operation of the Corporation are included in the statements of net position.

For financial accounting and reporting purposes, the Corporation follows all pronouncements of the GASB. All references to relevant authoritative literature issued by the GASB with which the Corporation must comply are hereinafter referred to generally as U.S. GAAP. The discretely presented component units, as previously described, report under Financial Accounting Standards Board (FASB) standards. As such, certain revenue recognition criteria and presentation features are different from GASB revenue recognition criteria and presentation features.

Use of estimates: The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The reserve for uncollectible accounts, contractual allowances, estimated third-party payor settlements, workers compensation reserves, malpractice reserves, net pension assets/obligations, other post-employment benefit obligations, self-insured obligations, as well as, Disproportionate Share (DSH) revenue and certain other accounts, require the use of estimates. Actual results could differ from those estimates.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Included in net patient service revenue are adjustments to prior year estimated third-party payor settlements, and their related estimated receivables and payables that were originally recorded in the period the related services were rendered, as well as adjustments to the net realization rate for collections on patient accounts receivable. These adjustments are made in the normal course of operations and amounts reported are consistent with the approach in prior years. The adjustments to prior year estimates and other third-party reimbursement or recoveries that relate to prior years also impact DSH revenues as discussed in Note 5. The combined effect of changes related to prior years' estimates resulted in an increase of \$5,472 and \$196 in total operating revenues for the years ended December 31, 2023 and 2022, respectively.

Cash and cash equivalents: The Corporation's cash and cash equivalents include cash on hand and cash in checking and money market accounts as well as investments with a maturity of three months or less when purchased. Cash and cash equivalents designated for long-term purposes or received with donor-imposed restrictions limiting their use to long-term purposes are not considered cash and cash equivalents for purposes of the statements of cash flows. Monies deposited in Federal Deposit Insurance Corporation (FDIC) insured commercial banks are collateralized with specifically designated securities held by a pledging financial institution, as required by State regulations.

Patient accounts receivable: Patient accounts receivable are reported net of both an estimated allowance for contractual adjustments and an estimated allowance for uncollectible accounts. The contractual adjustments represent the difference between established billing rates and estimated reimbursement from Medicare, Medicaid and other third-party payor programs. Current operations are charged with an estimated provision for bad debts estimated based on the age of the account, prior experience and any other circumstances which affect collectability. The Corporation's policy does not require collateral or other security for patient accounts receivable and the Corporation routinely accepts assignment of, or is otherwise entitled to receive, patient benefits payable under health insurance programs, plans or policies. The allowance for estimated doubtful accounts at December 31, 2023 and 2022 was approximately \$64,577 and \$63,414, respectively.

Investments and assets whose use is limited: The Corporation generally records its investments at fair value. Such assets are comprised of cash and cash equivalents, including money market funds, fixed income securities, commercial paper and equity funds. Assets classified as investments are unrestricted. Assets classified as limited as to use are restricted under Board designation or terms of agreements with third parties and include debt service funds, funds for self-insured workers' compensation costs and medical malpractice costs, collateral for insured workers' compensation programs, patient and resident monies, funding for future retiree health costs, and funds limited as to use for the acquisition of property, plant and equipment.

Investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is at least possible that changes in risks in the near term could materially affect the net position of ECMCC.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other receivables: The composition of other receivables, as of December 31 is as follows:

| | 2023 | 2022 |
|--|-----------------------|-----------------------|
| DSH and Upper Payment Limit (UPL) (Note 5) Due from affiliated organizations and joint ventures | \$ 28,473 1,233 | \$ 50,330 1.928 |
| Due from third-party payors Other | 6,980 3,922 | 7,524 2.648 |
| outor | \$ 40,608 | \$ 62,430 |

Capital assets: Capital assets are stated at cost. Depreciation is computed under the straight-line method over the estimated useful life of the asset. Estimated useful lives of assets have been established as follows:

| Land and land improvements | e pulle | 5-25 years |
|----------------------------|---------|-------------|
| Buildings and improvements | | 10-40 years |
| Fixed equipment | | 10-20 years |
| Major movable equipment | | 3-20 years |

When assets are retired, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected for the period. Maintenance and repairs are charged to expense as incurred with significant renewals and betterments being capitalized.

Capital assets that are donated (without restriction) are recorded at their fair market values as a direct increase to the component of net investment in capital assets.

Deferred outflows of resources: Deferred outflows of resources represent a consumption of net position that applies to a future period(s) and therefore will not be recognized as an outflow of resources (expense) until that time. Deferred outflows of resources consist primarily of unrecognized items not yet charged to pension expense and retiree health expense related to the net pension (asset)/liability and post-employment benefit obligations, and items related to the 2017 financing transaction as described below, amongst other deferred resources.

The 2017 financing transaction included the payment of points, in the amount of \$17,040 to Erie County associated with the differential in interest rate on the 2017 financing using the credit rating of Erie County and the rate that the Corporation was projected to pay independent of a relationship with Erie County. The points are being amortized on the interest method over the term of the 2017 financing. The unamortized amount of points at December 31, 2023 and 2022, is \$8,712 and \$9,836, respectively. The 2017 financing transaction also included the advance refunding of the 2011 financing, the proceeds of which were used to finance the construction of the Terrace View Nursing Home on the Corporation's campus. The deposit required to the advance refunding escrow was greater than the balance outstanding on the 2011 financing in the amount of \$2,038 and is being amortized on the interest method over the life of the advance refunding component of the transaction. The unamortized portion of this advance refunding at December 31, 2023 and 2022 is \$652 and \$834, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other assets: Amounts due from the County, as noted in Note 14, as well as ownership interests in various business enterprises are included in other assets.

Collaborative Care Ventures, LLC (Collaborative Care) was formed in 2014 by ECMCC and KH. Collaborative Care was created as a vehicle for ECMCC and KH to participate in various investments in the future consistent with their missions. At December 31, 2023 and 2022, the Corporation's share of the net assets of Collaborative Care amounted to \$1,022 and \$1,060, respectively.

Great Lakes Health Integrated Network (GLIN) was formed in 2018 by ECMCC and KH. GLIN was formed to support, manage and negotiate value-based contracts and/or risk-based contracts with third-party payors for the purpose of managing population health and anticipated payment reform. The Corporation's share of contributed capital supports organizational development and ongoing operations. The Corporation's share of GLIN's profit or loss is recognized as non-operating revenue. At December 31, 2023 and 2022, the Corporation's share of the net assets of GLIN amounted to \$4,324 and \$2,179, respectively.

Leases: The Corporation is a lessee for noncancellable leases of real estate and equipment. The Corporation recognizes a lease liability and an intangible right-to-use lease asset in the financial statements for leases. At the commencement of a lease, the Corporation measures the lease liability at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate. The lease assets are amortized over the shorter of the lease term or the underlying asset useful life.

The Corporation is also a lessor for noncancellable leases of real estate. The Corporation recognizes a lease receivable and deferred inflow of resources in the financial statements for these leases. At the commencement of the lease, the Corporation measures the lease receivable at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate.

Subscription Based Information Technology Arrangements (SBITAs): The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its SBITAs. The subscription asset is measured as the subscription liability plus direct costs incurred in implementing the subscription asset. The subscription asset is amortized on a straight-line basis over the shorter of the subscription term or the useful life of the underlying subscription asset. At the subscription commencement, the subscription liability is measured at the present value of payments expected to be made during the subscription term and utilizes the interest rate charged in the SBITA, if available, or otherwise discounted using the Corporation's incremental borrowing rate to calculate the present value of the payments.

Unearned revenue: Unearned revenue represents funds received by the Corporation for the DSRIP Program and health care transformation funds received that have not yet been earned.

Compensated absences: The Corporation has accrued liabilities for certain compensated absences earned by its employees, to include vacation, sick, and compensatory time. The Corporation's employees are permitted to accumulate unused vacation and sick leave time up to certain maximum limits. The Corporation accrues the estimated obligation related to vacation pay based on pay rates currently in effect. Sick leave credits, if accumulated above certain prescribed levels, may be the basis of a supplemental payment to employees upon retirement. The Corporation accrues an estimated liability for these estimated terminal payments. These amounts have been included in the statements of net position at December 31, 2023 and 2022, within the caption accrued salaries, wages and employee benefits in the amounts of \$17,496 and \$15,295, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Deferred inflows of resources: Deferred inflows of resources represent an acquisition of net position that applies to a future period(s) and therefore will not be recognized as an inflow of resources (revenue) until that time. Deferred inflows of resources consist primarily of the unamortized portion of certain items related to the Corporation's pension, other post-employment benefits and the value of leases receivable plus any payments received at or before the commencement of the lease term that relates to future periods.

Net position: Net position is classified into three categories according to external donor restrictions or availability of assets for satisfaction of the Corporation's obligations. The Corporation's net position is described as follows:

Net investment in capital assets: This represents the Corporation's total investment in capital assets, net of accumulated depreciation and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets. To the extent debt has been incurred but not yet expended for capital assets, such amounts are not included as a component of net investment in capital assets.

Restricted: The restricted expendable component of net position consists of constraints placed on net position through external constraints imposed by creditors (such as through debt covenants), grantors, contributors, or laws or regulations of other governments or constraints imposed by law through constitutional provisions or enabling legislation. The restricted nonexpendable component of net position is permanently unavailable for use. The earnings on the nonexpendable net position are classified as restricted expendable.

Unrestricted: This component of net position consists of net position that does not meet the definition of other components of net position described above. These resources are used for transactions relating to the general health care operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Net patient service revenue: Net patient service revenue is reported as services are rendered at estimated net realizable amounts, including estimated retroactive revenue adjustments under reimbursement agreements with third-party payors. Estimated settlements under third-party reimbursement agreements are accrued in the period the related services are rendered and adjusted in future periods as final settlements are determined. An estimated provision for bad debts is included in net patient service revenue.

Charity care: The Corporation provides care to patients who meet certain criteria under its charity care policy, without charge or at amounts less than established rates. Because the Corporation does not pursue collection of amounts determined to qualify as charity care, they are not reported as net patient service revenue in the accompanying statements of revenues, expenses and changes in net position. The estimated costs of caring for charity care patients were \$4,459 and \$4,602 for the years ended December 31, 2023 and 2022, respectively. Additionally, the Corporation provided approximately \$2,397 and \$2,517 in discounts to self-pay patients for the years ended December 31, 2023 and 2022, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Contributions: The Foundation reports gifts of cash or promises to give as restricted contributions when they are received with donor stipulations that limit the use of the donated assets. When the intent of the donor is that the assets are to remain in perpetuity and the Foundation does not have the right to invade the original principal, the assets are reported as with donor restrictions. When a donor restriction expires, restricted-expendable net positions are released to unrestricted net position. The Foundation conducted a capital campaign to raise funds to support the construction of a new Level 1 Adult Trauma Center, Emergency Department and other capital needs in support of the mission of the Corporation. Receivables for pledges associated with this campaign are recorded net of a reserve for uncollectible pledges and are discounted to present value using a 4.79% discount rate, over the expected collection period of the pledges.

Classification of revenues: The Corporation has classified its revenues as either operating or non-operating revenues according to the following criteria:

Operating revenues: Operating revenues include activities that have the characteristics of exchange transactions, such as payments for providing services and payments for goods and services received, for health care services provided to patients, net of contractual adjustments and provisions for bad debts.

Nonoperating revenues: Nonoperating revenues include activities that have the characteristics of nonexchange transactions, such as gifts and contributions, CARES Act funding, NYSDOH grant funding, Federal Emergency Management Agency (FEMA) funding, income from investments and contributions.

Income taxes: The Corporation is a Public Benefit Corporation of the State of New York and is exempt from federal income taxes under Section 115 of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements.

Contributed services: RHEC receives contributions from the Corporation consisting primarily of donated space, equipment, and personnel support. During 2023 and 2022, the value of contributed services meeting the requirements for recognition in the financial statements was not material and has not been recorded.

Certain immaterial amounts related to contributed rents have been reflected in the Foundation's financial statements as contribution revenue. The Foundation generally pays for services requiring specific expertise. However, many individuals volunteer their time and perform a variety of tasks that assist the Foundation in meeting its goals and objectives. Such services are not recognized in the Foundation financial statements.

No amounts have been reflected in the Physician Endowment financial statements for contributed services, as the value of contributed services meeting the requirements for recognition in the financial statements was not material.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Recent and pending accounting pronouncements: Effective January 1, 2022, the Corporation adopted GASB issued Statement No. 96, Subscription-Based Information Technology Arrangements. This Statement provides guidance on the accounting and financial reporting for subscription-based information technology arrangements (SBITAs) for government end users. This Statement: (1) defines a SBITA; (2) establishes that a SBITA results in a right-to-use subscription asset—an intangible asset—and a corresponding subscription liability; (3) provides the capitalization criteria for outlays other than subscription payments, including implementation costs of a SBITA; and (4) requires note disclosures regarding a SBITA. To the extent relevant, the standards for SBITAs are based on the standards established in Statement No. 87, Leases. A SBITA is defined as a contract that conveys control of the right to use another party's information technology software alone or in combination with tangible capital assets as specified in the contract for a period of time in an exchange or exchange-like transaction. See Note 8, for further details regarding the implementation of this Standard.

Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 99, *Omnibus 2022*. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing (1) practice issues that have been identified during implementation and application of certain GASB Statements and (2) accounting and financial reporting for financial guarantees. The requirements of this Statement are effective at various dates as outlined in the Statement. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

In June 2022, GASB issued Statement No. 100, Accounting Changes and Error Corrections-An Amendment of GASB No. 62. This Statement defines accounting changes as changes in accounting principles, changes in accounting estimates, and changes to or within the financial reporting entity and describes the transactions or other events that constitute those changes. As part of those descriptions, for (1) certain changes in accounting principles and (2) certain changes in accounting estimates that result from a change in measurement methodology, a new principle or methodology should be justified on the basis that it is preferable to the principle or methodology used before the change. That preferability should be based on the qualitative characteristics of financial reporting-understandability, reliability, relevance, timeliness, consistency, and comparability. This Statement also addresses corrections of errors in previously issued financial statements. The requirements of this Statement are effective for accounting changes and error corrections made in fiscal years beginning after June 15, 2023, and all reporting periods thereafter. Earlier application is encouraged. The Corporation does not anticipate the adoption of this standard will have a significant impact on the financial statements.

In June 2022, GASB issued Statement No. 101, *Compensated Absences*. The objective of this Statement is to better meet the information needs of financial statement users by updating the recognition and measurement guidance for compensated absences. That objective is achieved by aligning the recognition and measurement guidance under a unified model and by amending certain previously required disclosures. The requirements of this Statement are effective for fiscal years beginning after December 15, 2023, and all reporting periods thereafter. Earlier application is encouraged. The Corporation does not anticipate adopting this standard will have a material impact on the financial statements.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

In December 2023, GASB issued Statement No. 102, *Certain Risk Disclosures*. The objective of this Statement is to provide users of government financial statements with essential information about risks related to a government's vulnerabilities due to certain concentrations or constraints. This Statement defines a *concentration* as a lack of diversity related to an aspect of a significant inflow of resources or outflow of resources. A *constraint* is a limitation imposed on a government by an external party or by formal action of the government's highest level of decision-making authority. Concentrations and constraints may limit a government's ability to acquire resources or control spending. This Statement requires a government to assess whether a concentration or constraint makes the primary government reporting unit or other reporting units that report a liability for revenue debt vulnerable to the risk of a substantial impact. Additionally, this Statement requires a government to assess whether an event or events associated with a concentration or constraint that could cause the substantial impact have occurred, have begun to occur, or are more likely than not to begin to occur within 12 months of the date the financial statements are issued. The requirements of this Statement are effective for fiscal years beginning after June 15, 2024, and all reporting periods thereafter. Earlier application is encouraged. The Corporation has not yet determined the impact this statement will have on the financial statements

Reclassifications: Certain prior-year amounts have been reclassified to conform to the current-year presentation. Such reclassifications had no effect on previously reported operating loss/income or changes in net position.

Subsequent events: The Corporation has evaluated subsequent events for potential recognition and/or disclosure through DATE, the date the financial statements were issued.

Note 3. Coronavirus Pandemic (COVID-19)

Under certain provisions in the CARES and American Rescue Plan (ARP) Acts, the Corporation recognized benefits totaling \$8,395, in its statements of revenues, expenses and changes in net position, for the year ended December 31, 2022 (\$0 in 2023). The benefit is entirely comprised of distributions from the Provider Relief Fund established under these Acts and is recognized as non-operating revenue. During 2020, the Corporation also deferred payment of \$10,926 for the employer portion of the Social Security payroll taxes as allowed by the CARES Act. In accordance with the CARES Act, 50% of the deferred payroll tax was paid on January 3, 2022, with the remainder paid on January 3, 2023.

Under the CARES Act, the Centers for Medicare & Medicaid Services (CMS) expanded the Medicare Accelerated and Advance Payment Program to provide necessary funds to Medicare providers to assist with the disruption in claims submission and claims processing. During 2020, the Corporation received advance payments under this program totaling \$39,101. As of December 31, 2022, Medicare had recouped the advance in its entirety with \$20,879 recouped during 2022 and \$18,222 recouped in prior years.

The CARES Act also includes financial relief through FEMA's Disaster Relief Fund. The Corporation has received \$3,829 and \$2,757 from FEMA to reimburse eligible incremental expenses as a result of COVID-19 during the years ended December 31, 2023 and 2022, respectively. The Corporation will continue to submit for grant reimbursement for any remaining eligible COVID-19 expenses under this program. Costs claimed under FEMA may not be reimbursed by any other funding source or payor, and may not be claimed though Provider Relief Funds (PRF) or other grants.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable

The Corporation has agreements with third-party payors that provide for payment to the Corporation at amounts different from its established rates. A summary of the payment arrangements for hospital services with major third-party payors is as follows:

Medicare: Inpatient acute care services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge and per patient day depending on the service. Acute care rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Certain inpatient and outpatient services, as well as defined organ acquisition, capital and medical education costs related to Medicare beneficiaries are paid based on regulatory proscribed formulae. The Corporation is reimbursed for such items at a tentative rate with final settlement determined after submission of annual cost reports by the Corporation and audits thereof by the Medicare fiscal intermediary. The Corporation's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Corporation. Most outpatient reimbursements are based on an Ambulatory Payment Classification weighting by acuity system, although some outpatient cost reimbursement still exists.

Medicaid: Inpatient services rendered to Medicaid program beneficiaries are reimbursed at prospectively determined rates in accordance with Part 86 of the New York Codes, Rules and Regulations and New York State Law which are promulgated by the New York State Department of Health (DOH). Outpatient services are similarly paid at either prospective rates or fee schedule amounts.

Under the New York Health Care Reform Act, the Corporation also enters into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Corporation under these agreements includes prospectively determined rates, discounts from charges, and prospectively determined per diem rates. Medicaid, Workers' Compensation and No-fault continue to have reimbursement rates determined based on New York's Prospective Reimbursement Methodology.

Terrace View provides services to residents under agreements with third-party payors (Medicaid, Medicare and HMO's) under provisions of their respective cost reimbursement formulas or contractually negotiated rates. If amounts received are less than established billing rates, the difference is accounted for as a reduction of revenue. Final determination of the reimbursement rates are subject to review by appropriate third-party payors. Provisions are made in the financial statements for anticipated adjustments that may result from such reviews. The difference between the estimated amounts accrued and final settlements are reported in operations in the year of settlement.

Net patient service revenue, as reported on the statements of revenues, expenses and changes in net position, is comprised of the following for the years ended December 31:

| | 2023 | 2022 |
|--------------------------|--------------|--------------|
| Gross charges | \$ 1,673,523 | \$ 1,514,854 |
| Less: | | |
| Discounts and allowances | 1,064,847 | 932,991 |
| Provision for bad debts | 4,956 | 15,474 |
| | \$ 603,720 | \$ 566,389 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable (Continued)

Net patient service revenue by payor for the years ended December 31 is as follows:

| | 2023 | | | | 2022 | | | |
|---|------|---------|-----|------|------|---------|--|--------|
| | | Amount | % | % | | Amount | | % |
| Medicare* | \$ | 247,282 | 41 | 1.0% | \$ | 229,412 | | 40.5% |
| Medicaid* | | 164,815 | 27 | 7.3% | | 156,183 | | 27.6% |
| Commercial and other third-party payors | | 164,704 | 27 | 7.3% | | 153,322 | | 27.1% |
| No-fault | | 20,452 | 3 | 3.4% | | 23,968 | | 4.2% |
| Self-pay | | 6,467 | 1 | 1.0% | | 3,504 | | 0.6% |
| | \$ | 603,720 | 100 | 0.0% | \$ | 566,389 | | 100.0% |

^{*}Medicare and Medicaid include Managed Care plans.

Laws and regulations governing Medicare, Medicaid, and other third-party payor programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in future periods. The Corporation believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs.

Patient accounts receivable consist of the following at December 31:

| | 2023 | 2022 |
|--|-------------------|-------------------|
| Gross accounts receivable Less: | \$ 295,805 | \$ 271,115 |
| Discounts and allowances Allowance for bad debts | 128,839 64,577 | 124,132 63,414 |
| | \$ 102,389 | \$ 83,569 |

Concentration of credit risk: The Corporation grants credit without collateral to its patients, most of whom are insured under third-party payor arrangements. The mix of net receivables from patients and third-party payors at December 31 is as follows:

| | 2023 | 2022 |
|---|--------|--------|
| Madiagra* | 22.20/ | 25.60/ |
| Medicare* | 33.2% | 35.6% |
| Commercial and other third party payors | 32.7% | 27.7% |
| Medicaid* | 27.8% | 32.1% |
| No-fault | 5.5% | 3.7% |
| Self-pay | 0.8% | 0.9% |
| Total | 100.0% | 100.0% |

^{*}Medicare and Medicaid include Managed Care plans.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 5. Disproportionate Share (DSH) Revenue

The Medicaid DSH program is designed to provide funds to certain hospitals to help offset the cost of uncompensated care provided to the uninsured. Each state has a specified Federal DSH allotment. In addition, New York State law authorizes the New York State Department of Health (DOH) to make supplemental DSH medical assistance payments to public hospitals located in Erie County, Nassau County, and Westchester County. For long term care facilities, DSH revenue is recognized in accordance with Upper Payment Limit (UPL) regulations promulgated by the Centers for Medicare and Medicaid Services (CMS).

In 2023 and 2022, DSH funding recorded by the Corporation totaled \$107,105 and \$68,295, respectively. The DSH funding process is complex and includes both tentative and final settlements for various state fiscal years which are subject to the availability of state and federal funding among other factors. As a result, DSH revenue is estimated and final settlements may vary significantly from the initial estimates.

For hospital services, DSH revenue of \$91,220 and \$58,295 was recognized in 2023 and 2022, respectively. In addition, during 2023 and 2022, the Corporation recognized \$15,885 and \$10,000, respectively, of UPL revenue for Terrace View. UPL revenue has been recognized based off New York State fiscal year 2023-2024, as determined by the DOH, using cost report year 2021 data.

CMS has indicated that cost reports dating back to the 2021 reporting year and the methodology employed to calculate DSH revenue are subject to audit for those years. Additionally, on February 24, 2024 CMS published the final rule addressing recent legislative changes to the Social Security Act, which changed hospital specific Medicaid DSH payment formulas. At this time, the impact of the CMS audit activity, and any DSH payment formula changes including implementation timing are not certain. Management has taken what it believes to be reasonable and appropriate steps to assure compliance with the CMS methodology.

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited

Cash and cash equivalents and investments: The Corporation's investments are made in accordance with State regulations and its own investment policy. The investment policy is regularly reviewed by an investment committee of the Board which evaluates the performance of investment managers and monitors compliance with the investment policy.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

The Corporation's investments are generally reported at fair value, as discussed in Note 2. The carrying amounts of cash and cash equivalents, investments and assets whose use is limited are included in the Corporation's statements of net position as follows:

| | 2023 | | | 2022 |
|--|---------|---------------------------------------|----|-------------------------------------|
| Cash and cash equivalents Investments Assets whose use is limited—current Assets whose use is limited—noncurrent | \$ | 20,773 10,646 113,986 56,635 | \$ | 44,195 7,253 99,078 58,438 |
| | \$ | 202,040 | \$ | 208,964 |
| Current portion of assets whose use is limited: Patient and residents trust cash |) \$ | 726 | \$ | 362 |
| Restricted for debt service (a) | | 13,570 | * | 2,360 |
| Designated for self-insurance obligations (b) | | 8,998 | | 9,356 |
| Designated for retiree health obligations (b) | | 12,326 | | 12,061 |
| Designated for DSRIP program (b) | | 71,684 | | 68,534 |
| NYS voluntary defined contribution plan escrow | | 49 | | 129 |
| Medical and dental staff funds | | 1,121 | | 1,004 |
| Restricted—self-insured workers' compensation collateral (d) | | 5,512 | | 5,272 |
| Total current portion of assets whose use is limited | \$ | 113,986 | \$ | 99,078 |
| Noncurrent portion of assets whose use is limited: | | | | |
| Restricted for debt service (a) | \$ | 10,302 | \$ | 9,825 |
| Designated for long-term investment (b) | | 5,091 | | 9,099 |
| Designated for retiree health obligations (b) | | 12,505 | | 12,770 |
| Designated for self-insurance obligations ^(b) | | 24,075 | | 21,808 |
| Restricted—insured workers' compensation collateral (c) | | 4,662 | | 4,936 |
| Total noncurrent portion of assets whose use is limited | \$ | 56,635 | \$ | 58,438 |

⁽a) Funds restricted by operation of indenture agreement

⁽b) Funds internally designated by operation of Board authority

⁽c) Funds restricted—insured workers' compensation collateral agreement

⁽d) Funds restricted—self-insured workers' compensation collateral agreements

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

The Corporation's cash and cash equivalents, as well as investments, are exposed to various risks, including credit, custodial credit, interest rate and market risks, as discussed in more detail below:

Deposits

All monies are deposited with banks or trust companies designated by the Corporation's investment committee of the Board of Directors. Funds not needed for immediate expenditure may be deposited in interest or non-interest-bearing accounts or invested in various marketable securities and bonds.

Custodial credit risk: Custodial credit risk is the risk that, in the event of bank failure, the Corporation's deposits might not be recovered. FDIC insurance through December 31, 2023 for funds held in interest bearing accounts is \$250 per depositor per category of legal ownership. New York law requires that deposits in excess of FDIC insured amounts are collateralized. The Corporation's bank deposits at December 31, 2023 and 2022, totaled \$27,068 and \$50,760, of which \$1,030 and \$1,043, respectively, were insured. Amounts over FDIC insured limits were fully collateralized with securities held by the pledging financial institution.

Investments

The Corporation's investment policy authorizes the Corporation to invest in accordance with New York State Finance Law Section 8(14), Section 201 and Public Authorities Law Article 9 Section 2800 to 2985, as well as the relevant provisions of the ECMCC Act. Compliance with the policy is monitored by the Corporation's investment committee and reported on regularly throughout the year by the Corporation's investment advisor.

Credit risk: Credit risk is the risk that the issuer or other counterparty to an investment will not fulfill its obligation, causing the Corporation to experience a loss of principal. The Corporation's investment policy limits investments in equity and fixed income securities with ratings only in the highest category. ECMCC's investments in government bonds carry the explicit guarantee of the U.S. government. The corporate bonds, short-term fixed income and government bonds are all rated AA+ or better by the Standards & Poor's rating agency.

Interest rate risk: Interest rate risk is the risk that changes in interest rates will adversely affect the fair value of an investment. The Corporation's cash equivalent securities are limited to maturities of no greater than eighteen months; short-term fixed income securities are limited to maturities of no greater than five years; and long-term fixed income securities are limited to maturities to no more than ten years. Substantially all of the Corporation's investments and assets whose use is limited have stated maturities of less than one year.

Custodial credit risk: For an investment, custodial credit risk is the risk that, in the event of the failure of the counterparty, the Corporation will not be able to recover the value of its investments or collateral securities that are in the possession of an outside party. The Corporation's investment policy does not address custodial credit risk.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

Concentration of credit risk: Concentration of credit risk is the risk of loss attributable to the magnitude of investments in any single issuer. The Corporation's investment policy indicates the combined holdings of securities from one issuer shall not constitute more than 5.0% of the fund except for issues guaranteed directly or indirectly by the U.S. Government. The Corporation had no holdings in Federal National Mortgage Association (Fannie Mae) or Federal Home Loan Mortgage Corporation (Freddie Mac) issues at December 31, 2023 and 2022.

Fair value of financial instruments: Fair value is defined in the accounting standards as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy established by GASB. Assets carried at fair value are required to be classified and disclosed in one of the following three categories:

- **Level 1:** Valuations based on quoted prices in active markets for identical assets that the Corporation has the ability to access.
- **Level 2:** Valuations based on quoted prices in active markets for similar assets, quoted prices in markets that are not active or for which all significant inputs are observable, directly or indirectly. The Corporation has no Level 2 assets.
- **Level 3:** Valuations based on inputs that are unobservable and significant to the overall fair value measurement. These are generally company generated inputs and are not market-based inputs. The Corporation has no Level 3 assets.

| | 2023 | | | | | | | | | |
|--|------|---------|----|---------|----|---------|----|---------|--|--|
| | | Level 1 | | Level 2 | | Level 3 | | Total | | |
| Cash and cash equivalents | \$ | 20,773 | \$ | - | \$ | - | \$ | 20,773 | | |
| Investments and assets whose use is limited: | | | | | | | | | | |
| Cash and cash equivalents Marketable equity securities: | | 115,448 | | - | | - | | 115,448 | | |
| Small/Mid cap equities | | 4,423 | | - | | - | | 4,423 | | |
| Growth equities | | 1,447 | | - | | - | | 1,447 | | |
| Core equities | | 9,921 | | - | | - | | 9,921 | | |
| International equities | | 10,190 | | - | | - | | 10,190 | | |
| U.S. fixed income | | 39,838 | | - | | - | | 39,838 | | |
| Total investments and assets | | | | | | | | | | |
| whose use is limited | | 181,267 | | - | | - | | 181,267 | | |
| Total | \$ | 202,040 | \$ | - | \$ | - | \$ | 202,040 | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

| | 2022 | | | | | | | | | |
|--|-------|---------|-------|--------|--------------|----|---------|--|--|--|
| | | Level 1 | Le | evel 2 | Level 3 | | Total | | | |
| Cash and cash equivalents | \$ | 44,195 | \$ | - | \$ - | \$ | 44,195 | | | |
| Investments and assets whose use is limited: | | | | | | | | | | |
| Cash and cash equivalents Marketable equity securities: | | 96,213 | | - | - | | 96,213 | | | |
| Small/Mid cap equities | | 4,117 | | _ | | | 4,117 | | | |
| Growth equities | | 1,459 | | - | ~ U'- | | 1,459 | | | |
| Core equities | | 9,070 | | - 6 | - | | 9,070 | | | |
| International equities | | 10,330 | | AMO O | - | | 10,330 | | | |
| U.S. fixed income | | 43,580 | P | Ma ā | - | | 43,580 | | | |
| Total investments and assets | M | AL RE | M. | 10 | | | | | | |
| whose use is limited | 11112 | 164,769 | | 1019 | | | 164,769 | | | |
| Total | \$ | 208,964 | \$ 31 | - a @ | \$ - | \$ | 208,964 | | | |

Note 7. Capital Assets, Net

Capital asset activity for the years ended December 31 is as follows:

| | E | Beginning | | | | Disposals/ | | Ending |
|--|----|-----------|----|-----------|----|------------|----|-----------|
| | | Balance | | Additions | - | Transfers | | Balance |
| Capital assets—being depreciated: | | | | | | | | |
| Land and land improvements | \$ | 41,166 | \$ | 31 | \$ | - | \$ | 41,197 |
| Buildings and improvements | | 545,092 | | 2,882 | | - | | 547,974 |
| Fixed/major moveable equipment | | 151,523 | | 5,096 | | (165) | | 156,454 |
| Total capital assets—being depreciated | | 737,781 | | 8,009 | | (165) | | 745,625 |
| deprediated | | 737,701 | | 0,003 | | (100) | | 740,020 |
| Less accumulated depreciation | | (461,308) | | (32,001) | | 165 | | (493,144) |
| Total capital assets—being depreciated, net | | 276,473 | | (23,992) | | - | | 252,481 |
| Capital assets—not being depreciated: | | | | | | | | |
| Construction in progress | | 21,643 | | 3,165 | | (16,382) | | 8,426 |
| Capital assets, net, excluding lease and SBITA assets | \$ | 298,116 | \$ | (20,827) | \$ | (16,382) | \$ | 260,907 |
| Lease and SBITA assets, net (Note 8) | | | | | | | \$ | 52,132 |
| Total capital assets, net, as reported in statements of net position | | | | | | | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 7. Capital Assets, Net (Continued)

| | 2022 | | | | | | | | |
|--|-----------|------------------------------|----|-----------------------|------|------------------------------|----|------------------------------|--|
| | Beginning | | | Disposals/ | | | | Ending | |
| | | Balance | - | Additions | | Fransfers | | Balance | |
| Capital assets—being depreciated: Land and land improvements Buildings and improvements Fixed/major moveable equipment | \$ | 41,624 547,713 160,780 | \$ | 525 4,763 5,632 | \$ | (983) (7,384) (14,889) | \$ | 41,166 545,092 151,523 | |
| Total capital assets—being depreciated | | 750,117 | | 10,920 | | (23,256) | | 737,781 | |
| Less accumulated depreciation | | (448,779) | | (34,911) | | 22,382 | | (461,308) | |
| Total capital assets—being depreciated, net | | 301,338 | | (23,991) | @(P) | (874) | | 276,473 | |
| Capital assets—not being depreciated: | | | | | | | | | |
| Construction in progress | | 19,699 | | 8,216 | | (6,272) | | 21,643 | |
| Capital assets, net, excluding lease and SBITA assets | \$ | 321,037 | \$ | (15,775) | \$ | (7,146) | \$ | 298,116 | |
| Lease and SBITA assets, net (Note 8) | | | | | | : | \$ | 61,270 | |
| Total capital assets, net, as reported in statements of net position | | | | | | | | 359,386 | |

Construction in progress at December 31, 2023 and 2022, includes costs associated with various mechanical, electrical and information-technology security projects. The costs associated with an ambulatory electronic medical records system project of \$11,239 were written off during the year ended December 31, 2023 and recorded within purchased services expenses within the statements of revenues, expenses and changes in net position.

Depreciation expense amounted to \$32,001 and \$34,911 for the years ended December 31, 2023 and 2022, respectively.

Note 8. Leases and Subscription-Based Information Technology Arrangements

The Corporation is a lessee for various noncancellable leases of real estate and equipment. The expected lease payments are discounted using the interest rate charged on the lease, if available, and are otherwise discounted using the Corporation's incremental borrowing rate. The right-to-use assets are amortized over the shorter of the lease term or the underlying asset useful life. Lease assets are reported within capital assets and lease and SBITA liabilities are reported separately in the statements of net position.

Effective January 1, 2022, the Corporation adopted GASB Statement No. 96, *Subscription-Based Information Technology Arrangements (SBITAs)*. This Statement provides guidance on the accounting and financial reporting for SBITAs for government end users. The implementation of this Statement required the restatement of certain expenses and the change in net position in the December 31, 2022 financial statements.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its subscription-based information technology agreements with others. These arrangements have terms requiring monthly, quarterly or annual payments. The expected payments are discounted using the interest rate charged on the arrangement, if available, or are otherwise discounted using the Corporation's incremental borrowing rate.

Right-to-use assets by major class and the related accumulated amortization for the years ended December 31 is summarized as follows:

| | | | | | | 2023 | | |
|--|---|--------------------|------|-----------|-------------|-------------------|-------------|-------------------|
| | | eginning alance | | Additions | Rem | easurements | Retirements | Ending Balance |
| Lease assets being amortized: | | | | | 9 | | 000 | |
| Real estate | \$ | 13,969 | \$ | 718 | \$ | | \$ 2,760 | \$ 11,927 |
| Equipment | | 34,696 | | 3,950 | | 1,413 | - | 40,059 |
| Total lease assets being amortized | | 48,665 | 1 | 4,668 | TRI | 1,413 | 2,760 | 51,986 |
| Less accumulated amortization: | | | | | | | | |
| Real estate | | 2,603 | | 1,156 | | - | 1,069 | 2,690 |
| Equipment | WMI | 16,008 | 300 | 6,917 | | 4 | - | 22,925 |
| Total accumulated amortization | 7/10 | 18,611 | | 8,073 | | | 1,069 | 25,615 |
| Lease assets, net | | 30,054 | 3(() | (3,405) | 10) | 1,413 | 1,691 | 26,371 |
| Subscription-based information technology assets | | 39,473 | | 4,349 | | _ | - | 43,822 |
| Accumulated amortization | | 8,257 | | 9,804 | | - | - | 18,061 |
| Subscription-based information technology assets, net | 7110 | 31,216 | 2 / | (5,455) | | - | - | 25,761 |
| Lease and SBITA assets, | | (0) | 9 | , | | | | |
| net of accumulated amortization | \$ { | 61,270 | \$ | (8,860) | \$ | 1,413 | \$ 1,691 | \$ 52,132 |
| | OR | | | | | | | |
| | | | | | | 202 | 2 | |
| | Beginning Balance Additions Remeasurements Retire | | | | Retirements | Ending Balance | | |
| Lease assets being amortized: | | alarice | | Additions | IXCIII | casurements | Retirements | Dalarice |
| Real estate | \$ | 13,541 | \$ | 428 | \$ | - | \$ - | \$ 13,969 |
| Equipment | | 26,194 | | 8,502 | | - | - | 34,696 |
| Total lease assets being amortized | | 39,735 | | 8,930 | | - | - | 48,665 |
| Less accumulated amortization: | | | | | | | | |
| Real estate | | 1,410 | | 1,193 | | - | - | 2,603 |
| Equipment | | 10,546 | | 5,462 | | - | - | 16,008 |
| Total accumulated amortization | | 11,956 | | 6,655 | | - | - | 18,611 |
| Lease assets, net | | 27,779 | | 2,275 | | - | - | 30,054 |
| Subscription-based information technology assets | | 34,370 | | 5,103 | | _ | _ | 39,473 |
| Accumulated amortization | | - | | 8,257 | | - | - | 8,257 |
| Subscription-based information technology assets, net Lease and SBITA assets. | | 34,370 | | (3,154) | | - | - | 31,216 |
| Lease and SBITA assets, net of accumulated amortization | \$ | 62,149 | \$ | (879) | \$ | - | \$ - | \$ 61,270 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

As of December 31, 2023, the principal and interest requirements to maturity for the lease liability are as follows:

| | Principal | Interest | | Total |
|-----------|-----------|--------------|----|--------|
| 0004 | Φ 7.005 | Φ 000 | Φ. | 0.000 |
| 2024 | \$ 7,685 | \$ 923 | \$ | 8,608 |
| 2025 | 5,794 | 655 | | 6,449 |
| 2026 | 3,916 | 447 | | 4,363 |
| 2027 | 2,549 | 303 | | 2,852 |
| 2028 | 1,543 | 205 | | 1,748 |
| 2029-2033 | 3,669 | 538 | | 4,207 |
| 2034-2038 | 1,484 | 59 | | 1,543 |
| | \$ 26,640 | 3,130 | \$ | 29,770 |

As of December 31, 2023, the principal and interest requirements to maturity for the SBITA liability are as follows:

| | N. | Principal | Jul II | nterest | Total | | |
|--------------|----|----------------|-----------|------------|-------|----------------|--|
| 2024 | \$ | 8,724 | \$ | 800 | \$ | 9,524 | |
| 2025 2026 | | 7,129 5,568 | | 475 218 | | 7,604 5,786 | |
| 2027 | | 2,846 | | 49 | | 2,895 | |
| 2028 | | 135 | | 3 | | 138 | |
| 2029-2033 | | 49 | | 1 | | 50 | |
| | \$ | 24,451 | \$ | 1,546 | \$ | 25,997 | |

Lessor: The Corporation leases real estate to external parties. In accordance with GASB Statement No. 87, *Leases*, the Corporation records lease receivables and deferred inflows of resources based on the present value of expected receipts over the term of the respective leases. The Corporation recognized lease receivables (reported within other assets in the statements of net position) of \$753 and \$501 at December 31, 2023 and 2022, respectively, deferred inflows of resources of \$1,666 and \$1,440 at December 31, 2023 and 2022, respectively, and lease revenue of \$632 and \$931 during the years ended December 31, 2023 and 2022, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 9. Accrued Other Liabilities

The composition of accrued other liabilities as of December 31 is as follows:

| | _ | 2023 | | 2022 | |
|---|-------|------|--------|------|--------|
| Due to Erie County | | \$ | 12,767 | \$ | 11,880 |
| Due to joint venture | | | 326 | | 767 |
| Medical malpractice claims | | | 1,792 | | 1,800 |
| Estimated third-party payor settlements | | | 4,486 | | 2,736 |
| Asset retirement obligations | | | 2,167 | | 2,118 |
| Workers compensation claims | | | 7,416 | | 7,556 |
| Other | 757 | | 13,067 | 705 | 13,256 |
| Total | - AFI | \$ | 42,021 | \$ | 40,113 |

GASB Statement No. 83, Certain Asset Retirement Obligations, establishes criteria for determining the timing and pattern of recognition of a liability and a corresponding deferred outflow of resources for asset retirement obligations (AROs). An ARO is a legally enforceable liability associated with the retirement of a tangible capital asset. In accordance with this Statement, the Corporation completes an analysis of assets meeting the criteria of an ARO for specific types of medical equipment such as medical imaging equipment (e.g., MRIs, CT scanners, and PET scanners), X-Rays, and ultrasounds as well as computers containing information protected by HIPAA laws, and certain types of laboratory equipment. In addition, the Corporation evaluates the requirements for disposal of underground fuel and lab acid tanks. The Corporation determined, based on industry standards for disposition of similar assets, the total asset retirement obligation totaled \$2,167 and \$2,118 at December 31, 2023 and 2022, respectively. The assets have a remaining useful life ranging from 0 to 30 years. This obligation is discounted using a rate of 4.0% and an inflation factor of 3.0% at December 31, 2023 and 2022.

Note 10. Indebtedness

Long-term debt consisted of the following at December 31:

| Erie County—Guaranteed Senior | | | | | |
|--------------------------------|--|--|--|--|--|
| Revenue Bonds, Series 2004 | | | | | |
| Erie County—2017 loan payable | | | | | |
| Erie County—2017 loan payable | | | | | |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | | | | | |
| Finance obligations | | | | | |
| Total debt | | | | | |

| | | | | | 2023 | | | | | |
|----|----------|----|---------|-------------|----------|---------|---------|----------|------------|--|
| В | eginning | | | Payments/ | | | Ending | | Due Within | |
| E | Balance | Ad | ditions | Forgiveness | | Balance | | One Year | | |
| | | | | | | | | | | |
| \$ | 61,135 | \$ | - | \$ | (4,165) | \$ | 56,970 | \$ | 4,390 | |
| | 90,154 | | - | | (2,780) | | 87,374 | | 2,849 | |
| | 53,235 | | - | | (4,159) | | 49,076 | | 4,271 | |
| | | | | | | | | | | |
| | 7,505 | | - | | (231) | | 7,274 | | 237 | |
| | 2,328 | | - | | (379) | | 1,949 | | 381 | |
| \$ | 214,357 | \$ | - | \$ | (11,714) | \$ | 202,643 | \$ | 12,128 | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

| | | | 2022 | | |
|--------------------------------|------------|-----------|-------------|------------|------------|
| | Beginning | | Payments/ | Ending | Due Within |
| | Balance | Additions | Forgiveness | Balance | One Year |
| Erie County—Guaranteed Senior | | | _ | | |
| Revenue Bonds, Series 2004 | \$ 65,080 | \$ - | \$ (3,945) | \$ 61,135 | \$ 4,165 |
| Erie County—2017 Ioan payable | 92,867 | - | (2,713) | 90,154 | 2,780 |
| Erie County—2017 Ioan payable | 57,286 | - | (4,051) | 53,235 | 4,159 |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | 7,731 | - | (226) | 7,505 | 231 |
| Finance obligations | 2,710 | - | (382) | 2,328 | 381 |
| Total debt | \$ 225,674 | \$ - | \$ (11,317) | \$ 214,357 | \$ 11,716 |
| | | _ | TVD TI | 9 | |

Future annual principal payments applicable to long-term debt for the years subsequent to December 31, 2023 are as follows:

| 2024 2025 2026 2027 2028 2029-2033 2034-2038 2039-2042 | \$ 12,128 12,565 13,025 13,507 14,008 76,818 54,603 5,989 |
|---|---|
| Total | \$ 202,643 |

The Series 2004 Bonds are secured by a pledge of the gross receipts of the Corporation and amounts on deposit in certain debt service reserve funds. Interest rates on the bonds range from 5.5% to 5.7%, with principal payments ranging from \$4,165 to \$7,220 due annually on November 1 with interest payments due semi-annually on May 1 and November 1.

Pursuant to a Guaranty Agreement, the County has unconditionally guaranteed to the Corporation, the punctual payment of the principal, interest, and redemption premium, if any, on the Series 2004 Bonds, as the same shall become due and payable, and has pledged the faith and credit of the County for the performance of such guaranty. A municipal bond insurance policy has been purchased by the Corporation to guarantee all debt service payments in case of default by the Corporation and the County.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie, with the assistance of the Erie County Fiscal Stability Authority. The proceeds of the loan were used to finance the construction of a new Level 1 Adult Trauma Center and Emergency Department, fund various other capital projects on the Corporation's campus as well as refinance a 2011 loan. The loan has an interest rate of 3.377% with monthly principal and interest payments ranging from \$474 to \$930 during the term of the loan. In addition to the loan, the Corporation assumed the liability related to funds borrowed to pay capitalized interest during construction on the various projects noted above. The capitalized interest liability assumption has an interest rate of 3.377% with monthly principal and interest payments ranging from \$40 to \$77 during the term of the loan. The new money portion of the loan and the capitalized interest assumption agreement is fully amortized and matures in 2039. The refinancing component of the loan has an interest rate of 2.649% with monthly principal and interest payments ranging from \$300 to \$460 during the term of the loan and is fully amortized and maturing in 2034.

During 2018, the Corporation entered into a finance obligation agreement in the amount of \$2,044, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$29 and matures September 2025.

During 2018, the Corporation entered into a second finance obligation agreement in the amount of \$409, the proceeds of which were used to purchase various suite improvements. The agreement required principal and interest payments (cost of capital is estimated at 3.8%) of \$4 and was paid in full during 2023.

During 2019, the Corporation entered into a finance obligation agreement in the amount of \$1,805, the proceeds of which were used to finance various cafeteria improvements. The agreement requires principal and interest payments (cost of capital ranges from 0% to 9.0%) of \$17 and matures March 2029.

During 2020, the Corporation entered into a finance obligation agreement in the amount of \$2,555, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$39 and matures July 2026.

During 2021, the Corporation entered into a finance obligation agreement in the amount of \$1,552, the proceeds of which were used to finance a new food service line. The agreement requires principal and interest payments (cost of capital is 4.0%) of \$19 and matures in December 2028.

During 2021, the Corporation signed an agreement for an unsecured revolving line of credit with an original maturity date of November 2022 and was amended and extended to May 2024. The Corporation has available \$10,000 with interest payable at a variable rate of daily Secured Overnight Financing Rate (SOFR) plus 183 basis points. There was \$10,000 of outstanding borrowings against the line at December 31, 2023 and 2022, respectively. Management is currently negotiating an extension for the maturity date of this agreement.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan

Retirement plan: The Corporation participates in the New York State and Local Retirement System (NYSLRS or the System), which is a cost-sharing, multiple-employer public employees' retirement system. There are more than 515,000 pensioners and beneficiaries in the System with over 1.2 million participants.

For purposes of measuring the net pension liability (asset), deferred outflows of resources and deferred inflows of resources related to pensions, and pension expense/benefit, information about the fiduciary net position of the NYSLRS and additions to/deductions from NYSLRS' fiduciary net position have been determined on the same basis as they are reported by NYSLRS. For this purpose, benefit payments (including refunds of employee contributions) are recognized when due and payable in accordance with the benefit terms. The net pension liability (asset) is measured as the portion of the present value of projected benefit payments to be provided through the pension plan to current active and inactive employees that is attributed to those employees' past periods of service (total pension liability), less the amount of the pension plan's fiduciary net position. The net pension liability (asset) should be measured as of a date (measurement date) no earlier than the end of the employer's prior fiscal year, consistently applied from period to period.

Obligations of employers and employees to contribute and benefits to employees are governed by the New York State Retirement and Social Security Law (RSSL). As set forth in the RSSL, the Comptroller of the State of New York (the Comptroller) serves as sole trustee and administrative head of the System. The Comptroller shall adopt and may amend rules and regulations for the administration and transaction of the business of the System and for custody and control of its funds. The System issues a publicly available financial report that includes financial statements and required supplementary information. That report may be obtained by writing to the New York State and Local Retirement System, 110 State Street, Albany, NY 12244.

NYSLRS provides three main types of retirement benefits: service retirements, ordinary disability retirements (non-job-related disabilities), and accident disability retirements (job-related disabilities) to members who are in different Tiers. The members' Tier is determined by the date of membership. Subject to certain conditions, members generally become fully vested as to benefits upon the completion of five years of service depending on their Tier. Employees may be required to contribute a percentage of their salary to the pension plan based on their Tier, determined by their date of membership in the plan. Annual pension benefits can be calculated as a percentage of final average salary times number of years of service and changes with the number of years of membership within the plan.

At December 31, 2023 and 2022, the Corporation reported a liability of \$198,936 and an asset of \$77,538, respectively, for its proportionate share of the NYSLRS net pension liability (asset). The total pension liability (asset) used to calculate the net pension liability (asset) is determined by an actuarial valuation as of April 1st each year and rolled forward to March 31st. The Corporation's proportion for the net pension liability (asset) for each fiscal year was based on the Corporation's indexed present value of future compensation to NYSLRS of all participating employers for 2023 and 2022, which was 0.9277% and 0.9485%, respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(a) Actuarial Assumptions

The total pension liability for the March 31, 2023 measurement date was determined using an actuarial valuation as of April 1, 2022, with update procedures used to roll-forward the total pension liability to March 31, 2023. The actuarial valuations used the following actuarial assumptions:

Inflation 2.9% Salary increases 4.4%, including inflation Investment rate of return 5.9%, net of pension plan investment expense Cost of living adjustments

Mortality improvement Society of Actuaries Scale MP-2021

The total pension asset for the March 31, 2022, measurement date was determined using an actuarial valuation as of April 1, 2021, with update procedures used to roll-forward the total pension liability to March 31, 2022. The actuarial valuations used the following actuarial assumptions:

Inflation 2.7% Salary increases 4.4%, including inflation Investment rate of return 5.9%, net of pension plan investment expense Cost of living adjustments Mortality improvement

Society of Actuaries Scale MP-2020

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(b) Expected Rate of Return on Investments

The long-term expected rate of return on pension plan investments was determined using a building-block method in which best-estimate ranges of expected future real rates of return (expected return, net of investment expenses and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target allocation and best estimates of arithmetic real rates of return for each major asset class are summarized in the following tables at December 31:

| _ | 2023 | | | |
|---|------------------|----------------|--|--|
| | Target Long-Term | | | |
| | Asset | Expected Real | | |
| Asset class | Allocation | Rate of Return | | |
| | 20.00/ | 4.00/ | | |
| Domestic equity | 32.0% | 4.3% | | |
| International equity | 15.0% 10.0% | 6.9% 7.5% | | |
| Private equity Real estate | 9.0% | 4.6% | | |
| Fixed income | 23.0% | 1.5% | | |
| Credit | 4.0% | 5.4% | | |
| Real assets | 3.0% | 5.8% | | |
| Opportunistic/absolute return strategy | 3.0% | 5.4% | | |
| Cash | 1.0% | 0.0% | | |
| | 100.0% | | | |
| | | | | |
| _ | 20 | 22 | | |
| | Target | Long-Term | | |
| | Asset | Expected Real | | |
| Asset class | Allocation | Rate of Return | | |
| Demostic equity | 32.0% | 3.3% | | |
| Domestic equity International equity | 32.0% 15.0% | 5.9% | | |
| Private equity | 10.0% | 6.5% | | |
| Real estate | 9.0% | 5.0% | | |
| Fixed income | 23.0% | 0.0% | | |
| Credit | 4.0% | 3.8% | | |
| Real assets | 3.0% | 5.6% | | |
| Opportunistic/absolute return strategy | 3.0% | 4.1% | | |
| • | 0.070 | | | |
| Cash _ | 1.0% | -1.0% | | |
| Cash | | | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(c) Discount Rate

The discount rate used to measure the total pension liability (asset) as of December 31, 2023 and 2022 was 5.9%. The projection of cash flows used to determine the discount rate assumes that contributions from plan members will be made at the current contribution rates and that contributions from employers will be made at statutorily required rates, actuarially determined. Based on those assumptions, the NYSLRS fiduciary net position was projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on NYSLRS investments was applied to all periods of projected benefit payments to determine the total pension liability (asset).

Sensitivity of the Net Pension Liability (Asset) to the Discount Rate

The following presents the Corporation's proportionate share of the net pension liability (asset) calculated using the discount rate of 5.9% at December 31, 2023 and 2022, as well as what the Corporation's proportionate share of the net pension liability (asset) would be if it were calculated using a discount rate that is one percentage point lower or one percentage point higher than the current rate:

| | | | | 2023 | | |
|--|-----|------------|-----|-------------|--------|------------|
| | 19 | 6 Decrease | Dis | scount Rate | 19 | % Increase |
| | G | (4.9%) | | (5.9%) | (6.9%) | |
| Corporation's proportionate share of the | @ 1 | Mo II | | | | _ |
| net pension liability (asset) | \$ | 480,743 | \$ | 198,936 | \$ | (36,546) |
| | | | | | | |
| | | | | 2022 | | |
| | 1% | 6 Decrease | Dis | scount Rate | 19 | % Increase |
| | | (4.9%) | | (5.9%) | | (6.9%) |
| Corporation's proportionate share of the net pension (asset) liability | \$ | 199,582 | \$ | (77,538) | \$ | (309,335) |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(d) Deferred Outflows and Inflows of Resources

At December 31, 2023 and 2022, the Corporation reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

| | | 2023 | 2022 |
|--|----|---------|---------------|
| Deferred outflows of resources: | | | |
| Differences between expected and actual actuarial experience | \$ | 21,188 | \$ 5,872 |
| Changes in assumptions | | 96,616 | 129,402 |
| Other | | 5,311 | 8,419 |
| Total | \$ | 123,115 | \$ 143,693 |
| Deferred inflows of resources: | | | |
| Difference between expected and actual experience | \$ | 5,587 | \$ 7,616 |
| Change in assumptions | | 1,068 | 2,184 |
| Difference between projected and actual investment earnings | | | |
| on pension plan investments | | 1,168 | 253,904 |
| Changes in proportion and differences between Corporation | | | |
| contributions and proportionate share of contributions | 00 | 15,914 | 16,485 |
| Total OF TOTAL | \$ | 23,737 | \$ 280,189 |

The change in employer proportionate share is the difference between the employer proportionate share of net pension liability (asset) in the prior year compared to the current year. Changes in these amounts are amortized over a five-year closed period, reflecting the average remaining service life of plan members.

The net deferred outflows and inflows of resources of resources related to pensions, excluding contributions made subsequent to the measurement date, will be recognized in pension expense as follows:

| | Amount |
|---------------------------|--------------|
| Years ending December 31: | |
| 2024 | \$ 22,475 |
| 2025 | (13,480) |
| 2026 | 37,621 |
| 2027 | 52,762 |
| | \$ 99,378 |

Annual Pension Expense (Benefit)

The Corporation's annual pension expense (benefit) for calendar years ended 2023 and 2022, which includes contributions toward the actuarially determined asset or liability and the amortization of deferred outflows and inflows of resources, was approximately \$65,509 and \$(47), respectively.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB)

Plan description: The Corporation provides OPEB that include basic medical and hospitalization plan coverage to eligible retirees. Eligible retirees may only be covered under the indemnified plan of the Corporation. To qualify, a retiree must meet various eligibility requirements as agreed to in collective bargaining agreements. The Corporation pays varying amounts based on specific union agreements.

Funding the plan: Currently, there is no New York State statute that expressly authorizes local governments to create a trust for OPEB purposes. Additionally, New York State's General Municipal Law does not allow for a reserve fund to accumulate funds for OPEB obligations. The Corporation's Board of Directors and management believe it is prudent to reserve funds for the Plan and have therefore internally designated \$24,831 in 2023 and 2022, for purposes of funding future post-employment benefits. These internally designated funds are included within assets whose use is limited in the statements of net position. In addition to the funding for future post-employment benefits, the Corporation continues to finance current benefits on a pay-as-you-go basis.

Annual OPEB cost and net OPEB obligation: The Corporation's total OPEB liability measured at December 31, 2023 and 2022, of \$293,911 and \$271,395, was determined by an actuarial valuation as of January 1, 2023 and 2022, respectively. The measurement date of the obligation is December 31, 2023 and 2022.

(a) Actuarial Assumptions

The total OPEB liability in the December 31, 2023, actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

| Inflation | 2.5% |
|--------------------------------|---|
| Salary increases | 3.3% per annum |
| Pre-Medicare Plans | 7.8% for 2023, 4.0% ultimate trend rate in 2075 |
| Medicare Plans | 4.6% for 2023, 4.0% ultimate trend rate in 2075 |
| Pre-Medicare Prescription Plan | 7.8% for 2023, 4.0% ultimate trend rate in 2075 |
| Medicare Prescription Plan | 7.0% for 2023, 4.0% ultimate trend rate in 2075 |
| Mortality | Society of Actuaries Scale MP-2021 |

The total OPEB liability in the December 31, 2022 actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

| Inflation | 2.5% |
|--------------------------------|---|
| Salary increases | 3.7% per annum |
| Pre-Medicare Plans | 7.8% for 2022, 4.0% ultimate trend rate in 2075 |
| Medicare Plans | 4.5% for 2022, 4.0% ultimate trend rate in 2075 |
| Pre-Medicare Prescription Plan | 7.8% for 2022, 4.0% ultimate trend rate in 2075 |
| Medicare Prescription Plan | 6.5% for 2022, 4.0% ultimate trend rate in 2075 |
| Mortality | Society of Actuaries Scale MP-2021 |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

(b) Changes in the OPEB Liability

| | 2023 | | 2022 |
|--|------|------------|----------|
| Changes in the OPEB obligation: | | | |
| Projected OPEB obligation at the beginning of year | \$ | 271,395 \$ | 379,106 |
| Service cost | | 2,620 | 4,528 |
| Interest cost | | 9,722 | 6,959 |
| Difference between expected and actual experience | | 232 | (34,085) |
| Change in assumptions | | 26,546 | (69,430) |
| Actual benefit payments | | (16,604) | (15,683) |
| Projected OPEB obligation at the end of year | \$ | 293,911 \$ | 271,395 |

(c) Discount Rate

The discount rate used to measure the total OPEB liability was 3.3% and 3.7%, based on the Bond Buyer 20-year Bond GO index rate as of December 31, 2023 and 2022, respectively.

Sensitivity of the OPEB Liability to the Discount Rate

The following presents the Corporation's total OPEB liability calculated using the discount rate of 3.3%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (2.3%) or one percentage point higher (4.3%) than the current rate.

| | 2023 | | | | | | |
|--|---------------------------|---------|----|-------------|----|---------|------------|
| | 1% Decrease Discount Rate | | | 1% Decrease | | 1% | 6 Increase |
| | | (2.3%) | | (3.3%) | | (4.3%) | |
| The Corporation's total OPEB liability | \$ | 337,382 | \$ | 293,911 | \$ | 258,462 | |

The discount rate used to measure the total OPEB liability as of December 31, 2022, was 3.7%, based on the Bond Buyer 20-year Bond GO index rate.

The following presents the Corporation's total OPEB liability calculated using the discount rate of 3.7%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (2.7%) or one percentage point higher (4.7%) than the current rate.

| | 2022 | | | | | | | |
|--|------|---|----|---------|----|----------------------|--|--|
| | 1% | 1% Decrease Discount Rate 1 (2.7%) (3.7%) | | | | % Increase (4.7%) | | |
| The Corporation's total OPEB liability | \$ | 310,620 | \$ | 271,395 | \$ | 239,334 | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

Sensitivity of the OPEB Liability to the Healthcare Cost Trend Rates

The following presents the Corporation's total OPEB liability calculated using healthcare cost trend rates that are one percentage point lower or one percentage point higher than the current healthcare cost trend rates.

| | 2023 | | | | | | |
|--|------------|----------|------|----------------|----|------------|--|
| | Healthcare | | | | | | |
| | 1% | Decrease | Cos | st Trend Rates | 19 | % Increase | |
| The Corporation's total OPEB liability | \$ | 255,222 | \$ | 293,911 | \$ | 341,658 | |
| | | | | 2022 | | | |
| <u>-</u> | 11 | | POP | ealthcare | | | |
| | 1% | Decrease | Cost | Trend Rates | 1% | Increase | |
| | | | | | | | |
| The Corporation's total OPEB liability | \$5\ | 236,278 | \$ | 271,395 | \$ | 314,630 | |
| | | | | | | | |

(d) Deferred Outflows and Inflows of Resources

The following are components of deferred outflows and inflows at December 31, 2023 and 2022:

| | 2023 | | | | | |
|---|-----------|---------------|-----|----------------------|--|--|
| | | Deferred | | | | |
| | | Inflows | | | | |
| Differences between expected and actual actuarial experience Changes in assumptions | \$ | 544 25,126 | \$ | (27,754) (31,583) | | |
| Total | <u>\$</u> | 25,670 | \$ | (59,337) | | |
| | | 20 | 022 | | | |
| | | eferred | | Deferred | | |
| | | Outflows | | Inflows | | |
| | _ | | | (=0.000) | | |
| Differences between expected and actual actuarial experience | \$ | 96 | \$ | (58,636) | | |
| Changes in assumptions | | 22,588 | | (56,176) | | |
| Total | \$ | 22,684 | \$ | (114,812) | | |

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

The net deferred outflows and inflows of resources at December 31, 2023, will be recognized as follows:

| | Amount |
|------|----------------|
| 2024 | \$ (24,297) |
| 2025 | (12,810) |
| 2026 | 3,440 |
| | \$ (33,667) |

(e) Annual OPEB Benefit

The Corporation's annual OPEB benefit for the years ended December 31, 2023 and 2022, was \$19,343 and \$31,319, respectively.

Note 13. New York State Department of Health (NYSDOH) Grant Programs

The NYSDOH offers the Vital Access Provider Assurance Program (VAPAP) program. Funding under this program is made to public or safety net hospitals and health systems that meet certain criteria or that have been designated as critical access or sole community hospitals and is awarded to enable these facilities to maintain operations and provision of vital services while they implement longer-term solutions to achieve sustainable health care service delivery. During the years ended December 31, 2023 and 2022, the Corporation received grant payments under this program in the amount of \$76,838 and \$78,998, respectively. Specifically related to these grants, during the years ended December 31, 2023 and 2022, \$103,838 and \$51,998, respectively, was recognized in the statement of revenues, expenses and changes in net position as non-operating revenue.

Note 14. Transactions With the County of Erie

On December 30, 2009, the Corporation and the County entered into a Settlement Agreement. The Settlement Agreement resulted in the Corporation and the County entering into a number of transactions to resolve litigation and prepare for implementing the Corporation's master facility plan.

In October 2012, the Corporation and the County signed an amendment to the 2009 Settlement Agreement (the Amendment). The terms of the Amendment provide for the County to be reimbursed from the Corporation for certain workers' compensation claims incurred by Corporation employees that were paid by the County. The Amendment also provides for the County to reimburse the Corporation, over time, for post-retirement health expenses that the Corporation incurred for Corporation employees with service time at the County.

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie. A component of the loan agreement included the payment of points by the Corporation to the County of Erie in the amount of \$17,040 as further described in Note 2 and 10.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 14. Transactions With the County of Erie (Continued)

Other transactions: Amounts that are included in operating revenues and expenses in the statements of revenues, expenses and changes in net position, which represent related-party transactions that occurred between the Corporation and the County during the years ended December 31, 2023 and 2022, are as follows:

The Corporation earned revenue totaling \$3,902 and \$3,856 for the years ended December 31, 2023 and 2022, respectively, from the County. Revenue earned relates to services provided to School 84, mental health services and various other charges related to County departments located within the Corporation's physical plant.

The net amount due to the County of approximately \$12,661 and \$11,393 at December 31, 2023 and 2022, respectively, is non-interest bearing and reflect the Corporation's net amount owed to the County as a result of various transactions and services between parties. This balance is reported as a component of accounts payable and accrued other liabilities in the statements of net position at December 31, 2023 and 2022, respectively.

Note 15. Self-Insured Obligations

The Corporation is self-insured for all medical malpractice claims for occurrences on or after January 1, 2004. Additionally, the Corporation began purchasing excess stop-loss insurance on a claims made basis for medical malpractice effective November 2008. The current policy provides \$35,000 of coverage in excess of a self-insured retention (SIR) of \$4,000 of individual claims or \$12,000 in aggregate claims effective November 19, 2018. Immediately previously, the policy provided \$35,000 of coverage in excess of a SIR \$3,000 of individual claims or \$10,000 in aggregate claims.

Effective April 1, 2016, the Corporation became self-insured for workers' compensation claims through a combination of self-insurance and a high-deductible plan for certain periods as follows: The Corporation maintains a stop-loss insurance policy for the claims in excess of \$750. As required by the NYS Workers' Compensation Board, ECMCC maintains a security deposit on its self-insured workers' compensation obligations. The value of the security deposit was \$30,689 and \$26,128 as of December 31, 2023 and 2022, respectively. The deposit is maintained through a surety bond. The surety requires a collateral deposit to maintain the bond. The value of the collateral held by the surety was \$5,512 and \$5,272 as of December 31, 2023 and 2022, respectively. Effective January 1, 2012, the Corporation insured a portion of its workers' compensation exposure through an occurrence basis high-deductible plan. The Corporation remains responsible for the first \$750 of an individual claim payment after December 31, 2023 and 2022, \$4,662 and \$4,936, respectively, has been designated to service workers' compensation claims and included as part of assets whose use is limited. The Corporation remains self-insured for workers' compensation claims prior to January 1, 2012. The County has assumed a portion of liabilities for all occurrences originating prior to 2004.

Losses from asserted and unasserted medical malpractice and workers' compensation claims are accrued based on actuarial estimates that incorporate the Corporation's past experience, the nature of each claim or incident, relevant trend factors, and estimated recoveries, if any, on unsettled claims.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 15. Self-Insured Obligations (Continued)

The Corporation has accrued \$33,407 and \$30,975 at December 31, 2023 and 2022, respectively, for medical malpractice related exposures. Such amounts have been discounted at 2.0% for 2023 and 2022 and the accrued liabilities are included within the accrued other liabilities and self-insured obligations caption of the accompanying statements of net position. Charges to expense for medical malpractice costs are included within the other operating expenses caption of the accompanying statements of revenues, expenses and changes in net position.

The Corporation has accrued \$27,922 and \$27,264 at December 31, 2023 and 2022, respectively, for workers' compensation related exposures. Such amounts have been discounted at 1.75% for 2023 and 2022, and the liabilities are included within the accrued other liabilities and self-insured obligations captions of the accompanying statements of net position. Charges to expense for workers' compensation costs approximated \$7,376 and \$7,884 in 2023 and 2022, respectively, and are included within the payroll, employee benefits and contract labor caption of the accompanying statements of revenues, expenses and changes in net position.

Eligible retirees are provided basic medical and hospitalization coverage by the Corporation as more fully described in Note 12.

The composition of self-insured obligations as of December 31, is as follows:

| 2023 | | | | | | | | | | |
|-----------------------|------|-------------------------------------|------|-------------|-----|---------|--------|---------|------------|----------|
| • | 10. | Ell 1 | TO Y | Actuarial |),, | | | | | |
| | ME | Beginning Estimate of Claims Ending | | | | | | | | e Within |
| | | Balance | Clai | ms Incurred | | Paid | | Balance | | ne Year |
| | (| For- | Re | | | | | | | |
| Medical malpractice | \$ | 30,975 | \$ | 4,750 | \$ | (2,318) | \$ | 33,407 | \$ | 1,792 |
| Workers' compensation | | 27,264 | | 6,145 | | (5,487) | | 27,922 | | 7,416 |
| | \$ | 58,239 | \$ | 10,895 | \$ | (7,805) | \$ | 61,329 | \$ | 9,208 |
| | 2022 | | | | | | | | | |
| | | | - | Actuarial | | | | | | |
| | Е | Beginning | Ε | stimate of | | Claims | Ending | | Due Within | |
| | | Balance | Clai | ms Incurred | | Paid | E | 3alance | Or | ne Year |
| | | | | | | | | | | |
| Medical malpractice | \$ | 28,159 | \$ | 3,797 | \$ | (981) | \$ | 30,975 | \$ | 1,800 |
| Workers' compensation | | 28,348 | | 6,378 | | (7,462) | | 27,264 | | 7,556 |
| | \$ | 56,507 | \$ | 10,175 | \$ | (8,443) | \$ | 58,239 | \$ | 9,356 |

Medical malpractice and workers' compensation amounts due within one year are management's estimates based on historical claims.

Notes to the Financial Statements Year Ended December 31, 2023 (Dollars in Thousands)

Note 16. Commitments and Contingencies

The health care industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations is subject to future government review and interpretation as well as regulatory actions unknown or unasserted at the time. Government activity, in recent years, has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse statutes and regulations, which could result in the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. While no regulatory allegations have been made against the Corporation, compliance with such laws and regulations can be subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time. Management and its counsel are not aware of any such actions that will have a material adverse effect on the Corporation's financial statements.

Loss contingency liabilities are recorded in accordance with U.S. GAAP, which requires recognition of a loss when it is deemed probable that an asset has been impaired or a liability has been incurred, and the amount of the loss can be reasonably estimated. As of December 31, 2023 and 2022, the Corporation has recorded no loss contingencies except as disclosed in Note 15.

The Corporation formed 1827 Fillmore, LLC (1827) for the purpose of acquiring and developing land immediately adjacent to its Grider Street campus. A condition of the acquisition was that 1827 demolish a building on the site with known asbestos abatement requirements. This condition was met in 2018. The Corporation has undertaken a community planning process to determine the future use(s) of the site. The site requires the environmental remediation expenditures; however, the amount of such expenditures is dependent on the ultimate use of the site and requirements from regulators. Through December 31, 2023, approximately \$4,600 has been spent on remediating and improving the land.

Required Supplementary Information

Required Supplementary Information Schedule of Corporation's Contributions NYSLRS Pension Plan December 31, 2023 (Dollars in Thousands)

| | 2023 | | 2022 | 2021 | | 2020 | 2019 | | 2018 | | 2017 | | 2016 | 2015 | 2014 |
|--|---------------|----|---------|---------------|----|---------|---------------|----|---------|--------|---------|----|---------|---------------|---------------|
| Contractually required contribution | \$ 25,153 | \$ | 31,946 | \$ 30,167 | \$ | 27,343 | \$ 26,447 | \$ | 25,803 | \$ | 25,235 | \$ | 26,722 | \$ 29,771 | \$ 29,835 |
| Contributions in relation to the contractually required contribution | 25,153 | | 31,946 | 30,167 | | 27,343 | 26,447 | | 25,803 | | 25,235 | | 26,722 | 29,771 | 29,835 |
| Contribution deficiency | \$ - | \$ | - | \$ - | \$ | - | \$ 701 | \$ | - | \$ | - | \$ | - | \$ - | \$ - |
| | | | | | | MEN. | _@\$ | | | | | | | | |
| ECMCC covered-employee payroll | \$ 245,606 | \$ | 244,519 | \$ 235,767 | \$ | 216,871 | \$ 204,007 | \$ | 193,386 | \$ | 183,540 | \$ | 166,691 | \$ 175,409 | \$ 163,395 |
| | | | | · ON | W. | OUNT | | | | | | | | | |
| Contributions as a percentage of covered-employee payroll | 10.2% | Ď | 13.1% | 12.8% | | 12.6% | 13.0% |) | 13.3% | , o | 13.7% | Ď | 16.0% | 17.0% | 18.3% |

Required Supplementary Information Schedule of Corporation's Proportionate Share of Net Pension Liability (Asset) NYSLRS Pension Plan December 31, 2023 (Dollars in Thousands)

| | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|--|------------|-------------|---------|------------|-----------|-----------|-----------|------------|-----------|
| | | | | | | | | | |
| ECMCC proportion of the net pension (asset) liability | 0.9277% | 0.9485% | 0.9187% | 0.8504% | 0.8079% | 0.7646% | 0.7614% | 0.7228% | 0.7137% |
| ECMCC proportionate share of the net pension (asset) liability | \$ 198,936 | \$ (77,538) | \$ 915 | \$ 225,197 | \$ 57,240 | \$ 24,677 | \$ 71,544 | \$ 116,006 | \$ 24,112 |
| ECMCC covered-employee payroll | 245,606 | 273,555 | 249,490 | 246,772 | 235,284 | 216,044 | 183,540 | 166,691 | 175,409 |
| ECMCC proportionate share of the net pension liability | | | | | | | | | |
| as a percentage of its covered-employee payroll | 81.0% | -28.3% | 0.4% | 91.3% | 24.3% | 11.4% | 39.0% | 69.6% | 13.7% |
| Plan fiduciary net position as a percentage of the | | | | | | | | | |
| total pension liability | 90.8% | 103.7% | 100.0% | 86.4% | 96.3% | 98.2% | 94.7% | 90.7% | 97.9% |

Note: GASB requires 10 years of information to be presented in this table. However, until a full 10-year trend is compiled, the Corporation will present information for those year for which information is available.

Change in Benefit Terms

The New York State Legislature lowered the vesting requirement for Tier 5 and Tier 6 from ten years to five years (Chapter 56 0f the Laws of 2022), prior to the April 1, 2022 actuarial valuation.

Changes of Assumptions

2023: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2021, inflation was updated to 2.9%, cost-of-living updated to 1.5%, for the April 1, 2022 actuarial valuation.

2022: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2020, inflation was updated to 2.7%, cost-of-living updated to 1.4%, and the interest rate assumption was reduced to 5.9% for the April 1, 2021 actuarial valuation.

Required Supplementary Information Schedule of Corporation's Changes in Total OPEB Liability and Related Ratios December 31, 2023 and 2022 (Dollars in Thousands)

| | 2023 | 2022 |
|--|---------------|---------------|
| Total OPEB liability: | | |
| Service cost | \$ 2,620 | \$ 4,528 |
| Interest cost | 9,722 | 6,959 |
| Differences between expected and actual experience | 232 | (34,085) |
| Changes of assumptions | 26,546 | (69,430) |
| Benefit payments | (16,604) | (15,683) |
| Net change in total OPEB liability | 22,516 | (107,711) |
| Total OPEB liability—beginning | 271,395 | 379,106 |
| Total OPEB liability—ending | \$ 293,911 | \$ 271,395 |
| Covered employee payroll | \$ 87,249 | \$ 87,719 |
| Total OPEB liability as a percentage of covered employee payroll | 336.86% | 309.39% |
| Discount rate | 3.3% | 3.7% |

Change in Benefit Terms

There were no significant changes in benefits during 2023 and 2022.

Changes of Assumptions

2023: The discount rate was decreased from 3.7% to 3.3%, while salary increases were adjusted from 3.7% to 3.3% as well as an update to the medical and prescription trend rates.

2022: The annual rate of increase in healthcare costs were revised to better reflect future expectations.

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Uniform Guidance Audit Requirements December 31, 2023

Review and Discrete Deproduced

Review And Discrete Deproduced

Schedule of Expenditures of Federal Awards For the Year Ended December 31, 2023

| Federal Grantor/Pass-Through Grantor/Program or Cluster Title | Federal Assistance Listing Number | Pass-Through Entity Identifying Number | Provided to Subrecipient | Total Federal Expenditures | |
|--|--------------------------------------|---|-----------------------------|-------------------------------|--|
| U.S. Department of Health and Human Services Health Resources and | | | | | |
| Services Administration Direct Programs | | | | | |
| COVID-19: Provider Relief Fund and American Rescue Plan (ARP) | | | | | |
| Rural Distribution | 93.498 | N/A | \$ - | \$ 8,394,858 | |
| Training in General, Pediatric, and Public Health Dentistry | 93.059 | N/A | - | 370,983 | |
| Ryan White HIV/AIDS Dental Reimbursement and Community | | | | | |
| Based Dental Partnership Grants | 93.924 | N/A | - | 50,607 | |
| Oral Diseases and Disorders Research | 93.121 | N/A | | 186,894 | |
| Total U.S. Department of Health and Human Services Health Resources and Services Administration Direct Programs | | | | 9,003,342 | |
| U.S. Department of Health and Human Services pass-through program from: | | | | 0,000,042 | |
| Health Research Inc. | | | | | |
| National Bioterrorism Hospital Preparedness Program | 93.889 | 2430-18 | - | 40,000 | |
| New York State Office of Mental Health | | | | | |
| | 93.958 | C21661GG | | 373,988 | |
| COVID-19: Block Grants for Community Mental Health Services | 93.958 | C21001GG | - | 373,988 | |
| Total U.S. Department of Health and Human Services Pass-Through Programs | | | _ | 413,988 | |
| U.S. Department of Justice Pass-Through Program From: | | | | | |
| New York State Office of Victim Crime Services | | | | | |
| Crime Victim Assistance | 16.575 | OVS01-C10952GG-1080200 | - | 390,981 | |
| New York State Division Criminal Justice Services | | | | | |
| Crime Victim Assistance | 16.575 | OVS01-T11152GG-1080200 | - | 212,673 | |
| New York State Division Criminal Justice Services | | | | | |
| Crime Victim Assistance | 16.575 | N/A | | 426,815 | |
| | | | - | 1,030,469 | |
| New York State Office of Victim Crime Services | | AFRONO OO OK OATOO NONE | | 450.000 | |
| Crime Victim Assistance/Discretionary Grants | 16.582 | 15POVC-22-GK-01799-NONF | - | 159,983 | |
| New York State Division Criminal Justice Services | | | | | |
| Violence Against Women Formula Grants | 16.588 | C00256GG-1090000 | - | 50,000 | |
| and form a latter of the latte | | | | | |
| Total U.S. Department of Justice Pass-Through Program | | | | 1,240,452 | |
| | | | | | |
| U.S. Department of Homeland Security (Federal Emergency Management Agency) | | | | | |
| COVID-19: Disaster Grants - Public Assistance (Presidentially Declared Disasters) | 97.036 | N/A | | 3,861,791 | |
| Total Expenditures of Federal Awards | | | ¢ | \$ 14,519,573 | |
| Total Expolititues of Federal Awards | | | Ψ | Ψ 14,010,010 | |

See notes to the schedule of expenditures of federal awards.

Notes to Schedule of Expenditures of Federal Awards Year Ended December 31, 2023

Note 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of the Erie County Medical Center Corporation (the Corporation) under programs of the federal government for the year ended December 31, 2023. The information on this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).

For purposes of the Schedule, federal awards include all federal assistance entered into directly between the Corporation and the federal government and sub-awards from nonfederal organizations made under federally sponsored agreements. The Schedule does not include payments received under Medicare and Medicaid reimbursement programs. Because the Schedule presents only a selected portion of the activities of the Corporation, it is not intended to, and does not, present the financial position, changes in net position and cash flows of the Corporation.

Note 2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Corporation has elected to not exercise its option to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 3. Other Federal Awards

There were no federal awards expended for noncash assistance, insurance, or any loans, loan guarantees, or interest subsidies outstanding at December 31, 2023.

Note 4. Subrecipients

The Corporation did not provide federal awards to any subrecipients during the year ended December 31, 2023.

Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

Independent Auditor's Report

Board of Directors
Erie County Medical Center Corporation

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of the business-type activities and the aggregate discretely presented component units of Erie Medical Center Corporation (the Corporation), as of and for the year ended December 31, 2023, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements, and have issued our report thereon dated DATE.

The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*, and accordingly, this report does not include reporting on internal controls over financial reporting or instances of reportable noncompliance associated with ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County. Inc.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Corporation's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the basic financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



FRELIMINARY DRAFT
PRELIMINARY DRAFT
PUMPOSES Only
PRELIMINARY
PRELIMINARY
PUMPOSES ONLY
PRELIMINARY
PUMPOSES ONLY
PRELIMINARY
PRELIMINARY
PUMPOSES ONLY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRELIMINARY
PRICER
PROBLEM
PRELIMINARY
PRICER
PROBLEM
PROBLEM
PRICER
PROBLEM
PROBLEM
PRICER
PROBLEM
PROBLEM
PRICER
PROBLEM

Report on Compliance For Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Erie County Medical Center Corporation's (the Corporation) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Corporation's major federal programs for the year ended December 31, 2023. The Corporation's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Corporation complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Corporation's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Corporation's federal programs.

Auditor's Responsibility for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Corporation's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Corporation's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design
 and perform audit procedures responsive to those risks. Such procedures include examining, on a
 test basis, evidence regarding the Corporation's compliance with the compliance requirements
 referred to above and performing such other procedures as we considered necessary in the
 circumstances.
- obtain an understanding of the Corporation's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the Corporation's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance We have audited the financial statements of the Corporation as of and for the year ended December 31, 2023 and have issued our report thereon dated DATE, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the basic financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditure of federal awards is fairly stated in all material respects in relation to the basic financial statements as a whole.

Firm Signature DATE

Schedule of Findings and Questioned Costs Year Ended December 31, 2023

Section I—Summary of Auditor's Results

| Financial Statements | | | | |
|--|-----------------|-------------|------------------|---------------------|
| Type of auditor's report issued on whether the financial statements audited were prepared in accordance with GAAP: | | Unmodifie | ed | |
| Internal control over financial reporting: Material weakness(es) identified? Significant deficiency(ies) identified? | | yes yes | X | no none reported |
| Noncompliance material to financial statements noted? | PAFT | yes | X | no |
| Federal Awards | | | | |
| Internal control over major programs: Material weakness(es) identified? Significant deficiency(ies) identified? | Straing On n | yes yes | X X | no none reported |
| Type of auditor's report issued on compliance for major programs: | 3640 a | Unmodifie | ed | |
| Any audit findings disclosed that are required to be reported in accordance with 2 CFR Section 200.516(a)? | | yes | X | . no |
| Identification of major federal programs: | | | | |
| Federal Assistance Listing Number(s) | Name of Fe | ederal Prog | gram or Cluste | <u>er</u> |
| 93.498 | | | Relief Fund and | |
| 93.059 | | | Pediatric, and F | |
| Dollar threshold used to distinguish between Type A and Type B programs: | | | \$ 750,000 | : |
| Auditee qualified as a low risk auditee? | X | yes | | no |

(Continued)

Schedule of Findings and Questioned Costs (Continued) Year Ended December 31, 2023

Section II—Financial Statement Findings

No findings noted.

Section III—Findings and Questioned Costs for Federal Awards

No findings noted.



Summary Schedule of Prior Year Findings and Questioned Costs Year Ended December 31, 2023

Section I—Financial Statement Findings

No findings noted.

Section II—Findings and Questioned Costs for Federal Awards

No findings noted.








Table of Contents

| <u>Page</u> |
|-------------|
| 3-8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13-15 |
| 16 |
| 17-24 |
| 25 |
| 26 |
| 27 |
| 28-31 |
| |





The industry is experiencing similar financial and operational challenges both locally and nationally. Given the extent of the financial impact these challenges have had, ECMCC has recognized that time along with future external support are needed to properly recover. Given the time needed, the 2024 goal is to achieve improved operating and investing cash flow through the improvement in operating results through efficiency improvements and programmatic changes without sacrificing quality or the critical services we provide. The proposed 2024 operating budget reflects an operating loss of \$35 million, an improvement of over 57% from the projected 2023 operating results before grant support. The proposed budget has been developed with the following goals in mind:

Budget Goals

- Maintain the highest quality of care provided
- Maintain critical services provided to the community
- Continue a stepped approach to recovery with a significant reduction in operating loss from 2023
- Maintain routine capital and equipment upgrades
- Maximize retention of staff, improve staffing efficiency and meet NYS minimum standards
- Prepare the budget to accomplish the goals without significant job actions

Budgetary assumptions are a key component of the process that was followed in developing the Budget. The following summarizes Management's perspective in the development of these assumptions

Activity Levels

The Budget has been prepared consistent with actual volume seen during 2023. Further consideration was given to the changes internally related to recent trends in volume and activity, an improvement in the ability to discharge patients and ultimately reduced length of stay, the shift of inpatient cases into the outpatient setting as a result of changing regulations and payer payment policies, new physician recruitment, as well as other factors. Management believes that the levels of activity contained within the Budget are achievable.



Revenue and Reimbursement

Projected reimbursement from government payers is based on current and proposed regulations where Management has evaluated as probable. Reimbursement from commercial payers is based on current contracts or at rates that Management has evaluated as probable for contracts currently being negotiated. Increases in net revenue associated with revenue cycle improvement initiatives related to contract underpayments and payer denial management have also been incorporated at levels that Management believes are attainable.

Other operating revenue has been budgeted based on historical experience while taking into account the recent growth in the operation of ECMCC's Specialty Pharmacy.

Disproportionate share and upper payment limit payments have been budgeted based on the most current information available to Management.



Operating Expenses

Projected operating expenses are budgeted based on the volume of anticipated activity, along with adjustments for salary rate increases consistent with current collective bargaining agreements, estimated benefit costs as adjusted for actuarially projected gains or losses, supply and other expense inflation rates as well as impacts of performance improvement initiatives. Management believes that the overall growth in expenses of approximately 3.7% contained in the budget are reasonable and attainable.

Non-Operating Revenue

Non-Operating Revenues have been budgeted consistent with the recent historical trends related to investment income. The reduction is the result of a reduction in available investments in 2023. Although ECMCC expects to continue to work closely with NYS on future funding needs both for the remainder of 2023 and 2024 as a participant in the Vital Access Provider Assurance grant program, Management has elected <u>not</u> to include any additional Federal or New York State operational support for planning purposes in the 2024 operating budget.

Page 252 of 330



Management Discussion and Analysis

Cash Flows

2024 cash flow will remain a key focus of Management given the challenges. Cash flows have been budgeted based on the results of operations, investments in routine and nonroutine capital assets, principal payments on long-term debt, continued investments in a clinically integrated network and the funding of employee benefit plans. In an effort to avoid reducing critical services the budget reflects losses which will result in a need for operational cash flow support from governmental agency partners including New York State.

Range of Outcomes and Contingency Plans

Management has considered the sensitivity of each material assumption within the Budget. Management believes that the Budget is reasonably positioned within the range of potential outcomes and recognizes its responsibility for achieving these results. Given the uncertainty of certain material assumptions related to uncertain inflationary pressures, community post-acute capacity, staffing and retention challenges, future governmental reimbursement and benefit cost fluctuation, Management acknowledges that it may have to adjust operationally during 2024.

Page 253 of 330


Regulatory Budget Reporting Requirements

- All requirements have been met
 - NYCRR, Part 203, Chapter V, Title 2
 - This package communicates each of the 18 requirements
- New York State Office Of The State Comptroller
- Authority Budget Office
- PARIS submission and certification



Budget Process

- Executive Leadership Team (ELT) adopt budget schedule and goals
- Using 2023 year-to-date performance and known or anticipated budget variances, a baseline budget and financial projections were prepared
- Department managers worked with ELT to develop departmental targets and performance improvement initiatives
- ELT budget recommendation reviewed and approved by Finance Committee of ECMCC Board
- Budget recommendation reviewed and approved by **ECMCC Board**





Key Financial Ratios

| | | | <u>Projected</u> | Budget |
|---|---------|---------|------------------|--------|
| | 2021 | 2022 | 2023 | 2024 |
| Operating Margin % | -10.60% | -12.42% | -11.07% | -4.27% |
| NYS PBC Average % | -9.40% | -8.00% | | |
| Operating EBITDA % | -2.66% | -4.47% | -4.15% | 1.45% |
| NYS PBC Average % | -3.20% | -2.20% | | |
| FTE's | 3,453 | 3,473 | 3,676 | 3,700 |
| Days Operating Cash On Hand | 47.8 | 24.6 | 29.0 | 13.4 |
| NYS PBC Average | 26.9 | 41.6 | | |
| Debt Service Coverage | 1.1 | 1.5 | (0.4) | 0.3 |
| NYS PBC Average | 1.4 | 3.1 | | |
| Salaries, Wages & Benefits % of Revenue | 63.60% | 61.49% | 73.77% | 69.21% |
| Supply Expense % of Revenue | 19.90% | 20.81% | 21.48% | 20.23% |
| Benefit % of Salaries and Wages | 31.20% | 12.93% | 30.88% | 27.22% |
| Days In Accounts Receivable, net | 49.5 | 53.9 | 63.0 | 59.1 |



Statements of Revenues and Expenses

(Thousands)

| | 2022 Audited | 2023 Projection | 2024 Budget | Increase (Dec | rease) |
|---|--------------|------------------|-------------|---------------|------------------|
| Net Pati ent Revenue | \$ 566,389 | \$ 583,869 | \$ 645,857 | \$ 61,988 | 10.6% |
| Disproportionate Share / IGT and UPL Payments | 68,295 | 114,851 | 123,280 | 8,428 | 7.3% |
| Other Operating Revenues | 26,095 | 42,576 | 49,890 | 7,314 | <u>17.2</u> % |
| Total Operating Revenues | 660,779 | 741 ,2 97 | 819,027 | 77,730 | 10.5% |
| Operating Expenses | | | | | |
| Salaries and Benefits | 348,266 | 430,721 | 446,981 | 16,260 | 3.8% |
| Physician Fees and Professional Services | 194,970 | 187,212 | 199,443 | 12,231 | 6.5% |
| Supplies | 117,877 | 125,413 | 130,625 | 5,212 | 4.2% |
| Other Expenses | 81,728 | 80,009 | 76,982 | (3,027) | - <u>3.8</u> % |
| Total Operating Expenses | 742,841 | 823,355 | 854,032 | 30,677 | <u>3.7</u> % |
| Operating Income before grants | (82,062) | (82,058) | (35,005) | 47,053 | -57 .3 % |
| Grant revenue | 63,151 | 29,469 | | (29,469) | - <u>100.0</u> % |
| Income/(Loss) from Operations with grants | (18,911) | (52,589) | (35,005) | 17,584 | -33.4% |
| Other Non-Operating Revenues | (13,967) | 4,814 | 1,205 | (3,609) | - <u>75.0</u> % |
| Excess of Revenues Over Expenses | \$ (32,878) | \$ (47,776) | \$ (33,800) | \$ 13,975 | -29.3% |

Page 258 of 330



(Thousands)

| | 2022 Aug | dited | 2023 Proje | ection | 2024 Bu | dget | Increase (D | ecrease) |
|---|-----------|--------|------------|--------|-----------|--------|-------------|----------------|
| Assets | A C | 100 | - AT | | * | | | - |
| Current Assets | | | | | | | | |
| Cash and Investments | 44,195 | 4.6% | 62,284 | 6.4% | 29,848 | 3.3% | (32,436) | -52.1% |
| Patient Accounts Receivable, Net | 83,569 | 8.7% | 100,777 | 10.4% | 104,371 | 11.5% | 3,594 | 3.6% |
| Other Current Assets | 85,197 | 8.9% | 88,670 | 9.1% | 90,555 | 10.0% | 1,885 | 2.1% |
| Total Current Assets | 212,961 | 22.1% | 251,731 | 26.0% | 224,774 | 24.8% | (26,957) | -10.7% |
| Assets Whose Use Is Limited | 157,515 | 16.4% | 159,704 | 16.5% | 159,951 | 17.6% | 247 | -0.4% |
| Property and Equipment, Net | 328,170 | 34.1% | 295,976 | 30.5% | 266,876 | 29.4% | (29,099) | -9.8% |
| Other Assets | 263,731 | 27.4% | 261,854 | 27.0% | 254,780 | 28.1% | (7,074) | - <u>2.7</u> % |
| Total Assets | 962,377 | 100.0% | 969, 265 | 100.0% | 906,381 | 100.0% | (62,883) | -6.5% |
| Liabilities and Net Assets | | | | | | | | |
| Current Liabilities | | | | | | | | |
| Current Portion of Long Term Debt | 28,795 | 3.0% | 28,586 | 2.9% | 27,568 | 3.0% | (1,018) | -3.6% |
| Accounts Payable, Third-Party & Accrued | 267,492 | 27.8% | 344,776 | 35.6% | 328,724 | 36.3% | (16,051) | -4.7% |
| Total Current Liabilities | 296,287 | 30.8% | 373,362 | 38.5% | 356,292 | 39.3% | (17,070) | - <u>4.6</u> % |
| Long Term Debt | 225,833 | 23.5% | 218,783 | 22.6% | 201,215 | 22.2% | (17,568) | -8.0% |
| Deferred Inflows | 395,002 | 41.0% | 396, 144 | 40.9% | 396,002 | 43.7% | (142) | 0.0% |
| Other Post Employment Benefits | 259,334 | 26.9% | 250,051 | 25.8% | 257,553 | 28.4% | 7,502 | 3.0% |
| Self Insurance Liabilities | 54,340 | 5.6% | 47,118 | 4.9% | 45,313 | 5.0% | (1,805) | -3.8% |
| Total Liabilities | 1,230,796 | 127.9% | 1,285,459 | 132.6% | 1,256,375 | 138.6% | (29,084) | -2.3% |
| Net Position | (268,419) | -27.9% | (316,194) | -32.6% | (349,994) | -38.6% | (33,800) | 10.7% |
| Total Liabilities and Net Assets | 962,377 | 100.0% | 969, 265 | 100.0% | 906,381 | 100.0% | (62,884) | -6.5% |



Statements of Cash Flow

(Thousands)

| | Audited | Projected | Budget | Increase (De | crease) |
|--|-----------|-----------|----------|--------------|---------------|
| | 2022 | 2023 | 2024 | | <u>%</u> |
| Cash Flows From Operating Activities | | | | | |
| Excess of Revenues Over Expenses | (32,878) | (47,776) | (33,800) | 13,975 | -29% |
| Depreciation & Amortization | 41,615 | 40,195 | 37,100 | (3,095) | -8% |
| Provision for Bad Debt | 15,474 | 12,537 | 12,674 | 137 | 1% |
| Medicare Advanced Payment Program | (20,879) | 0.7 | 15 | 7: | N/A |
| (Increase) Decrease in Non-operating revenues | (38,256) | (23,188) | 8,542 | 31,730 | -137% |
| (Increase) Decrease in Patient Accounts Receivable, Net | (22,328) | (29,745) | (16,267) | 13,478 | -45% |
| (Increase) Decrease in Current and Other Assets | 144,272 | (1,596) | 5,189 | 6, 785 | -425% |
| Increase (Decrease) in Accounts Payable, Third-Party & Accrued | (105,832) | 77,284 | (16,051) | (93,335) | -121% |
| Increase (Decrease) in Deferred In-Flows | (69,022) | 1,142 | (142) | (1,284) | -112% |
| Increase (Decrease) in Self Insurance Liabilities | 1,322 | (16,505) | 5,696 | 22,201 | -135% |
| Net Cash Provided By (Used In) Operating Activities | (86,512) | 12,347 | 2,939 | (9,408) | -76% |
| Cash Flows From Investing Activities | | | | | |
| Other Investing Activities, Net | 10,192 | 2,625 | 959 | (1,666) | -63% |
| Net Cash Provided By (Used In) Investing Activities | 10,192 | 2,625 | 959 | (1,666) | - <u>63</u> % |
| Cash Flows From Financing Activities | | | | | |
| Additions to Property and Equipment | (26,856) | (8,000) | (8,000) | 7. | 0% |
| Non-operating grants | 90,152 | 29,469 | | (29,469) | -100% |
| Changes in Long Term Debt | (12,245) | (18,353) | (28,333) | (9,980) | 54% |
| Net Cash Provided By (Used In) Financing Activities | 51,051 | 3,116 | (36,333) | (39,449) | -1266% |
| Net Increase (Decrease) in Cash and Investments | (25,269) | 18,089 | (32,435) | (50,524) | -279% |
| Cash and Investments, Beginning | 69,464 | 44,195 | 62,284 | 18,089 | 41% |
| Cash and Investments, Ending | 44,195 | 62,284 | 29,849 | (32,435) | -52% |



Operating Performance Reconciliation

(Thousands)

| | <u>2023 Budget</u> | <u>2024 Budget</u> | Increase / (Decrease) |
|---|--------------------|--------------------|--------------------------|
| 2023 Budgeted Income from Operations | | | (34,997) |
| Operating Revenues | | | |
| Net Patient Service Revenue | 611,984 | 645,857 | 33,873 |
| Disproportionate Share, IGT and UPL Revenue | 116,351 | 123,280 | 6,929 |
| Other Operating Revenue | 37,635 | 49,890 | 12,255 |
| Total Operating Revenues | 765,970 | 819,027 | 53,057 |
| Operating Expenses | | | |
| Salaries and Benefits | 409,792 | 446,981 | 37,189 |
| Physician Fees and Professional Services | 182,590 | 199,443 | 16,853 |
| Supplies | 128,714 | 130,625 | 1,911 |
| Other Expenses | 36,271 | 30,136 | (6,135) |
| Depreciation and Amortization | 34,142 | 37,100 | 2,958 |
| Interest | 9,458 | 9,747 | 289 |
| Total Operating Expenses | 800,967 | 854,032 | 53,065 |
| 2024 Budgeted Loss from Operations | (34,997) | (35,005) | (35,005) |

Page 261 of 330



Principal Budget Assumptions

- Volume
- Patient Revenue and Reimbursement
- IGT / UPL Payments
- Other Revenues
- Staffing Costs / Vacancy Management
- Other Expenses
- Cash Flows

| | 2022 | 2023 | 2024 | Increase (De | ecrease) |
|------------------------|---------|-------------------|---------|--------------|----------|
| | Actual | <u>Projection</u> | Budget | 24 - 23 | % |
| Discharges | | | | | |
| Acute | 12,266 | 12,249 | 12,534 | 285 | 2.3% |
| Other | 5,146 | 5,155 | 5,466 | 311 | 6.0% |
| Total | 17,412 | 17,404 | 18,000 | 596 | 3.4% |
| Average Length of Stay | | | | | |
| Acute | 8.2 | 8.4 | 7.5 | (0.9) | -10.9% |
| Other | 10.9 | 12.0 | 10.8 | (1.2) | -10.1% |
| Total | 9.5 | 10.2 | 8.5 | (1.7) | -16.5% |
| Observation Cases | 2,342 | 2,808 | 3,008 | 200 | 7.1% |
| Outpatient Visits | 274,530 | 297,426 | 306,613 | 9,187 | 3.1% |
| Clinics | 138,044 | 152,206 | 159,124 | 6,918 | 4.5% |
| Behavioral Health | 32,674 | 36,730 | 37,316 | 586 | 1.6% |
| Chemical Dependency | 22,258 | 23,270 | 23,314 | 44 | 0.2% |
| Dialysis | 24,962 | 25,258 | 26,269 | 1,011 | 4.0% |
| Other | 56,592 | 59,962 | 60,590 | 628 | 1.0% |
| Surgical Cases | | | | | |
| Inpatient | 5,145 | 5,343 | 5,598 | 255 | 4.8% |
| Outpatient | 7,334 | 7,723 | 7,865 | 142 | 1.8% |
| Total | 12,479 | 13,066 | 13,463 | 397 | 3.0% |
| Case Mix Index - Acute | 1.83 | 1.76 | 1.78 | 0.02 | 1.2% |
| Emergency Visits | 50,473 | 52,202 | 55,040 | 2,838 | 5.4% |
| CPEP Visits | 9,606 | 9,812 | 10,239 | 427 | 4.4% |
| Terrace View ADC | 345.5 | 364.3 | 378.1 | 13.7 | 3.8% |



Revenue

- Net average revenue rate increase of 8% (includes all payers)
 - Larger increase is driven by add-ons for Medicare Wage Index, Behavioral Health and other Medicaid rate increases and Essential Plan increases
- Acute IP Discharges increase from 2023 levels
 - Growth in inpatient cases related to improved community skilled nursing facility access, average length of stay management, and the improving trends in 2023
- Outpatient volume slight increase from 2023 levels
 - Increases in clinic visits (Dialysis, primary care, transplant and rehab medicine)
- Terrace View average daily census increase to 378 residents
 - Staffing levels have increased and will allow for increased census.
- IGT Year over year growth based upon estimated net changes in allowable costs net of increases in associated Medicaid revenue.
- Revenue cycle process improvements of \$5M included within contract underpayments, professional billing, denials and bad debt expense

Page 264 of 330



IGT and UPL Revenue (Accrual Basis Revenue)

| | Budget <u>2023</u> | Projected <u>2023</u> | Budget <u>2024</u> |
|-------|-----------------------|--------------------------|-----------------------|
| DSH | 107,962 | 106,462 | 107,280 |
| UPL | 8,389 | 8,389 | 16,000 |
| Total | 116,351 | 114,851 | 123,280 |



Expenses

Salaries

- Increase in overall FTE's to 3,700 (3,686 @ 8/21/23)
 - Vacancy management
- Reduced premium costs (OT and shift bonuses)
- Contracted salary increases total an average of 4.0%
- Non-Union wage increases total 3%
- Implementation of other contracted enhancements (step changes, other shift pay changes)

Benefits

- Increased health insurance costs, workers compensation, unemployment related costs and pension expense
- Decrease in post-retiree health benefit cost as a result of actuarial assumption impact estimates



Expenses (cont'd)

- Physician & Residents
 - Notable increases
 - Contracted fee and certain rate increases
 - · University faculty (GME) and resident salary inflation
 - New physicians Neurosurgery, ED, Family Medicine, Oncology and Gastroenterology
 - Increase in GPPC total cost related to new physicians, physicians transitioned from ECMC, and expanded practice operations (volume and revenue also included)
- Contractual Fees/Purchased Services
 - Reduction in contractual fees associated with temporary agency nursing personnel, while maintaining desired staffing
 - · Continued at Terrace View but with reduced contracted staffing



Expenses (cont'd)

Supplies

- Increase in volume from projected 2023 volume levels including an increase in total surgeries
- Inflationary increases in all supply categories, most significant in pharmacy costs partially offset by savings initiatives (physician preference, pricing, joint contracting)
- Increase in specialty pharmacy drug costs related to volume due to growth
- Supply chain cost savings initiatives of \$2.5 million

Depreciation and Interest

- Decreased overall depreciation and interest costs
 - Expense based upon remaining depreciation on existing assets plus new capital anticipated.
 - Reduced non-project capital expenditures during 2020 2023.

Page 268 of 330



Cash Flow Assumptions

- Net change in cash of (\$32.4) Million without any 2024 NYS operating grants
 - Days operating cash on hand decreased to 13 days from projected 2023 (excludes designated funds)
- Days in accounts receivable improving to 59.3 days
- Days in accounts payable at 60 days
- Routine capital budget spend consistent with 2022 and 2023 at \$8.0 million
- Line of credit balance remains outstanding



Performance Improvement Initiatives

- Length of stay improvements
- Revenue cycle improvements
- Vacancy management / premium time reduction
- Value analysis program growth reducing supply costs
- Reduction in certain purchased services
- Continued inpatient and outpatient growth strategies
- Continued infrastructure investment and accelerated growth in population health strategies
- Outpatient service line improvements (efficiency and focused growth)
- Insurance plan relationships, increased rates through contracting, MCR wage index, improved governance

Page 270 of 330



Emerging Issues and Risk Areas

- Timing of future DSH/IGT payments
- Operating performance improvements
 - Market driven length of stay risks
 - Recruitment and retention risks
 - FTE vacancy management risks
- Continued inflationary pressures on non-salary operating costs and pharmaceutical shortages
- Federal and NYS operational support uncertainty
- Federal and NYS reimbursement uncertainty
- Inpatient and outpatient volume sensitivity
 - Ambulatory surgery market
- Benefit expense and contribution changes
 - Pension and OPEB
- Medical malpractice regulatory environment
- Technology limitations EHR

2024 Capital Budget Summary

Given stepped recovery, ECMCC must limit capital spending and remain consistent with 2023

- \$8.0 Million routine capital spend
 - \$8M from internal operating funds

5 Year Financial Projections

- Reimbursement rate increases adjusted to usual historical net rate increases, excluding one-time increases
- IGT/UPL at current projections
- Salary expense consistent with current collective bargaining agreements
- Benefits % of salary expense steady throughout projection period
- Supply and other expense inflation reduced from 2023 and 2024 to reflect more reasonable growth after 2024
- Reflects need for additional operational Federal and/or New York State support in addition to management's achievement of ongoing operational improvements



Statements of Revenues and Expenses - Projected

(Thousands)

| | Audited | Projected | Budget | | | Projected | | |
|--|-------------|-------------|-------------|-------------|----------|-----------|-------------|-------------|
| | <u>2022</u> | <u>2023</u> | <u>2024</u> | <u>2025</u> | 2026 | 2027 | <u>2028</u> | <u>2029</u> |
| Operating Revenues | | | | | | | | |
| Net Patient Service Revenue | 566,389 | 583,869 | 645,857 | 676,083 | 707,089 | 738,464 | 770,218 | 802,360 |
| Disproportionate Share, IGT and UPL Revenue | 68,295 | 114,851 | 123,280 | 123,280 | 123,280 | 123,280 | 123,280 | 123,280 |
| Other Operating Revenue | 26,095 | 42,576 | 49,890 | 50,389 | 50,893 | 51,402 | 51,916 | 52,435 |
| Total Operating Revenues | 660,779 | 741,297 | 819,027 | 849,752 | 881,262 | 913,146 | 945,414 | 978,076 |
| Operating Expenses | | | | | | | | |
| Salaries and Benefits | 348,266 | 430,721 | 446,981 | 487,255 | 510,698 | 535,236 | 560,920 | 587,803 |
| Physician Fees and Professional Services | 194,970 | 187,212 | 199,443 | 203,432 | 207,501 | 211,651 | 215,884 | 220,201 |
| Supplies | 117,877 | 125,413 | 130,625 | 136,811 | 142,168 | 147,635 | 153,216 | 158,915 |
| Other Expenses | 29,185 | 28,720 | 30,136 | 31,972 | 33,919 | 35,984 | 38,176 | 40,501 |
| Depreciation and Amortization | 41,615 | 40,195 | 37,100 | 30,407 | 30,104 | 31,023 | 32,158 | 33,493 |
| Interest | 10,928 | 11,095 | 9,747 | 8,315 | 7,717 | 7,166 | 6,480 | 5,744 |
| Total Operating Expenses | 742,841 | 823,355 | 854,032 | 898,192 | 932,106 | 968,695 | 1,006,834 | 1,046,656 |
| | (82,062) | (82,058) | (35,005) | (48,440) | (50,844) | (55,548) | (61,420) | (68,581) |
| Operational Support / Performance Improvements | | | | 30,940 | 40,844 | 50,548 | 61,920 | 69,081 |
| Income/(Loss) from Operations | (82,062) | (82,058) | (35,005) | (17,500) | (10,000) | (5,000) | 500 | 500 |
| Grant revenue | 63,151 | 29,469 | - | - | - | - | <u> </u> | 3.55 |
| Income/(Loss) from Operations with Grants | (18,911) | (52,589) | (35,005) | (17,500) | (10,000) | (5,000) | 500 | 500 |
| Non Operating Revenues & Capital Contributions | (13,967) | 4,814 | 1,205 | 1,205 | 1,205 | 1,205 | 1,205 | 1,205 |
| Excess of Revenues Over Expenses | (32,878) | (47,776) | (33,800) | (16,295) | (8,795) | (3,795) | 1,705 | 1,705 |



| | (Tho | usands |) | | | | | |
|---|-----------|-----------|------------|-----------|-----------|------------|-----------|-----------|
| | Audited | Projected | Budget | | | Projected | | |
| NAME OF THE PARTY | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ASSETS | | | | | | | | |
| Current Assets | 0.0000 | 1001020 | 50/12/52/1 | 10016925 | 70000000 | 12/20/2004 | 1224500 | 1000000 |
| Cash & Investments | 44,195 | 62,284 | 29,848 | 32,635 | 33,710 | 33,411 | 38,484 | 45,412 |
| Patient Accounts Receivable | 83,569 | 100,777 | 104, 371 | 100,008 | 96,850 | 101,150 | 105,500 | 109,900 |
| Other Current Assets | 85,197 | 88,670 | 90,555 | 91,287 | 91,974 | 92,625 | 95,342 | 98,125 |
| Total Current Assets | 212,961 | 251,731 | 224,774 | 223,931 | 222,534 | 227,186 | 239,326 | 253,437 |
| Assets Whose Use Is Limited | 157,515 | 159,704 | 159,951 | 159,607 | 159,258 | 159,904 | 160,558 | 161,219 |
| Property and Equipment | 328,170 | 295,976 | 266,876 | 246,469 | 241,365 | 235, 342 | 228,184 | 219,691 |
| Other Assets | 263,731 | 261,854 | 254,780 | 253,222 | 252,014 | 250,886 | 249,875 | 249,090 |
| Total Assets | 962,377 | 969,264 | 906, 381 | 883,229 | 875,171 | 873,318 | 877,942 | 883,437 |
| LIABILITIES AND NET ASSETS | | | | | | | | |
| Current Liabilities | | | | | | | | |
| Current Portion of Long Term Debt | 28,795 | 28,586 | 27,568 | 15,604 | 14,934 | 14,507 | 14,207 | 13,757 |
| Accounts Payable, Third-Party & Accrued | 267,492 | 344,776 | 328,724 | 337,734 | 343,869 | 350, 258 | 356,906 | 363,822 |
| Total Current Liabilities | 296,287 | 373,362 | 356, 292 | 353,338 | 358,803 | 364, 765 | 371,113 | 377,579 |
| Long Term Debt | 225,833 | 218,783 | 201, 215 | 185,611 | 170,677 | 156,170 | 141,963 | 128,206 |
| Deferred Inflows | 395,002 | 396,144 | 396,002 | 397,002 | 398,002 | 399,002 | 400,002 | 401,002 |
| Other Post Employment Benefits | 259,334 | 250,051 | 257,553 | 265,280 | 273,238 | 281,435 | 289,878 | 298,575 |
| Self Insurance Reserves | 54,340 | 47,118 | 45, 313 | 48,288 | 49,535 | 50,826 | 52,162 | 53,545 |
| Total Liabilities | 1,230,796 | 1,285,459 | 1,256,375 | 1,249,518 | 1,250,255 | 1,252,198 | 1,255,117 | 1,258,907 |
| Net Position | (268,419) | (316,194) | (349, 994) | (366,290) | (375,085) | (378, 880) | (377,175) | (375,470) |
| Total Liabilities and Net Assets | 962,377 | 969,264 | 906, 381 | 883,228 | 875,170 | 873,318 | 877,942 | 883,436 |

Statements of Cash Flow - Projected

(Thousands)

| | Audited | Projected | Budget | | | Projected | | |
|---|-----------|-----------|-----------|----------|----------|-----------|----------|----------|
| | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| Cash Flows From Operating Activities | | | | | | | | |
| Excess of Revenues Over Expenses | (32,878) | (47,776) | (33,800) | (16,295) | (8,795) | (3,795) | 1,705 | 1,705 |
| Depreciation & Amortization | 41,615 | 40,195 | 37,100 | 30,407 | 30,104 | 31,023 | 32,158 | 33,493 |
| Provision for bad debt | 15,474 | 12,537 | 12,674 | 13,206 | 13,236 | 13,266 | 13,297 | 13,328 |
| Me dicare Advance d Payment Program | (20,879) | - | 2 | - | 1 | 1 | | 2 |
| (Increase) Decrease in Non-operating revenues | (38,256) | (23,188) | 8,542 | 7,110 | 6,512 | 5,961 | 5,275 | 4,539 |
| (Increase) Decrease in Patient Accounts Receivable, Net | (22,328) | (29,745) | (16, 267) | (8,843) | (10,078) | (17,566) | (17,647) | (17,728) |
| (Increase) Decrease in Current and Other Assets | 144,272 | (1,596) | 5, 189 | 826 | 522 | 476 | (1,706) | (1,998) |
| Increase (Decrease) in Accounts Payable, Third-Pary & Accrued | (105,832) | 77,284 | (16,051) | 9,009 | 6,136 | 6,388 | 6,648 | 6,917 |
| Increase (Decrease) in Deferred In Flows | (69,022) | 1,142 | (142) | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| Increase (Decrease) in Self Insurance Liabilities | 1,322 | (16,505) | 5, 696 | 10,702 | 9,205 | 9,488 | 9,779 | 10,079 |
| Net Cash Provided By (Used In) Operating Activities | (86,512) | 12,347 | 2,939 | 47,121 | 47,842 | 46, 242 | 50,510 | 51,335 |
| Cash Flows From Investing Activities | | | | | | | | |
| Other Investing Activities, Net | 10,192 | 2,625 | 958 | 1,549 | 1,554 | 559 | 551 | 544 |
| Net Cash Provided By (Used In) Investing Activities | 10,192 | 2,625 | 958 | 1,549 | 1,554 | 559 | 551 | 544 |
| Cash Flows From Financing Activities | | | | | | | | |
| Additions to Property and Equipment | (26,856) | (8,000) | (8,000) | (10,000) | (25,000) | (25,000) | (25,000) | (25,000) |
| Non-operating grants | 90,152 | 29,469 | - | - | 7: | | - | - |
| Changes in Long Term Debt | (12,245) | (18,353) | (28, 333) | (35,883) | (23,321) | (22, 100) | (20,987) | (19,951) |
| Net Cash Provided By (Used In) Financing Activities | 51,051 | 3,116 | (36, 333) | (45,883) | (48,321) | (47,100) | (45,987) | (44,951) |
| Net Increase (Decrease) in Cash and Investments | (25,269) | 18,089 | (32, 436) | 2,787 | 1,075 | (299) | 5,073 | 6,928 |
| Cash and Investments, Beginning | 69,464 | 44,195 | 62, 284 | 29,848 | 32,635 | 33,710 | 33,411 | 38,484 |
| Cash and Investments, Ending | 44,195 | 62,284 | 29,848 | 32,635 | 33,710 | 33, 411 | 38,484 | 45,412 |

Appendix A

Outstanding Bonds and Notes

Erie County Guaranteed Senior Revenue Bonds, Series 2004

No bonds were issued, called, or re-financed during 2023.

\$4,165,000 of bonds matured or were redeemed in 2023.

\$56,970,000 of 2004 bonds remain outstanding on December 31, 2023.

Erie County Loan Payable-2017 (Refinance)

During 2017, the Corporation refinanced its 2011 Loan with a \$74,366,859 loan from the County of Erie.

\$4,158,603 in principal payments were made in 2023.

\$49,076,847 of debt is outstanding on December 31, 2023.

Erie County Loan Payable-201 (New Money)

During 2017, the Corporation entered into a \$99,492,034 loan with the County of Erie.

\$2,780,391 in principal payments were made in 2023.

\$87,374,270 of debt is outstanding on December 31, 2023.

Erie County Capitalized Interest Assumption Obligation-2017

During 2017, the Corporation entered into an \$8,281,141 capitalized interest assumption obligation with the County of Erie.

\$231,424 in principal payments were made in 2023.

\$7,272,529 of debt is outstanding on December 31, 2023.

Line of Credit

During 2021, the Corporation signed an agreement for an unsecured revolving line of credit.

\$0 in principal payments were made in 2023.

\$10,000,000 of outstanding borrowings against the line of credit on December 31, 2023.

Metz Culinary Management Food Service Improvements Loan

During 2019, the Corporation entered into a \$1,805,430 loan with Metz Culinary Management.

\$180,543 in principal payments were made in 2023.

\$947,860 of debt is outstanding on December 31, 2023.

During 2021, the Corporation entered into a \$1,552,000 loan with Metz Culinary Management.

\$200,258 in principal payments were made in 2023.

\$1,001,290 of debt is outstanding on December 31, 2023.

| Name | Job Title | 2023 Gross Earnings | Annual Salary |
|---------------------------|--|------------------------|---------------|
| Abafita, Aziza | General Duty Nurse | 122,268 | 102,186 |
| Addison, Jessica | Charge Nurse | 170,206 | 110,700 |
| Aiad, Jean | Dentist ECMC RPT | 117,237 | 117,237 |
| Albanese, Pamela | Identity & Access Accounts Control Coord | 100,928 | 101,005 |
| Albert, Alison | Director of Admissions Medical Rehabilit | 127,717 | 119,974 |
| Almeter, Katherine | Charge Nurse | 125,540 | 104,337 |
| Ambrose, Keith | Director of Capital Projects | 114,587 | 113,815 |
| Amendola, Amy | General Duty Nurse | 110,349 | 102,186 |
| Anders, Mark | Medical Specialist | 180,646 | 168,808 |
| Anderson, Jennifer | Charge Nurse | 137,917 | 110,700 |
| Andrews, Kristin | Assistant Head Nurse | 124,440 | 110,700 |
| Artieri, Diane | Vice President of Materials Management | 180,048 | 180,250 |
| Augostini, Anna | Pharmacist ECMC | 142,395 | 139,258 |
| Austin, Cheryl | Director of Imaging Services | 139,292 | 139,156 |
| Baetzhold-Fabiniak, Karen | Physician Assistant | 145,481 | 145,643 |
| Bailen, Matthew | Director of Nursing Education-CC | 135,128 | 131,840 |
| Bailey, Steven | Nursing Supervisor LTC RPT | 142,977 | 119,672 |
| Baker, Aimee | General Duty Nurse | 103,335 | 102,186 |
| Baker, Shawn | General Duty Nurse | 108,568 | 102,186 |
| Balk, Andrew | Healthcare Information Security Analyst | 108,555 | 101,005 |
| Ballard, Katrina | Nurse Case Manager - Behavioral Health | 127,154 | 123,583 |
| Bandoh, Anthony | Healthcare Information Security Analyst | 109,769 | 101,005 |
| Barr-Buday, Tamara | Clinical Documentation Specialist | 118,921 | 101,290 |
| Barry, Jennifer | PROGRAM DIRECTOR-BEHAVIORAL HEALTH | 110,401 | 105,000 |
| Basher, William | Nursing Team Leader Dialysis Services | 126,965 | 119,276 |
| Bass, Cynthia | Director of Diversity and Inclusion | 141,097 | 133,900 |
| Bass, Edmond | Nursing Informatics Mgr. | 140,667 | 137,565 |
| Bastian, Michele | General Duty Nurse | 110,416 | 102,186 |
| Bauer, Christine | Charge Nurse | 99,793 | 101,290 |
| Beaver, Michael | Pharmacist ECMC | 140,535 | 136,186 |
| Becker, Cynthia | General Duty Nurse | 103,473 | 102,186 |
| Becker, Melissa | Unit Manager Operating Room | 160,116 | 128,567 |
| Becker, Paula | Pharmacist ECMC | 148,993 | 148,439 |
| Beiter, Sean | Director of Labor & Employee Relations | 150,382 | 149,350 |
| Bell, Shentelle | Director of Nursing Services Ambulatory | 128,605 | 128,750 |
| Bellido-Clark, Dana | Unit Manager MedicalSurgical | 135,048 | 132,429 |
| Bennett, Murnita | General Duty Nurse | 103,881 | 102,186 |
| Benson, Amanda | Charge Nurse | 110,699 | 107,457 |
| Bermingham, Morgan | Pharmacist ECMC | 49,978 | 136,186 |
| Bernier, Deborah | Operations Manager LTC | 122,874 | 118,450 |
| Bethea, Marquita | Director of Admissions LTC | 139,183 | 130,491 |
| Bielicki, Kim | General Duty Nurse | 123,595 | 102,186 |
| Bielmann, Beth | General Duty Nurse | 103,924 | 102,186 |
| Biersbach, Bret | Anesthesiologist | 529,769 | 475,000 |

| Bisulca, Amanda | General Duty Nurse | 76,967 | 102,186 |
|----------------------|--|---------|---------|
| Bittner, Michelle | Charge Nurse | 118,420 | 110,700 |
| Blair, Lawrence | Behavioral Health Clinical Manager | 127,864 | 118,450 |
| Blair, Lindsey | Nursing Inservice Instructor ECMC | 124,741 | 119,276 |
| Blair, Sean | Nurse Case Manager | 142,552 | 131,102 |
| Blecha, Kortney | Charge Nurse | 176,991 | 110,700 |
| Boice, Allison | Nurse Case Manager | 131,209 | 127,296 |
| Bolden, Taywanda | Behavioral Health Clinical Manager | 121,018 | 118,450 |
| Bonito, Nicole | Anesthetist | 274,353 | 236,023 |
| Borton, Angela | Pharmacist ECMC | 141,672 | 139,258 |
| Brennan, Melinda | Unit Manager MedicalSurgical | 133,413 | 128,567 |
| Brennan, Stephanie | Pharmacist ECMC | 146,087 | 139,258 |
| Brian, Stephanie | Pharmacist ECMC | 5,238 | 136,186 |
| Brindisi, Joseph | Nurse Practitioner ECMC | 136,075 | 137,825 |
| Brinker, Debra | Charge Nurse | 131,969 | 110,700 |
| Brinkworth, Jennifer | Charge Nurse | 162,111 | 110,700 |
| Broeneman, Kourtney | Nurse Case Manager | 134,502 | 131,102 |
| Brooks, Latoya | Unit Manager MedicalSurgical | 130,086 | 136,386 |
| Brown, Alesha | Charge Nurse | 128,256 | 101,290 |
| Brown, Dana | Anesthetist | 307,801 | 236,023 |
| Brown, Donna | Associate Hospital Administrator | 137,615 | 137,769 |
| Brown, Jillian | VP of Behavioral Health Services | 175,814 | 163,894 |
| Brundin Jr, Douglas | Anesthetist | 257,882 | 236,023 |
| Brunner, Stephanie | Transplant Coordinator | 107,072 | 116,478 |
| Bryant, Monica | Nursing Team Leader | 102,071 | 109,173 |
| Buckley, Peter | Nursing Team Leader LTC | 121,386 | 109,173 |
| Budde, Ronald | PROGRAM DIRECTOR-BEHAVIORAL HEALTH | 35,455 | 105,000 |
| Bufalino, Rosalia | General Duty Nurse | 124,881 | 102,186 |
| Bulinski, Alexis | Charge Nurse | 166,004 | 101,290 |
| Buono, Deanne | General Duty Nurse | 115,657 | 102,186 |
| Burgio, Susan | Clinical Laboratory Quality Coordinator | 142,732 | 114,895 |
| Burke, Mark | Attending Physician | 772,460 | 737,032 |
| Burnett, Wayne | Senior Physical Therapist | 107,709 | 103,091 |
| Burridge, Suzanne | Pharmacist ECMC RPT | 105,273 | 101,626 |
| Burt, Mary | Nursing Team Leader | 180,949 | 119,276 |
| Calicutt, Steven | Chief Healthcare Information Security Of | 65,538 | 213,000 |
| Calire, Gina | Clinical Documentation Specialist | 129,034 | 104,337 |
| Canallatos, Jessica | Dentist ECMC RPT | 133,506 | 121,892 |
| Canallatos, Paul | Dentist ECMC | 224,362 | 228,093 |
| Cantie, Shawn | Anesthesiologist | 534,353 | 504,000 |
| Capozzi, Nicole | General Duty Nurse | 127,940 | 102,186 |
| Carl, Karen | Nursing Team Leader | 126,948 | 119,276 |
| Carnevale, Marinela | Emergency Department Patient Flow TL | 144,674 | 119,276 |
| Carpenter, Cheryl | Director of Medical Dental Staff Svcs | 122,455 | 122,592 |
| Carroll, Jennifer | Behavioral Health Clinical Manager | 129,838 | 123,600 |
| Casali, Colleen | General Duty Nurse | 135,886 | 102,186 |
| Castonguay, Andrea | Physician Assistant | 117,425 | 115,000 |

| Cavo, Paul | Clinical Systems Analyst | 127,008 | 105,498 |
|------------------------|--|---------|---------|
| Cheng, Yi Shun | Attending Physician | 297,566 | 288,400 |
| Chikaraishi, Juli | Director of Outpatient Opers & Oncolog | 121,938 | 119,995 |
| Chilbert, Kevin | Clinical Pharmacy Specialist | 154,130 | 151,199 |
| Ciancone, Gabriella | Infection Prevention Practioner | 124,518 | 119,276 |
| Cicchinelli, Salvadore | Project Manager HIT | 106,359 | 102,531 |
| Cieri, Margaret | Nursing Care Coordinator | 159,425 | 141,669 |
| Cirillo, Joseph | Director of Public Relations Communic. | 144,434 | 138,898 |
| Ciurczak, Tiffany | Emergency Department Patient Flow TL | 137,044 | 119,276 |
| Clark, Cynthia | Nurse Case Manager | 138,899 | 131,102 |
| Cleckley, Shonda | General Duty Nurse | 200,741 | 102,186 |
| Cloud, Samuel | Medical Director ECMC | 537,545 | 550,000 |
| Colebeck, Amanda | Dentist ECMC | 309,437 | 313,120 |
| Colucci, Anthony | Executive Vice President | 652,602 | 652,463 |
| Comstock, Scott | Charge Nurse | 128,244 | 110,700 |
| Coniglio, Julia | Anesthetist | 251,303 | 236,023 |
| Conley, Meghan | Charge Nurse | 115,008 | 107,457 |
| Connors, Marchelle | Charge Nurse | 112,022 | 110,700 |
| Contino, Alyse | Charge Nurse | 115,872 | 101,290 |
| Cornelius, Rhonda | Nursing Care Coordinator | 57,568 | 127,496 |
| Cretacci, Nicole | Unit Manager MedicalSurgical | 139,350 | 136,386 |
| Culligan, Tanya | Clinical Documentation Specialist | 124,303 | 110,700 |
| Cumbo, John | Vice President of Information Technology | 254,857 | 236,900 |
| Currin, Shawntres | Unit Manager MedicalSurgical | 144,803 | 132,429 |
| Cutler, Peter | VP of Communications & External Affairs | 271,100 | 267,800 |
| Cutting, Karen | Healthcare Business Sys Analyst | 103,091 | 103,243 |
| Czerwinski-Brown, Lynn | General Duty Nurse | 112,045 | 102,186 |
| Dalton, Wendy | Nursing Team Leader LTC | 138,096 | 112,455 |
| D'Angelo, Dino | Charge Nurse | 114,969 | 107,457 |
| Daniels, Steven | Sr. Human Resources Info System Admin | 128,215 | 123,600 |
| Daoust, Jeffrey | Physician Assistant | 102,161 | 132,009 |
| Davis, Andrew | Chief Operating Officer ECMC | 682,320 | 657,758 |
| Davis, Cassandra | Senior Vice President of Operations-Outp | 300,208 | 293,550 |
| Davis, Karen | Charge Nurse | 123,042 | 107,457 |
| Dean, Rachel | Charge Nurse | 118,481 | 101,290 |
| DeFilippo, Jenna | Assistant Head Nurse | 162,218 | 107,457 |
| Deguire, Janelle | Assistant Nurse Case Manager | 106,840 | 107,457 |
| DelGuidice, Natalie | Clinical Pharmacy Specialist | 152,796 | 154,565 |
| DelPrince, Becky | VP of Systems and Integrated Care | 200,482 | 193,905 |
| DelVecchio, Regina | Staff Counsel ECMC | 201,146 | 193,905 |
| DePlato, Anthony | Anesthesiologist | 591,867 | 553,340 |
| Derenda, Nicole | Director of Nursing Education Med/Surg | 54,744 | 133,738 |
| DeSantis-Evans, Leigh | General Duty Nurse | 120,156 | 102,186 |
| Dettman, Brittany | Nursing Supervisor LTC | 106,118 | 107,353 |
| DeYoung, Candice | Nursing Team Leader | 117,553 | 119,276 |
| Diez, Tyler | Senior Director Outpatient Operations | 82,789 | 123,000 |
| Diina, David | Nurse Practitioner Transplant | 306,815 | 155,116 |

| Dillabough, Andrew | Point of Care Clinical Laboratory Coord | 94,966 | 110,644 |
|----------------------|---|---------|---------|
| DiOrio, Leigh-Anne | Nurse Practitioner Transplant | 173,881 | 124,016 |
| Dishunts, Olga | Clinical Informatics Educator | 119,528 | 103,243 |
| Dobson, Judy | VP Medical Surgical Nursing Services | 188,543 | 188,153 |
| Dolansky, Evan | Pharmacist ECMC | 150,389 | 148,439 |
| Dombrowski, Jennifer | Senior Occupational Therapist | 105,499 | 100,225 |
| Donegan, Shawn | Charge Nurse | 114,511 | 104,337 |
| Donovan, Kevin | General Duty Nurse | 100,069 | 102,186 |
| Dove, Theresa | General Duty Nurse | 100,438 | 102,186 |
| Dowdell, Anne | General Duty Nurse | 106,899 | 102,186 |
| Draper, Cristina | General Duty Nurse | 120,087 | 102,186 |
| Drysdale, Michelle | InService Education Coordinator | 170,256 | 123,583 |
| Duell, Susan | Minimum Data Set Director | 139,161 | 119,974 |
| Duffin, Joy | Transplant Coordinator | 202,221 | 131,102 |
| Duffy, Brian | Anesthesiologist | 102,175 | 395,391 |
| Duman, Eileen | Administrative Director of Laboratory Se | 161,184 | 156,560 |
| Durant, Jason | Systems Administrator | 135,847 | 111,234 |
| Dvinova, Larisa | Charge Nurse | 165,705 | 110,700 |
| Dwyer, Lisa | General Duty Nurse | 112,721 | 102,186 |
| Dyson, Alicia | General Duty Nurse | 98,478 | 102,186 |
| Eccleston, Bobby | NURSING INSERVICE INSTRUCTOR (EMERGENCY | 48,786 | 105,993 |
| Eck, Brooke | Director of Respiratory Therapy Services | 113,685 | 114,729 |
| Egan, Carol | | 122,618 | 110,700 |
| | Charge Nurse | | |
| Eleey, Lynnette | Charge Nurse | 126,146 | 110,700 |
| Elliott, Karen | Senior Clinical Laboratory Technologist | 24,838 | 102,066 |
| Erhardt, Laurie | Minimum Data Set Specialist | 115,048 | 112,455 |
| Erhardt, Robert | Chief Hospital Public Safety Officer Senior Pharmacist ECMC | 167,631 | 123,768 |
| Ervolina, Daryl | + | 176,150 | 164,717 |
| Eustace, Amy | General Duty Nurse | 121,711 | 102,186 |
| Evans, Maureen | Pharmacist ECMC RPT | 115,911 | 114,061 |
| Evans, Michele | Nursing Team Leader LTC | 143,996 | 119,276 |
| Falco, Mark | Attending Physician | 527,310 | 494,400 |
| Fanning, Rozalyn | Charge Nurse | 122,652 | 104,337 |
| Farrell, Amanda | Population Health Clinical Data Analyst | 126,670 | 123,583 |
| Fenner, Nicholas | Pharmacist ECMC | 146,699 | 139,258 |
| Ferguson, Richard | Director of Neurology RPT | 438,240 | 392,256 |
| Fezer III, Stephen | Anesthetist | 259,236 | 236,023 |
| Fiden, Donna | General Duty Nurse | 133,851 | 102,186 |
| Firestone, Lisa | Nurse Case Manager - Ambulatory Services | 126,984 | 123,583 |
| Flaherty, Amy | Staff Counsel - Risk Management | 163,710 | 163,894 |
| Fleming, Laura | Privacy Officer | 112,529 | 109,051 |
| Fletcher, Lynn | Nursing Care Coordinator | 114,313 | 133,553 |
| Flett, Deborah | Nursing Team Leader LTC | 127,942 | 119,276 |
| Floyd, Kaitlin | Nursing Team Leader | 40 | 110,583 |
| Flynn, William | Director of Surgery RPT | 259,164 | 255,564 |
| Forgensi, Stacey | Anesthetist | 226,176 | 236,023 |
| Fowler, Julia | Nursing Care Coordinator | 159,246 | 141,669 |

| Fox, Heather | Nurse Case Manager - Ambulatory Services | 135,121 | 131,102 |
|-----------------------|--|---------|---------|
| Frey, Jordan | Attending Physician | 524,537 | 498,623 |
| Friend, Dawn | Director of Nursing Service LTC | 65,186 | 144,612 |
| Frustino, Jennifer | Dentist ECMC | 263,287 | 265,407 |
| Furlani, Lisa | Anesthetist | 248,708 | 236,023 |
| Furnari, Graziella | Clinical Pharmacy Specialist | 150,994 | 151,199 |
| Gallagher, Heather | Senior Director Of Comp. Benefits HRIS | 148,943 | 144,612 |
| Galley, Sarah | Charge Nurse | 114,307 | 101,290 |
| Gallineau, Anne-Marie | Nursing Care Coordinator | 171,285 | 141,669 |
| Gan, Dalong | Anesthetist | 87,138 | 218,753 |
| Gant, Ramona | Director of Nursing Service LTC | 122,784 | 152,500 |
| Gardy-Batson, Marcell | Assistant Director Nursing LTC | 130,105 | 128,750 |
| Garfoot, John | Attending Physician | 383,000 | 350,000 |
| Garvey, Benjamin | RN Renal/Hemo Data Reviewer | 100,689 | 104,337 |
| Gary, Stephen | Consultant IV | 411,829 | 411,829 |
| George, Kristin | Charge Nurse Ambulatory Care | 105,846 | 104,337 |
| Gian, Kathleen | General Duty Nurse | 189,705 | 102,186 |
| Giglia, Joseph | General Counsel | 522,229 | 530,000 |
| Gill, Elise | Physician Assistant | 117,518 | 115,000 |
| Gloss, Margaret | Technical Director Echocardiography | 106,498 | 101,005 |
| Gomez, Melissa | Director of Clin. Coding Record Qual Mg | 104,086 | 104,204 |
| Gompah, Santosha | Unit Manager MedicalSurgical | 143,070 | 136,386 |
| Gonzalez, Susan | Executive Director ECMC Lifeline Foundat | 204,279 | 200,905 |
| Gorczynski II, Thomas | Director of Technical Services | 156,142 | 155,000 |
| Gozdalski, Nicole | Charge Nurse | 146,515 | 110,700 |
| Grabski, Meghan | Charge Nurse | 215,099 | 101,290 |
| Grantham, Ayanna | Assistant Director Nursing LTC | 130,105 | 128,750 |
| Green, Kimberly | Nursing Team Leader | 120,604 | 112,455 |
| Greenaway, Wanda | Nurse Practitioner Surgical Services | 124,733 | 150,615 |
| Greene Clark, Maria | Director of CPEP | 128,605 | 128,750 |
| Gregorio, Tara | Unit Manager MedicalSurgical | 146,667 | 136,386 |
| Grimm, Jessica | Nursing Team Leader | 118,678 | 109,173 |
| Grolemund, Stephanie | Anesthetist | 266,155 | 236,023 |
| Grzebinski, Jane | Pharmacist ECMC | 157,350 | 151,574 |
| Grzybowski, Helen | InService Education Coordinator | 160,673 | 131,102 |
| Gulczewski, Michelle | General Duty Nurse | 106,497 | 102,186 |
| Habonimana, Colette | Charge Nurse | 140,526 | 110,700 |
| Haefner, Lori | Charge Nurse | 122,970 | 110,700 |
| Haefner, Paula | Project Manager HIT | 110,061 | 108,104 |
| Haines, Tracey | Charge Nurse | 148,176 | 104,337 |
| Halladay, Nicholas | Charge Nurse | 129,007 | 104,337 |
| Halloran, Ashley | Vice President of Pharmacy Operations | 195,826 | 195,700 |
| Hamilton, Catherine | Director of Patient Financial Services | 128,021 | 128,164 |
| Hamilton, Holly | Pharmacist ECMC | 137,490 | 139,258 |
| Handley, Sarah | Pharmacist ECMC | 43,364 | 139,258 |
| Hanlon, Barbara | Assistant Head Nurse | 117,701 | 110,700 |
| Hanna, Jennifer | Charge Nurse | 134,398 | 104,337 |

| Harhara, Ameen | Nursing Care Coordinator | 139,475 | 115,931 |
|--------------------------------------|---|---------|---------|
| Harris, Rachel | Nurse Practitioner Plastic Recon Surger | 140,281 | 137,825 |
| Hartman, Nancy | Registered Nurse Trauma Registrar | 119,230 | 119,276 |
| Hartman, Sandra | Nursing Supervisor LTC | 152,293 | 131,102 |
| Hartmann, Erica | Dentist ECMC | 176,488 | 180,250 |
| Haseley, Nicole | Nurse Practitioner Transplant | 231,273 | 155,116 |
| Hatten, Khadija | Nursing Care Coordinator | 147,364 | 133,553 |
| Hauss, Lisa Marie | Nurse Case Manager | 83,626 | 131,102 |
| Havers, Amy | Charge Nurse | 121,978 | 107,457 |
| Hayes, Renee | Charge Nurse | 218,047 | 104,337 |
| Healy, Jaclyn | Pharmacist ECMC | 139,792 | 136,186 |
| Herdman, Jennifer | General Duty Nurse | 100,395 | 102,186 |
| Herr, Alexandra | Staff Counsel ECMC | 118,707 | 123,600 |
| Hidalgo, Francisco | Code Compliance Manager | 129,974 | 126,325 |
| Hierl, Michele | Charge Nurse | 97,455 | 107,457 |
| Highway, Lisa | Director of Recruitment and Retention | 128,215 | 123,600 |
| Hinckley, Debbra | General Duty Nurse | 117,060 | 102,186 |
| Hinderliter, Vanessa | VP of Finance ECMC | 201,385 | 195,700 |
| Hines, Holly | Nurse Case Manager | 133,198 | 131,102 |
| Hodan, Patricia | Infection Prevention Practioner | 122,508 | 119,276 |
| Hodgson, Matthew | Nurse Practitioner Plastic Recon Surger | 151,683 | 155,116 |
| Hoerner, Audrey | Senior Nurse Practitioner - Burn Unit | 185,493 | 173,663 |
| Hoerner, Nadine | Clinical Documentation Specialist | 109,489 | 110,700 |
| Honkomp, Cheryl | Assistant Head Nurse | 127,826 | 110,700 |
| Horesh, Fayelyn | Anesthetist RPT | 178,476 | 177,772 |
| Hovak, Melissa | Nurse Practitioner Transplant | 240,067 | 155,116 |
| Hughes, Christopher | Attending Physician RPT | 279,265 | 269,108 |
| Hulme, Christine | General Duty Nurse | 114,824 | 102,186 |
| Hunley, Kizzie | Clinical Patient Care Liaison | 154,365 | 137,565 |
| Hunt, Benjamin | Nursing Inservice Instructor Psych | 122,364 | 115,835 |
| Hunter, Renee | Charge Nurse | 144,893 | 101,290 |
| Hunter, Thameena | Unit Manager Ambulatory Care | 133,955 | 136,386 |
| Hutchings, Michelle | Nurse Case Manager | 129,934 | 131,102 |
| Hyman, Daniel | Assistant VP of Operations | 5,000 | 130,000 |
| lancu, Adriana | Charge Nurse | 4,518 | 102,584 |
| Ireland, Shari | Charge Nurse | 375 | 105,681 |
| Isch, Pamela | Assistant Director Ambulatory Services | 112,569 | 111,234 |
| Jack, Dennis | Nurse Practitioner Transplant | 244,950 | 129,913 |
| Jack, Jennifer | Charge Nurse | 150,782 | 107,457 |
| Jackson, Seanessa | Nurse Case Manager | 138,877 | 131,102 |
| Jacob, Avneet | Nursing Team Leader | 122,416 | 105,993 |
| Jamison, Shannon | Charge Nurse | 119,586 | 110,700 |
| Janetzke, David | Charge Nurse | 129,159 | 104,337 |
| Jellinick, Lori | Supervisor of Rehab Medicine | 111,863 | 110,485 |
| Jenney, Kevin | Supervisor of Rehab Medicine | 118,405 | 110,485 |
| Jensen, Erik Jerzewski, Stephanie | Anesthesiologist Clinical Systems Analyst | 574,177 | 516,816 |
| Jerzewski, Stephanie | Cillical Systems Alialyst | 116,009 | 101,005 |

| Jimerson, Mary | Nursing Team Leader Ambulatory Services | 143,831 | 109,173 |
|--------------------------|--|---------|---------|
| Jocoy, Angela | Rehab Services Quality Coordinator-ECMCC | 109,239 | 103,091 |
| Johnson, Desiree | Charge Nurse | 141,500 | 101,290 |
| Johnson, Marie | Vice President of Rehab Services | 169,210 | 169,399 |
| Johnson, Maureen | Charge Nurse | 198,832 | 110,700 |
| Jones, Donna | Chief Quality of Care Officer and Operat | 267,500 | 267,800 |
| Jones, Veronica | Charge Nurse | 135,632 | 110,700 |
| Jonmaire, Kenneth | Senior Director Outpatient Operations | 140,539 | 132,010 |
| Julyan, Erika | Senior Occupational Therapist | 106,854 | 101,648 |
| Juncewicz, Edmund | Anesthesiologist | 520,682 | 477,544 |
| Kabayiza, Thamar | General Duty Nurse | 115,301 | 102,186 |
| Kaid, Rafiq | Charge Nurse | 131,768 | 104,337 |
| Kalinka, Lisa | Nurse Practitioner Transplant | 253,847 | 146,209 |
| Kaminska, Stephanie | Physician Assistant | 115,822 | 115,000 |
| Kane, Justin | General Duty Nurse | 138,239 | 102,186 |
| Kapral, Elizabeth | Dentist ECMC | 209,480 | 213,029 |
| Karl, Stephanie | Nurse Case Manager | 125,623 | 127,296 |
| Kaurich, Justine | Vice President of Operations | 205,946 | 206,178 |
| Kawka, April | General Duty Nurse | 116,892 | 102,186 |
| Kayler, Liise | Attending Physician RPT | 203,750 | 168,750 |
| Keenan-Uschold, Lisa | Chief Clinical Psychologist | 142,134 | 142,314 |
| Keeney, Alicia | Nursing Inservice Instructor Ambulatory | 119,863 | 119,276 |
| Kelly-Planter, Jan-Marie | General Duty Nurse | 114,419 | 102,186 |
| Kemp, Amanda | Charge Nurse | 145,551 | 101,290 |
| Kemp, Michelle | Nurse Case Manager | 125,732 | 123,583 |
| Kent, Joanne | Charge Nurse | 132,128 | 104,337 |
| Killion, Valerie | Assistant Director Nursing Sub Acute Ser | 103,514 | 118,450 |
| Kimble, Karen | Behavioral Health Clinical Manager | 121,018 | 118,450 |
| Kinkade, Phillip | General Duty Nurse | 126,838 | 102,186 |
| Kinney, Elizabeth | Charge Nurse | 142,661 | 110,700 |
| Kitson, Rebecca | General Duty Nurse | 103,979 | 102,186 |
| Kleinhans, Shannon | Quality Care Coordinator | 121,901 | 116,478 |
| Klinger, Cathy | General Duty Nurse | 99,748 | 102,186 |
| Koch, Elizabeth | Anesthesiologist | 513,266 | 468,180 |
| Kocz, Remek | Anesthesiologist | 492,443 | 452,574 |
| Kolb, Beth | Charge Nurse | 144,647 | 101,290 |
| Kolber, Brooke | Dentist ECMC RPT | 112,107 | 112,107 |
| Kolbert, Cynthia | Charge Nurse | 135,003 | 110,700 |
| Konikoff, Karen | VP Critical Care & Emergency Services | 191,922 | 183,856 |
| Kordasiewicz, Lynn | Nurse Practitioner Wound Care | 165,792 | 155,116 |
| Korff, Kathryn | Dentist ECMC | 201,285 | 201,510 |
| Kostek, Heather | Nursing Team Leader | 115,824 | 115,835 |
| Koszuta, Ceilia | Nurse Case Manager | 136,743 | 131,102 |
| Kotoroka-Yiadom, Martin | Charge Nurse | 143,424 | 101,290 |
| Krakowiak, Daryl | Assistant Director of Social Work BH | 111,796 | 110,015 |
| Krawczyk, Heather | Charge Nurse | 135,961 | 104,337 |
| Kuechle, Claire | Staff Counsel ECMC | 48,942 | 172,744 |

| Kunak Alasia | Linit Managay MadicalCursical | 150,000 | 126 206 |
|----------------------|--|-----------|---------|
| Kurek, Alecia | Unit Manager MedicalSurgical | 158,686 | 136,386 |
| Kuropatwinski, David | Nursing Team Leader | 116,860 | 115,835 |
| Kwiatkowski, Andrew | Director of Project Management HIT | 170,307 | 160,706 |
| La Porta, Kathleen | Senior Clinical Laboratory Technologist | 104,523 | 102,066 |
| Labelle, Jamie | Unit Manager Hemodialysis | 142,186 | 136,386 |
| Labelle, Marc | VP Surgical Services | 178,352 | 177,351 |
| LaMacchia, Brandy | Charge Nurse | 119,601 | 107,457 |
| Lang, Julie | Project Manager HIT | 107,982 | 108,104 |
| Larkin, Rachel | Nursing Team Leader | 122,677 | 119,276 |
| Lauer, Sandra | Director of Continuum Care | 145,858 | 135,519 |
| Lavarnway, Nicole | Nursing Supervisor LTC | 156,035 | 131,102 |
| Lawley, Melinda | Unit Manager Critical Care | 157,763 | 136,386 |
| Leas, Adam | General Duty Nurse | 123,447 | 102,186 |
| Leas, Christie | Unit Manager Critical Care | 131,217 | 128,567 |
| Lee, Pamela | Senior VP of Operations ECMC | 317,346 | 321,415 |
| Leitten, Deborah | General Duty Nurse | 123,000 | 102,186 |
| Lenhard, Eric | Pharmacist ECMC | 147,577 | 142,314 |
| Leonard, Jamie | Charge Nurse | 126,266 | 104,337 |
| Lewandowski, Emily | Pharmacist ECMC | 139,159 | 136,186 |
| Lewis, Jennifer | Charge Nurse | 143,651 | 101,290 |
| Lezynski, Sharon | General Duty Nurse | 141,347 | 102,186 |
| Lilic, Dijana | Charge Nurse | 174,352 | 110,700 |
| Linneborn, Tracey | Assistant Director Social Work Servs | 104,670 | 103,243 |
| Lipiarz, Jennifer | Charge Nurse | 111,803 | 101,290 |
| Logel, Cassandra | Charge Nurse | 120,812 | 101,230 |
| | Network Analyst | - | |
| Lorden, Bernard | | 137,661 | 107,761 |
| Loree, Thom | Attending Physician | 1,004,478 | 962,261 |
| Loughran, Vicki | General Duty Nurse | 105,753 | 102,186 |
| Lucas, Paul | General Duty Nurse | 120,714 | 102,186 |
| Ludlow, Charlene | Senior VP of Nursing | 360,096 | 360,500 |
| Lydo, Kaitlin | Registered Nurse Trauma Registrar | 113,338 | 112,455 |
| Macaluso, Ann | Pharmacist ECMC | 57,860 | 136,186 |
| Mack, Markita | Unit Manager Critical Care | 139,697 | 132,429 |
| MacNeil, Sarah | General Duty Nurse | 141,779 | 102,186 |
| MacTurk, Nancy | General Duty Nurse | 115,337 | 102,186 |
| Madison, Mark | General Duty Nurse | 104,449 | 102,186 |
| Madoo, Kevin | Director of Plant Operations | 126,130 | 126,271 |
| Madore, Donat | General Duty Nurse | 122,071 | 102,186 |
| Maggio, Sarah | ASSISTANT VP of BH, Nrsing & Edu | 154,962 | 149,350 |
| Maloney, Jennifer | Unit Manager MedicalSurgical | 138,304 | 136,386 |
| Manning, Jeremy | Charge Nurse | 103,138 | 107,457 |
| Marasco, Marjorie | Nurse Case Manager - Behavioral Health | 71,396 | 121,522 |
| Marczak, Juliet | Nurse Practitioner ECMC | 153,217 | 155,116 |
| Markiewicz, Anthony | VP Clinical Business Intelligence and In | 201,367 | 190,649 |
| Marks, Jack | General Duty Nurse | 113,769 | 102,186 |
| Marshall, Michelle | PROGRAM DIRECTOR-BEHAVIORAL HEALTH | 122,216 | 120,000 |
| Marso, Lisa | Anesthetist | 263,650 | 236,023 |
| | | 203,030 | 230,023 |

| Martin, Alana | Pharmacist ECMC | 139,756 | 136,186 |
|----------------------|--|---------|---------|
| Martin, Donna | General Duty Nurse | 106,919 | 102,186 |
| Martina, Kristin | Nursing Team Leader | 143,945 | 112,455 |
| Martinez, Kristen | Director of Rehabilation Services | 107,685 | 103,515 |
| Masters, Raymond | Anesthetist | 236,046 | 218,753 |
| Mattina, Adrianne | General Duty Nurse | 120,812 | 102,186 |
| Matyjasik, Robin | Clinical Resource Nurse Emerg Services | 141,154 | 104,337 |
| Maul, Sara | Charge Nurse | 115,282 | 104,337 |
| Maxson, Karen | General Duty Nurse | 117,010 | 102,186 |
| Mayer, John | Director of System Health and Safety | 123,977 | 124,115 |
| Mazur, Christopher | Senior Pharmacist ECMC | 170,523 | 154,565 |
| McAndrews, Lisa | Charge Nurse | 136,137 | 110,700 |
| McCartan, Daniel | Emergency Preparedness Manager | 107,836 | 106,756 |
| McCloud, Arletha | Charge Nurse | 126,406 | 110,700 |
| McCullor, Sandra | Charge Nurse | 130,449 | 110,700 |
| Mcdougall, Sarah | Pharmacist ECMC | 139,118 | 139,258 |
| McDuffie, Ann | Nursing Team Leader Orthopedics | 125,096 | 119,276 |
| McGuigan, Jessica | Unit Manager MedicalSurgical | 143,212 | 136,386 |
| McGuire, Julie | General Duty Nurse | 105,119 | 102,186 |
| McKeever, Ashley | Anesthetist | 262,394 | 236,023 |
| McLaughlin, Gloria | General Duty Nurse | 113,822 | 102,186 |
| McLean, Terrence | Dentist ECMC | 458,934 | 459,710 |
| McRae, Jennifer | Nursing Team Leader LTC | 128,387 | 105,993 |
| Mehmedovic, Andrea | Chief Clinical Laboratory Technologist | 146,472 | 112,748 |
| Mendola, Kathryn | Director of Campaigns & Major Gifts | 107,120 | 105,060 |
| Menter, Danielle | Charge Nurse | 161,709 | 110,700 |
| Merineau, Rock | Project Manager HIT | 105,275 | 102,531 |
| Metz, Martha | Clinical Nurse Specialist Crit Care ER | 128,728 | 129,913 |
| Metzler, Ashley | Unit Manager Post Anesthesia Care | 143,563 | 136,386 |
| Meyers, Tracy | Nursing Team Leader | 130,652 | 119,276 |
| Miano, Joanne | Nurse Case Manager | 131,520 | 131,102 |
| Milbrand, Alison | Pharmacist ECMC | 15,870 | 139,258 |
| Miller, Crystal | General Duty Nurse RPT | 151,161 | 105,700 |
| Miller, Kelly | Emergency Department Patient Flow TL | 141,818 | 115,835 |
| Miller, Loretta | Safe Patient Handling Coordinator | 120,868 | 110,485 |
| Miller, Melissa | General Duty Nurse | 110,442 | 102,186 |
| Minhas, Parveen | Nurse Practitioner Transplant | 268,168 | 155,116 |
| Mitchell, Alexandria | Unit Manager MedicalSurgical | 139,385 | 136,386 |
| Mitchell, Shawn | General Duty Nurse | 194,206 | 102,186 |
| Mogavero, Joseph | Healthcare Business System Manager | 133,073 | 133,270 |
| Mondoux, Jessica | Director of Transplantation | 131,610 | 131,758 |
| Monnier, Thomas | Director of Biomedical Services | 111,453 | 108,150 |
| Montague, Victoria | Nursing Inservice Instructor ECMC | 115,944 | 112,455 |
| Mooney, Michelle | Nurse Case Manager | 133,629 | 131,102 |
| Moore-Haley, Maureen | General Duty Nurse | 123,444 | 102,186 |
| Morrissey, Colin | Anesthetist | 247,607 | 218,753 |
| Moses, Beth | Trauma Injury Prevention & Education Coo | 126,719 | 119,276 |

| Mosley, Steven | Healthcare Information Security Analyst | 98,612 | 101,005 |
|----------------------|--|---------|---------|
| Mullen, Meghan | Trauma Program Manager | 157,885 | 155,116 |
| Mulvenna, Tina | Admissions Coordinator LTC | 104,249 | 104,337 |
| Mund, Nadine | Director of Corporate Compliance RPT | 135,379 | 135,379 |
| Murawski, Phyllis | VP Transplantation & Renal Care | 215,574 | 208,978 |
| Murphy, Evelyn | General Duty Nurse | 106,023 | 102,186 |
| Murray, Brian | Medical Director ECMC | 641,182 | 551,719 |
| Nagai, Michael | Attending Physician | 648,566 | 581,950 |
| Najmulski, Kellie | Nursing Team Leader | 133,026 | 102,881 |
| Nance, Michele | Assistant Nurse Case Manager | 121,301 | 110,700 |
| Napierala, Randal | Pharmacist ECMC | 140,873 | 139,258 |
| Nasca, Maureen | Chief of Service Dentistry | 469,844 | 470,371 |
| Nawojski, Kari | Charge Nurse | 250,269 | 110,700 |
| Nawojski, Michelle | Minimum Data Set Specialist | 104,686 | 102,881 |
| Nazzarett, Jody | Nursing Team Leader | 120,906 | 119,276 |
| Neff, Melissa | Unit Manager Cardiac Cath Lab | 216,901 | 136,386 |
| Nesbitt, David | Asst VP of Compliance and Senior Counsel | 216,057 | 216,300 |
| Newell, William | Charge Nurse | 114,357 | 101,290 |
| Niemira, Brittany | Manager of Revenue Capture and Integrity | 72,014 | 105,498 |
| Nieswiadomy, Kayla | Nurse Practitioner Transplant | | |
| Noble, Phillip | Anesthetist | 116,550 | 141,966 |
| • | | 97,756 | 218,753 |
| Noller, Dawn | General Duty Nurse | 105,021 | 102,186 |
| Nowak, Kevin | Anesthesiologist | 515,414 | 448,800 |
| Nowak, Kristine | Behavioral Health Clinical Manager | 126,660 | 118,450 |
| Nowak, Lisa | Nursing Team Leader LTC | 133,935 | 112,455 |
| Nye, Maria | Charge Nurse | 136,184 | 110,700 |
| Obstarczyk, Valerie | Nursing Team Leader Ambulatory Services | 113,145 | 112,455 |
| Occhino, Erin | Clinical Pharmacy Specialist | 148,492 | 151,199 |
| O'Connor, Brendan | Clinical Resource Nurse Emerg Services | 123,072 | 107,457 |
| Ordon, Cheryl | Nurse Case Manager | 133,347 | 131,102 |
| Orloff, Patrick | Director of Internal Audit | 128,400 | 128,544 |
| Orta, Adrian | Clinical Systems Analyst | 112,619 | 103,243 |
| Ott, Michael | Clinical Coord Pharmacy Services | 155,073 | 154,565 |
| Ott, Sarah | RN Behavioral Health Data Reviewer | 115,157 | 112,455 |
| Pacelli, Kathleen | Senior Speech Pathologist | 27,681 | 103,091 |
| Pagano, Christina | Physician Assistant | 142,690 | 132,009 |
| Pajek, Lisa | Charge Nurse Ambulatory Care | 36 | 105,681 |
| Paladino, Matthew | Anesthesiologist | 535,376 | 477,544 |
| Palermo, Loretta | Emergency Department Patient Flow TL | 157,735 | 119,276 |
| Panesar, Mandip | Chief Medical Information Officer | 469,789 | 470,457 |
| Paolini, Cherise | General Duty Nurse | 86,132 | 102,186 |
| Park-Brooks, Jessica | General Duty Nurse | 119,632 | 102,186 |
| Parker, Adam | Assistant Director of Pharmacy | 153,551 | 148,750 |
| Parks, Mary | Charge Nurse | 145,280 | 107,457 |
| Parmenter, Tonya | General Duty Nurse | 18,387 | 102,186 |
| Patterson, Caralyn | Nursing Team Leader LTC | 138,782 | 112,455 |
| Patterson, Sandra | Nursing Team Leader Ambulatory Services | 124,749 | 119,276 |
| . accersori, sariara | Traising realit Leader Allibalatory Services | 147,143 | 113,270 |

| Pawar, Ravinder | General Duty Nurse | 106,244 | 102,186 |
|-------------------------|--|-----------|-----------|
| Payne, Angela | Unit Manager Emergency | 146,358 | 121,172 |
| Peals, Letrice | Charge Nurse | 116,686 | 110,700 |
| Pellicane, Stephen | General Duty Nurse | 161,709 | 102,186 |
| Pelton, Lisa | General Duty Nurse | 102,822 | 102,186 |
| Perkins, Melissa | Unit Manager MedicalSurgical | 143,076 | 136,386 |
| Pesta, Joslyn | Pharmacist ECMC | 138,538 | 136,186 |
| Petronsky, William | Senior Rad Techonologist Imaging Spec | 114,186 | 101,712 |
| Petry, Christina | Nursing Team Leader Ostomy WC | 133,768 | 119,276 |
| Phillips, Kristen | Anesthetist | 133,116 | 218,753 |
| Picciano, Cathleen | Lead Clinical Documentation Specialist | 121,444 | 119,276 |
| Picciano, Thomas | Manager - Care Management | 135,250 | 133,900 |
| Pierce, Erin | General Duty Nurse | 123,611 | 102,186 |
| Pietrzyk, Mathew | Clinical Teacher | 109,319 | 133,553 |
| Pilat, Cynthia | Charge Nurse | 143,218 | 110,700 |
| Piniewski, Jillian | Nurse Practitioner Orthopedic Services | 151,862 | 137,825 |
| Piscatelli, Nicole | Dentist ECMC | 190,531 | 191,227 |
| Pittman, Courtney | Director of Patient Access Services | 125,455 | 122,592 |
| Pitz, Anita | Charge Nurse | 139,370 | 110,700 |
| Plueckhahn, Jennifer | Minimum Data Set Specialist | 109,634 | 109,173 |
| Pollock, Michael | Info Technology Operations Manager | 145,474 | 133,270 |
| Poodry, Abby | Charge Nurse | 132,657 | 110,700 |
| Popat, Saurin | Attending Physician RPT | 487,908 | 450,203 |
| Porter, Bradley | Nursing Team Leader LTC | 113,605 | 105,993 |
| Porter, Tricia | General Duty Nurse | 148,308 | 102,186 |
| Powers, Paul | Information Systems Analyst | 121,758 | 105,498 |
| Powers, Shawntey | Nursing Team Leader | 122,415 | 115,835 |
| Pressley III, Charles | Staff Counsel ECMC | 131,688 | 132,829 |
| Principe, Tamara | Charge Nurse | 132,167 | 101,290 |
| Pulka, Ashley | Pharmacist ECMC | 139,078 | 139,258 |
| Quatroche Jr., Thomas | Chief Executive Officer ECMC | 1,682,168 | 1,220,035 |
| Queener, Fontella | General Duty Nurse | 117,479 | 102,186 |
| Radovic, Vladan | Attending Physician | 413,129 | 376,764 |
| Rassman, Jeffrey | Physician Assistant | 130,645 | 129,289 |
| Rathgeber, Pandora | General Duty Nurse | 119,704 | 102,186 |
| Reamsnyder, Cynthia | General Duty Nurse | 133,447 | 102,186 |
| Reed, Karen | Anesthesiologist | 559,530 | 516,815 |
| Reeners, Eric | Director of Finance ECMC | 142,692 | 140,000 |
| Reeves, Sandra | Charge Nurse | 41,198 | 105,681 |
| Regelin, Lucas | Pharmacist ECMC | 97,942 | 136,186 |
| Reigle, Corey | Charge Nurse | 129,523 | 110,700 |
| Reilly, Mary | Assistant VP of Critical Care & Emergenc | 152,733 | 149,350 |
| Reinhardt, Julie | General Duty Nurse | 93,855 | 102,186 |
| Reinhardt, Kaitlyn | Pharmacist ECMC | 104,159 | 136,186 |
| Resetarits, Christopher | Chief Anesthetist | 251,185 | 280,000 |
| Reynolds, Katrina | General Duty Nurse | 102,285 | 102,186 |
| Richardson, Eden | Charge Nurse | 83,876 | 107,457 |

| Riley, Peggy-Sue | Charge Nurse | 144,591 | 110,700 |
|-------------------------|--|---------|---------|
| Ring, Alan | Anesthetist | 237,615 | 218,753 |
| Riter, Debra | Assistant Director of Social Work BH | 111,354 | 110,015 |
| Rizzo, Ann | General Duty Nurse | 111,085 | 102,186 |
| Rizzo, Heather | Anesthetist RPT | 190,374 | 189,670 |
| Rizzo, John | Unit Manager MedicalSurgical | 134,807 | 128,567 |
| Robb, Noel | Charge Nurse | 122,368 | 110,700 |
| Roberts, Sara | Clinical Documentation Specialist | 118,046 | 104,337 |
| Robertson, Heather | Charge Nurse | 133,483 | 110,700 |
| Roblee, Chelsey | Nursing Team Leader | 136,513 | 119,276 |
| Rodriguez, Erin | Charge Nurse | 115,618 | 110,700 |
| Roeder, Anastasia | Director of Development & Marketing ECMC | 114,833 | 114,962 |
| Rogers, Angeline | Nurse Case Manager | 131,748 | 131,102 |
| Rohl, Kathleen | Assistant Head Nurse | 122,169 | 110,700 |
| Rohloff, Sarina | Director of Procurement Compliance | 104,642 | 104,760 |
| Rohrbacher, Bernhard | Medical Specialist RPT | 130,162 | 128,162 |
| Roman, Julie | Clinical Documentation Specialist | 137,269 | 110,700 |
| Roof, Angela | Nurse Case Manager | 117,849 | 119,974 |
| Roof, Donald | Director of Materials Management | 116,871 | 114,792 |
| Roopchand, John-Paul | Network Analyst | 99,112 | 101,005 |
| Root, Sarah | Infection & Wound Care Preventionist LTC | 131,126 | 131,102 |
| Ross, Nicole | Pharmacist ECMC | 141,533 | 136,186 |
| Rossi, Lucia | VP of Ambulatory Svs & Population Health | 170,954 | 164,800 |
| Rossitto, Rachael | Dentist ECMC | 335,271 | 334,335 |
| Ross-McComb, Holly | Clinical Nurse Specialist Behavioral Hea | 131,554 | 141,966 |
| Rubin, Kari | Nurse Case Manager | 133,677 | 131,102 |
| Rudyk, Jenine | Unit Manager Critical Care | 142,392 | 136,386 |
| Ruh, Christine | Assistant Director of Pharmacy | 162,595 | 162,740 |
| Rust, Shawna | Charge Nurse | 134,980 | 110,700 |
| Rutkowski, Tammy | General Duty Nurse | 117,042 | 102,186 |
| Rutty, Amy | General Duty Nurse | 109,266 | 102,186 |
| Sammarco-Delmont, Renee | Unit Manager MedicalSurgical | 153,722 | 136,386 |
| Sands, Robert | Anesthesiologist | 552,389 | 516,816 |
| Santillo, Alexis | Physician Assistant | 117,149 | 110,000 |
| Santo, Angela | Charge Nurse | 129,019 | 101,290 |
| Sarkisian, Kevin | Sr Healthcare Info Reporting Specialist | 120,167 | 103,243 |
| Sauer, Jillian | Unit Manager MedicalSurgical | 133,568 | 128,567 |
| Scherer, Paul | Healthcare Business Sys Analyst | 114,485 | 110,015 |
| Schoelerman, Ronald | VP of Behavioral Health Services | 159,449 | 155,000 |
| Schubbe, Jayson | Healthcare Data Warehouse Architect | 125,469 | 120,953 |
| Schubbe, Michele | Healthcare Business Sys Analyst | 125,797 | 107,761 |
| Schummer, Abby | General Duty Nurse | 120,654 | 102,186 |
| Schunke, Katrina | Pharmacist ECMC | 155,541 | 151,574 |
| Schurr, Karen | Clinical Asst to VP Surg & Card. Svcs | 144,456 | 140,000 |
| Schwanekamp, Karen | Anesthetist | 263,580 | 236,023 |
| Schwenk, Kurt | Director of Budget ECMCC | 128,605 | 128,750 |
| Scrocco, Mary Carol | Nurse Practitioner Cardiovascular Lab | 195,919 | 155,116 |

| Scruggs, Tammie | General Duty Nurse | 106,096 | 102,186 |
|-----------------------|--|---------|---------|
| Seay, Michelle | Assistant Vice President CPEP | 151,952 | 149,350 |
| Semrau, Jeffrey | Senior Pharmacist ECMC | 176,298 | 151,199 |
| Senchoway, Laura | Anesthetist | 228,876 | 218,753 |
| Serafin, Laura | General Duty Nurse RPT | 145,047 | 102,793 |
| Shanahan, Robert | Network Analyst | 135,551 | 107,761 |
| Shaw, Patrick | Clinical Resource Nurse | 117,234 | 110,700 |
| Sheppard, Judith | Nursing Supervisor LTC | 159,370 | 131,102 |
| Simon, Alexander | Clinical Application Systems Manager | 124,988 | 117,019 |
| Simone, Jessica | Nursing Inservice Instructor Crit Care | 112,106 | 109,173 |
| Sitgreaves, Theressa | Charge Nurse | 111,988 | 104,337 |
| Skomra, Richard | Chief Anesthetist | 139,717 | 285,082 |
| Smith, Andrew | Nurse Case Manager | 138,309 | 131,102 |
| Smith, Jennifer | General Duty Nurse | 118,106 | 102,186 |
| Smith, Sandra | Clinical Documentation Specialist | 121,580 | 110,700 |
| Smith, Taneca | Nurse Case Manager | 124,157 | 123,583 |
| Smolen, Ashley | General Duty Nurse | 41,981 | 102,186 |
| Snyder, Gina | General Duty Nurse | 117,306 | 102,186 |
| So, Timmy | Assistant Director of Social Work BH | 115,405 | 107,761 |
| Sole, Jennifer | Nursing Team Leader | 133,910 | 119,276 |
| Sorce, Lynn | Charge Nurse | 114,023 | 110,700 |
| Sousis, Julie | Assistant Director Ambulatory Services | 119,434 | 116,245 |
| Sperry, Howard | Clinical Director Medicine | 339,140 | 328,638 |
| Stanford, Benjamin | Unit Manager MedicalSurgical | 135,733 | 132,429 |
| Staniorski, Paula | General Duty Nurse | 107,452 | 102,186 |
| Steffen, Tracy | Nurse Case Manager | 120,377 | 131,102 |
| Stegemann, Philip | Chief of Orthopedic Surgery | 117,148 | 117,148 |
| Steward, Kevin | Nursing Care Coordinator | 161,180 | 141,669 |
| Stobnicki, Cortney | Anesthetist | 259,720 | 236,023 |
| Stokes, Laura | Point of Care Clinical Laboratory Coord | 113,193 | 119,319 |
| Stroud, Kerry | Nursing Care Coordinator | 154,701 | 141,669 |
| Sturtz, Janice | Nursing Team Leader Ostomy WC | 130,934 | 119,276 |
| Suchy III, Thomas | Attending Physician | 487,982 | 484,100 |
| Sullivan, Michele | General Duty Nurse | 129,284 | 102,186 |
| Sutkowski, Jordan | Charge Nurse | 118,311 | 104,337 |
| Sutton, Danielle | Charge Nurse | 127,934 | 110,700 |
| Swain, Anthony | Charge Nurse | 118,282 | 110,700 |
| Swain, Maureen | Charge Nurse | 126,294 | 110,700 |
| Sweetland, Jennifer | Nursing Informatics Mgr. | 143,056 | 141,669 |
| Swiatkowski, Jonathan | Chief Financial Officer ECMC | 573,695 | 575,000 |
| Szejnar, Michael | Charge Nurse | 6,637 | 105,681 |
| Tadak, Monica | Director of Revenue Capture and Integrit | 141,889 | 138,841 |
| Tadt, Stephanie | Nurse Case Manager | 131,761 | 131,102 |
| Tague, Dana | Nurse Practitioner Rehab Services | 174,995 | 155,116 |
| Tait, Christopher | Nurse Case Manager | 141,183 | 131,102 |
| Thanki, Pamela | Senior Financial Analyst | 113,828 | 109,731 |
| Thomas, Dylan | Pharmacist ECMC | 141,632 | 136,186 |

| Thomas, Katheleen | Infection Prevention Practioner | 142,019 | 119,276 |
|--------------------|--|---------|---------|
| Thomas, Sherry | General Duty Nurse | 106,038 | 102,186 |
| Thompson, Denise | Nursing Care Coordinator | 154,357 | 141,669 |
| Thoms, Amy | Clinical Documentation Specialist | 123,611 | 110,700 |
| Thorpe, Lisa | Director of Rehabilation Services | 145,590 | 138,898 |
| Tiwana, Harwinder | General Duty Nurse | 114,828 | 102,186 |
| Toal, Emily | Charge Nurse | 125,531 | 110,700 |
| Tomljanovich, Paul | Attending Physician PT | 137,145 | 128,395 |
| Tornambe, Lynne | Pharmacist ECMC | 155,479 | 145,373 |
| Torres, Carmen | Nurse Practitioner ECMC | 154,088 | 155,116 |
| Toy, Amy | Charge Nurse | 122,847 | 110,700 |
| Troise, Emily | Nursing Inservice Instructor Crit Care | 118,100 | 115,835 |
| Turner, Charlaina | Assistant Head Nurse | 193,139 | 110,700 |
| Turner, Jacqueline | General Duty Nurse | 113,139 | 102,186 |
| Turner, James | Senior VP of Surgical and Ambulatory Ser | 312,426 | 344,374 |
| Twichell, Jerome | Senior Director Outpatient Operations | 136,939 | 132,010 |
| Urban, Paul | Assistant Info Tech Sys Architect | 128,021 | 128,164 |
| Vacanti, Angela | Manager Infection Control | 152,586 | 141,669 |
| Vacanti, Charles | Nursing Team Leader | 230,722 | 119,276 |
| Vaccaro, Jessica | Charge Nurse | 125,263 | 104,337 |
| Vail, Robert | Healthcare Information Security Officer | 11,235 | 150,507 |
| Vazquez, Alexandra | Charge Nurse | 119,743 | 104,337 |
| Villacorta, Maria | Charge Nurse | 154,492 | 110,700 |
| Vullo, Lori | General Duty Nurse | 121,225 | 102,186 |
| Walden, Jenna | Nurse Practitioner Transplant | 138,766 | 141,966 |
| Wallace, Lauren | Nursing Team Leader LTC | 118,795 | 102,881 |
| Walsh, Evelyn | Attending Physician | 257,192 | 267,800 |
| Walter, Robert | Chief Clinical Laboratory Technologist | 151,752 | 119,319 |
| Walters, Amy | General Duty Nurse | 133,107 | 102,186 |
| Walters, Kimberly | General Duty Nurse | 158,043 | 102,186 |
| Wang, Nana | Pharmacist ECMC | 138,554 | 136,186 |
| Warmus, Renelle | Nurse Case Manager | 135,929 | 131,102 |
| Warne, Matthew | General Duty Nurse | 119,416 | 102,186 |
| Warren, Daniel | Manager of Financial Reporting | 103,695 | 100,000 |
| Warren, Susan | General Duty Nurse | 120,861 | 102,186 |
| Weaver, Stephanie | Clin Tch?Dedicated Edu Unit Instructor | 133,637 | 123,583 |
| Weber, Joseph | Network Analyst | 132,761 | 107,761 |
| Weiss, Katherine | Pharmacist ECMC | 180,073 | 151,574 |
| Weiss, Nicole | Pharmacist ECMC | 49,295 | 136,186 |
| Weld, Tiffani | Charge Nurse | 131,430 | 101,290 |
| Welka, Andrew | Anesthesiologist | 500,530 | 457,011 |
| West, Ashley | Nurse Case Manager | 130,948 | 131,102 |
| West, Lindsey | Unit Manager MedicalSurgical | 130,683 | 128,567 |
| Whipkey, Colleen | Charge Nurse | 112,908 | 110,700 |
| Wik, Michelle | Nursing Inservice Instructor ECMC | 118,565 | 112,455 |
| Wilde, Michelle | General Duty Nurse | 127,236 | 102,186 |
| Williams, Sonia | Assistant Director Ambulatory Services | 127,448 | 123,768 |

| Williams, Stephanie | Charge Nurse | 152,656 | 107,457 |
|----------------------|--|---------|---------|
| Williamson, Katrina | General Duty Nurse | 103,020 | 102,186 |
| Wilson, Karyn | Assistant Director Ambulatory Services | 113,130 | 111,234 |
| Wilson, Nicolette | VP Revenue Cycle | 183,682 | 183,888 |
| Wilson, Tiffany | Charge Nurse | 123,943 | 107,457 |
| Wing, Kathryn | General Duty Nurse | 103,534 | 102,186 |
| Wittenbrink, Timothy | Charge Nurse | 112,956 | 104,337 |
| Wittmann, Paula | Charge Nurse | 126,033 | 110,700 |
| Wojtowicz, Jean | General Duty Nurse | 103,521 | 102,186 |
| Wolf, Joann | Assistant Vice President Surgical Nursin | 150,024 | 149,350 |
| Wood, Jamie | General Duty Nurse | 118,366 | 102,186 |
| Wood, Rebecca | Charge Nurse | 112,611 | 104,337 |
| Woodruff, Stephen | Administrator LTC | 169,759 | 169,950 |
| Woods, Kara | Physician Assistant | 135,462 | 132,010 |
| Wright, Shaunda | Unit Manager Behavioral Health | 146,890 | 136,386 |
| Yak, Joseph | Chief Clinical Laboratory Technologist | 136,504 | 110,644 |
| Yates, Robert | Anesthetist | 236,637 | 218,753 |
| York-Renaud, Jamie | Nursing Inservice Instructor OR | 133,299 | 119,276 |
| Yotter, Emily | Charge Nurse | 120,743 | 104,337 |
| Young, Amanda | Junior Staff Counsel ECMC | 57,693 | 100,000 |
| Zajac, Jamie | Emergency Department Patient Flow TL | 157,092 | 119,276 |
| Zak, Katherine | General Duty Nurse | 116,486 | 102,186 |
| Zanghi, Marie | Assistant Nurse Case Manager | 113,633 | 110,700 |
| Zayac, Jason | Anesthesiologist | 148,750 | 325,000 |
| Zdon, Glen | Unit Manager Hemodialysis | 128,651 | 132,429 |
| Zimmer, Michelle | Charge Nurse | 155,110 | 110,700 |
| Zolnowski, Kimberly | Charge Nurse | 145,728 | 107,457 |
| Zynda, Elizabeth | Nurse Practitioner Transplant | 223,901 | 150,615 |

| | | 2023 \$10 |
|---|------|------------------------|
| Vendor Name | Payı | ments |
| McKESSON DRUG CO | \$ | 41,588,826 |
| GENERAL PHYSICIAN, P.C. | \$ | 20,298,743 |
| METZ CULINARY MANAGEMENT | \$ | 14,500,561 |
| CARDINAL HEALTH | \$ | 13,021,777 |
| UNIVERSITY MEDICAL RESIDENT SERVICES, P.C. | \$ | 12,522,884 |
| UBMD PSYCHIATRY | \$ | 12,247,778 |
| APOGEE MEDICAL MANAGEMENT | \$ | 12,006,934 |
| UPSTATE NEW YORK TRANSPLANT | \$ | 10,866,343 |
| ACADEMIC MEDICAL SERVICES, INC. | \$ | 9,006,855 |
| UNVERSITY AT BUFFALO SURGEONS, INC. | \$ | 8,842,979 |
| THE RESEARCH FOUNDATION | \$ | 8,524,327 |
| GREAT LAKES MEDICAL IMAGING, LLC | \$ | 8,112,541 |
| ZIMMER US INC | \$ | 7,195,528 |
| MORRISON MANAGEMENT SPECIALISTS | \$ | 7,012,364 |
| BUFFALO INTERNIST AND ASSOCIATES | \$ | 5,169,265 |
| UNIVERSITY EMERGENCY MEDICAL SERVICES, INC. | \$ | 4,412,224 |
| SUPPLEMENTAL HEALTH CARE | \$ | 4,322,400 |
| SYNTHES | \$ | 4,116,893 |
| ROCHE DIAGNOSTICS CORPORATION | \$ | 3,594,995 |
| TRELLIS RX, LLC | \$ | 3,405,914 |
| CARDINAL HEALTH MED PRODUCTS & SERVICES | \$ | 3,372,171 |
| STRYKER ORTHOPAEDICS | \$ | 3,338,914 |
| SMITH & NEPHEW ORTHOPAEDICS | \$ | 3,285,724 |
| ERIE COUNTY COMPTROLLER'S OFFICE | \$ | 2,923,484 |
| GLOBUS MEDICAL INC | \$ | 2,767,541 2,755,024 |
| UNIVERSITY ORTHOPAEDIC SERVICES | \$ | 2,733,024 |
| UB FAMILY MEDICINE INC. | \$ | 2,275,701 |
| CARDINAL HEALTH | \$ | 2,179,683 |
| KALEIDA HEALTH | \$ | 2,148,295 |
| GRIDER SUPPORT SERVICES, LLC | \$ | 2,082,844 |
| ARTHREX INC | \$ | 2,019,621 |
| CROTHALL HEALTHCARE | \$ | 1,900,325 |
| CLEAN CARE LINEN | \$ | 1,798,075 |
| DELL FINANCIAL SERVICES LLC | \$ | 1,751,711 |
| UNIVERSITY AT BUFFALO PATHOLOGISTS | \$ | 1,727,300 |
| UNIVERSITY AT BUFFALO NEUROSURGERY, INC. | \$ | 1,722,515 |
| AMERISOURCE BERGEN DRUG CORP | \$ | 1,607,778 |
| THE MARTIN GROUP LLC | \$ | 1,504,771 |
| LAB CORP OF AMERICA | \$ | 1,497,307 |
| INTUITIVE SURGICAL INC | \$ | 1,476,795 |
| GILBANE BUILDING COMPANY | \$ | 1,379,867 |
| ABBOTT LABORATORIES, INC. | \$ | 1,339,056 |
| KSL DIAGNOSTICS, INC | \$ | 1,247,025 |
| J&J DETAILS & MAINTENANCE LLC | \$ | 1,215,800 |

| CTEDIC CORDODATION | | 1 121 100 |
|--|----|-----------|
| STERIS CORPORATION | \$ | 1,134,409 |
| CHANGE HEALTHCARE | \$ | 1,132,605 |
| BUFFALO PAPER AND TWINE CO | \$ | 1,125,534 |
| TORNIER INC | \$ | 1,117,126 |
| FAVORITE HEALTHCARE STAFFING INC | \$ | 1,115,548 |
| PHILIPS MEDICAL SYSTEMS | \$ | 1,101,135 |
| INTEGRA LIFESCIENCES CORP | \$ | 1,097,925 |
| CREEKRIDGE CAPITAL-LB | \$ | 1,075,868 |
| MEDICAL INFO TECH INC | \$ | 1,050,118 |
| UNIVERSITY DENTAL RESIDENT SERVICES, P.C. | \$ | 1,032,432 |
| IMMCO DIAGNOSTICS INC | \$ | 1,026,755 |
| CORE BTS INC | \$ | 1,003,187 |
| DELL MARKETING LP / DELL USA LP | \$ | 993,775 |
| PHARMERICA | \$ | 960,548 |
| HP, INC. | \$ | 959,533 |
| MEDLINE INDUSTRIES INC | \$ | 923,788 |
| FERGUSON ELECTRIC SVC | \$ | 909,763 |
| ALLSCRIPTS LLC | \$ | 896,326 |
| DEPUY SYNTHES JOINT RECONSTRUCTION | \$ | 891,722 |
| MEDTRONIC SD USA INC | \$ | 888,533 |
| STRYKER SALES CORP | \$ | 844,678 |
| NATIONAL GRID | \$ | 808,277 |
| PHILIPS MEDICAL SYSTEMS NA CO | \$ | 804,120 |
| JOHNSON & JOHNSON HLTH CARE SYS INC | \$ | 799,479 |
| BOSTON SCIENTIFIC CORPORATION | \$ | 793,547 |
| EXPERIAN HEALTH, INC. | \$ | 793,025 |
| WILLIAM BELLES, M.D., PC | \$ | 778,379 |
| FRESENIUS USA MARKETING, INC. | \$ | 750,909 |
| JOHNSON CONTROLS FIRE PROTECTION LP | \$ | 730,677 |
| FFF ENTERPRISES | \$ | 726,801 |
| BIOCARE SD | \$ | 719,205 |
| BUFFALO TRANSPORTATION INC. | \$ | 706,464 |
| ABBOTT LABORATORIES DIAGNOSTIC DIV | \$ | 705,466 |
| CITY OF BUFFALO | \$ | 698,350 |
| W L GORE & ASSOC INC | \$ | 693,203 |
| 3M HEALTH INFORMATION SYSTEMS, INC | \$ | 681,364 |
| INSPIRE MEDICAL SYSTEMS, INC. | \$ | 672,250 |
| MERIDIAN IT INC. | \$ | 658,162 |
| STERICYCLE INC | \$ | 651,142 |
| SIEMENS MEDICAL SOLUTIONS USA | \$ | 648,322 |
| MANUFACTURERS & TRADERS TRUST | \$ | 644,033 |
| WNY UROLOGY ASSOCIATES LLC | \$ | 624,542 |
| STRYKER SPINE | \$ | 624,012 |
| SUICIDE PREVENTION & CRISIS SERVICES, INC. | \$ | 584,009 |
| BECTON, DICKINSON AND COMPANY | \$ | 579,922 |
| MERGE HEALTHCARE | \$ | 572,573 |
| MAGAVERN, MAGAVERN & GRIMM LLP | \$ | 562,480 |
| IVIAGAVENIN, IVIAGAVENIN & GNIIVIIVI ELP | ۶ | 302,460 |

| | 1 | |
|--|----|---------|
| UB FOUNDATION ACTIVITES | \$ | 539,792 |
| STANSBERRY AND KNIGHT | \$ | 529,553 |
| KEYSTONE PERFUSION SERVICES, PC | \$ | 512,958 |
| AMER RED CROSS | \$ | 509,905 |
| STRYKER CRAINOMAXILLOFACIAL | \$ | 476,320 |
| KCI USA, INC. | \$ | 467,185 |
| HEALTH SYSTEM SERVICE | \$ | 442,119 |
| CRS NUCLEAR SERVICES LLC | \$ | 434,605 |
| GRAYLINE NIAGARA FALLS/BUFFALO | \$ | 433,135 |
| BRITE COMPUTERS | \$ | 426,107 |
| UNIVERSITY GYNECOLOGISTS | \$ | 422,496 |
| MEDTRONIC USA INC | \$ | 422,373 |
| RUPP BAASE PFALZGRAF | \$ | 406,212 |
| WRIGHT MEDICAL TECHNOLOGY INC | \$ | 404,652 |
| KYRUUS, INC | \$ | 397,781 |
| FREED MAXICK CPAs PC | \$ | 387,314 |
| PATTERSON DENTAL INC | \$ | 384,211 |
| UNIVERISTY AT BUFFALO ORAL AND MAXILLOFACIAL | \$ | 371,118 |
| HILL-ROM | \$ | 370,376 |
| HEALOGICS WOUND CARE | \$ | 369,462 |
| SWISSLOG HEALTHCARE SOLUTIONS | \$ | 368,420 |
| B.E. SMITH LLC | \$ | 364,394 |
| NUANCE COMMUNICATIONS INC | \$ | 360,247 |
| PARTS SOURCE | \$ | 360,113 |
| NXSTAGE | \$ | 358,914 |
| ROACH, BROWN | \$ | 358,021 |
| UNIVERSITY OPHTHALMOLOGY SERVICE, INC. | \$ | 356,647 |
| TREACE MEDICAL CONCEPTS, INC | \$ | 352,306 |
| CARAHSOFT TECHNOLOGY CORPORATION | \$ | 337,839 |
| ARTHUR E. ORLICK MD PLLC | \$ | 323,475 |
| KRONOS | \$ | 317,554 |
| AXOGEN INC | \$ | 316,386 |
| DCB ELEVATOR CO INC | \$ | 316,029 |
| US POSTAL SERVICE | \$ | 315,000 |
| RICOTTA & VISCO | \$ | 314,860 |
| INTIVITY, INC. | \$ | 307,417 |
| KIDENEY ARCHITECTS PC | \$ | 307,009 |
| SUMMIT HEALTH CARE | \$ | 306,100 |
| MAXIM STAFFING SOL | \$ | 302,613 |
| CAREFUSION 2200, INC. | \$ | 299,302 |
| MEDTRONIC MIDAS REX | \$ | 298,920 |
| BROOK, INC | \$ | 295,070 |
| FREE UP MD, LLC | \$ | 291,212 |
| INTERIM PHYSICIANS LLC | \$ | 288,569 |
| 1 ACCORD SERVICES INC | \$ | 288,113 |
| LAWLEY AGENCY, LLC | \$ | 284,540 |
| SYNTHES MAXILLOFACIAL | \$ | 283,021 |
| STRUTTES MANIEUT ACIAL | 7 | 203,021 |

| OFFICE DEPOT | \$ 282,316 |
|------------------------------------|---------------|
| DRFIRST.COM INC. | \$ 279,333 |
| TRI-DELTA RESOURCES CORP | \$ 278,520 |
| SYSMEX AMERICA INC | \$ 276,741 |
| PMA COMPANIES | \$ 275,770 |
| ORTHOFIX, INC. | \$ 266,951 |
| WNY TRANSPORTATION SERVICES, | \$ 263,491 |
| AMER EXPRESS CPC | \$ 261,928 |
| CDW GOVERNMENT INC | \$ 261,343 |
| CROWN CASTLE FIBER, LLC. | \$ 260,471 |
| STRYKER ENDOSCOPY | \$ 256,227 |
| THIRD PARTY REIMBURSEMENT | \$ 258,313 |
| HEALTH CATALYST, INC | \$ 252,500 |
| ASPIRE TECHNOLOGY PARTNERS | \$ 249,810 |
| ARC BUILDING PARTNERS, LLC | \$ 247,829 |
| WELLSKY CORPORATION | \$ 245,203 |
| CARESTREAM HEALTH | \$ 243,607 |
| AQUA SCIENCES INC | \$ 242,000 |
| KARL STORZ ENDOSCOPY-AMERICA INC | \$ 237,307 |
| OLYMPUS AMERICA INC | \$ 236,351 |
| OPTUM360 LLC | \$ 233,704 |
| BAXTER HEALTHCARE CORP | \$ 230,167 |
| BAYER HEALTHCARE LLC | \$ 229,979 |
| INTERNATIONAL INSTITUTE OF BUFFALO | \$ 225,597 |
| FISHER HEALTHCARE | \$ 220,904 |
| CTM BIOMEDICAL, LLC | \$ 218,573 |
| RISKONNECT, INC. | \$ 214,580 |
| INTELLIGENT MEDICAL OBJECTS, INC. | \$ 214,024 |
| KLS MARTIN L P | \$ 213,804 |
| CERAPEDICS, INC. | \$ 210,597 |
| SIEMENS INDUSTRY INC | \$ 207,596 |
| PRESS GANEY ASSOCIATES INC | \$ 203,838 |
| VERIZON WIRELESS | \$ 202,933 |
| AIRGAS USA, LLC | \$ 202,426 |
| BUFFALO CITY MISSION | \$ 200,570 |
| GREYCASTLE SECURITY, LLC | \$ 198,746 |
| NAT'L ASSOC PUBLIC HOSPITALS | \$ 198,250 |
| PENTAX MEDICAL | \$ 197,696 |
| DENTSPLY IMPLANTS DEPT IMP | \$ 197,507 |
| INARI MEDICAL, INC. | \$ 197,000 |
| PARTS SOURCE | \$ 196,097 |
| UNITED NETWORK FOR ORGAN SHARING | \$ 193,583 |
| HEALTHCARE ASSOC OF NYS | \$ 192,698 |
| QIAGEN | \$ 187,637 |
| GENERAL PHYSICIAN SUB II, PLLC | \$ 187,440 |
| TELEFLEX LLC | \$ 186,129 |
| COCHLEAR AMERICAS | \$ 177,658 |

| RSM US LLP | \$ | 176,000 |
|---|----------|--------------------|
| GOVERNMENT MARKETING & PROCUREMENT, LLC | \$ | 175,517 |
| MOHAMMAD REZA SAMIE, M.D., PLLC | \$ | 173,515 |
| GLAXOSMITHKLINE FINANCIAL INC | \$ | 173,449 |
| ARTERIOCYTE MEDICAL SYSTEMS | \$ | 172,175 |
| LARRY'S DENTAL LAB, INC. | \$ | 172,026 |
| PARAGON 28, INC. | \$ | 171,793 |
| RWO MEDICAL CONSULTING | \$ | 169,057 |
| MENTAL HEALTH ADVOCATES | \$ | 168,125 |
| WNY INDEPENDENT LIVING | \$ | 167,973 |
| ORTHO CLINICAL DIAGNOSTICS, INC | \$ | 165,923 |
| WESCO DISTRIBUTION INC. | \$ | 199,690 |
| BIOFIRE DIAGNOSTICS LLC | \$ | 158,143 |
| INTELLIPRINT SOLUTIONS, INC. | \$ | 157,004 |
| ABBVIE INC | \$ | 155,880 |
| UNITED UNIFORM CO INC | \$ | 153,629 |
| PENUMBRA, INC. DEPT. 34153 | \$ | 151,372 |
| DRAEGER MEDICAL | \$ | 149,755 |
| LAUNCHTECH | \$ | 149,670 |
| LIFENET HEALTH | \$ | 148,126 |
| BAXTER | \$ | 147,918 |
| GREAT LAKES BUILDING SYSTEMS INC. | \$ | 147,577 |
| MID-CITY OFFICE FURNITURE | \$ | 146,642 |
| HYRO AI INC | \$ | 145,000 |
| C R BARD BARD PHERIPHERAL VASCULAR | \$ | 144,967 |
| PRAXAIR DIST INC | \$ | 138,995 |
| VOYCE, INC. | \$ | 138,899 |
| COOK INC | \$ | 135,879 |
| UNIVERSITY NEUROLOGY, INC. | \$ | 135,496 |
| CARINGTON HOME SAFETY, INC | \$ | 135,487 |
| QUICK INTERNATIONAL COURIER | \$ | 134,350 |
| VERITY SOLUTIONS GROUP, INC. | \$ | 132,000 |
| CONSORTIUM INFORMATION SERVICES INC HEALTH SCIENCES LIBRARY | \$ | 130,333 |
| ALLOSOURCE | \$ | 128,794 |
| CONVERGINT TECHNOLOGIES LLC | \$ | 127,747 |
| MCG HEALTH LLC | \$ | 127,526 |
| BUFFALO CANVAS | | 125,755 |
| GE HEALTHCARE OEC | \$ | 125,716 |
| MLP PLUMBING & MECHANICAL INC. | \$ | 125,569 |
| ISECURE, LLC WNY CLINICAL | \$ \$ | 125,271 |
| | \$ | 122,500 |
| STANDARD BARIATRICS, INC BE WELL HEALTHCARE MEDICINE | \$ | 118,329 |
| CANON MEDICAL SYSTEMS USA, INC. | \$ | 120,585 118,169 |
| UP TO DATE | \$ | 117,280 |
| ANGIO DYNAMICS INC | \$ | 117,280 |
| ALERE INC. DBA ABBOTT RAPID DX NORTH AMERICA, LLC | \$ | 116,465 |
| ALLINE INC. DDA ADDOTT NAPID DA NORTH ANIERICA, LLC | P | 110,403 |

| TELETRACKING | \$ 116,150 |
|----------------------------------|---------------|
| METRO COMMUNICATIONS | \$ 116,030 |
| ECOLAB/MICROTEK MEDICAL | \$ 115,993 |
| BIO RAD LABORATORIES | \$ 115,570 |
| SPOK, INC. | \$ 113,959 |
| SCHAEFER PLUMBING SUPPLY INC | \$ 113,806 |
| NALCO CO | \$ 112,707 |
| FOXY DELIVERY SERVICE INC | \$ 112,059 |
| PEOPLE INC | \$ 111,042 |
| SIEMENS MEDICAL | \$ 110,710 |
| WINDSTREAM PAETEC | \$ 106,416 |
| JOHN W DANFORTH CO | \$ 106,302 |
| SIRTEX MEDICAL, INC. | \$ 106,050 |
| BUFFALO CPR | \$ 105,940 |
| EAST COAST ORTHOTIC | \$ 105,199 |
| MICROSOFT CORPORATION | \$ 105,000 |
| TRI-ANIM HEALTH SERVICES INC | \$ 104,803 |
| MED-METRIX, LLC | \$ 104,000 |
| SYMPLR | \$ 103,396 |
| CANON MEDICAL SYSTEMS USA, INC. | \$ 103,323 |
| SYNOVIS MICRO COMPANIES ALLIANCE | \$ 102,560 |
| XEROX CORPORATION | \$ 102,370 |
| MEDICAL SOLUTIONS, LLC | \$ 102,181 |
| IMPRIVATA INC | \$ 101,928 |
| FORWARD ADVANTAGE | \$ 101,273 |
| ALPHATEC SPINE INC | \$ 100,915 |
| HENRY SCHEIN PRACTICE SOLUTIONS | \$ 100,675 |

| 0k Procurement Re | port ECMCC | |
|--|--|---|
| Reporting Year | Contract Start | Contract End |
| 2023 | 3/19/2019 | 3/18/2024 |
| 2023 | 11/28/2020 | 11/30/2028 |
| 2023 | 4/6/2019 | 8/31/2027 |
| 2023 | 12/1/2012 | 6/30/2027 |
| 2023 | 1/4/2019 | 1/3/2029 |
| 2023 | Various | Evergreen |
| 2023 | 9/1/2015 | 3/31/2024 |
| 2023 | 8/2/2016 | Evergreen |
| 2023 | Various | Evergreen |
| 2023 | Various | Evergreen |
| 2023 | Various | Evergreen |
| 2023 | 9/1/2015 | Evergreen |
| 2023 | 12/29/2022 | 6/30/2026 |
| 2023 | 1/1/2013 | 12/31/2023 |
| 2023 | 6/13/2017 | 6/30/2024 |
| 2023 | 8/1/2017 | 12/31/2024 |
| 2023 | 12/8/2016 | 10/27/2024 |
| 2023 | 9/18/2019 | 10/24/2024 |
| 2023 | 5/1/2002 | 5/21/2025 |
| 2023 | 5/1/2021 | 4/30/2026 |
| 2023 | 12/1/2012 | 6/30/2027 |
| 2023 | 5/19/2021 | 12/31/2025 |
| 2023 | 9/11/2020 | 9/10/2024 |
| 2023 | Various | Evergreen |
| 2023 | 6/16/2021 | Evergreen |
| 2023 | 4/30/2015 | 9/30/2026 |
| 2023 | 6/1/2017 | 12/31/2024 |
| 2023 2023 | Various 1/1/2016 | Evergreen 4/8/2024 |
| 2023 | Various | |
| 2023 | 3/1/2012 | Evergreen Evergreen |
| 2023 | 10/1/2018 | 9/30/2024 |
| 2023 | 3/1/2019 | 12/31/2023 |
| 2023 | 5/2/2019 | 5/1/2024 |
| 2023 | 11/30/2022 | 11/29/2025 |
| 2023 | 2/14/2022 | 2/13/2025 |
| 2023 | Various | Evergreen |
| 2023 | 2/5/2021 | 2/4/2028 |
| 2023 | 6/9/2014 | 6/30/2024 |
| | | |
| | | |
| | | |
| | | |
| 2023 | | |
| 2023 | 3/24/2020 | 12/31/2023 |
| 2023 2023 2023 2023 2023 2023 | 10/1/2018 12/31/2021 5/1/2018 11/1/2019 1/7/2019 | 9/30/2026 12/30/2026 Project Completion 2/28/2025 9/30/2025 |

| 2023 | Various | Evergreen |
|--------------|-----------------------|------------------------|
| 2023 | 6/1/2008 | 8/31/2024 |
| 2023 | 11/1/2020 | 10/23/2026 |
| 2023 | 9/1/2019 | 12/31/2023 |
| 2023 | 7/22/2021 | 12/31/2025 |
| 2023 | 6/1/2021 | 5/31/2024 |
| 2023 | Various | Evergreen |
| 2023 | 4/1/2011 | 7/31/2026 |
| 2023 | 7/14/2011 | 7/13/2024 |
| 2023 | 1/4/2019 | 1/3/2029 |
| 2023 | 3/19/2020 | Evergreen |
| 2023 | 9/11/2009 | Evergreen |
| 2023 | 11/30/2015 | 11/29/2025 |
| 2023 | 12/1/2022 | 11/30/2024 |
| 2023 | 11/30/2015 | 11/29/2025 |
| 2023 | Various | Evergreen |
| 2023 | 10/1/2020 | 9/30/2025 |
| 2023 | 5/4/2010 | Evergreen |
| 2023 | 9/18/2019 | 10/24/2024 |
| 2023 | 5/2/2012 | 9/30/2026 |
| 2023 | 6/27/2001 | Evergreen |
| 2023 | 4/21/2010 | Evergreen |
| 2023 | 6/1/2021 | 5/31/2024 |
| 2023 | 9/18/2019 | 10/24/2024 |
| 2023 | Various | Evergreen |
| 2023 | 12/21/2021 | 12/21/2024 |
| 2023 | 12/1/2022 | 11/30/2025 |
| 2023 | 8/1/2020 | 7/31/2028 |
| 2023 | 8/27/2019 | 8/26/2024 |
| 2023 | 9/9/2020 | 10/31/2024 |
| 2023 | 1/1/2015 | 12/31/2023 |
| 2023 | 5/24/2021 | 5/23/2024 |
| 2023 | 7/11/2001 | Evergreen |
| 2023 | 1/3/2012 | Evergreen |
| 2023 | 9/3/2020 10/1/2018 | 7/1/2024 |
| 2023 2023 | 4/2/2018 | Evergreen 4/1/2024 |
| 2023 | 6/28/2016 | |
| 2023 | 2/1/2017 | Evergreen 1/31/2024 |
| 2023 | 10/1/2015 | 12/31/2024 |
| 2023 | 11/12/2021 | 5/11/2024 |
| 2023 | 10/1/2018 | 9/30/2025 |
| 2023 | 5/10/2019 | 6/30/2025 |
| 2023 | 10/1/2018 | 9/30/2024 |
| 2023 | 1/24/2012 | Evergreen |
| 2023 | 6/29/2017 | Evergreen |
| 2023 | 7/1/2022 | 7/1/2027 |
| 2023 | //1/2022 | //1/202/ |

| 2023 | 1/4/2019 | 1/3/2029 |
|------|------------|------------|
| 2023 | 3/28/2018 | 12/31/2024 |
| 2023 | 1/1/2020 | 12/31/2024 |
| 2023 | 7/19/2021 | 7/19/2024 |
| 2023 | 11/1/2019 | 10/31/2025 |
| 2023 | 6/1/2019 | 5/31/2025 |
| 2023 | 6/1/2016 | 5/31/2024 |
| 2023 | 3/15/2002 | Evergreen |
| 2023 | 12/4/2017 | 12/3/2024 |
| 2023 | 12/23/2022 | 1/31/2025 |
| 2023 | 10/1/2016 | 9/30/2025 |
| 2023 | Various | Evergreen |
| 2023 | 11/1/2019 | 5/3/2027 |
| 2023 | 9/1/2018 | 8/21/2024 |
| 2023 | 10/29/2021 | 2/28/2025 |
| 2023 | 5/15/2015 | 12/31/2024 |
| 2023 | 6/21/2001 | Evergreen |
| 2023 | 6/17/2020 | 6/16/2024 |
| 2023 | 6/15/2001 | Evergreen |
| 2023 | 1/18/2019 | 1/18/2024 |
| 2023 | 6/9/2016 | Evergreen |
| 2023 | 4/9/2018 | 4/9/2024 |
| 2023 | 6/30/2014 | 6/30/2024 |
| 2023 | 7/16/2013 | 8/31/2023 |
| 2023 | 12/11/2017 | 12/10/2024 |
| 2023 | 4/13/2021 | 4/14/2024 |
| 2023 | 4/1/2013 | 9/30/2024 |
| 2023 | 10/23/2020 | 10/31/2025 |
| 2023 | 1/12/2018 | 6/4/2024 |
| 2023 | 1/1/2018 | 12/31/2024 |
| 2023 | 7/20/2019 | 7/19/2024 |
| 2023 | 8/4/2021 | 3/31/2024 |
| 2023 | 3/22/2017 | 7/19/2028 |
| 2023 | 6/4/2001 | Evergreen |
| 2023 | 4/1/2021 | 4/1/2024 |
| 2023 | 8/22/2012 | |
| | | Evergreen |
| 2023 | 5/31/2018 | 5/30/2025 |
| 2023 | 3/28/2008 | Evergreen |
| 2023 | 8/23/2023 | 8/22/2026 |
| 2023 | 9/13/2001 | Evergreen |
| 2023 | Various | Evergreen |
| 2023 | 7/1/2022 | 6/30/2025 |
| 2023 | 1/12/2023 | 1/11/2024 |
| 2023 | 11/9/2018 | Evergreen |
| 2023 | 3/6/2012 | 12/31/2023 |
| 2023 | 5/1/2021 | 4/30/2024 |
| 2023 | 9/18/2020 | 3/17/2024 |

| 2023 | 8/1/2020 | 7/31/2026 |
|------|-----------------------|-----------------------|
| 2023 | 9/1/2011 | 9/15/2025 |
| 2023 | 5/1/2022 | 4/30/2025 |
| 2023 | 12/1/2022 | 11/30/2025 |
| 2023 | 10/1/2021 | 9/30/2026 |
| 2023 | 11/1/2020 | 10/31/2026 |
| 2023 | 10/1/2020 | 9/30/2024 |
| 2023 | 9/30/2021 | 9/30/2026 |
| 2023 | 11/1/2020 | 10/31/2026 |
| 2023 | 9/16/2019 | 9/15/2024 |
| 2023 | 1/19/2012 | Evergreen |
| 2023 | 1/31/2022 | 1/30/2025 |
| 2023 | 10/29/2021 | 10/28/2024 |
| 2023 | 11/4/2021 | 11/3/2024 |
| 2023 | 2/18/2019 | 2/18/2024 |
| 2023 | 3/26/2019 | 3/26/2024 |
| 2023 | 11/12/2020 | 12/25/2027 |
| 2023 | 10/17/2001 | Evergreen |
| 2023 | Various | Evergreen |
| 2023 | 1/1/2021 | 12/31/2023 |
| 2023 | 10/23/2014 | Evergreen |
| 2023 | 2/1/2014 | 1/31/2025 |
| 2023 | 1/1/2021 | 12/31/2023 |
| 2023 | 3/1/2021 | 3/1/2024 |
| 2023 | | |
| 2023 | 6/18/2001 7/1/2022 | Evergreen 7/1/2025 |
| 2023 | 6/17/2022 | 6/16/2025 |
| 2023 | | |
| 2023 | 8/1/2013 11/1/2019 | 11/19/2024 |
| | | 10/31/2025 |
| 2023 | 7/1/2021 | 6/30/2024 |
| 2023 | 5/20/2022 | 3/1/2024 |
| 2023 | 7/1/2014 | 1/31/2024 |
| 2023 | 5/30/2008 | 2/25/2030 |
| 2023 | 11/1/2020 | 10/31/2025 |
| 2023 | 8/3/2015 | 10/31/2024 |
| 2023 | 11/1/2020 | 10/31/2025 |
| 2023 | 5/1/2012 | Evergreen |
| 2023 | 4/1/2018 | 12/31/2023 |
| 2023 | 6/2/2014 | Evergreen |
| 2023 | 2/27/2020 | 2/27/2030 |
| 2023 | 7/16/2013 | 8/31/2026 |
| 2023 | 3/31/2017 | Evergreen |
| 2023 | 11/9/2001 | Evergreen |
| 2023 | 3/15/2021 | Evergreen |
| 2023 | Various | Evergreen |
| 2023 | 7/1/2022 | 6/30/2026 |
| 2023 | 1/12/2022 | 1/12/2025 |

| 2023 | 12/3/2018 | 12/31/2023 |
|------|------------|------------|
| 2023 | 12/13/2019 | 12/14/2025 |
| 2023 | 6/1/2016 | 5/31/2024 |
| 2023 | 8/23/2012 | Evergreen |
| 2023 | 4/1/2021 | 3/31/2024 |
| 2023 | 12/31/2022 | 12/31/2025 |
| 2023 | 9/21/2020 | 9/30/2025 |
| 2023 | 3/6/2019 | 12/31/2023 |
| 2023 | 5/1/2019 | 5/8/2024 |
| 2023 | 9/1/2020 | 8/31/2026 |
| 2023 | 7/25/2001 | Evergreen |
| 2023 | 11/10/2022 | 11/8/2026 |
| 2023 | 1/1/2021 | 1/31/2024 |
| 2023 | 8/1/2022 | 7/31/2025 |
| 2023 | 2/1/2020 | 1/31/2026 |
| 2023 | 4/29/2022 | 4/28/2025 |
| 2023 | 1/1/2018 | 10/31/2024 |
| 2023 | 1/12/2018 | 6/30/2026 |
| 2023 | 9/1/2022 | 9/17/2024 |
| 2023 | 7/1/2021 | 6/30/2024 |
| 2023 | 2/1/2014 | 1/31/2025 |
| 2023 | 8/27/2019 | 8/26/2024 |
| 2023 | 12/2/2018 | 12/1/2023 |
| 2023 | 10/1/2021 | 9/30/2027 |
| 2023 | 2/1/2020 | 1/31/2026 |
| 2023 | 11/1/2020 | 10/31/2025 |
| 2023 | 8/1/2021 | 7/31/2024 |
| 2023 | 2/1/2023 | 1/31/2026 |
| 2023 | 6/14/2016 | 10/31/2024 |
| 2023 | 3/31/2023 | 3/30/2026 |
| 2023 | 3/24/2022 | Evergreen |
| 2023 | 6/15/2018 | 6/14/2024 |
| 2023 | 7/2/2001 | Evergreen |
| 2023 | 7/1/2021 | 6/30/2024 |
| 2023 | 9/9/2015 | 9/8/2024 |
| 2023 | 8/1/2022 | 7/31/2025 |
| 2023 | 11/1/2020 | 10/31/2024 |
| 2023 | 10/1/2015 | 12/31/2024 |
| 2023 | 7/19/2023 | 7/19/2026 |
| 2023 | 7/24/2022 | 7/23/2025 |
| 2023 | 1/13/2020 | Evergreen |
| 2023 | 6/1/2021 | 5/31/2023 |
| 2023 | 1/1/2017 | Evergreen |
| 2023 | 2/10/2021 | 2/9/2026 |
| 2023 | 9/1/2017 | 8/31/2024 |
| 2023 | 11/1/2022 | 10/31/2025 |
| 2023 | 4/15/2011 | 4/14/2024 |

| 2023 | 3/1/2016 | 10/5/2028 |
|------|------------|------------|
| 2023 | 2/27/2012 | Evergreen |
| 2023 | 3/1/2020 | 2/28/2025 |
| 2023 | 7/1/2022 | 3/31/2026 |
| 2023 | 9/16/2019 | 9/15/2024 |
| 2023 | 7/7/2022 | 7/6/2025 |
| 2023 | 4/27/2018 | 4/26/2024 |
| 2023 | 9/7/2016 | Evergreen |
| 2023 | 4/15/2021 | 4/14/2024 |
| 2023 | 12/15/2022 | 12/15/2027 |
| 2023 | 9/28/2021 | 9/15/2024 |
| 2023 | 1/4/2012 | 8/24/2023 |
| 2023 | 8/25/2015 | 7/12/2023 |
| 2023 | 8/16/2017 | Evergreen |
| 2023 | 1/1/2021 | Evergreen |
| 2023 | 1/26/2022 | 1/25/2027 |
| 2023 | 8/1/2019 | 8/31/2026 |
| 2023 | 8/1/2018 | 7/31/2024 |
| 2023 | 6/1/2010 | 12/31/2023 |
| 2023 | 11/1/2021 | 10/31/2024 |
| 2023 | 1/31/2012 | Evergreen |
| 2023 | 8/1/2019 | 7/31/2025 |
| 2023 | 12/4/2018 | 12/3/2025 |
| 2023 | 10/3/2017 | 10/2/2024 |
| 2023 | 6/15/2018 | 6/20/2024 |
| 2023 | 4/1/2018 | 7/31/2025 |
| 2023 | 6/21/2012 | Evergreen |

| Purpose |
|---|
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| |
| Commodities/Supplies Other Professional Services |
| |
| Other Professional Services |
| Staffing Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Other |
| Other |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Other |
| Other |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Telecommunication Equipment or Services |
| Other Professional Services |
| Commodities/Supplies |
| Design and Construction/Maintenance |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services Other Professional Services |
| Other Frotessional Services |

| Commodities/Supplies |
|-------------------------------------|
| Financial Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Staffing Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Financial Services |
| Technology - Software |
| Other Professional Services |
| Other Professional Services |
| Technology - Software |
| Technology - Hardware |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Design and Construction/Maintenance |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Other |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Technology - Software |
| Other Professional Services |
| Commodities/Supplies |
| Design and Construction/Maintenance |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Other |
| Commodities/Supplies |
| Technology - Software |
| Commodities/Supplies |
| Technology - Software |
| Other Professional Services |
| Other Professional Services |
| Financial Services |
| Other Professional Services |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Technology - Software |
| Legal Services |

| Other Professional Services |
|-------------------------------------|
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Other Professional Services |
| Technology - Software |
| Other Professional Services |
| Commodities/Supplies |
| Legal Services |
| Commodities/Supplies |
| Technology - Software |
| Consulting Services |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Consulting Services |
| Other |
| Other Professional Services |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |
| Legal Services |
| Other Professional Services |
| Commodities/Supplies |
| Technology - Software |
| Other Professional Services |
| |
| Technology - Software |
| Commodities/Supplies |
| Design and Construction/Maintenance |
| Commodities/Supplies |
| Legal Services |
| Commodities/Supplies |
| Design and Construction/Maintenance |
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |

| Commodities/Supplies |
|---|
| Technology - Software |
| Technology - Software |
| Commodities/Supplies |
| Financial Services |
| Commodities/Supplies |
| Other Professional Services |
| Other |
| Commodities/Supplies |
| Other |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Technology - Software |
| Design and Construction/Maintenance Other Professional Services |
| |
| Technology - Software Other Professional Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Technology - Software |
| Technology - Software |
| Other |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Other |
| Commodities/Supplies |
| Other |
| Technology - Software |
| Other |
| Commodities/Supplies |
| other |
| Other |
| Staffing Services |
| Commodities/Supplies |
| Commodities/Supplies |

| Other Professional Services |
|--|
| Technology - Consulting/Development or Support |
| Other Professional Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Other |
| Other Professional Services |
| Other |
| Commodities/Supplies |
| Technology - Hardware |
| Commodities/Supplies |
| Commodities/Supplies |
| Design and Construction/Maintenance |
| Commodities/Supplies |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Technology - Software |
| Other |
| Technology - Software |
| Technology - Software |
| Commodities/Supplies |
| Technology - Software |
| Technology - Software |
| Commodities/Supplies |
| Technology - Consulting/Development or Support |
| Design and Construction/Maintenance |
| Technology - Software |
| Technology - Software |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |

| Technology - Software |
|---|
| Telecommunication Equipment or Services |
| Commodities/Supplies |
| Commodities/Supplies |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |
| Other Professional Services |
| Other Professional Services |
| Commodities/Supplies |
| Telecommunication Equipment or Services |
| Design and Construction/Maintenance |
| Commodities/Supplies |
| Other Professional Services |
| Commodities/Supplies |
| Technology - Software |
| Commodities/Supplies |
| Financial Services |
| Technology - Software |
| Other Professional Services |
| Other |
| Other |
| Other Professional Services |
| Technology - Software |
| Technology - Software |
| Commodities/Supplies |
| Commodities/Supplies |
| · |




TABLE OF CONTENTS

| Preamble | 1 |
|--|---|
| Article I - Offices | 1 |
| Article II - Purpose of By-Laws | 1 |
| Article III - Corporate Purpose | 1 |
| Article IV - Erie County Medical Center Corporation Board of Directors | 1 |
| Section 1 – General Powers | 1 |
| Section 2 –Hiring Powers | 2 |
| Section 3 - Voting Directors | 2 |
| Section 4 - Nonvoting Representatives | 2 |
| Section 5 - Resignation | 2 |
| Section 6 - Removal | 2 |
| Section 7 – Vacancies | 2 |
| Section 8 - Monthly Meetings | 2 |
| Section 9 - Annual & Special Meetings | 3 |
| Section 10 - Open Meetings Law | 3 |
| Section 11 - Quorum | 3 |
| Section 12 – Telephone Meetings | 3 |
| Section 13 – Action by Written Consent | 3 |
| Section 14 – Minutes of Meetings | 3 |
| Section 15 - Compensation | 3 |
| Section 16 – Defense and Indemnification | 3 |
| Section 17 – Extension of Credit | 4 |

| Article | V - Officers | 4 |
|---------|--|-----|
| | Section 1 - General | . 4 |
| | Section 2 - Election, Term of Office | . 4 |
| | Section 3 - Resignation | . 4 |
| | Section 4 - Removal | . 4 |
| | Section 5 - Vacancies | . 4 |
| | Section 6 – Chairperson of the Board | . 4 |
| | Section 7 – Vice-Chairperson(s) of the Board | . 5 |
| | Section 8 - Chief Executive Officer | . 5 |
| | Section 9 – President | . 5 |
| | Section 10 – Secretary & Assistant Secretary | . 5 |
| | Section 11 - Treasurer | . 6 |
| | Section 12 – Immediate Past Chair | . 6 |
| Article | VI - Committees | . 6 |
| | Section 1 – General | 6 |
| | Section 2 – Appointment of Committees | . 6 |
| | Section 3 – Structure of Committees | . 6 |
| | Section 4 – Resignation | 6 |
| | Section 5 – Removal | 7 |
| | Section 6 – Vacancies | . 7 |
| | Section 7 - Quorum | . 7 |
| | Section 8 - Voting | .7 |
| | Section 9 - Minutes | .7 |
| | Section 10 - The Executive Committee | . 7 |

| Se | ection 11 - The Quality Improvement Committee | 7 |
|------------|--|----|
| Se | ection 12 - The Finance Committee | 8 |
| Se | ection 13 - The Audit & Compliance Committee | 8 |
| Se | ection 14 – Buildings and Grounds Committee | 9 |
| Se | ection 15 - The Human Resources Committee | 9 |
| Se | ection 16 - The Executive Compensation/Evaluation Committee | 9 |
| Se | ection 17 - Terrace View Quality Improvement Committee | 9 |
| Se | ection 18 - The Governance Committee | 10 |
| Se | ection 19 - The Investment Committee | 10 |
| Se | ection 20 - The Contracts Committee | 11 |
| Article V | TII - Medical/Dental Staff | 11 |
| Se | ection 1 – Organization | 11 |
| Se | ection 2 - Medical Staff Governance Documents | 11 |
| Se | ection 3 - Appointment of Medical Staff | 11 |
| Se | ection 4 – Authority for Medical Staff Conduct | 12 |
| Se | ection 5 - Duties of the Medical Staff | 12 |
| Se | ection 6 – Quality of Patient Care | 12 |
| Se | ection 7 - Rights at Meetings | 12 |
| Article V | VIII - Standards of Patient Care | 12 |
| Article IX | X - The School of Medicine - State University of New York at Buffalo | 13 |
| Article X | X - Subsidiary Corporations and Entities | 13 |

| Article XI - Code of Ethics and Conflicts of Interest | |
|--|----|
| Section 1 – Responsibility of Members of the Board and Employees | 13 |
| Section 2 – Implementation of Code of Ethics | 14 |
| Section 3 - Compliance | 14 |
| Section 4 – Conflict of Interest Policy | 14 |
| Section 5 – Disclosure of Personal Interest and Abstention | 15 |
| Section 6 – Self-Dealing | 15 |
| Section 7 – Influence of Decision Makers | 15 |
| Section 8 – No Forfeit of Office of Employment | 15 |
| Article XII - Amendments | 15 |

BY-LAWS

OF

ERIE COUNTY MEDICAL CENTER CORPORATION

PREAMBLE

The State of New York has enacted legislation, codified at Article 10-C of the Public Authorities Law of the State of New York (the "Act"), creating the Erie County Medical Center Corporation ("ECMCC" or the "Corporation"). These by-laws are intended to supplement the requirements of the Act.

ARTICLE I OFFICES

ECMCC may maintain offices at such places within or without Erie County, New York as the Board of Directors may, from time to time, determine.

ARTICLE II PURPOSE OF BY-LAWS

Pursuant to the broad powers granted by the Act, the Board of Directors of ECMCC (the "Board") has adopted these By-Laws, to govern and manage its proceedings and affairs and for the advice and guidance of its members, and nothing contained in these By-Laws shall be deemed, nor are they intended in any manner or degree, to limit or restrict the power and right of the Board under existing law, to manage, control, operate and administer ECMCC and its personnel, patients and medical staff.

ARTICLE III CORPORATE PURPOSE

To continue as a general, municipal hospital and provide health care services and health facilities for the benefit of the residents of the State of New York and the County of Erie, including persons in need of health care services without the ability to pay, as required by law.

ARTICLE IV ERIE COUNTY MEDICAL CENTER CORPORATION BOARD OF DIRECTORS

Section 1. General Powers.

In addition to the powers and authorities expressly conferred by these By-laws, the Board may exercise all such general and special powers of the Corporation and do all such lawful acts and things as enumerated by the Act.

Section 2. Hiring Powers.

The Board shall hire, determine the compensation and benefits, and annually review the performance of the Chief Executive Officer ("CEO") and President of the Corporation. Appointments made to fill the roles of the Chief Operating Officer ("COO"), Chief Financial Officer ("CFO"), Chief Medical Officer ("CMO"), Administrator of Terrace View, Chief Nursing Officer ("CNO"), Chief Strategy Officer, and General Counsel of the Corporation shall be made by the CEO of the Corporation, who shall thereafter also be responsible for determining the compensation and benefits of the persons occupying these positions and for the annual review of the incumbents. The Board shall have the authority to discharge the CEO with or without cause; provided that the removal shall not prejudice the contract rights, if any, of such executive. The CEO shall have the authority to discharge the COO, CFO, CMO, Administrator of Terrace View, Chief Nursing Officer, Chief Strategy Officer, and General Counsel with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executive.

Section 3. Voting Directors.

The Corporation shall be governed by fifteen voting Directors. The membership, term of office, selection of the voting Directors and the powers and duties of the Board shall be in accordance with the Act and these By-laws.

Section 4. Nonvoting Representatives.

The Corporation shall have four nonvoting Representatives. The term of office, selection and powers and duties of the nonvoting Representatives shall be in accordance with the Act and these By-laws. For the purpose of these By-Laws, the term "member" or "Board member" shall refer to both voting Directors and non- voting Representatives.

Section 5. Resignation.

Any Director or Representative may resign at any time by giving written notice to the Chairperson of the Board. Such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 6. Removal.

Members of the Board may be removed from office by the Board for inefficiency, neglect of duty, or misconduct of any kind, including but not limited to violation of the law, after the Board has given such member a copy of the charges against him or her and an opportunity to be heard in person or by counsel in his or her defense, upon not less than ten days' notice.

Section 7. Vacancies.

Vacancies occurring other than by expiration of term shall be filled for the unexpired terms in the manner provided for original appointment in accordance with the Act.

Section 8. Monthly Meetings.

The Board shall hold regular monthly meetings at the ECMCC offices or other convenient locations as designated by the Board at such time as the Board may designate. In the event that a previously scheduled regular monthly meeting may not be required for a particular month, the Board may cancel that meeting.

Section 9. Annual & Special Meetings.

A meeting of the Board shall be held annually at which time officers of the Corporation shall be elected. A special meeting may be called by the Chairperson or Vice Chairperson acting in the Chairperson's absence, or by any three (3) members of the Board at any time upon proper notice under the Public Officers Law. The only action that can be taken at a special meeting is the consideration of the subject or subjects designated in the notice for the special meeting.

Section 10. Open Meetings Law.

All meetings of the Board shall comply with the requirements of Article 7 of the Public Officers Law. In a regular, annual or special meeting, the Board may request an Executive Session pursuant to Article 7 of the Public Officers Law or applicable sections of the Act.

Section 11. Quorum.

The powers of the Corporation shall be vested in and shall be exercised by the Board at a duly called and held meeting, where a quorum of eight Directors is present. No action shall be taken by the Corporation except pursuant to the favorable vote of at least eight Directors present at the meeting at which such action is taken.

Section 12. <u>Telephone Meetings.</u>

The members of the Board or any committee thereof may participate in a meeting of such Board or committee by means of a conference telephone or similar communications equipment allowing all persons participating in the meeting to hear each other at the same time. Participation by such means shall constitute presence in person at a meeting.

Section 13. Action by Written Consent.

To the extent permitted by law, any action required or permitted to be taken by the Board or any committee thereof may be taken without a meeting if all members of the Board or the committee consent in writing to the adoption of a resolution authorizing the action. The resolution and the written consents thereto by the members of the Board or committee shall be filed with the minutes of the proceedings of the Board or committee.

Section 14. Minutes of Meetings.

The Board shall keep a written record of all business conducted, including resolutions, findings, conclusions and recommendations that shall be filed with the minutes of the proceedings of the Board or committee.

Section 15. Compensation.

Neither the voting Directors nor the nonvoting Representatives shall receive compensation for their services but shall be reimbursed for all their actual and necessary expenses incurred in connection with their duties under the Act and these By-laws.

Section 16. Defense and Indemnification.

The Corporation shall defend and indemnify the Directors of the Corporation and its officers for any and all lawful actions executed in the performance of their duties, to the full extent to which indemnification is permitted under the laws of the State of New York.

Section 17. Extension of Credit.

Pursuant to New York Public Authorities Law Section 2824(5), the Corporation shall not, directly, or indirectly, including through any subsidiary, extend or maintain credit, arrange for the extension of credit, or renew any extension of credit, in the form of a personal loan to or for any Director, officer, or employee (or equivalent thereof) of the Corporation.

ARTICLE V OFFICERS

Section 1. General.

The officers of the Corporation shall be elected by the Board and shall be comprised of a Chairperson of the Board, a Vice Chairperson of the Board, a CEO, a Secretary, and a Treasurer. The Board may also appoint an Assistant Secretary and such other officers as the Board shall from time to time provide. All such officers shall exercise the duties as described in the Act, applicable law, by these By-Laws, and/or by Board resolution.

Section 2. Election, Term of Office.

The officers of the Corporation shall be elected by the Board at its annual meeting. Each officer elected shall hold office until his successor has been duly chosen and has qualified or until his or her earlier resignation or removal.

Section 3. Resignation.

Any officer may resign at any time by giving written notice thereof to the Board, provided that the resignation shall not prejudice the contract rights, if any, of the Corporation. Any such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 4. Removal.

The Directors shall have the authority to discharge any officer with or without cause; provided that the removal without cause shall not prejudice the contract rights, if any, of the officer.

Section 5. Vacancies.

In the event of a vacancy occurring in the office of the Chairperson or Vice Chairperson, any member designated by the Board shall serve as Acting Chairperson for that meeting. In the event of a vacancy occurring in any other office, any member designated by the Board shall serve as an Acting officer for that meeting.

Section 6. Chairperson of the Board.

The Directors shall, by majority vote, select one of the fifteen Directors as the Chairperson of the Board. The Chairperson shall preside over all meetings of the Board, shall chair the Executive Committee of the Board, and shall have such other duties as the Directors may provide. Other than the Governance Committee, the Chairperson shall serve <u>ex officio</u> on all Board committees with full voting rights. The Chairperson shall serve for a two-year term of office. No member of the Board shall be permitted to serve more than two consecutive two-year terms as Chairperson of the Board.

<u>Section 7.</u> <u>Vice-Chairperson(s) of the Board.</u>

The Directors shall, by majority vote, select one or more of the fifteen Directors as the Vice-Chairperson of the Board. The Vice-Chairperson shall preside over all meetings where the Chairperson of the Board is absent and shall have such other duties as the Directors may provide. The Vice-Chairperson shall serve for a two-year term of office. At least one Vice-Chairperson shall be designated by a majority vote of the Board as "Vice-Chair, Chair-Elect" in the second year of that Vice- Chairperson's term of office. At the conclusion of the term of the Vice-Chair, Chair-Elect, the Board shall retain authority to appoint the Vice-Chair, Chair-Elect or any other member of the Board of Directors as Chairperson of the Board of Directors.

Section 8. Chief Executive Officer.

The Board shall hire, set the compensation of, execute direct oversight of, and annually review the performance of the CEO. The CEO shall carry out the policies of the Board, provide services to the Board; and shall be subject to the By-Laws, rules and regulations of the Board. He or she shall have all the general powers and duties of a Superintendent of a public general municipal hospital as set forth and enumerated in the General Municipal Law of the State of New York, Section 129, sub. 1 through 9 as amended and of a chief executive officer as set forth in Title 10, subpart 405.3 of the New York Codes, Rules and Regulations and the Act. The CEO shall provide leadership, direction, and administration in all aspects of the Corporation's activities and other corporate entities to ensure compliance with established objectives and the realization of quality, economical health care services, and other related lines of business. The CEO shall ensure the Corporation's compliance with all applicable laws and regulations. The CEO shall submit monthly and special reports to the Board and its committees regarding strategic, operational and financial performance, along with the current status of ECMCC services and facilities. The CEO shall be expected to provide feedback to the Board regarding those employees which report directly to the CEO. The CEO shall ensure that subordinate officers provide meaningful reports to the Board regarding the previous month's activities. The CEO shall coordinate with the Board, Medical Staff, and other Corporation personnel to respond to the community's needs for quality healthcare services and monitor the adequacy of the Corporation's medical activities.

Section 9. President.

The Board shall hire, set the compensation and annually review the performance of the President. The duties of the President shall be distinct from the duties of other officers of the Corporation and shall be enumerated in a job description reviewed by the Executive Committee of the Board.

Section 10. Secretary & Assistant Secretary.

The Board shall, by majority vote, select either Directors or Representatives to serve as the Secretary and Assistant Secretary, if applicable. The Secretary shall send notices for all meetings of the Board. The Secretary shall act as custodian for all records and reports and shall be responsible for keeping and reporting of adequate records of all meetings of the Board. The Secretary may delegate these duties to another officer or employee of the Corporation to act on his/her behalf. The Secretary will approve and sign the minutes of all meetings of the Board which shall be kept in an official record book. In the absence of the Secretary at any meeting, the Assistant Secretary, if applicable, or any member designated by the Chairperson shall act as the Secretary for that meeting.

Section 11. Treasurer.

The Board shall, by majority vote, select either a Director or a Representative to serve as the Treasurer. The Treasurer shall monitor the financial affairs of ECMCC as managed by the officers of the Corporation. The Treasurer will also have the power to establish bank accounts in the name of the Corporation. He or she shall do and perform all other duties incident to the office of Treasurer as may be prescribed by the Board from time to time.

Section 12. Immediate Past Chair.

The Immediate Past Chair of the Board shall remain available to the Board and the Chair for purposes of transitional continuity and may be appointed to serve as a member of any Standing or Special Committee of the Board, assuming his or her term of office as a Director has not expired.

ARTICLE VI COMMITTEES

General Rules

Section 1. General.

The Standing Committees of the Board shall be: the Executive Committee, the Quality Improvement Committee, the Finance Committee, the Audit and Compliance Committee, the Building and Grounds Committee, the Human Resources Committee, the Executive Compensation Committee, the Terrace View Quality Improvement Committee, the Governance Committee, the Investment Committee and the Contracts Committee. At the discretion of the Chairperson, and upon the advice of the Board, additional special committees may be appointed to address specific issues.

Section 2. Appointment of Committees.

The Chairperson of the Board shall appoint all members of standing and special committees. Appointments will be made at the first regular meeting following the annual election of officers, or at such other time deemed necessary by the Chairperson. The Chairperson of the Board shall appoint a Chairperson for each committee. Committee Chairpersons shall serve one-year terms of office but are not prohibited from serving consecutive one-year terms. The Chairperson may appoint individuals other than Board members to committees either standing or special, except the Executive Committee.

<u>Section 3.</u> <u>Structure of Committees.</u>

In addition to the individual Committee duties set forth below, each Committee shall be tasked annually with reviewing their applicable charter and recommending changes thereto, as well as setting forth goals for the Committee for the upcoming year. Such goals shall be determined in consultation with the Chairperson of the Board.

Section 4. Resignation.

A committee member may resign at any time by giving written notice to the Chairperson of the Board. Such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 5. Removal.

Committee members may be removed from committee membership by the Board for inefficiency, neglect of duty, or misconduct of any kind, including but not limited to, violation of the law, after the board has given such member a copy of the charges against him or her and an opportunity to be heard in person or by counsel in his or her defense, upon not less than ten days' notice.

Section 6. Vacancies.

Vacancies occurring otherwise than by expiration of term of office shall be filled for the unexpired terms by appointment from the Chairperson of the Board.

Section 7. Quorum.

At a committee meeting, a quorum shall be one-half the number of members of the committee.

Section 8. Voting.

Only the members of the Board serving on a Standing or Special Committee, or an appointed non-member of the Board serving on a Standing or Special Committee, and the Chairperson of the Board serving ex officio, shall have a vote.

Section 9. Minutes.

Each committee meeting shall have an agenda, time convened and adjourned recorded, and shall submit minutes of its meeting to the Secretary of the Board in advance of the regular monthly meeting.

Standing Committees

Section 10. The Executive Committee.

The Executive Committee shall consist of four (4) Board members. The Corporation's General Counsel and Chief Executive Officer shall serve ex officio as members of the Executive Committee. Other members of the Board may be added when advisable. The Chairperson shall preside at all meetings of the Committee. The Executive Committee shall meet at least quarterly, or upon the call of the Chairperson.

Section 11. The Quality Improvement Committee.

The Quality Improvement Committee shall consist of three (3) members. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Inform the Board of patient safety, performance improvement and quality assurance issues of relevance to ECMCC.
- b. Establishment, maintenance and operation of a coordinated quality assurance program integrating the review of activities of all hospital services in order to enhance the quality of patient care and to identify and prevent professional malpractice. The specific responsibilities of the Committee are further set forth in the quality assurance plan of the hospital.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 12. The Finance Committee.

The Finance Committee shall consist of five (5) financially literate members of the Board. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Finance Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Review relevant budgets of the Corporation and maintain ongoing oversight of the financial situation of the Corporation.
- b. Oversee, evaluate, and where appropriate, make recommendations with respect to financial operations of the Corporation.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 13. The Audit & Compliance Committee.

The Audit & Compliance Committee shall consist of at least four (4) members. At least three (3) of the Committee's members shall be independent, as that term is defined by state law. The Corporation's General Counsel shall serve <u>ex officio</u> as a member of the Audit & Compliance Committee. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the committee may dictate. The Audit & Compliance Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Oversight of any independent auditors engaged by ECMCC.
- b. Oversight of all ECMCC internal audit processes.
- c. Collaboration with the Quality Improvement Committee in the establishment and maintenance of a coordinated quality assurance program.
- d. Collaboration with the Compliance Officer on the establishment, maintenance and operation of a comprehensive compliance program, which shall comply with the Office of the Inspector General Compliance Program Guidance for Hospitals. Specifically, the Committee shall:
 - 1. Analyze the legal requirements and specific risk areas of the health care industry,
 - 2. Assess existing policies that address legal requirements and risk areas for possible incorporation into the ECMCC compliance program,
 - 3. Work with ECMCC departments to develop standards of conduct and policies and procedures to promote compliance with the ECMCC compliance program,
 - 4. Recommend and monitor the development of internal systems and controls to carry out ECMCC's standards, policies and procedures as part of its daily operations,
 - 5. Determine appropriate strategy to promote compliance with the ECMCC compliance program and detection of possible violations, including fraud reporting mechanisms,
 - 6. Develop a system to solicit, evaluate and respond to complaints and problems, and
 - 7. Promote ethics, integrity, and compliance with laws, policies, and procedures.
- e. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 14. Buildings and Grounds Committee.

The Buildings and Grounds Committee shall consist of three (3) members. The Corporation's General Counsel shall serve <u>ex officio</u> as a member of the Buildings and Grounds Committee. The Chairperson of the Committee may, at his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Buildings and Grounds Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Evaluation and provision of recommendations with respect to proposed and ongoing construction and renovation projects and budgets.
- b. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 15. The Human Resources Committee.

The Human Resources Committee shall consist of three (3) members. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Committee will meet at least quarterly or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Establishment of a formal channel of communication among the Board, ECMCC management and the Labor Unions.
- b. Responsibility for assuring that appropriate guidelines are in place and monitored to ensure and maintain open communication.
- c. Discussion of issues that arise in the operation of the hospital as they affect all parties.
- d. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 16. The Executive Compensation/Evaluation Committee.

The Executive Compensation/Evaluation Committee shall consist of no more than four (4) members of the Board. No person whose compensation is determined by the Executive Compensation/Evaluation Committee may serve as a member of the Committee. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the committee may dictate. The Executive Compensation/Evaluation Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Evaluation, at least annually, of the CEO and President of the Corporation.
- b. Determination of the compensation, including benefits, of the above listed Corporation executives.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 17. The Terrace View Quality Improvement Committee.

The Terrace View Quality Improvement Committee shall consist of at least three (3) members. The Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Establishment and maintenance of a coordinated quality assurance program as specifically applicable to Terrace View.
- b. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 18. The Governance Committee.

The Governance Committee shall consist of at least four (4) independent members, as that term is defined in New York Public Authorities Law §2825. The Chief Executive Officer and the General Counsel for the Corporation shall serve ex officio as members of the Committee, and the Chairperson of the Board may attend Committee meetings but will not be a member of the Committee and will not vote. The Committee Chairperson may, at his or her discretion, request the presence of other persons as issues before the Committee may dictate. The Governance Committee shall meet at least semi- annually, or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Provision of information to the Board regarding current best governance practices.
- b. Review of corporate governance trends.
- c. Recommend updates to the Corporation's governance principles.
- d. Provision of advice to the Governor and to the Erie County Executive in their appointment of potential Board members regarding the skills and experience required of Board members.
- e. Annually review and, as necessary, make recommendations to the Board regarding updating of the Corporation's Bylaws; annually review and, as necessary, make recommendations to the applicable Committees regarding updates to Committee charters.
- f. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 19. The Investment Committee.

The Investment Committee shall consist of at least three (3) members. The Chair of the Finance Committee and the Chief Executive Officer shall serve <u>ex officio</u> as members of the Investment Committee and the Chief Financial Officer shall serve as staff to the Committee. The Committee Chairperson may, at his or her discretion, request the presence of other persons as issues before the Committee may dictate. The Investment Committee shall meet at least semi-annually, or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Recommendations regarding the designation of the Corporation's investment officer.
- b. Recommendations regarding investment policies and procedures consistent with applicable law and the needs of the Corporation.
- c. Implementation of appropriate internal controls for investments.
- d. Recommendations regarding the selection of the Corporation's investment advisors and investment managers.
- e. Review of independent audits of the investment program.
- f. Review of quarterly reports from the Corporation's investment advisors and investment managers.
- g. Reports to the Board on a quarterly basis.
- h. Monitoring the Corporation's system of internal controls and the performance of the Corporation's investment advisors and investment managers.
- i. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 20. The Contracts Committee.

The Contracts Committee shall consist of at least three (3) members. The Contracts Committee shall review and make recommendations to the Board with respect to the approval of all contracts required to be approved by the Board pursuant to Corporation policy and applicable law, including Section 2879(3)(b)(ii) of the Public Authorities Law. The Contracts Committee shall meet at least quarterly or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Review of contracts of the Corporation requiring Board approval and make recommendations to the Board regarding such contracts.
- b.
- c. Annually review contracts requiring such review pursuant to Corporation policy and/or applicable law.
- d. Redacting sensitive information from contracts before presentation to the Board to ensure compliance with the Corporation's contractual and confidentiality requirements.
- e. Report to the Board on a quarterly basis regarding the foregoing subsections.
- f. Other duties and responsibilities as may be assigned from time to time by the Board.

ARTICLE VII MEDICAL/DENTAL STAFF

Section 1. Organization.

The Board shall cause to be created a medical staff organization to be known as the ECMC Medical Dental Staff ("Medical Staff") whose membership shall be comprised of certain categories of health care practitioners, as determined by the Board. Members of the Medical Staff may only practice within the scope of privileges granted by the Board.

Section 2. Medical Staff Governance Documents.

The Medical Staff shall develop, adopt and at least once every three years review the following Medical Staff Governance Documents: By-Laws; Rules & Regulations; Credentials Procedures Manual; and Collegial Intervention, Peer Review, Fair Hearing & Appellate Review Procedures. These Governance Documents shall establish controls that are designed to ensure the achievement and maintenance of the highest quality medical care and high standards of professional and ethical practice. The Board shall approve all such Medical Staff Governance Documents.

Section 3. Appointment of Medical Staff.

Appointments and reappointments to the Medical Staff shall be made by the Board. The Board shall be responsible for granting and defining the scope of the clinical privileges to be exercised by each member of the Medical Staff, including but not limited to providing approval of modifications, suspensions and termination of such privileges and Medical Staff membership in accordance with the Medical Staff Governance Documents and written ECMCC policies. In acting on matters of Medical Staff membership and scope of privileges, the Board shall consider the recommendations of the Medical Staff's Medical Executive Committee. The procedures for Medical Staff appointment are more specifically outlined in the Medical Staff's Credentials Procedure Manual.

Section 4. Authority for Medical Staff Conduct.

Ultimate responsibility for the conduct of the Medical Staff remains with the Board. The Board shall enforce compliance with all medical staff Governance Documents by all members of the Medical Staff. No assignment, referral or delegation of authority by the Board to the Medical Director, COO, CEO, the Medical Staff or any other person shall preclude the Board from exercising the authority required to meet its responsibility for the conduct of the Corporation. The Board retains the right to rescind any such delegation.

Section 5. Duties of the Medical Staff.

The Board shall delegate to the Medical Staff the authority to monitor, evaluate and document professional performance of Medical Staff members in accordance with its Governance Documents. The Board shall hold the Medical Staff accountable, through the chiefs of service of the departments and the Medical Director, for making recommendations based on well-defined and written criteria related to the goals and standards of the Corporation concerning Medical Staff appointments, reappointments and clinical privileges.

Section 6. Quality of Patient Care.

The Medical Staff is accountable to the Board for the quality of care provided to patients.

Section 7. Rights at Meetings.

Members of the Medical Staff shall be entitled to be heard at all public meetings and committee meetings of the Board.

ARTICLE VIII STANDARDS OF PATIENT CARE

The Board shall require that the following patient care practices are implemented, shall monitor ECMCC's compliance with these patient care practices, and shall take corrective action as necessary to attain compliance:

- a. Every patient of ECMCC, whether an in-patient, emergency patient, or out-patient, shall be provided care that meets generally accepted standards of professional practice.
- b. Every patient is under the care of a health care practitioner who is a member of the medical staff.
- c. Patients are admitted to ECMCC only on the recommendation of a member of the medical staff permitted by the State law and Medical Staff Governance Documents to admit patients to the hospital.
- d. A physician, a registered physician's assistant or a nurse practitioner, under the general supervision of a physician, is on duty at all times in the hospital.
- e. A physician shall be responsible for the care of each patient with respect to any medical or psychiatric problem that is present on admission or develops during hospitalization.
- f. In the event that human research is conducted within ECMCC, written policies and procedures shall be adopted and implemented pursuant to the provisions of Public Health Law Article 24-A for the protection of human subjects.
- g. ECMCC shall have available at all times personnel sufficient to meet patient care needs.

ARTICLE IX <u>THE SCHOOL OF MEDICINE</u> STATE UNIVERSITY OF NEW YORK AT BUFFALO

The Board strongly supports the relationship between ECMCC and the School of Medicine and Biomedical Sciences of the State University of New York at Buffalo through an affiliation agreement. The Board shall take all appropriate action to retain and enhance the benefits arising from said relationship provided that the Board shall hold uppermost the discharge of its legal and fiduciary duties to ECMCC.

ARTICLE X SUBSIDIARY CORPORATIONS AND ENTITIES

Except as expressly limited by law, the Corporation may exercise and perform all or part of its purposes, powers, duties, functions or activities through one or more subsidiary corporations or companies owned or controlled wholly or in part by the Corporation, which shall be formed pursuant to the Business Corporation Law, the Limited Liability Company Law, or the Not-For-Profit Corporation Law. Any such subsidiary may be authorized to act as a general or limited partner in a partnership or as a member of a limited liability company and to enter into an arrangement calling for an initial and subsequent payment by such subsidiary in consideration of an interest in revenues or other contractual rights. The Board has the exclusive authority to create subsidiaries or other entities related to the Corporation.

ARTICLE XI CODE OF ETHICS AND CONFLICTS OF INTEREST

Section 1. Responsibility of Members of the Board and Employees.

This Code of Ethics shall apply to all officers and employees of the Corporation. These policies shall serve as a guide for official conduct and are intended to enhance the ethical and professional performance of the Corporation's directors and employees and to preserve public confidence in the Corporation's mission. It is accordingly the responsibility of each member of the Board and each employee to perform in accordance with the following:

- a. Each member of the Board and all employees of the Corporation shall perform their duties with transparency, without favor and refrain from engaging in outside matters of financial or personal interest, including other employment, that could impair independence of judgment, or prevent the proper exercise of one's official duties.
- b. Each member of the Board and all employees shall not directly or indirectly, make, advise, or assist any person to make any financial investment based upon information available through the director's or employee's official position that could create any conflict between their public duties and interests and their private interests.
- c. Each member of the Board and all employees shall not accept or receive any gift or gratuities where the circumstances would permit the inference that: (a) the gift is intended to influence the individual in the performance of official business or (b) the gift constitutes a tip, reward, or sign of appreciation for any official act by the

individual. This prohibition extends to any form of financial payments, services, loans, travel reimbursement, entertainment, hospitality, thing or promise from any entity doing business with or before the Corporation.

- d. Each member of the Board and all employees shall not use or attempt to use their official position with the Corporation to secure unwarranted privileges for themselves, members of their family or others, including employment with the Corporation or contracts for materials or services with the Corporation.
- e. Each member of the Board and all employees must conduct themselves at all times in a manner that avoids any appearance that they can be improperly or unduly influenced, that they could be affected by the position of or relationship with any other party, or that they are acting in violation of their public trust.
- f. Each member of the Board and all employees may not engage in any official transaction with an outside entity in which they have a direct or indirect financial interest that may reasonably conflict with the proper discharge of their official duties.
- g. Each member of the Board and all employees shall manage all matters within the scope of the Corporation's mission independent of any other affiliations or employment. Directors, including ex officio board members, and employees employed by more than one government entity shall strive to fulfill their professional responsibility to the Corporation without bias and shall support the Corporation's mission to the fullest.
- h. Each member of the Board and all employees shall not use Corporation property, including equipment, telephones, vehicles, computers, or other resources, or disclose information acquired in the course of their official duties in a manner inconsistent with State or local law or policy and the Corporation's mission and goals.
- i. Each member of the Board and all employees are prohibited from appearing or practicing before the Corporation for two (2) years following employment with the Corporation consistent with the provisions of Public Officers Law.

Section 2. <u>Implementation of Code of Ethics.</u>

This Code of Ethics shall be provided to all members of the Board and all employees upon commencement of employment or appointment and shall be reviewed annually by the Governance Committee.

Section 3. Compliance.

The members of the Board agree to comply with all applicable local and state regulations and laws regarding conflicts of interest.

Section 4. Conflict of Interest Policy.

The Board shall develop, implement, and update as needed a written policy governing conflict of interest by members of the Board. The policy shall be reviewed annually by the Governance Committee and included and incorporated into these By-Laws as Appendix A.

Section 5. <u>Disclosure of Personal Interest and Abstention.</u>

It is the responsibility of every Board member to disclose to the Chairperson of the Board any personal or business interest in any matter that comes before the Board for consideration. Each member of the Board shall abstain from voting on any matter in which he or she has a personal or business interest.

Section 6. Self-Dealing.

The Corporation shall not engage in any transaction with a person, firm, or other business entity in which one or more of the Board members has a financial interest in such person, firm or other business entity, unless such interest is disclosed in good faith to the Board, and the Board authorizes such transaction by a vote sufficient for such purpose, without counting the vote of the interested Board member.

Section 7. <u>Influence of Decision Makers.</u>

No member of the Board shall use his or her position to influence the judgment or any decision of any Corporation employee concerning the procurement of goods or services on behalf of the Corporation.

Section 8. No Forfeit of Office or Employment.

Except as provided by law, no officer, member, or employee of the state or of any public corporation shall forfeit his or her office or employment by reason of his or her acceptance of appointment as a director, nonvoting representative, officer, or employee of the Corporation, nor shall such service as such a director, nonvoting representative, officer or employee be deemed incompatible or in conflict with such office or employment; and provided further, however, that no public officer elected to his or her office pursuant to the laws of the state or any municipality thereof may serve as a member of the governing body of the Corporation during his or her term of office.

ARTICLE XII AMENDMENTS

These By-Laws of the Board may be amended by the affirmative vote of a quorum of members at the annual meeting, special or regular meetings of the Board, provided that a full presentation of such proposed amendment(s) shall have been presented to the Board at least thirty (30) days prior to the meeting, unless waived by majority of the whole number of the members of the Board.